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Abbreviation list 
ACU: N-adamantyl-N’-cyclohexylurea 
AD: Alzheimer’s disease 
ADME: Absorption, Distribution, 
Metabolism and Excretion process 
ADMET: Absorption, Distribution, 
Metabolism, Excretion and Toxicology 
AEPU: N-adamantanyl-N’-(5-(2-(2-
ethoxyethoxy)ethoxy)pentyl)urea 
AIBN: azobisisobutyronitrile 
AMCU: 1-adamantan-1-yl-3-(4-(3-
morpholinopropoxy)cyclohexyl)urea 
AMPA: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
APAU: N-(1-acetylpiperidin-4-yl)-N’-
adamantylurea 
API: active pharmaceutical ingredient 
ARA: arachidonic acid 
ATF3: activating transcription factor 3 
ATF4: activating transcription factor 4 
ATF6: activating transcription factor 6 
AUDA: N-adamantanyl-N’-dodecanoic 
acid urea 
AUSM: 4-(3-adamantan-1-yl-ureido)-2-
hydroxyl-benzoic acid methyl ester 
BBB: blood-brain barrier 
BiP (or GRP78): immunoglobulin-heavy-
chain-binding protein 
BSA: bovine serum albumin 
cAMP: cyclic adenosine monophosphate 
CDI: N,N’-carbonyldiimidazole 
CGC: cerebellar granule cells 
 
 
CHOP (or GADD153): CCAAT 
enhancer-binding protein (C/EBP) 
homologous protein 
CNS: central nervous system 
COX: cyclooxygenase 
CT: control 
CV: cardiovascular 
CYP450: cytochrome P-450 
DAST: (diethylamino)sulfur trifluoride 
DCE: 1,2-dichloroethane 
DCM: dichloromethane 
DCU: N,N’-dicyclohexylurea 
DHET: dihydroeicosatrienoic acid 
DIPEA: N,N’-diisopropylethylamine 
DMAP: 4-dimethylaminopyridine 
DMF: dimethylformamide 
DMSO: dimethylsulfoxide 
DNA: deoxyribonucleic acid 
DPPA: diphenylphosphoryl azide 
DPP-IV: dipeptidyl peptidase IV 
DTBP: di-tert-butyl peroxide 
EDC: 1-ethyl-3-(3’-
dimethylaminopropyl)carbodiimide 
EDG: electron-donating group 
EET: epoxyeicosatrienoid acid 
eIF2: eukaryotic translation initiation 
factor 2 
EMA: European Medicines Agency 
ER: endoplasmic reticulum 
ERAD: ER-associated degradation 
EWG: electron-withdrawing group 
FDA: Food & Drugs Administration 
Fura-2 AM: Fura-2-acetoxymethyl ester 
GABA: γ-aminobutiric acid 
GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase 
GC: glucocorticoid 
GPCR: G protein-coupled receptor 
GR: glucocorticoid receptor 
GSK: GlaxoSmithKline 
HATU: 1-
[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 
HDL: high-density lipoprotein 
hERG: human Ether-à-go-go-Related 
Gene 
HMPA: hexamethylphosphoramide 
HOAt: 7-aza-1-hydroxybenzotriazole 
HOBt: hydroxybenzotriazole 
HPA: hypothalamic-pituitary-adrenal 
HPLC: high performance liquid 
chromatography 
HRMS: high resolution-mass 
spectrometry 
11β-HSD1: 11β-hydroxysteroid 
dehydrogenase type 1 
11β-HSD1: 11β-hydroxysteroid 
dehydrogenase type 2 
17β-HSD: 17β-hydroxysteroid 
dehydrogenase 
HTS: high-throughput screening 
IC50: half-maximal inhibitory 
concentration 
IKK: inhibitor of κB kinase 
IR: infrared 
IRE1: inositol-requiring enzyme 1 
JNK: c-Jun amino-terminal kinase 
LC-MS: liquid chromatography-mass 
spectrometry 
LDA: lithim diisopropylamide 
LE: ligand efficiency 
LHS: left-hand side 
LipE: lipophilic ligand efficiency 
LKT: leukotriene 
LOX: lipoxygenase 
MD: molecular dynamics 
mEH: microsomal epoxide hydrolase 
MetS: metabolic syndrome 
mp: melting point 
MR: mineralocorticoid receptor 
mRNA: messenger ribonucleic acid 
MS: mass spectrometry 
MW: molecular weight 
NADPH: nicotinamide adenine 
dinucleotide phosphate 
ND: not determined 
NEPC: 4-nitrophenyl-trans-2,3-epoxy-3-
phenylpropyl carbonate 
NF-κB: nuclear factor-κB 
NMDA: N-methyl-D-aspartic acid 
NMDAR: N-methyl-D-aspartic acid 
receptor 
NMR: nuclear magnetic resonance 
NSAID: nonsteroidal anti-inflammatory 
drug 
PAL: palmitate 
PBA: 4-phenyl butyric acid 
PCR: polymerase chain reaction 
PD: pharmacodynamics 
PDB: Protein Data Bank 
PERK: PKR-like ER-regulated kinase 
PG: prostaglandin 
PHOME: (3-phenyl-oxiranyl)-acetic acid 
cyano-(6-methoxy-naphthalen-2-yl)-methyl 
ester 
PK: pharmacokinetic 
PP: primary pharmacophore 
PPAR: peroxisome proliferator-activated 
receptor 
PSA: polar surface area 
PVT: polyvinyl toluene 
RHS: right-hand side  
ROS: reactive oxygen species  
RT: room temperature 
S: solubility 
SAR: structure-activity relationship 
SD: Standard deviation  
SEM: Standard error of the mean 
SET: single electron transfer 
sEH: soluble epoxide hydrolase 
SP: secondary pharmacophore 
SPA: scintillation proximity assay  
t-AUCB: trans-4-[4-(3-adamantan-1-
ylureido)cyclohexyloxy]benzoic acid 
T2DM: type 2 Diabetes Mellitus 
t-DPPO: trans-diphenyl-propene oxide 
TEA: triethylamine 
TFA: trifluoroacetic acid 
TFAA: trifluoroacetic anhydride 
THF: tetrahydrofuran 
TNF-α: tumor necrosis factor-α 
TP: tertiary pharmacophore 
t-SO: trans-stilbene oxide 
UPR: unfolded protein response 
UV: ultraviolet 
vs: versus 
WHO: World Health Organization 
XBP1: X-box-binding protein 1 
µW: microwave apparatus 
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1. ADAMANTANE: THE PRECIOUS NUCLEUS  
For over eighty years, the adamantane nucleus has interested organic chemists for its 
simplicity and symmetry.1 ,2 The rigid tricyclo[3.3.1.13,7]decane skeleton has provided a 
unique structural template for evaluating important theoretical concepts in chemistry (Fig. 
1).3,4,5,6,7 From its discovery, adamantanes have been particularly useful for proving through-
bond and through-space electronic effects of different substituents in saturated systems and 
have significantly contributed to our understanding of hyperconjugation and degenerate 
isomerization. Furthermore they have provided molecular scaffolds for investigating the 
chemical reactivity and the diastereoselectivity of addition/elimination reactions in 
saturated polycyclic cages. 
                         
Fig. 1. Structural representations of tricyclo[3.3.1.13,7]decane, widely referred as 
adamantane ring. Hydrogen atoms are shown in blue. Representations done by ChemBio3D 
Ultra. Energy minimized through MM2. 
 
The physical and chemical properties of the adamantane nucleus have largely 
overshadowed the structure’s contribution to the discovery of human therapeutics. 
Nevertheless in the last decades its application has become more and more significant in 
medicinal chemistry, where the adamantane ring is identified as a key structural subunit in 
several synthetic drugs for multiple targets. 8 , 9 , 10  But prior to an in-depth analysis of 
adamantane’s role in drug discovery, it is worth to introduce it from its onset.   
1.1 Origin of adamantane and first synthesis  
 
Adamantane belongs to the lower diamondoids, which are a group of saturated cage-
like hydrocarbon compounds with a diamond structure present in crude oil in highly 
variable concentrations (Fig. 2).11 Adamantane owes its name to its structural relation with 
                                                          
1 Landa, S. Chem. Listy 1933, 27, 415-418 and 1933, 27, 443-448. 
2 Fort, R. C., Jr.; Schleyer, P. von R. Chem. Rev. 1964, 277-300. 
3 Adcock, W.; Kok, G. B. J. Org. Chem. 1987, 52, 356-364. 
4 Duddeck, H. Tetrahedron 1978, 34, 247-251. 
5 Kaselj, M.; Adcock, J. L.; Luo, H.; Zhang, H.; Li, H.; William, J. le N. J. Am. Chem. Soc. 1995, 117, 7088-
7091. 
6 Adcock, W.; Trout, N. A. Chem. Rev. 1999, 99, 1415-1435. 
7 Gleicher, G. J.; Schleyer, P. von R. J. Am. Chem. Soc. 1967, 89, 582-593. 
8 Wishnok, J. J. Chem. Educ. 1973, 50, 780-781. 
9 Wanka, L.; Iqbal, K.; Schreiner, P. R. Chem. Rev. 2013, 113, 3516-3604. 
10 Lamoureux, G.; Artavia, G. Curr. Med. Chem. 2010, 17, 2967-2978. 
11 Dahl, J. E.; Liu, S. G.; Carlson, R. M. K. Science 2003, 299, 96-99. 
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the diamond, as it is derived from the Greek adamantinos (of steel, of diamond).12 The 
smallest diamondoid, adamantane (C10H16), was the first isolated from petroleum oil in the 
early 1930s and its amount was estimated to be 0.0004% by volume.13 
 
 
 
Fig. 2. The relation between the face-centered cubic diamond lattice and diamondoid 
structures.11 
 
Nowadays diamandoids are of current interest because of their ready accessibility and 
the ease of selective functionalizations, yielding building blocks highly employed in 
nanotechnology and electronics.14 
 
Nature is the oldest contributor to adamantane ring-containing substances and several 
natural products with biological activity incorporate an adamantane motif. Tetrodotoxin, 
the potent toxic principle from puffer fish (Tora fugu), contains an oxygenated adamantane 
framework in its structure,15 and Nature-inspired heteroadamantane antiviral ansabananin 
incorporates an azaadamantane moiety plus a “trioxaadamantane” ring (Fig. 3).16 Besides, 
other natural compounds enclose the adamantane hydrocarbon system itself, such as 
sampsonione I and hyperibone K, both of them showing moderate cytotoxicity against 
                                                          
12 Senning, A. Elsevier’s Dictionary of Chemoetymology; Elsevier: Oxford, 2007. 
13 Mair, B. J.; Shamaiengar, M.; Krouskop, N. C.; Rossini, F. D. Anal. Chem. 1959, 31, 2082-2083. 
14 Schreiner, P. R.; Fokina, N. A.; Tkachenko, B. A.; Hausmann, H.; Serafin, M.; Dahl, J. E. P.; Liu, S.; Carlson, 
R. M. K.; Fokin, A. A. J. Org. Chem. 2006, 71, 6709-6720. 
15 Woodward, R. B.; Gougoutas, J. Z. J. Am. Chem. Soc. 1964, 86, 5030-5030. 
16 Tanner, J. A.; Zheng, B.-J.; Zhou, J.; Watt, R. M.; Jiang, J.-Q.; Wong, K.-L.; Lin, Y.-P.; Lu, L.-Y.; He, M.-L.; 
Kung, H.-F.; Kesel, A. J.; Huang, J.-D. Chem. Biol. 2005, 12, 303-311. 
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different tumoral cell lines.17,18 Even though adamantane is present in Nature, it is not 
considered as a “natural product” nor a “native biological substrate” but it is classified as a 
“mineral”. 
 
 
Fig. 3. Nature-occurring and Nature-inspired adamantane-containing products. 
 
Albeit adamantane was isolated from petroleum oil and synthesized chemically in 
earliest approaches,19 its availability was limited until the Schleyer’s synthesis which allowed 
the wide study of adamantane and its functionalization.20,21 The synthetic route entailed a 
Lewis-acid induced rearrangement of the C10H16 precursor tetrahydrodicyclopentadiene 
(Scheme 1).  
 
 
 
Scheme 1. Schleyer’s synthesis. 
 
This ready access to the adamantane scaffold constituted its birth as a precursor in 
pharmaceutical sciences, while its derivatives expanded the application in medicinal 
chemistry thereof, and they are still doing so to date. 
 
                                                          
17 Hu, L. H.; Sim, K. Y. Org. Lett. 1999, 1, 879-882. 
18 Tanaka, N.; Takaishi, Y.; Shikishima, Y.; Nakanishi, Y.; Bastow, K.; Lee, K.-H.; Honda, G.; Ito, M.; Takeda, 
Y.; Kodzhimatov, O. K.; Ashurmetov, O. J. Nat. Prod. 2004, 67, 1870-1875. 
19 Prelog, V.; Seiwerth, R. Ber. Dtsch. Chem. Ges. 1941, 74, 1644-1648. 
20 Schleyer, P. v. R. J. Am. Chem. Soc. 1957, 79, 3292-3292. 
21 Schleyer, P. v. R.; Donaldson, M. M.; Nicholas, R. D.; Cupas, C. Org. Synth. Coll. Vol. V 1973, 16-19. 
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1.2 Adamantane’s physicochemical properties and its multidimensional value  
 The closing section will provide the physicochemical profile of the adamantane moiety, 
the structural relationships between adamantane-bearing compounds and protein targets 
as well as the general aspects in the pharmacokinetics of the adamantane group, with the 
aim of supplying an overview of the role of this valuable ring. 
1.2.1 Physicochemical properties 
 The four cyclohexanes in chair conformation contained within the adamantane ring 
are the source of its uniqueness in that it is both rigid and virtually stress-free. If we bear in 
mind the three-dimensional structure in figure 1, adamantane possesses a spherical shape 
with a diameter of about 6.4 Å.22 Compared to a benzene molecule, the adamantane ring 
displays a larger volume not depending on its orientation, whereas the benzene ring is 
planar (Fig. 4).10  
 
 
Fig. 4. Structural representations of adamantane and benzene in space-filling mode and 
their dimensions. Hydrogen bonds are shown in blue. Representations done by ChemBio3D 
Ultra. Energy minimized through MM2. 
 
 Polarizability is another property that affects the binding between the ligand or drug 
and its target, not only influencing the hydrophobicity but also the biological activity. 
Polarization is the phenomenon whereby the charge distribution in a molecule is modified 
due to the presence of an external field.23 Whereas benzene shows a quadrupole, which 
forms π-type interactions, adamantane presents an octapole, with a higher polarizability 
value than benzene, which indicates that the electrostatic forces between adamantane and 
its target could have a greater effect on the binding than previously thought. It is worth to 
                                                          
22 Morel-Desrosiers, N.; Morel, J.-P.  J. Solution Chem. 1979, 8, 579-592. 
23 Leach, A. R. Compr. Med. Chem. II 2007, 4, 87-118. 
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highlight that the interest in the polarizable force fields for small molecules in organic and 
biochemical systems is currently increasing, drawing the attention of many scientists.24,25 
Nevertheless, the most significant property that characterizes the adamantane group is 
its high lipophilicity. Considered the most important drug-like physical property, 
lipophilicity is one of the main criteria relevant for oral bioavailability, included in the well-
known Lipinski’s rules.26 The lipophilic value is commonly estimated by the logarithm of 
the octanol/water partition coefficient (log P), which is defined as the ratio of non-ionized 
drug distributed between octanol and water phases at equilibrium. Higher values imply 
greater lipophilicity and often a log P value of 5 or higher is considered as an upper limit 
of desired lipophilicity in drug discovery.27 Generally, an adamantane-bearing compound 
will be more lipophilic than the des-adamantyl analogue. Calculation of the hydrophobic 
substituent constant determined by non-empirical methods for the adamantane group, the 
clog P (calculated log P) measures of the known adamantane-containing compounds and 
the des-adamantyl derivatives, revealed a πadamantyl  value of 3.1.28 That is, the incorporation 
of an adamantane motif will increase by about 3.1 log units the log P value of any given 
drug. As a consequence, adamantane is considered as a “lipophilic carrier” that allows 
poorly absorbed drugs to slipping across cell membranes, such as the Blood-Brain Barrier 
(BBB) enhancing Central Nervous System (CNS) access.29,30 
 Inasmuch as clog P is a composite property dependent on molecular size, polarity and 
hydrogen bonding,31 it is related to solubility. In almost all cases the adamantane group 
lowers the clog P compared to the linear constitutional isomer (Fig. 5). This effect is partly 
due to the fact that the adamantane-based compounds feature a close lateral packing, with 
the interstitial space present in solution increasing the propensity towards solvation. Hence 
molecules hosting an adamantane moiety will have solubility properties more tractable in 
medicinal chemistry setting compared to other C10-based frameworks.28  
 
 
Fig. 5. clog P values of adamantane derivatives and their linear analogues, calculated using Bio-
Loom®. 
                                                          
24 Kaminski, G. A.; Stern, H. A.; Berne, B. J.; Friesner, R. A. J. Phys. Chem. A 2004, 108, 621-627. 
25 Maple, J. R.; Cao, Y.; Damm, W.; Halgren, T. A.; Kaminski, G. A.; Zhang, L. Y.; Friesner, R. A. J. Chem. 
Theory Comput. 2005, 1, 694-715. 
26 Lipinski, C. A; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Deliv. Rev. 1997, 23, 3-25. 
27 Leeson, P. D.; Springthorpe, B. Nat. Rev. Drug Discov. 2007, 6, 881-890. 
28 Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R. Eur. J. Med. Chem. 2011, 46, 1949-1963. 
29 Terasaki, T.; Pardridge, W. M. J. Drug Targets 2000, 8, 353-355. 
30 Tsuzuki, N.; Hama, T.; Kawada, M.; Hasui, A.; Konishi, R.; Shiwa, S.; Ochi, Y.; Futaki, S.; Kitagawa, K. J. 
Pharm. Sci. 1994, 83, 481-484. 
31 Abraham, M. H., Chadha, H. S., Whiting, G. S.; Mitchell, R. C. J. Pharm. Sci. 1994, 83, 1085-1100. 
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 Worth to bear in mind, is the fact that, notwithstanding the increase in the solubility 
of the adamantane-containing compounds with respect to their linear structural isomers as 
a result of the above mentioned, incorporation of an adamantane ring in any given 
structure will compromise the water solubility of the molecule since the log P is enlarged 
by about 3.1 log units, which represents a considerable increment in drug design. 
1.2.2 Adamantane ring as a pharmacophore  
 The three-dimensional structure is essential for the sheer activity of a drug, exerted by 
the fit into the receptor’s binding site. The target-ligand interaction was generally described 
as the “key-lock” model, but currently the “induced fit” principle has been more accepted, 
which expresses a more dynamic understanding of the receptor−ligand interactions. 32 
Accordingly, the adamantane core has been used to organize the spatial position of the 
functional groups that form the pharmacophore of a lead molecule, providing an ideal 
skeleton for this purpose. That is, to fix the molecular features that are essential for 
molecular recognition.10 Thus adamantane scaffold plays a decisive role in the three-
dimensional adjustment of the pharmacophores to its protein target. The favourable 
chemical and geometric properties of adamantane make it possible to introduce several 
functional groups, consisting drug, targeting part, linker, or similar, without undesirable 
interactions between such groups.33 
 Adamantane’s physicochemical properties and structural uniqueness are in 
consequence directly related to its binding mode with specific therapeutic targets. Firstly, 
adamantane moiety can bind to hydrophobic pockets of enzymes, and secondly it can affect 
ion channels by disrupting the transmembrane flow. Worth to highlight is the difference 
between the term “blocker” and the term “antagonist”. The first locution concerns the 
alteration of the permeability of the ion channels by the interaction of the ligand with 
these. The second term refers to these drugs binding to an enzyme or receptor, which can 
control an ion channel, preventing the binding of the natural mediator and thus 
eliminating the physiological response related to the enzyme/ion channel. A deeper but 
brief look into adamantane’s role in medicinal chemistry will be discussed later on. 
1.2.3 ADME properties of adamantane-containing compounds 
 As most part of the drugs that are administered, compounds incorporating 
adamantane as a building block suffer from metabolism once they are inside the organism. 
With regard to Absorption and Distribution, incorporation of the cage-shaped adamantane 
nucleus into medicinal agents has provided a viable approach for designing molecules that 
can access lipophilic cell membranes, as aforementioned. Therefore, targets of the CNS are 
being addressed today with, remarkably structurally simple adamantane derivatives, such as 
                                                          
32 Spyrakis, F.; Bidon-Chanal, A.; Barril, X.; Luque, F. J. Curr. Top. Med. Chem. 2011, 11, 192-210. 
33 Mansoori, G. A.; George, T. F.; Assoufid, L.; Zhang, G. Molecular building blocks for nanotechnology. 
From diamondoids to nanoscale materials and applications. Springer: New York, 2007. 
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amantadine and memantine, with anti-Parkinson and anti-Alzheimer activities respectively 
(Fig. 6). 
 
 
Fig. 6. Structures of amantadine and memantine. 
  
 In terms of Metabolism and Excretion, the cytochrome P-450 is believed to control the 
oxidative metabolism for a rapid excretion of the adamantane derivatives,34 mainly through 
hydroxylation with mono- and dihydroxylated derivatives as common metabolites. As it can 
be deduced from the crystal structure of CYP450CAM (bacterial camphor hydroxylase P-450) 
complexed with adamantane, this process is generally not selective and, in the absence of 
further functional groups in the drug that could orientate the cage hydrocarbon, several 
sites are being hydroxylated, as can be seen with, for example, amantadine,35 memantine,36 
rimantadine,37,38  and saxagliptin39 (Fig. 7). 
 
 
Fig. 7. Main metabolites of amantadine, memantine, rimantadine, and saxagliptin. 
                                                          
34 Raags, R.; Poulos, T. L. Biochemistry 1991, 30, 2674-2684. 
35 Suckow, R. F. J. Chromatogr. B Biomed. Sci. Appl. 2001, 764, 313-325. 
36 Sturm, G.; Schollmeyer, J. D.; Wesemann, W. IRCS Medical Science: Library Compendium, 1976, 4, 55. 
37 Hayden, F. G.; Minocha, A.; Spyker, D. A.; Hoffman, H. E. Antimicrob. Agents Chemother. 1985, 28, 216-
221. 
38 Rubio, F. A.; Choma, N.; Fukuda, E. K. J. Chromatogr. 1989, 497, 147-157. 
39 Su, H.; Boulton, D. W.; Barros, A. Jr.; Wang, L.; Cao, K.; Bonacorsi, S. J. Jr.; Iyer, R. A.; Humphreys, W. 
G.; Christopher, L. J. Drug Metab. Dispos. 2012, 40, 1345-1356. 
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Metabolism studies have shown that the bridgehead hydroxylation (tertiary carbon) is 
favoured over the secondary carbon positions, producing water-soluble 
hydroxyadamantane derivatives in the liver, which are then easily excreted. This 
hydroxylation mechanism is prevalent for electron-rich adamantane cores.40 As an example, 
while amantadine is not metabolized by hydroxylation of the adamantane nucleus, cage 
hydroxylation is the main metabolic degradation for its dimethyl derivative memantine. 
 In addition, the steric bulk of the adamantane motif can reduce the amidase or esterase 
enzyme activity in the regions proximal to the scaffold, especially where the adamantyl 
group has been appended to the parent drug via an amide or an ester bond. So the rigid 
hydrocarbon skeleton protects functional groups in its proximity from metabolic cleavage, 
enhancing the duration of action of peptide-derived drugs, among others, that feature an 
adamantane ring.41 
1.3 Medicinal chemistry of adamantane: the promiscuous lipophilic pellet  
1.3.1 Clinically approved adamantane-based drugs 
At the time of writing this thesis, eight drugs are marketed featuring the adamantane 
motif. A brief introduction of each one will be commented below. 
· Amantadine: considered the birth of the adamantane derivatives in medicinal 
chemistry, amantadine constituted the structurally simplest monofunctionalized 
adamantane drug with application in medicinal chemistry. Discovered in the early 1960s,42 
1-aminoadamantane was found to be a selective antiviral, especially against influenza A and 
rubella virus. Related to influenza A virus, the mechanism of action consists in the blockade 
of the M2 ion channel. This protein is essential for viral replication and is involved in the 
endosomal uptake of protons, thus acidifying the interior of the virus that leads to the 
uncoating of the viral genetic material.43,44 The inhibitory activity of amantadine is by 
different mechanisms; the adamantane hydrophobic sphere physically occludes the 
transmembrane flux of protons, locks the protein conformation in a single state hampering 
its plasticity, and perturbs the pKa of the His37 tetrad by H-bonding through the entry of 
water cluster.45  
Furthermore, amantadine was found to be useful for the treatment of Parkinson’s 
disease when in 1968 a patient who was taking amantadine to prevent the flu, experienced 
a remarkably remission in her symptoms of rigidity, tremor and akinesia.46 This fortuitous 
                                                          
40 Fokin, A. A.; Schreiner, P. R. Chem. Rev. 2002, 102, 1551-1593. 
41 Nagasawa, H. T.; Elberling, J. A.; Shirota, F. N. J. Med. Chem. 1975, 18, 826-830. 
42 Davies, W. L.; Grunert, R. R.; Haff, R. F.; McGahen, J. W.; Neumayer, E. M.; Paulshock, N.; Watts, J. C.; 
Wood, T. R.; Hermann, E. C.; Hoffman, C. E. Science 1964, 144, 862-863. 
43 De Clercq, E. Nat. Rev. Drug Discov. 2006, 5, 1015-1025. 
44 Cady, S. D.; Luo, W.; Hu, F.; Hong, M. Biochemistry 2009, 48, 7356-7364. 
45 Cady, S. D.; Wang, J.; Wu, Y.; DeGrado, W. F.; Hong, M. J. Am. Chem. Soc. 2011, 133, 4274-4284. 
46 Schwab, R. S.; England, A. C. Jr.; Poskanzer, D. C.; Young, R. R. J. Am. Med. Assoc. 1969, 208, 1168-1170. 
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finding marked the beginning of medicinal chemistry of adamantane derivatives in the 
context of diseases affecting the CNS, accounting for its lipophilicity and BBB-penetration, 
enhancing properties of the adamantane motif. In Parkinson’s disease, the Food and Drugs 
Administration (FDA) approved amantadine has been demonstrated to act directly on the 
D2 dopamine receptors, resulting in enhanced dopamine release, while inhibiting post-
synaptic uptake.  
Besides, amantadine has antiglutamatergic properties via the non-competitive 
antagonism of N-methyl-D-aspartic acid (NMDA) receptors,47,48 and displays trypanocidal 
activity along with rimantadine and memantine.49,50 However, amantadine is not clinically 
used exploiting these properties. 
 · Memantine: the 3,5-dimethyl-1-aminoadamantane was approved in 2002 by the 
European Medicines Agency (EMA) and in 2003 by the FDA for use in treatment of 
patients with moderate-to-severe Alzheimer’s disease (AD). Memantine is an non-
competitive, low- to moderate-affinity NMDA receptor (NMDAR) antagonist, with strong 
voltage dependency and rapid blocking and unblocking kinetics.51,52 Memantine is efficient 
in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, 
producing excessive Ca2+ influx through the receptor’s associated ion channel and 
consequent free-radical formation, leading to cellular damage and death.53 The NMDA 
receptor antagonism is a topic of the present thesis, hence it will be discussed further on.  
     · Rimantadine: soon after amantadine introduction in clinic, several compounds 
were developed with the insertion of a bridge of one or more carbon atoms between the 1-
adamantyl and the amino group, which led to compounds with generally high antiviral 
activity, with rimantadine outperforming amantadine in terms of activity (Fig. 8).54 The α-
methyl adamantanemethanamine have been found to be active among a wider range of 
viruses, although its main use is for the treatment and prophylaxis of influenza A infection.43 
Compared to amantadine, rimantadine has a comparable or higher oral availability, 
produces fewer side effects and is absorbed well from the gastrointestinal tract.55 As well as 
amantadine, rimantadine is also a trypanocidal agent, whose activity is generally associated 
with a blockade of a membrane ion channel. Trypanosoma brucei is carried by the Tse-tse fly 
                                                          
47 Kornhuber, J.; Bormann, J.; Hubers, M.; Rusche, K.; Riederer, P. J Pharmacol. 1991, 206, 297-300. 
48 Blanpied, T. A.; Clarke, R. J.; Johnson, J. W. J. Neurosci. 2005, 25, 3312-3322. 
49 Kelly, J. M.; Miles, M. A.; Skinner, A. C. Antimicrob. Agents Chemother. 1999, 43, 985-987. 
50 Kelly, J. M.; Quack, G.; Miles, M. A. Antimicrob. Agents Chemother. 2001, 45, 1360-1366. 
51 Rammes, G.; Danysz, W.; Parsons, C. G. Curr. Neuropharmacol. 2008, 6, 55-78. 
52 Herrmann, N.; Li, A.; Lanctôt, K. Expert Opin. Pharmacother. 2011, 12, 787-800. 
53 Lipton, S. A. Nat. Rev. Drug Discov. 2006, 5, 160-170. 
54 Tsunoda, A.; Maassab, H. F.; Cochran, K. W.; Eveland, W. C. Antimicrob. Agents Chemother. 1965, 5, 
553-560. 
55 Hayden, F. G.; Minocha, A.; Spyker, D. A.; Hoffman, H. E. Antimicrob. Agents Chemother. 1985, 28, 216-
221. 
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and causes the so-called sleeping sickness, which is a serious health issue in many areas of 
the sub-Saharan Africa, considered as a “neglected disease”.56  
 
 
Fig. 8. Structures of the adamantane-based drugs rimantadine, saxagliptin, vildagliptin, 
tromantadine, adapalene and arterolane. 
 
 · Saxagliptin and vildagliptin: in the multibillion dollar market of type 2 Diabetes 
Mellitus (T2DM), big pharmaceutical companies  have initiated drug development 
programs around dipeptidyl peptidase IV (DPP-IV) inhibitors.57 The activity of DDP-IV 
negatively affects glucose homeostasis, and its inhibition increases the levels of incretin 
hormones, such as glucagon-like peptide-1. This target is successfully hit by adamantane 
compounds; saxagliptin and vildagliptin, which have been approved in recent years.58,59 The 
adamantyl group in saxagliptin and vildagliptin serves a dual role in terms of directing inter- 
and intramolecular interactions in the DPP-IV binding site and in reducing the propensity 
towards intramolecular cyclisation reactions, by means of the encumbrance supplied by the 
adamantane moiety (Fig. 9).60  The production of the inactive cyclic amidine form of 
saxagliptin has been observed during process-scale production. 
 
 
                                                          
56 Barret, M. P.; Burchmore, R. J. S.; Stich, A.; Lazzari, J. O.; Frasch, A. C.; Cazzulo, J. J.; Krishna, S. Lancet 
2003, 362, 1469-1480. 
57 von Geldern, T. W.; Trevillyan, J. M. Drug Dev. Res. 2006, 67, 627-642. 
58 Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; 
Russell, M. E.; Hughes, T. E. J. Med. Chem. 2003, 46, 2774-2789. 
59 Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; 
Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, 
G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. J. 
Med. Chem. 2005, 48, 5025-5037. 
60 Metzler, W. J.; Yanchunas, J.; Weigelt, C.; Kish, K.; Klei, H. E.; Xie, D.; Zhang, Y.; Corbett, M.; Tamura, J. 
K.; He, B.; Hamann, L. G.; Kirby, M. S.; Marcinkeviciene, J. Protein Sci. 2008, 17, 240-250. 
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Fig. 9. Internal cyclization can play a decisive role in inactivating cyanopyrrolidine-based DPP-
IV inhibitors. 
 
 · Tromantadine: this aminoadamantane marks the third adamantane derivative that 
was successfully introduced to the market, even though its identification as an anti-Herpes 
simplex agent was not so much the result of research specifically addressing this issue. 
Tromantadine is a derivative of amantadine that is used topically for the treatment of the 
herpes virus, being inactive against influenza A.61 Its precise mechanism of action is still 
unknown, despite numerous studies taking aim at it. However, tromantadine apparently 
exerts, at least in part, its activity through influencing the fusion of lipid membranes.62 
Tromantadine is particularly interesting for the treatment of aciclovir-resistant strains since 
it does not require a viral kinase to become activated, unlike aciclovir.  
 . Adapalene: this adamantyl retinoid is used for the topical treatment of Acne vulgaris 
sold as hydrogel in combination with the antimicrobial benzoyl peroxide. 63  Its 
pharmacological and chemical properties include photochemical stability, local activity, 
high stability, and as expected, low local side-effect profile. The lipophilicity of the 
adamantyl group contributes to the low percutaneous flux of adapalene and an improved 
penetration into the pilosebaceous follicles.64  
 · Arterolane: this adamantyl ozonide has been recently approved for the treatment 
of Plasmodium falciparum infection. It constitutes the first Indian new molecular entity that 
has reached the market. Since 2014, this anti-malaria drug is available combined with 
piperaquine phosphate in African and Asian countries.65 
1.3.2 Adamantane-containing candidates in development 
 The quest for new applications of the adamantane ring is an issue on the rise in 
medicinal chemistry. Thanks to the great efforts from the academy and industry, many 
                                                          
61 Rosenthal, K. S.; Sokol, M. S.; Ingram, R. L.; Subramanian, R.; Fort, R. C. Antimicrob. Agents Chemother. 
1982, 22, 1031-1036. 
62 Ickes, D. E.; Venetta, T. M.; Phonphok, Y.; Rosenthal, K. S. Antiviral Res. 1990, 14, 75-85. 
63 Shroot, B.; Michel, S. J. Am. Acad. Dermatol. 1997, 36 (Suppl.), S96-S103. 
64 Piérard, G. E.; Piérard-Franchimont, C.; Paquet, P.; Quatresooz, P. Expert Opin. Drug Metab. Toxicol. 
2009, 5, 1565-1575. 
65 Wells, T. N.; Alonso, P. L.; Gutteridge, W. E. Nat. Rev. Drug Discovery 2009, 8, 879-891. 
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adamantyl-based compounds have been studied as potential therapeutics for conditions 
including cancer,66 neurological conditions, hypertension,67 malaria,68,69 and tuberculosis.70  
 For the sake of brevity, table 1 encloses some of the main targets that are hit by 
adamantane-bearing compounds that are still under development, as well as the 
pharmacodynamic (PD) and pharmacokinetic (PK) modulation exerted by adamantane. 
For a deeper study on the subject, the reading of the reviews by Wanka, Iqbal and 
Schreiner,9 Lamoureux and Artavia,10 and Codd and coworkers, is recommended.28  
Table 1. Representative adamantane-based biologically active compounds. CCK-B: 
cholecystokinins B; ROS: reactive oxygen species.  
Compound Target Condition Main features 
 
171 
CCK-B 
receptor 
Anxiety 
Neuropeptide with 
better penetration of 
the BBB 
 
2 (top) and 3 (bottom)72,73 
Plasmodium 
falciparum 
Malaria 
Improved 
pharmacological 
profile, whether 
displaying greater oral 
bioavailability or 
higher activity against 
resistant strains 
                                                          
66 Glennon, R. A. Drug Dev. Res. 1992, 26, 251-274. 
67 Imig, J. D.; Zhao, X.; Zaharis, C. Z.; Olearczyk, J. J.; Pollock, D. M.; Newman, J. W.; Kim, I. H.; Watanabe, 
T.; Hammock, B. D. Hypertension 2005, 46, 975-981. 
68 Fieser, L. F.; Nazer, M. Z.; Archer, S.; Berberian, D. A.; Slighter, R. G. J. Med. Chem. 1967, 10, 517-521. 
69 Wang, X.; Dong, Y.; Wittlin, S.; Creek, D.; Chollet, J.; Charman, S. A.; SantoTomas, J.; Scheurer, C.; Snyder, 
C.; Vennerstrom, J. L. J. Med. Chem. 2007, 50, 5840-5847. 
70 Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.;  Nacy, C. A. 
J. Antimicrob. Chemother. 2005, 56, 968-974. 
71 Trivedi, B. K.; Padia, J. K.; Holmes, A.; Rose, S.; Wright, D. S.; Hinton, J. P.; Pritchard, M. C.; Eden, J. M.; 
Kneen, C.; Webdale, L.; Suman-Chauhan, N.; Boden, P.; Singh, L.; Field, M. J.; Hill, D. J. Med. Chem. 1998, 
41, 38-45. 
72 Solaja, B. A.; Opsenica, D.; Smith, K. S.; Milhous, W. K.; Terzic, N.; Opsenica, I.; Burnett, J. C.; Nuss, J.; 
Gussio, R.; Bavari, S. J. Med. Chem. 2008, 51, 4388-4391. 
73 Moehrle, J. J.; Duparc, S.; Siethoff, C.; van Giersbergen, P. L.; Craft, J. C.; Arbe-Barnes, S.; Charman, S. 
A.; Gutierrez, M.; Wittlin, S.; Vennertrom, J. L. Br. J. Clin. Pharmacol. 2012, 75, 524-537. 
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450 
Trypanosoma 
brucei  
Sleeping 
sickness 
Improvement in the 
anti-parasitic activity 
 
570 
Mycobacterium 
tuberculosis 
Tuberculosis 
Improved in vivo 
potency and limited 
in vitro  and in vivo  
toxicity 
 
 
6 (adaphostin)74,75 
Tyrosine 
kinase and 
/or ROS 
Cancer 
Less susceptible of 
hydrolysis by means 
of a superior 
lipophilicity and 
encumbrance 
 
776 
DNA Cancer 
Cisplatin-analogue 
with improved 
therapeutic index and 
oral bioavailability 
 
877,78 
P2X7 receptor Inflammation 
Good balance 
between potency, 
molecular weight and 
lipophilicity 
                                                          
74 Le, S. B.; Hailer, M. K.; Buhrow, S.; Wang, Q.; Flatten, K.; Pediaditakis, P.; Bible, K. C.; Lewis, L. D.; 
Sausville, E. A.; Pang, Y. P.; Ames, M. M.; Lemasters, J. J.; Holmuhamedov, E. L.; Kaufmann, S. H. J. Biol. 
Chem. 2007, 282, 8860-8872. 
75 Kaur, G.; Narayanan, V. L.; Risbood, P. A.; Hollingshead, M. G.; Stinson, S. F.; Varma, R. K.; Sausville, E. 
A. Bioorg. Med. Chem. 2005, 13, 1749-1761. 
76 Kelland, L. R.; Barnard, F. J.; Evans, I. G.; Murrer, B. A.; Theobald, B. R. C.; Wyer, S. B.; Goddard, P. M.; 
Jones, M.; Valenti, M.; Bryant, A.; Rogers, P. M.; Harrap, K. R. J. Med. Chem. 1995, 38, 3016-3024. 
77 Guile, S. D.; Alcaraz, L.; Birkinshaw, T. N.; Bowers, K. C.; Ebden, M. R.; Furber, M.; Stocks, M. J. J. Med. 
Chem. 2009, 52, 3123-3141.  
78 Mehta, N.; Kaur, M.; Singh, M.; Chand, S.; Vyas, B.; Silakari, P.; Bahia, M. S.; Silakari, O. Bioorg. Med. 
Chem. 2014, 22, 54-88. 
 
16  INTRODUCTION 
 
979,80 
δ/µ-opioid 
receptors 
Analgesia 
Modification of the 
selectivity pattern, 
and better in crossing 
the BBB 
 
 
 Other protein targets than the already introduced are hit by adamantane-based 
compounds. An emerging field is the inhibition of enzymes with therapeutically interesting 
profiles, such as the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the soluble 
epoxide hydrolase (sEH). These targets will be two independent topics of this manuscript, 
hence they will be discussed in the next chapters.  
All these examples prove that the value of the adamantyl group in drug design is 
multifunctional, and that its study is of major importance to understand the influence of 
this simple, yet potent, structural element. 
1.4 Not all that glitters is gold: a moot point of perfection  
In the previous sections we have gone through the value of the adamantane nucleus in 
medicinal chemistry, and the early examples of adamantane-based compounds have shown 
that this precious ring modulates different properties essential for drug behaviour within 
the organism. Despite all the advantages the adamantane offers, a few drawbacks are 
identified, which render the adamantane group not as a magic bullet but as a ring whose 
introduction should be given careful considerations. The following section encloses these 
disadvantages and the way they affect to the drug discovery process.  
1.4.1 High lipophilicity compromises PK properties 
Lipophilicity is the most critical property from the famous Lipinski’s rule or ‘rule of 
five’,26  which states that drug permeability and absorption are threatened if: 
i. clog P is > 5; 
ii. molecular weight is > 500 Da; 
iii. number of hydrogen-bond donors is > 5; 
iv. number of hydrogen-bond acceptors is > 10. 
 
Since its appearance, several studies have highlighted the polar surface area (PSA) and 
the number of rotatable bonds as other key parameters that control permeability and 
                                                          
79 Horvat, S.; Varga-Defterdarovic, L.; Horvat, J.; Jukic, R.; Kantoci, D.; Chung, N. N.; Schiller, P. W.; Biesert, 
L.; Pfutzner, A.; Suhartono, H.; Rubsamen-Waigmann, H. J. Pept. Sci. 1995, 1, 303-310. 
80 Lovekamp, T.; Cooper, P. S.; Hardison, J.; Bryant, S. D.; Guerrini, R.; Balboni, G.; Salvadori, S.; Lazarus, L. 
H. Brain Res. 2001, 902, 131-134. 
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absorption.81 Thus, overall oral bioavailability can be simply predicted by number of rule-
of-five violations, PSA and number of rotatable bonds. Although these physical properties 
play an important role in the assessment of the drug bioavailability, lipophilicity stands out 
among them since it is decisive to avoid later attrition during the discovery of drug 
candidates, as numerous studies have confirmed it.82 
 
During the last two decades, clog P has barely changed for approved oral drugs. 
However, there is a noted trend that lipophilicity increases as candidate molecules progress 
through clinical trials. A recent study published in 2007 compared the physicochemical 
properties of more than 500 marketed drugs and compounds in development from big 
pharmaceutical companies such as GlaxoSmithKline (GSK), Merck, AstraZeneca and 
Pfizer.27 The authors observed that the average clog P value was higher than 4.1 in the 
patent literature, whereas the more recent drugs have a median clog P of 3.1 (Fig. 10). 
 
 
Fig. 10. Mean molecular weight and clog P values of oral drugs according to time of 
publication.83 
  
On the other hand, a comparison of marketed oral drugs with compounds in early 
stages of the drug discovery shows that high lipophilicity (clog P > 4) leads to compounds 
with: 
i. poor solubility; 
ii. rapid metabolic turnover; 
iii. low bioavailability;  
iv. off-target promiscuity. 
                                                          
81 Lu, J. J.; Crimin, K.; Goodwin, J. T.; Crivori, P.; Orrenius, C.; Xing, L.; Tandler, P. J.; Vidmar, T. J.; Amore, 
B. M.; Wilson, A. G. E.; Stouten, P. F. W.; Burton, P. S. J. Med. Chem. 2004, 47, 6104-6107. 
82 Arnott, J. A.; Planey, S. L. Expert Opin. Drug Discov. 2012, 7, 863-875.  
83 (a) Leeson, P. D.; Young, R. J. ACS Med. Chem. Lett. 2015, 6, 722-725. (b) Waring, M. J.; Arrowsmith, J.; 
Leach, A. R.; Leeson, P. D.; Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S. D.; Wang, 
J.; Wallace, O.; Weir, A. Nat. Rev. Drug Discov. 2015, 14, 475-486. 
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The later refers to the increase in the likelihood of binding to multiple targets, such as 
the human Ether-à-go-go-Related Gene (hERG) ion channel, that can result in the 
appearance of side effects and toxicology.  
A deeper study performed by GSK from the ADMET profile and physicochemical data 
of ~ 30,000 molecules revealed that compounds that display a clog P < 4 appear to be 
optimal for achieving appropriate physicochemical characteristics to ensure downstream 
drug success.84 Table 2 summarizes the effects of the molecular weight and the clog P in the 
main set of PK assays applied in industry. Because of approximately two-thirds of all existing 
drug entities are classified as basic or acidic molecules,85 these two types are the ones 
disclosed below. 
Table 2. Influence of the key molecular properties on the ADMET parameters.84 
Basic molecules 
MW < 400 
and clog P < 4 
MW > 400 
and clog P > 4 
Solubility high/average low/average 
Permeability high/average average 
Bioavailability average low 
Volume of 
distribution high/average high 
Plasma protein 
binding low average 
CNS penetration high/average average/low 
Brain tissue binding low high 
P-gp efflux average high/average 
in vivo clearance average high/average 
hERG inhibition average/high high 
CYP450 inhibition 
low 1A2, 2C9 
& 2C19 
inhibition 
low 1A2 
inhibition 
CYP450 inhibition 
average 2D6 
& 3A4 
inhibition 
average 2C9 
& 2C19 
inhibition 
P-450 inhibition   
high 2D6 & 
3A4 
inhibition 
                                                          
84 Gleeson, M. P. J. Med. Chem. 2008, 51, 817-834. 
85 Charifson, P. S.; Walters, W. P. J. Med. Chem. 2014, 57, 9701-9717. 
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Acidic molecules 
MW < 400 
and clog P < 4 
MW > 400 
and clog P > 4 
Solubility high average/high 
Permeability low average/low 
Bioavailability average average 
Volume of 
distribution low low 
Plasma protein 
binding average/higher high 
CNS penetration low low 
Brain tissue binding low high 
P-gp efflux low low 
in vivo clearance low/average average 
hERG inhibition low low 
CYP450 inhibition 
low 1A2, 2C9, 
2C19, 2D6 & 
3A4 
inhibition 
low 1A2, 
2C19, 2D6 & 
3A4 
inhibition 
CYP450 inhibition   
high 2C9 
inhibition 
 
As mentioned in section 1.2.1, having an adamantane present in a test drug gives a 
molecule of significantly higher lipophilicity compared to a molecule with just a proton or 
a methyl group instead. Specifically, the log P increases 3.1 log units when an adamantane 
is incorporated into a molecule. An increase in lipophilicity can be beneficial, but there is 
obviously a “size limit” of the lipophilic add-on.   
Considering the above mentioned, it seems evident that the adamantane ring does not 
always possess the optimal properties as a scaffold in medicinal chemistry. A decrease in 
the overall lipophilicity will lead to compounds with an improved PK profile, which will 
therefore be more “drug-like”.86 In this sense, there is an urgent need for the development 
of new scaffolds that could provide compounds with more optimal physicochemical 
properties to avoid attrition in later stages of the drug discovery process.  
1.4.2 Ready access to intermediates that prevent scaffold optimization 
 Taking into account what it has been stated so far, it is logical to wonder why the 
adamantane ring is widely used in medicinal chemistry. And the answer is simple. Apart 
from the fact that in some cases the adamantane ring is the more suitable structure for any 
taken target, the easy access to adamantyl intermediates restrains the use of similar, yet 
disparate, analogues.  
 The adamantane-based pharmaceuticals are derived from a small library of 
adamantane derivatives, mostly bearing simple functional groups, like amines or carboxylic 
                                                          
86 Zhang, M.-Q. Methods Mol. Biol. 2012, 803, 297-307. 
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acids. These intermediates are commercially available from common suppliers, such as 
Sigma-Aldrich, Fluorochem or TCI. In particular, from 100 to 150 derivatives can be easily 
purchased from their webpage in a timely and cost effective way, at least for the developed 
countries. For this reason, the adamantane ring is considered as a standard lipophilic 
building block in test drug library syntheses.  
 Frequently, the industry, with its desire to make more and more compounds for testing 
in a fast turnaround time, makes no efforts in the optimization of this kind of polycycles, 
since medicinal chemistry strategies around other functionalities and structures of parent 
molecules are more straightforward. However, the employment of similar polycycles as 
adamantane-like analogues can overcome the related issues to the use of the adamantane 
itself. Although some of the alternative cores entail tedious and long synthetic routes, 
others can be prepared in a synthetically feasible way.  
1.4.3 Adamantane group as an imperfect space-filling pharmacophore 
The lipophilic cage structure of adamantane has been used to rigidify the 
pharmacophore. True is the fact that in some cases the adamantane ring possesses the 
optimum molecular dimensions to functionally hit its target. Notwithstanding that, the 
adamantane does not always fill perfectly the active site of the desired target. Its dimensions 
are limited and the adamantane moiety can exceed or lose in filling the space of the target 
cavity. The binding constant for the ligand-receptor interaction can be optimized by varying 
the shape, orientation and flexibility of the scaffold. Since adamantane is a rigid structure 
with a well-defined geometry, the manipulation of this structure can give rise to several 
different scaffolds with diverse effects on its interaction to the target. 
Several research groups have worked, and still are, in the development of different 
polycycles for their use in diverse targets as surrogates of the adamantane ring with 
promising results.  These adamantane-like scaffolds have been applied in targets such as 
influenza A and vaccinia viruses,87 or against CNS disorders, targeting the γ-aminobutiric 
acid (GABA) or 5-HT2 receptors of serotonin, among others. 88 , 89  This issue will be 
examined in detail in the section that follows.  
1.5 Adamantane alternatives: previous work of the group  
Over the last few years, the research group headed by Dr. Santiago Vázquez Cruz has 
gained a wide expertise in the synthesis of adamantane-like polycyclic scaffolds and their 
application to different therapeutical targets. In this regard, ring-expanded, ring-contracted, 
oxa-derivatives and related cage compounds have been explored by the group as analogues 
                                                          
87 Jordan, R.; Bailey, T. R.; Rippin, S. R.; Dai, D. WO 2008130348, 2008. 
88 Zoidis, G.; Papanastasiou, I.; Dotsikas, I.; Sandoval, A.; Dos Santos, R. G.; Papadopoulou-Daifoti, Z.; 
Vamvakides, A.; Kolocouris, N.; Felix, R. Bioorg. Med. Chem. 2005, 13, 2791-2798. 
89 Becker, D. P.; Flynn, D. L.; Shone, R. L.; Gullikson, G. Bioorg. Med. Chem. Lett. 2004, 14, 5509-5512. 
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to the drugs amantadine, memantine and rimantadine. Figure 11 summarizes the 
mentioned polycycles. 
 
 
Fig. 11. Polycyclic scaffolds applied in different therapeutic targets by the group. 
 
The potential of these polycycles to substitute the adamantane ring in known bioactive 
compounds has been proven in multiple cases for a few targets. At the beginning of this 
thesis, three main targets had been hit with these cage structures: 
 the M2 channel of influenza A virus90,91,92,93,94  
                                                          
90 Duque, M. D.; Ma, C.; Torres, E.; Wang, J.; Naesens, L.; Juárez-Jiménez, J.; Camps, P.; Luque, F. J.; 
DeGrado, W. F.; Lamb, R. A.; Pinto, L. H.; Vázquez, S. J. Med. Chem. 2011, 54, 2646-2657. 
91 Rey-Carrizo, M.; Torres, E.; Ma, C.; Barniol-Xicota, M.; Wang, J.; Wu, Y.; Naesens, L.; Degrado, W. F.; 
Lamb, R. A.; Pinto, L. H.; Vázquez, S. J. Med. Chem. 2013, 56, 9265-9274. 
92 Torres, E.; Leiva, R.; Gazzarrini, S.; Rey-Carrizo, M.; Frigolé-Vivas, M.; Moroni, A.; Naesens, L.; Vázquez, 
S. ACS Med. Chem. Lett. 2014, 5, 831-836. 
93 Rey-Carrizo, M.; Barniol-Xicota, M.; Ma, C.; Frigolé-Vivas, M.; Torres, E.; Naesens, L.; Llabrés, S.; Juárez-
Jiménez, J.; Luque, F. J.; Degrado, W. F.; Lamb, R. A.; Pinto, L. H.; Vázquez, S. J. Med. Chem. 2014, 57, 5738-
5747. 
94  Rey-Carrizo, M.; Gazzarrini, S.; Llabrés, S.; Frigolé-Vivas, M.; Juárez-Jiménez, J.; Font-Bardia, M.; 
Naesens, L.; Moroni, A.; Luque, F. J.; Vázquez, S.Eur. J. Med. Chem. 2015, 96, 318-329. 
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 and the NMDA receptor of glutamate and the parasite Trypanosoma 
brucei.95,96,97,98 
The particular and unique shape and size of each scaffold has given new insights into 
the binding mode of the different targets, as well as a better understanding of how to 
rationally design compounds with improved activities and physicochemical properties. The 
chief idiosyncrasy of the new polycycles is the different space-filling that they provide within 
their target. The results that the group has obtained have evidenced the unsuitable fit of 
the adamantane ring into the different active sites of the considered targets.  
Probably, the research around the inhibition of the M2 channel is the most clear and 
obvious example of this inappropriate space-filling of the adamantane. Briefly, inhibition 
of M2 channel by amantadine became futile with the appearance of mutant strains, namely 
L26F, V27A and S31N.99 These amantadine-insensitive M2 channels display a different 
pore size, rendering the aminoadamantane ineffective. The design and synthesis of a wide 
array of adamantane-like scaffolds have provided molecules with greater activities against 
the wild-type than amantadine, establishing that the latter was not fully optimized inside 
the M2 channel lumen. Furthermore, enlarged derivatives have displayed interesting 
inhibitory activities against both wild-type and the V27A M2 mutant protein (Fig. 12). 
                                                          
95 Camps, P.; Duque, M. D.; Vázquez, S.; Naesens, L.; De Clercq, E.; Sureda, F. X.; López-Querol, M.; Camins, 
A.; Pallàs, M.; Prathalingam, S. R.; Kelly, J. M.; Romero, V.; Ivorra, D.; Cortés, D. Bioorg. Med. Chem. 2008, 
16, 9925-9936. 
96 Duque, M. D.; Camps, P.; Profire, L.; Montaner, S.; Vázquez, S.; Sureda, F. X.; Mallol, J.; López-Querol, 
M.; Naesens, L.; De Clercq, E.; Prathalingam, S. R.; Kelly, J. M. Bioorg. Med. Chem. 2009, 17, 3198-3206. 
97  Duque, M. D.; Camps, P.; Torres, E.; Valverde, E.; Sureda, F. X.; López-Querol, M.; Camins, A.; 
Prathalingam, S. R.; Kelly, J. M.; Vázquez, S. Bioorg. Med. Chem. 2010, 18, 46-57. 
98 Torres, E.; Duque, M. D.; López-Querol, M.; Taylor, M. C.; Naesens, L.; Ma, C.; Pinto, L. H.; Sureda, F. X.; 
Kelly, J. M.; Vázquez, S. Bioorg. Med. Chem. 2012, 20, 942-948. 
99 Gu, R.-X.; Liu, L. A.; Wang, Y.-H.; Xu, Q.; Wei, D.-Q. J. Phys. Chem. B 2013, 117, 6042-6051. 
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Fig. 12. Representation of the predicted binding mode (down, up) of amantadine (shown as 
gray sticks) and two different polycyclic scaffolds (shown as orange and yellow sticks) in the 
interior of the wild type M2 channel and its V27A variant.94 
 
With these encouraging results in hand, much is to be expected for adamantane-like 
scaffolds as modifiers or enhancers of active pharmacophores. This uncharted territory 
certainly holds great promise for the pharmaceutical industry. 
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1. NMDA receptor antagonism by adamantane-like scaffolds 
The following section will introduce the glutamatergic system and the NMDA receptor 
(NMDAR), as well as their role in the development of neurodegenerative disorders. More 
in detail, the adamantane-based compound memantine will be discussed as NMDAR 
antagonist, along with its application in the Alzheimer’s disease (AD). Finally, a review of 
the previous work of the group related to the discovery of new NMDAR antagonists will be 
covered. 
1.1 The glutamatergic neurotransmitter system  
The amino acid glutamate is the main excitatory neurotransmitter and is involved in 
almost all CNS functions, especially in cortical and hippocampal regions, hence being 
crucial for the normal functioning of the brain (Fig. 14a).100 It is released upon 
depolarization of the nerve terminals, which accumulate the glutamate in its inactive form 
glutamine.101 Once in the extracellular fluid, the glutamate exerts its signalling function by 
binding to three different ionotropic receptors, which are classified according to their 
selective, synthetic agonists (Fig. 14b): α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA), kainate, and NMDA receptors. These glutamate-gated ion channels are 
permeable to Ca2+, Na+ and/or K+ ions.102 
 
Fig. 14. Glutamic acid (a) and its analogues (b). The compounds are represented in their neutral 
form, and named accordingly. 
 
Worth to mention is that apart from the ionotropic receptors, glutamate binds also to 
metabotropic receptors, which are coupled to G-proteins and are divided into three major 
groups, I-III.103 
1.1.1 NMDA receptor and its physiological function  
 The tetrameric assembly of the NMDA receptor confers a three-dimensional channel 
that allows the influx of Ca2+ and Na+ ions and the efflux of K+ ions when opened. The 
NMDA receptor is unique among the ionotropic receptors since it needs the presence of 
two agonists for its activation; glutamate and glycine.104 Albeit these are the two essential 
                                                          
100 Watkins, J. C.; Evans, R. H. Annu. Rev. Pharmacol. Toxicol. 1981, 21, 165-204. 
101 Danbolt, N. C. Prog. Neurobiol. 2001, 65, 1-105. 
102 Traynelis, S. F.; Wollmuth, L. P.; McBain, C. J.; Menniti, F. S.; Vance, K. M.; Ogden, K. K.; Hansen, K. B.; 
Yuan, H.; Myers, S. J.; Dingledine, R. Pharmacol. Rev. 2010, 62, 405-496. 
103 Niswender, C. M.; Conn, P. J. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322. 
104 Kleckner, N. W.; Dingledine, R. Science 1988, 241, 835-837. 
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ligands, the NMDA receptor features several modulating binding sites for, for instance, 
polyamines.105 The endogenous channel blocker is the Mg2+ ion, whose binding site is 
within the pore (Fig. 15).106 The activation of the receptor is voltage-dependent, whereupon 
the Mg2+ ion is displaced. Thus, for the permeation of Ca2+ ions the two following 
conditions need to be fulfilled: activation by endogenous ligands, and depolarization of the 
neuron, for example prior activation of AMPA or kainate receptors. 
 
Fig. 15. Schematic representation of the NMDA receptor, including the topology and 
pharmacological recognition sites.107 
 The X-ray crystal structures of the intact heterodimeric and heterotetrameric NMDA 
receptor have been published recently almost simultaneously in two of the most 
distinguished journals; Science and Nature.108,109 The NMDA receptor can be formed by 
combination of three different subunits designated as GluN1, GluN2A-D, and GluN3 (also 
referred as NR1, NR2 and NR3 in former literature). However, the heterotetramers are 
chiefly composed of two copies each of GluN1 and GluN2, where glycine binds to GluN1 
and glutamate to GluN2.110 The overall structure of the NMDA receptor possesses a 
modular domain architecture, with extracellular amino-terminal domains (ATDs) and 
ligand-binding domains (LBDs), a transmembrane domain (TMD) and an intracellular 
carboxy-terminal domain (CTD) (Fig. 16). The discovery of the crystal structure of the 
NMDA receptor offers new insights into the ion channel function and the allosteric 
binding of modulators and antagonists.  
                                                          
105 Chris Parsons web page. Projects: NMDA receptors. http://www.chrisparsons.de/Chris/nmda.htm 
(accessed on 11th September 2015). Dr. Christopher Parsons is the head of the In vitro Pharmacology at 
Merz, the pharmaceutical company that developed memantine. 
106 Bleich, S.; Romer, K.; Wiltfang, J.; Kornhuber, J. Int. J. Geriatr. Psychiatry 2003, 18, S33-S40. 
107 Parsons, C. G.; Stöffler, A.; Danysz, W. Neuropharmacology 2007, 53, 699-723. 
108 Karakas, E.; Furukawa, H. Science 2014, 344, 992-997. 
109 Lee, C.-H.; Lü, W.; Michel, J. C.; Goehring, A.; Du, J.; Song, X.; Gouaux, E. Nature 2014, 511, 191-197. 
110 Karakas, E.; Regan, M. C.; Furukawa, H. Trends Biochem. Sci. 2015, 40, 328-337. 
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Fig. 16. Overall structure of the heterotetrameric GluN1a-GluN2B NMDA receptor. Protein 
Data Bank (PDB) code: 4PE5.108 
 A further significant characteristic of the NMDA receptor is its slow gating kinetics, 
which control the postsynaptic Ca2+ levels in physiological conditions. The influx of calcium 
ions triggers signal transduction cascades that control the strength of neural connectivity 
and neuroplasticity.111 The specific attributes of the activation of the NMDA receptors by 
glutamate are accepted to be an intrinsic synaptic mechanism for cognition, learning and 
memory processes.112  
1.1.2 Glutamate and related pathological states 
Normal glutamate receptor activity mediates, in large measure, physiological excitatory 
synaptic transmission in the brain, as just mentioned. The maintenance of low extracellular 
levels of glutamate is essential for controlling the CNS functions.101 However, in a variety 
of pathological conditions, including various neurodegenerative disorders, there is an 
excessive activation of the NMDA receptor by the glutamate that leads to an increase in the 
intracellular calcium concentration. This contributes to the subsequent formation of 
                                                          
111 Danysz, W.; Parsons, C. G. Br. J. Pharmacol. 2012, 167, 324-352. 
112 Butterfield, D. A.; Pocernich, C. B. CNS Drugs 2003, 17, 641-652. 
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harmful free radicals and activation of proteolytic cascades which eventually cause cell 
damage or death (Fig. 17).113,114  
 
Fig. 17. Cellular apoptotic pathways triggered by excessive NMDAR activation. a) NMDAR 
hyperactivation; b) activation  of the p38 mitogen-activated kinase (MAPK)-MEF2C pathway; c) 
toxic effects of free radicals such as ROS; and d) activation of apoptosis-inducing enzymes. 115  
This overactivation of the NMDAR is attributable to a combination of different 
occurrences. Firstly, glutamate is not cleared properly and/or can even be inappropriately 
released during acute and chronic neurodegenerative disorders.115 Secondly, under these 
conditions, neurons become depolarized in a sustained manner and the cells cannot 
maintain their ionic homeostasis. This contributes to the permanent liberation of the Mg2+ 
by NMDAR.116 The combination of some or all of these events leads to the so-called 
excitotoxicity, which is defined as cell death from the toxicity of an excessive action of 
excitatory amino acids, such as glutamate.117  
                                                          
113 Lipton, S. A.; Rosenberg, P. A. N. Engl. J. Med. 1994, 330, 613-622. 
114 Lipton, S. A.; Nicoreta, P. Cell Calcium 1998, 23, 165-171. 
115 Lipton, S. A. Nat. Rev. Drug Discov. 2006, 5, 160-170. 
116 Zeevalk, G. D.; Nicklas, W. J. J. Neurochem. 1992, 59, 1211-1220. 
117 Herrmann, N.; Li, A.; Lanctôt, K. Expert Opin. Pharmacother. 2011, 12, 787-800. 
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According to the aforementioned, disorders including Alzheimer’s, Parkinson’s and 
Huntington’s diseases, depression, schizophrenia, ischemic injuries associated with stroke, 
HIV-associated dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic 
pain and glaucoma share a final common pathway to neuronal damage and death, i.e. 
overstimulation of the NMDAR and excitotoxicity.112,118,119,120 NMDAR antagonism could 
therefore potentially be of therapeutic interest in a number of neurological disorders. 
1.2 NMDA as a therapeutic target 
The pursuit of strategies for the development of neuroprotective agents that are both 
effective and well tolerated has been bourgeoning in the last decades.121  Theoretically, any 
disorder of the CNS characterized by glutamate excitotoxicity-induced neuronal death, 
should be relieved by a treatment with NMDA receptor antagonists. In this sense, several 
NMDAR antagonists have been developed disclosing different binding modes and clinical 
tolerations.122,123,124 
1.2.1 Competitive NMDAR antagonists 
 NMDAR antagonists that compete directly with glutamate at its binding site block the 
natural neuronal communication. Since the desired therapy must re-establish the normal 
function of this excitatory neurotransmitter, the development of competitive NMDAR 
blockers was dismissed due to the appearance of intolerable side effects. A few compounds 
have been identified as competitive NMDAR antagonist, although their use has been 
reduced only to comparative studies and target validation (Fig. 18).125,126,127,128,129 
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Fig. 18. Structures of competitive NMDAR antagonists. CPP: 3-(2-carboxypiperazin-4-yl)propyl-
1-phosphonic acid; ᴅ-AP5: ᴅ -2-amino-5-phosphonopentanoate. 
 Recently, novel competitive antagonists with preference for the glycine-binding site in 
the GluN3B subunit have appeared, such as TK80 (Fig. 19).130 Their discovery have clarified 
the structural differences between the orthosteric binding site of GluN1 and GluN3. 
 
Fig. 19. Structure of a GluN3B subunit antagonist. 
1.2.2 Uncompetitive NMDAR antagonists 
Before explaining this type of antagonism, it is worth distinguishing it from the non-
competitive one. The latter refers to the allosteric binding of the antagonist whose 
availability is not affected by the concentration of agonist – in this case glutamate – whereas 
in the uncompetitive antagonism the inhibitory effect depends on prior activation of the 
receptor by the agonist.121,122  
The majority of the uncompetitive NMDAR antagonists block the ion channel by 
occluding the pore, in a similar way to the Mg2+ ion. Among them, two classes of antagonists 
are differentiated depending on their off-rate constant: 
- High-affinity blockers: these antagonists show slow ‘off’ constants and low voltage 
dependency. These features render the NMDA receptor virtually almost fully 
occupied by the blocker, which cannot be stimulated under physiological 
conditions. The inability of the receptor to recover from the inhibition is reflected 
in the appearance of side effects on the CNS, such as hallucination, agitation, 
catatonia, centrally-mediated increase in the blood pressure and anaesthesia. Indeed, 
some of these antagonists have been developed as anaesthetics only, like ketamine 
and phencyclidine (Fig. 20).131,132  
                                                          
130 Kvist, T.; Greenwood, J. R.; Hansen, K. B.; Traynelis, S. F.; Bräuner-Osborne, H. Neuropharmacology 
2013, 75, 324-336. 
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Fig. 20. High-affinity uncompetitive NMDAR antagonists. PCP: N-(1-
phenylcyclohexyl)piperidine; TCP: N-[1-(2-thienyl)cyclohexyl]piperidine. Ketamine is 
represented as racemate. 
Besides, ketamine, dizocilpine and analogues of phencyclidine were studied as 
anticonvulsants, albeit their high neurobehavioural toxicity.133,134 
 
- Low- and moderate-affinity blockers: offset kinetics are inversely related to affinity, and 
low- and moderate-affinity compounds show faster relief of blockade upon removal 
of the antagonist or upon physiological glutamatergic activation than high-affinity 
inhibitors.135 This critical characteristic allows the inhibition only in pathological 
conditions, leaving physiological functions unaltered. Moreover, low- and moderate-
affinity blockers have a better therapeutic window than high-affinity blockers.122 For 
these reasons, low- and moderate-affinity antagonists have been more successful in 
clinical studies than the ones displaying high affinity. A few number of compounds 
have been identified as low- and moderate-affinity NMDAR antagonists in the last 
decades (Fig. 21).136,137,138,139,140 Recently, propellanamines have appeared with an 
affinity similar to amantadine and memantine to the PCP binding site.141 
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Fig. 21. Structures of low- and moderate-affinity uncompetitive NMDAR antagonists. 
1.2.3 Non-competitive NMDAR antagonists 
Whilst competitive antagonists bind to the same binding site as glutamate or glycine, 
and the uncompetitive antagonists we have seen so far exert their interactions within the 
ion channel, other types of blockers owe their activity by binding to allosteric sites. This is 
the case for the compounds ifenprodil and eliprodil, whose binding site is located in the 
GluN2B subunit (Fig. 22).142,143 Ifenprodil has shown considerable attenuation of the 
neurotoxicity in animal models.144 Ifenprodil and ifenprodil-like inhibitors have a reduced 
affinity and unbind from inactivated receptors leaving transiently activated receptors 
relatively unaffected.145 Other high-affinity GluN2B ligands that modulate NMDAR 
activity have appeared recently, such as benzo[7]annulen-7-amines.146 Similar to ifenprodil, 
TCN-201 binds also to allosteric sites, but in this case to GluN2A.147 Many other allosteric 
modulators have emerged with distinct binding regions all along the ion channel.148 
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Fig. 22. NMDAR antagonists with allosteric binding mode. 
 
Inasmuch as the sole compound that has reached the market as NMDAR antagonist 
is memantine, a broader analysis will be performed thereof. 
1.3 The neuroprotector memantine 
Memantine is a low- to moderate-affinity uncompetitive NMDAR antagonist, with 
strong voltage dependency and rapid blocking and unblocking kinetics.120 Thanks to these 
particular qualities, memantine shows the effect known as partial trapping, where around 
one sixth of the ion channels remain free of the antagonist under resting conditions and 
are directly available for physiological transmission, unlike in the presence of high-affinity 
antagonists.149 Thus, memantine blocks the neurotoxicity of glutamate in pathological 
conditions without interfering with its physiological actions required for learning and 
memory (Fig. 23).111  
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Fig. 23. Schematic illustration of the glutamatergic system involving the NMDA receptor based on 
the signal-noise hypothesis. A) Normal physiological transmission of glutamate resulting in a 
sufficient signal-to-noise ratio. B) In neurodegenerative disorders, like in AD, there is a sustained 
activation of the NMDARs, which leads to the rise of the synaptic noise. The impaired detection 
of the relevant synaptic signal hampers the learning and plasticity processes. C) Synaptic plasticity 
recovery by antagonism with memantine.111 
Further studies indicate that memantine exerts its effect by binding at or near the Mg2+ 
site within the ion channel (Fig. 24).150,151 More precisely, it is believed that memantine is 
placed with the charged nitrogen close to the critical NMDAR channel asparagines. At the 
time of writing this thesis, there is any resolved structure of the NMDAR with a channel 
blocker. However, a recent computational study has revealed that the excellent affinity of 
memantine is due to the presence of hydrophobic binding pockets in the binding site for 
the two methyl groups of memantine. The removal of these two groups, leading to 
amantadine, or the addition of a third methyl group diminished affinity.152 
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Fig. 24. Images of NMDAR channel blocked by memantine, representing the likely location of 
memantine binding site. PDB code: 4TLM.109 
Memantine was approved by the EMA in 2002 and by the FDA in 2003 for the 
treatment of moderate to severe AD.153,154 AD is the most common type of dementia, and 
there is no effective cure. The American Alzheimer’s association estimated current cost to 
the healthcare system of $250 billion, and the number of patients to rise by three times by 
2050.155 In consequence, there is an urgent need to discover new therapeutics for the 
treatment of AD. Memantine has shown modest efficacy in randomized controlled trials in 
improving cognition, function, and global status, either as monotherapy or in combination 
with acetylcholinesterase inhibitors.117,156,157 Memantine has also been shown to improve 
behavioural disturbances such as agitation and aggression.158 In other dementias, 
memantine has not yet been shown to be beneficial, although an intense research is being 
conducted around that matter.159 Besides, memantine has been studied for different 
conditions, such as Huntington’s disease,160 depression,161 Down’s syndrome,162 and drug 
addiction.163  
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On account to the outstanding mechanism of action of memantine and its success in 
the treatment of moderate to severe AD, numerous research groups from industry and 
academia have developed new NMDAR antagonist that are currently in distinct stages of 
the drug discovery process.124 Related to this, the group of Dr. Santiago Vázquez Cruz has 
discovered several compounds with activity as NMDAR antagonists. The following section 
will cover them. 
1.4 Previous work of the group: new antagonists of the NMDAR 
As stated in the previous introduction, the group has a wide expertise in the synthesis 
of cage compounds and their application as bioactive molecules. In 2008, a new research 
line targeting the NMDA receptor emerged with the initial results of the polycyclic amines 
shown in Figure 25.95,96,164 
 
Fig. 25. Memantine analogues with moderate to good activity as NMDAR antagonists prepared 
by the group. R1 and R2 are H, alkyl, methylene-spaced aryl, guanidine or acetamidine. R3 is H, 
alkyl or phenyl. Functional data were obtained from primary cultures of cerebellar granule 
neurons by measuring the intracellular calcium concentration. Cells were challenged with 
glutamate NMDA (100 µM). Data shown are means of at least three separate experiments 
carried out on three different batches of cultured cells. 
Thereafter, several (1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4-benzoxonin-3-
yl)amines with general structure I, and 6,7,8,9,10,11-hexahydro-9-methyl-5,7:9,11-
dimethano-5H-benzocyclononen-7-amines with general structure II, were synthesized by Dr. 
M. D. Duque and Dr. E. Torres and their activity against NMDAR was evaluated.97,98 Table 
3 includes the more potent polycyclic compounds of the two series. 
 
 
 
                                                          
164 Duque, M. D. Ph.D. Dissertation, University of Barcelona, 2010. 
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Table 3. Benzo-homoxaadamantane, I, and benzo-homoadamantane, II, derivatives active as 
NMDAR antagonists. Functional data were obtained from primary cultures of cerebellar granule 
neurons by measuring the intracellular calcium concentration. Cells were challenged with 
glutamate NMDA (100 µM). Data shown are means ± SEM of at least three separate experiments 
carried out on three different batches of cultured cells. 
  
 
Comp. R1 R2 R3 IC50 (µM)  Comp. R1 R2 IC50 (µM) 
10 H H H 35 ± 6.8  19 H H 13.6 ± 3.4 
11 H Me H 6.0 ± 1.3  20 H Me 19.4 ± 3.3 
12 H Me Me 3.8 ± 0.3  21 Me Me 11.8 ± 3.1 
13 H Et Et 14 ± 1.1  22 -(CH2)5- 101 ± 25 
14 H -(CH2)5- 30 ± 1.0      
15 Me H H 98 ± 26      
16 Me Me Me 3.9 ± 0.4      
17 Me Et Et 7.7 ± 1.0      
18 Et H H > 200      
 
Overall, a few trends were noted: 
- Generally, tertiary amines were slightly more potent than their parent secondary 
amines, and the latter were more potent than the primary ones. For instance, 
compare 12 vs 11, and 11 vs 10. Also, small groups, such as methyl group, were 
more tolerated than large groups; see compound 12 vs 13, and compound 16 vs 17. 
- Furthermore, 8-oxapolycyclic primary amines were less potent than their 
corresponding 8-carba analogues. For example, compound 19 showed a 7-fold 
increase in potency compared to its oxapolycyclic analogue 15.  
- Of note, while memantine (IC50 = 1.5 ± 0.1 µM), which features two methyl groups 
in its structure, is much more potent than amantadine (IC50 = 92 ± 29 µM), 
compound 10 was more active than its methyl analogue, 15.  
- The introduction of an oxygen atom was deleterious for the activity, as well as 
bearing an alkyl group at the bridgehead position (Fig. 26). 
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Fig. 26. Observed trend in the benzopolycyclic scaffolds. The increase in potency goes from left 
to right. 
 
  
 
 
 
 
 
 
 
 
 
 
Objetives 
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Bearing in mind what has been mentioned, it seems logical that derivative 23 which 
combines the best findings of our previously studies on benzo-adamantanic amines, that is 
a hydrogen atom at C-9 position and a methylene group in C-8 position (Fig. 27), may 
display a better inhibitory activity against the NMDA receptor than its predecessors. 
 
Fig. 27. Previous results suggest compound 23 as a potential NMDAR antagonist.  
Considering this fact, we established the following goals of this chapter: 
1. Synthesis and pharmacological evaluation of compound 23 and its 
corresponding methylated tertiary amine 24 (Fig. 28). The preparation of the 
secondary amine was discarded due to the preceding results, where tertiary 
amines proved to be the most potent derivatives. With this objective in mind, 
we aimed to confirm our hypothesis that both compounds would show higher 
potencies compared to previous derivatives. 
 
 
 
Fig. 28. Amines to synthesize as potential NMDAR antagonists. 
2. Exploration of a structure-activity relationship (SAR) around the C-9 position, 
with the introduction of different groups such as halogens or a hydroxyl group 
(Fig. 29). This study would include the preparation of 5,6,8,9,10,11-hexahydro-
7H-5,9:7,11-dimethanobenzo[9]annulen-7-amines with general structure III, as 
well as their corresponding tertiary amines. We aimed to find the effect of the 
different substituents at the C-9 position on the inhibitory activity. 
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Fig. 29. Amines with general structure III. 
 
  
 
 
 
 
 
 
 
 
 
 
Results & Discussion 
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1. Effect of the C-9 substitution in new benzopolycyclic compounds  
1.1 Synthesis of the C9-demethylated compound, 23 
 
According to the previous work of the group related to the synthesis of benzopolycyclic 
cage amines, a benzo-homoadamantane with a hydrogen atom at the C-9 position would 
fulfil the gap existing between the former families. Hence, following the SAR studies we 
envisaged compound 23 as a potential antagonist of the NMDAR with hypothetical 
improved potency (Fig. 30). 
 
Fig. 30. Compound to prepare from rational design.  
The synthesis was designed based on prior synthetic routes described by our group. 
We conceived enone 25 as the starting point for the preparation of compound 23 (Scheme 
2). This enone is a homoconjugated system that allows the 1,4-like addition of nucleophiles 
to the alkene, whereupon a transannular cyclization occurs with the attack to the carbonyl. 
This intramolecular through-space interaction between the two π-orbitals of 25 has been 
exploited in many transformations, such as in the intramolecular cyclization through a 
Ritter transformation, as it will be discussed later on.165,166 
 
 
Scheme 2. Enone 25 as a precursor of amine 23. 
In this way, we decided to prepare enone 25 following the procedure firstly reported 
by Föhlisch et al.167,168 and widely employed by our group. Starting from commercially 
available o-phthaldialdehyde and dimethyl-1,3-acetonedicarboxylate, a Weiss-Cook 
condensation took place affording  tetraester intermediate 26. Taking advantage of the 
keto-enol tautomerism of dimethyl-1,3-acetonedicarboxylate, the reaction proceeded 
through a double aldol condensation and subsequent dehydration, under basic catalysis. 
                                                          
165 Amini; Bishop, R. Aust. J. Chem. 1983, 36, 2465-2472. 
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168 Föhlisch, B.; Dukek, U.; Graessle, I.; Novotny, B.; Schupp, E.; Schwaiger, G.; Widmann, E. Justus Liebigs 
Ann. Chem. 1973, 1839-1850. 
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The second equivalent of the β-keto ester underwent a double Michael addition to the α,β-
unsaturated ketone leading to the dienol-tetraester (Scheme 3).  
 
Scheme 3. Weiss-Cook condensation of o-phthaldialdehyde and two equivalents of dimethyl-1,3-
acetondicarboxylate. 
Acid hydrolysis of the ester groups rendered β-keto acids which decarboxylated 
spontaneously to furnish a mixture of diketone 27 and its hydrate 28 in a 1:3 ratio (Scheme 
4). Of note, the amount of the hydrate increased over time because of the atmospheric 
moisture, and even in a short period of time the equilibrium was utterly shifted to the 
hydrate. In order to procure the pure ketone, the mixture was refluxed in toluene using a 
Dean-Stark apparatus to finally provide pure diketone 27 in 64% overall yield.169 
 
Scheme 4. Acid hydrolysis and decarboxylation of tetraester 26. 
                                                          
169 The previous method used for dehydration of the hydrate was to sublimate the mixture at 160 ºC and 
0.5 Torr. 
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The next step was a Wittig reaction of a single ketone to form enone 25. This 
conversion was inspired from the Corey procedure for the Wittig reaction,170,171 and needed 
sodium hydride in anhydrous DMSO and methyltriphenylphosphonium iodide as the ylide 
counterpart. The double Wittig transformation of diketone 27 to form the corresponding 
diene 29 was earlier optimized by Dr. E. Torres, although using a large excess (8 equivalents) 
of NaH and of the Wittig reagent.172 We believed that the reaction was poorly efficient due 
to the water content of the self-prepared anhydrous DMSO. Based on that, we aimed to 
optimize the mono-Wittig reaction adjusting the equivalents of both reagents and using a 
fresh bottle of anhydrous DMSO purchased from a chemical supplier. A short optimization 
process was performed (Table 4). Worth to note is the formation of diene 29 with only 2.1 
equivalents of each reagent (entry 3), compared with the 8 equivalents needed in the 
previous procedure. 
Table 4. Optimization process for the preparation of enone 25. Yields are of isolated products. 
  
 
 
 
Entry Ph3PCH3I (eq.) NaH (eq.) 25 (% yield) 29 (% yield)  
1 1.1 1.1 63 -  
2 1.25 1.25 84 -  
3 2.1 2.1 - 80  
 
In this transformation, a mixture of NaH in anhydrous DMSO was heated to 75 ºC 
for 45 minutes so as to form the conjugate base of DMSO, which is the actual species that 
deprotonated the phosphonium salt upon its addition in order to obtain the ylide. Twenty 
minutes after, a solution of diketone 27 in anhydrous DMSO was added to the mixture 
and heated to 75 ºC overnight. The best conditions were the ones from entry 2 in table 4, 
with 1.25 equivalents of the base and of the ylide that furnished desired enone 25 in 84% 
yield.  
Apart from the reaction optimization, an easy and efficient purification process was 
required in order to remove the phosphine oxide, which in many cases can be tedious. 
With the aim of avoiding the purification by column chromatography, we came up with a 
handy method by means of packing the impure mixture with silica gel followed by 
extraction with an appropriate mixture of petroleum ether and diethyl ether.  
                                                          
170 Greenwald, R.; Chaykovsky, M.; Corey, E. J. J. Org. Chem. 1963, 28, 1128-1129. 
171 Coxon, J. M.; Maclagan, R. G. A. R.; McDonald, D. Q.; Steel, P. J. J. Org. Chem. 1991, 56, 2542-2549. 
172 Torres, E. Ph.D. Dissertation, University of Barcelona, 2013. 
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Noteworthy, all the reactions so far were carried out in a multigram scale.    
With pure enone 25 in hand, we envisaged the preparation of amine 23 from alcohol 
30 (Scheme 5). A bridgehead alcohol can be replaced by an amino group via different 
procedures, such as the already mentioned Ritter reaction,173 the metal-catalysed addition 
of ammonia to alcohols,174,175 or the nucleophilic substitution prior functional group 
interconversion to a better leaving group, like a halide or a mesylate group. 
Inspired by the work of Itoh et al.,176 where 1-adamantanol was obtained from 7-
methylenebicyclo[3.3.1]nonan-3-one through an electroreductive transannular reaction, 
and by the boron chemistry for the 1,4-enone reduction,177 a 1,4-conjugated-like reduction 
of enone 25 would afford desired alcohol 30. 
 
Scheme 5. Plausible formation of alcohol 30 from enone 25 by a 1,4-conjugated-like reduction. 
Many hydrides have been applied as reductive agents in the 1,4-reduction of α,β-
unsaturated ketones. Especially, alkali metal trialkylborohydride reagents are excellent 
choices for enone reduction that have been proved to give very high regio- and 
stereoselectivities.178 Organoboranes such as lithium tri-sec-butylborohydride (L-selectride®) 
or lithium n-butylborohydride have been largely employed in multiple reductions, although 
                                                          
173 Fokin, A. A.; Merz, A.; Fokina, N. A.; Schwertfeger, H.; Liu, S. L.; Dahl, J. E. P.; Carlson, R. K. M.; Schreiner, 
P. R. Synthesis 2009, 6, 909-912. 
174 Shimizu, K.-I.; Kanno, S.; Kon, K.; Hakim Siddiki, S. M. A.; Tanaka, H.; Sakata, Y. Catal. Today 2014, 232, 
134-138. 
175 Sigl, M.; Heidemann, T. Process for preparing a primary amine with a tertiary alpha carbon atom by 
reacting a tertiary alcohol with ammonia. WO 2009/053275 A1. 
176 Itoh, H.; Kato, I.; Unoura, K.; Senda, Y. Bull. Chem. Soc. Jpn. 2001, 74, 339-345. 
177 Burkhardt, E. R.; Matos, K. Chem. Rev. 2006, 106, 2617-2650. 
178 Fortunato, J. M.; Ganem, B. J. Org. Chem. 1976, 41, 2194-2200. 
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1,2- or 1,4-hydride additions are mainly controlled by substrate structure.179,180,181 Hence, 
we treated enone 25 with L-selectride® in anhydrous THF with or without triethylamine 
(TEA), and under short or longer reaction times, without success under any condition 
(Table 5).  
Table 5. Attempt to prepare alcohol 30 through reduction with lithium tri-sec-butylborohydride. 
  
 
Entry TEA Temp. (ºC) Time (h) 30 (% yield)  
1  -78 0.5 -  
2  25 18 -  
 
On the other hand, sodium hydrogen telluride (NaHTe) was successfully employed in 
the selective 1,4-reduction of α,β-unsaturated carbonyl compounds.182,183,184 However, the 
requirement of its in situ formation from telluride powder and sodium borohydride was 
reason enough to preclude its use.  
Then, we explored the 1,4-conjugated-like reduction of enone 25 with other hydride 
sources such as sodium borohydride, which has been proved as an efficient reducing agent 
in several conjugated systems.185,186 Even though in most cases the 1,2-reduction prevails, 
we wondered if in our homoconjugated system the 1,4-reduction would overcome  the 1,2-
reduction (Scheme 6). Unfortunately, no expected compound was recovered but the 1,2-
reduced product 31. 
 
Scheme 6. Reduction of the ketone after treatment of enone 25 with NaBH4. 
                                                          
179 Martin, H. J.; Drescher, M.; Mulzer, J. Angew. Chem. Int. Ed. 2000, 39, 581-583. 
180 White, D. R. 6’-Alkylspectinomycins. US 4532336 A. 
181 Kim, S.; Choon Moon, Y.; Han Ahn, K. J. Org. Chem. 1982, 47, 3311-3315. 
182 Yamashita, M.; Kato, Y.; Suemitsu, R. Chem. Lett. 1980, 847-848. 
183 Barton, D. H. R.; Bohé, L.; Lusinchi, X. Tetrahedron 1990, 46, 5273-5284. 
184 Yamashita, M.; Tanaka, Y.; Arita, A.; Nishida, M. J. Org. Chem. 1994, 59, 3500-3502. 
185 Marchand, A. P.; LaRoe, W. D.; Sharma, G. V. M.; Suri, S. C.; Reddy, D. S. J. Org. Chem. 1986, 51, 1622-
1625. 
186 Jackson, W. R.; Zurqiyar, A. J. Chem. Soc. 1965, 5280-5287. 
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Searching for an alternative approach for the preparation of alcohol 30, different 
publications reached our hands reporting the catalytic hydrogenation at atmospheric 
pressure of 7-methylenebicyclo[3.3.1]nonan-3-one to afford 1-adamantanol in good 
yields.187,188 To our disappointment, when this conditions were undertaken with enone 25, 
we observed the double bond migration of enone 25 to furnish ketone 32, as well as the 
dihydroxylated compound 33 (Table 6). The formation of the latter can be reasoned via 
the addition of a water molecule, coming from the moisture in the Pd/C, to the conjugated-
like enone. The ratio of the resulting mixture depended on the reaction time and on the 
equivalents of the palladium catalyst. 
Table 6. Catalytic hydrogenation of enone 25 to provide different mixtures of 32 and 33. 
 
 
 
Entry Pd/C 
(eq.) 
Time (h) Solvent 25 (% yield) 32 (% yield) 33 (% yield)  
1 0.1 64 DCM 43 - 21  
2 0.1 64 Toluene 60 - 30  
3 0.2 72 Toluene - 71 -  
4 0.1 120 Toluene 50 - 50  
5 0.4 64 Toluene 22 - 58  
6 1 64 Toluene - 24 15  
    
All these failures did not discourage us to persist in the quest for amine 23, so we 
pursued its synthesis through a different approach. Instead of a conjugated-like addition to 
the well-known enone, we aimed to proceed by means of functional group replacement.  
To do so, the synthesis continued with a Prins-Ritter transannular cyclization with 
chloroacetonitrile in the presence of sulphuric acid from the same enone 25.165,166,189 The 
reaction mechanism for the formation of chloroacetamide 34 is displayed in scheme 7. The 
reaction involves the protonation of the carbonyl group followed by the attack of the π-
electrons of the alkene (Prins reaction) to generate a stable carbenium ion. The nitrile’s 
nitrogen then adds to the carbocation to give a nitrilium ion intermediate, which undergoes 
hydrolysis upon addition of water during the work-up affording the desired 
chloroacetamide (Ritter reaction). 
                                                          
187 Ishiyama, J.; Senda, Y.; Imaizumi, S. Chem . Lett. 1983, 771-774. 
188 Ishiyama, J.; Senda, Y.; Imaizumi, S. Chem . Lett. 1983, 1243-1244. 
189 Bishop, R. Ritter-Type Reactions, Comprehensive Organic Synthesis II; Elsevier Ltd., 2014.  
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Scheme 7. Mechanism of the Prins-Ritter transannulation. 
Other preparations of similar chloroacetamides entailed the combination of glacial 
acetic acid and sulphuric acid.98,190 The first attempts of the procedure led to the formation 
of the corresponding acetate 35, whose formation can be explained by the protonation of 
the hydroxyl group of 34, the formation of a stable carbenium ion with the loss of a 
molecule of water, and finally the nucleophilic addition of the acetate (Scheme 8). In the 
absence of acetic acid, the conjugate base of sulphuric acid is not nucleophilic enough to 
add to the carbocation. Hence, the hydroxyl group remains unaltered. 
                                                          
190 Schwertfeger, H.; Würtele, C.; Sefarin, M.; Hausmann, H.; Carlson, R. M. K.; Dahl, J. E. P.; Schreiner, P. 
R. J. Org. Chem. 2008, 73, 7789-7792. 
 
56   CHAPTER 1: NMDA receptor antagonism 
 
Scheme 8. Addition of an acetate to the carbocation generated during the course of the Prins-
Ritter transformation. 
Once chloroacetamide 34 was prepared in reasonable yield (49 %), we sought the 
known Barton-McCombie deoxygenation for the preparation of the chloroacetamide 36. 
This type of transformation consists in the radical deoxygenation of previously-modified 
alcohols.191,192,193 First, the alcohol needs to be temporally converted to an O-
alkylthiocarbonyl derivative, whose sulphur atom reacts with a radical M˙capable of 
forming a stable bond with it. The new bond fragments into a carbonyl compound and an 
alkyl radical, followed by a hydrogen atom abstraction to afford the reduced product 
(Scheme 9). The driving force of the reaction is the energy gained by the transition from 
the C=S to a C=O bond (C=S bond: 138 kcal mol-1, C=O bond: 178 kcal mol-1).194 On the 
basis of thermochemical data, trialkyltin hydrides seemed to be particularly suitable because 
of their exceptional behaviour as hydrogen-donors and the high stability of the Sn-S bond 
(Sn-S bond: 110 kcal mol-1). Hence, the reaction mechanism normally implies a radical 
initiator, like azobisisobutyronitrile (AIBN), to initiate the radical process. However, due 
to the inherent toxicity of tin hydrides, the development of tin-free Barton-McCombie 
deoxygenations has been rising since its discovery.195,196,197 Regarding O-alkylthiocarbonyl 
compounds, secondary and in a lesser extent primary and tertiary alcohols, are usually 
                                                          
191 Barton, D. H. R.; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1975, 1, 1574-1585. 
192 McCombie, S. W.; Motherwell, W. B.; Tozer, M. J. Org. React. 2012, 77, 161-591. 
193 Zard, S. Z. Xanthates and Related Derivatives as Radical Precursors, in Encyclopedia of Radicals in 
Chemistry, Biology and Materials; John Wiley & Sons, Ltd., Chichester, UK, 2012. 
194 Kerr, J. A. Chem. Rev. 1966, 66, 465-500. 
195 Chenneberg, L.; Baralle, A.; Daniel, M.; Fensterbank, L.; Goddard, J.-P.; Ollivier, C. Adv. Synth. Catal. 
2014, 356, 2756-2762. 
196 Chatgilialoglu, C.; Ferreri, C. Res. Chem. Intermed. 1993, 19, 755-775. 
197 Schummer, D.; Hoefle, G. Synlett 1990, 11, 705-706. 
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transformed to thiocarbonates, xanthates and thioesters, whose reactivity in Barton-
McCombie deoxygenations has been attested several times.  
 
Scheme 9. Mechanism of the radical Barton-McCombie deoxygenation. 
Encouraged by the literature precedents, we decided to convert 34 into 
phenylthiocarbonate 37 by applying the conditions reported in the literature (Table 7). 
Treatment of 34 with O-phenyl chlorothionoformate with no base added did not yield the 
expected product.198 Neither did the reaction with addition of a base such as NaH, pyridine 
or 4-dimethylaminopyridine (DMAP).199,200,201,202,203 In all the cases the starting material was 
recovered.  
 
 
 
 
 
 
 
                                                          
198 Xu, J.; Yadan, J. C. Tetrahedron Lett. 1996, 37, 2421-2424. 
199 Padwa, A.; Harring, S. R.; Semones, M. A. J. Org. Chem. 1998, 63, 44-54. 
200 Marino, J. P.; Osterhout, M. H.; Padwa, A. J. Org. Chem. 1995, 60, 2704-2713. 
201 Boussaguet, P.; Delmond, B.; Dumartin, G.; Pereyre, M. Tetrahedron Lett. 2000, 41, 3377-3380. 
202 Kaneko, S.; Watanabe, T.; Oda, K.; Mohan, R.; Schweiger, E. J.; Martin, R. Fused-ring pyrimidin-4(3H)-
one derivatives, processes for the preparation and uses thereof. WO 03/106435 A1. 
203 Luzzio, F. A.; Fitch, R. W. J. Org. Chem. 1999, 64, 5485-5493. 
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Table 7. No reaction observed with the treatment of 34 with O-phenyl chlorothionoformate. 
 
 
 
Entry O-phenyl 
chlorothionoformate (eq.) 
Base Solvent Temp. 
(ºC) 
Time 
(h) 
37 (% 
yield) 
 
1 1.2 DMAP 
(1.5 eq.) 
DCM 25 21 -  
2 1.1 NaH      
(3 eq.) 
THF 25 3 -  
3 2 NaH   
(4.4 eq.) 
THF reflux 21 -  
4 1.5 Pyridine 
(excess) 
DCM 25 24 -  
5 2 - THF From           
-70 to 25 
20 -  
 
In accordance with radical deoxygenations, Markó and co-workers published a 
procedure using toluates as simple and versatile radical precursors for the reduction of 
alcohols to alkanes.204 We contemplated hence the preparation of the corresponding 
toluate of 34 for its subsequent treatment with samarium(II) iodide and 
hexamethylphosphoramide (HMPA) (Table 8). The two different attempts for the 
formation of 38 did not afford the toluate and the starting material was again recovered. 
Thus, this approximation was abandoned. 
 
 
 
 
                                                          
204 Lam, K.; Markó, I. E. Org. Lett. 2008, 10, 2773-2776. 
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Table 8. Attempted reactions of 34 with toluolyl chloride and a base. 
 
 
Entry Base  Solvent 38 (% yield) 
1 TEA (2 eq.) DCM - 
2 NaH (2 eq.) THF - 
 
A similar procedure appeared in 2001 dealing with the radical deoxygenation of 
alcohols via their trifluoroacetate derivatives with diphenylsilane and di-tert-butyl peroxide 
(DTBP).205 In this case, the hydroxyl group of 34 needed to be turned into a trifluoroacetate 
group (Scheme 10). Two different pathways were essayed: 1) formation of a carbocation 
with conc. H2SO4 and ensuing addition of trifluoroacetate; or 2) deprotonation of the 
alcohol and nucleophilic attack to trifluoroacetic anhydride (TFAA). Unfortunately, none 
of the tested conditions yielded the desired product 39 nor the starting material but only a 
mixture of unknown compounds. Specifically, we observed by 1H-NMR the lack of proton 
signals for the methylene in C-8 position. This fact can be explained through a putative 
retro-Ritter reaction, although a mechanism cannot be postulated without having identified 
the product. 
                                                          
205 Jang, D. O.; Kim, J.; Cho, D. H.; Chung, C.-M. Tetrahedron Lett. 2001, 42, 1073-1075. 
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Scheme 10. Attempt to prepare compound 36 through a radical deoxygenation from a 
trifluoroacetate group. 
This large list of negative results did not dishearten us in our pursuit of deoxygenated 
compound 36. Further bibliographic search led us to the widely applied ionic 
deoxygenation triggered by organosilicon hydrides, which are used as a source of ionic 
hydride thanks to the presence of at least one Si-H bond.206 For alcohols that can form a 
sufficiently stabilized carbenium ion, treatment with a Brønsted or Lewis acid in the 
presence of triethylsilane or similar leads to their reduction. Tertiary alcohols are more 
effective in the transformation into the corresponding alkanes than secondary and primary 
alcohols. The mechanism of reaction entails the coordination of the oxygen atom to the 
acid, formation of a carbenium ion prior addition of the hydride. Taking this into account, 
compound 36 could be prepared from hydroxylated compound 34 in just one step by 
addition of Et3SiH and an acid.207,208,209,210 Different conditions were tested, using 
trifluoroacetic acid (TFA) or boron trifluoride etherate as Brønsted or Lewis acids 
respectively, and changing the equivalents of both partners as well as the reaction time 
(Table  9). Regrettably, even the best conditions, i.e. a large excess of Et3SiH and of 
BF3·Et2O, in anhydrous DCM at 75 ºC for 3 days, only gave a mixture of the intended 
product, unreacted starting material and unidentified products.  
 
 
                                                          
206 Larson, G. L.; Fry, J. L. Ionic and organometallic-catalyzed organosilane reductions, in Organic 
Reactions; John Wiley & Sons, Ltd., Chichester, UK, 2008. 
207 Gevorgyan, V.; Rubin, M.; Benson, S.; Liu, J.-X.; Yamamoto, Y. J. Org. Chem. 2000, 65, 6179-6186. 
208 Duddeck, H.; Rosenbaum, D. J. Org. Chem. 1991, 56, 1707-1713. 
209 Banide, E. V.; Molloy, B. C.; Ortin, Y.; Müller-Bunz, H.; McGlinchey, M. J. Eur. J. Org. Chem. 2007, 2611-
2622. 
210 Ito, M.; Konno, F.; Kunamoto, T.; Suzuki, N.; Kawahata, M.; Yamaguchi, K.; Ishikawa, T. Tetrahedron 
2011, 67, 8041-8049. 
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Table 9. Failed ionic hydrogenation of alcohol 34. 
 
 
 
Entry Et3SiH (eq.) Acid 
Temp. 
(ºC) 
Time (h) 34 (% 
yield) 
36 (% 
yield) 
1 excess TFA (excess) 25 1 Quant. - 
2 4 BF3·Et2O (1 eq.) 25 1 86 - 
3 excess BF3·Et2O (excess) 25 18 Quant. - 
4 4 BF3·Et2O (1 eq.) reflux 18 Quant. - 
5 excess BF3·Et2O (excess) reflux 6 Quant. - 
6 excess TFA (excess) reflux 15 Quant. - 
7 excess TFA (excess) reflux 24 40 - 
8 excess BF3·Et2O (excess) reflux 24 32 25 
9 excess BF3·Et2O (excess) reflux 48 26 45 
10 excess BF3·Et2O (excess) reflux 72 16 50 
    
Considering the high reactivity of bridgehead hydroxyl groups in traditional 
reductions, the difficulty of transforming alcohol 34 can be reasoned by the presence of the 
chloroacetamide in the molecule, which may facilitate the retro-Ritter reaction on one side, 
and possesses a high reactive chlorine atom on the other.  
In spite of all the efforts in performing Barton-McCombie and ionic deoxygenation 
reactions, we decided to tackle the synthesis of amine 23 by applying a different approach. 
Exploring alternative methodologies, dehalogenation seemed at first glance a feasible way 
to remove a tertiary alcohol through its prior interconversion to a halide. Different 
publications have appeared reporting the dechlorination of adamantane groups through 
diverse procedures, such as the use of a hydride source (e.g. lithium aluminium 
hydride),211,212 the radical dehalogenation with phenylsilane,213 or the photoinduced 
reduction of organic halides with samarium(II) iodide.214  
On that account, we needed to transform the hydroxyl group to a chloride. Alkyl 
chlorides are most easily prepared by reaction with thionyl chloride or phosphorous 
                                                          
211 Ashby, E. C.; Deshpande, A. K. J. Org. Chem. 1994, 59, 3798-3805. 
212 Banister, S. D.; Yoo, D. T.; Chua, S. W.; Cui, J.; Mach, R. H.; Kassiou, M. Bioorg. Med. Chem. Lett. 2011, 
21, 5289-5292. 
213 Jang, D. O. Synth. Commun. 1997, 27, 1023-1027. 
214 Sumino, Y.; Harato, N.; Tomisaka, Y.; Ogawa, A. Tetrahedron 2003, 59, 10499-10508. 
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trichloride, among other reagents. Hence, we treated chloroacetamide 34 with neat thionyl 
chloride for one hour under reflux, giving desired chloride 40 in 56% yield after 
purification by column chromatography (Scheme 11). 
 
Scheme 11. Replacement of the hydroxyl group by a chloride. 
Afterwards, reaction of chloro compound 40 with LiAlH4 in anhydrous dioxane for 18 
hours at reflux afforded a complex mixture of products. By gas chromatography-mass 
spectroscopy, the corresponding ene-imine product 41 was observed, whose formation can 
be explained by the attack of the hydride to the carbonyl group, which expelled the nitrogen 
atom generating an electron cascade movement with the final release of the chloride 
(Scheme 12). 
 
Scheme 12. Formation of ene-imine 41 after treatment of 40 with LiAlH4. 
Regardless of the unfortunate result of the aforementioned reaction, we wanted to 
further explore the potential of chloro derivative 40 as a precursor of unsubstituted scaffold 
in amine 23. Among all the reagents for the formation of radicals from halides, 
samarium(II) iodide is possible the most versatile and widely used after tributyltin 
hydride.215 In 2003, a publication came out describing the radical dechlorination of 1-
chloroadamantane using SmI2 in anhydrous THF under irradiation with a tungsten lamp 
to afford the adamantane ring in 86% yield.214 But because there is a potential coordination 
of samarium with the carboxyl group in a Lewis acid manner, we determined to hydrolyse 
the amide group prior to the radical dehalogenation in order to avoid side reactions. A 
previous exploration of the aqueous hydrolysis of related compounds gave either low yields 
in acid media, or high yields at the expense of drastic basic conditions.98 Searching for a 
substitutive method, it was found that the chloroacetyl group could be cleaved by thiourea 
in an efficient way for the synthesis of tert-alkylamines.216 Applying these conditions to our 
scaffold, chloroacetamide 40 was transformed into chloro-amine 42 in 73% yield (Scheme 
13). The deprotection mechanism entails the nucleophilic substitution of the chloride by 
the attack of the sulphur atom, followed by the formation of a thiazolidine ring as a by-
                                                          
215 Rowlands, G. J. Tetrahedron 2009, 65, 8603-8655. 
216 Jirgensons, A.; Kauss, V.; Kalvinsh, I.; Gold, M. R. Synthesis 2000, 12, 1709-1712. 
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product. Subsequent elimination of the amine provided compound 42 and 
pseudothiohydantoin as a by-product. The reaction is also amenable in DCM. 
 
Scheme 13. Deprotection of chloroacetamide with thiourea. The proton migrations have been 
obviated for the sake of clarity. 
Once deprotected, chloro-amine 42 was reacted with SmI2 and irradiated with a 100 
W lamp until the mixture shifted from dark blue to yellow.217 To our surprise, desired 
amine 23 was recovered along with the starting material 42 in an optimized 3:1 ratio 
(Scheme 14). Regrettably, the mixture was inseparable through column chromatography. 
 
Scheme 14. Partial dehalogenation of chloro-amine 42 with samarium(II) iodide. 
Based on the partial success of the previous reaction, we believed that the use of 
organotin reagents would facilitate the radical dehalogenation of our scaffold because of 
their proven reactivity and versatility.192,215,218,219 In addition, it is well-known that the bond 
dissociation enthalpy of the halogen strongly determines the dehalogenation rate.  
Accordingly, bond enthalpies decrease as we move down the periodic table, i.e. Cl > Br > 
I. So, instead of working with the chloro derivative, we decided to replace the hydroxyl 
group of 34 by a bromide following the aforementioned procedure but in this case with 
thionyl bromide (Scheme 15). Albeit the excellence conversion of the alcohol, we observed 
                                                          
217 The blue colour is distinctive of samarium(II), whereas the yellow colour of samarium(III). 
218 Jasch, H. Heinrich, M. R. Tin hydrides and functional group transformations, in Encyclopedia of Radicals 
in Chemistry, Biology and Materials; John Wiley & Sons, Ltd., Chichester, UK, 2012. 
219 Renaud, P.; Sibi, M. P. Radicals in Organic Synthesis Vol. 1; Wiley-VCH, Weinheim, Germany, 2001. 
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by gas chromatography-mass spectroscopy and 1H-NMR, the concomitant formation of  
bromoacetamide 44 by nucleophilic substitution of the chloro atom, as well as, to a lesser 
degree, the bromination of the aromatic ring as either chloro- or bromoacetamide, 45, 
whose rate of formation varied from one reaction to another. 
 
Scheme 15. Functional group interconversion of a hydroxyl group to a bromide. 
In order to avoid the chloro-bromo exchange of the acetamide, we ended up moving 
one-step forward and deprotecting chloroacetamide 34 to obtain the corresponding 
aminoalcohol 46. In this way, applying the previous conditions with thiourea and glacial 
acetic acid in absolute ethanol, primary amine 46 was prepared in quantitative yield 
(Scheme 16a). Afterwards, transformation of 46 to the bromo derivative with thionyl 
bromide in toluene afforded the desired halide 47 in 79% yield (Scheme 16b). 
 
Scheme 16. Thiourea-mediated deprotection of chloroacetamide 34, followed by bromination 
with thionyl bromide. 
Surprisingly, purification of bromo-amine 47 either by column chromatography or by 
an acid-base extraction led to the formation of enone 25. This fact can be explained through 
the elimination of the bromide pushed by the amino group. Final hydrolysis of the 
intermediate imine provides the former enone (Scheme 17). The formation of an enone 
from a cage-annulated fragmentation has been described, using in these cases different 
bases as the promoter of the ring-opening.220,221 Regardless of the vain efforts put on the 
purification of compound 47, we continued with the synthetic route without any 
purification. On the other hand, amine 47 was found to be bench-top unstable in a short 
period of time, so it had to be used right after its preparation in the next step. 
                                                          
220 Kumar, K.; Tepper, R. J.; Zeng, Y.; Zimmt, M. B. J. Org. Chem. 1995, 60, 4051-4066. 
221 Marchand, A. P.; Namboothiri, I. N. N. Heterocycles 2000, 52, 451-457. 
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Scheme 17. Formation of enone 25 from bromo-amine 47. 
The impure and unstable amine 47 was subjected to radical debromination conditions 
with tri-n-butyltin hydride and AIBN as the radical initiator (Scheme 18). To our delight, 
amine 23 was finally secured as the hydrochloride salt after its purification by column 
chromatography, despite of the low overall yield (12%). The mechanism of the reaction 
entails similar pathways to those shown in scheme 9, although the driving force in this case 
is provided by the formation of a C-H bond at the expense of a Sn-H (C-H bond: 80 kcal 
mol-1, Sn-H bond: 64 kcal mol-1), and then a Sn-Br at the expense of a C-Br (Sn-Br bond: 
81 kcal mol-1, C-Br bond: 67 kcal mol.1). 
 
Scheme 18. Synthesis of amine 23 via radical dehalogenation. 
Table 10 recapitulates the attempts for the synthesis of unsubstituted amine 23. 
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Table 10. Summary of the different routes applied for the preparation of amine 23. 
  
 
Entry Starting 
 material 
R1  R2  Reagents Product (% yield)  
1 25 - - L-Selectride -  
2 25 - - NaBH4 1,2-addition product  
3 25 - - H2, Pd/C Isomerization + diol  
4 34 OH Chloroacetamide 
O-phenyl 
chlorothiono-
formate 
34  
5 34 OH Chloroacetamide Toluolyl chloride 34  
6 34 OH Chloroacetamide TFA, conc. H2SO4 Unknown products  
7 34 OH Chloroacetamide TFAA, TEA Unknown products  
8 34 OH Chloroacetamide 
Et3SiH, TFA or 
BF3·Et2O 
Complex mixture  
9 40 Cl Chloroacetamide LiAlH4 Ene-imine  
10 42 Cl NH2 SmI2, hν 23 : 42 (3:1 ratio)  
11 47 Br NH2 Bu3SnH, AIBN 23 (12%)  
 
Once the desired amine 23 was prepared in reasonable amounts, we wished to appraise 
the effect on the alkylation on the amine group. As already mentioned in the introduction, 
the antagonist activity increased as the amine went from primary to secondary, and 
therefrom to tertiary. Moreover, it was observed that it was preferably to incorporate small 
alkyl groups, such as the methyl group. Taking into account the aforementioned, we settled 
the synthesis of dimethylated amine 24 following the described procedures.98 We proceeded 
through a reductive alkylation of amine 23 with formaldehyde and sodium 
cyanoborohydride (Scheme 19). The latter was chosen as hydride donor because its noted 
selectivity for the reduction of the formed iminium ion over the ketone or aldehyde, which 
remains unaltered and free to react with the amine.222,223 This phenomenon is due to the 
electron-withdrawing effect of the cyano moiety that stabilizes the negative charge on the 
boron, thus rendering it less reactive and more inclined to reduce the more unstable 
iminium ion than the carbonyl. Hence, this transformation can be performed in a one-pot 
                                                          
222 Borch, R. F.; Bernstein, M. D.; Durst, H. D. J. Am. Chem. Soc. 1971, 93, 2897-2904. 
223 Lane, C. F. Synthesis 1975, 1975, 135-146. 
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fashion, where the amine is mixed with the desired ketone or aldehyde in the presence of 
NaBH3CN in mild acidic conditions. 
 
 
Scheme 19. Reductive alkylation of amine 23 and schematic representation of the kinetics of 
sodium cyanoborohydride-mediated reduction of imines versus ketones or aldehydes. 
With compound 24 we expected an increase in the potency compared with primary 
amine 23, in agreement with the observed trend in former families of compounds. 
 
1.2 Exploration of the C-9 substitution of the benzo-homoadamantane scaffold 
As discussed earlier, in relation with the metabolism of the adamantane group, a 
bridgehead hydroxylation is favoured over the secondary carbon positions, producing 
water-soluble 1-hydroxyadamantane derivatives in the liver, which are then readily excreted. 
Hence, one of the most applied strategies to avoid this issue is to prolong the 
pharmacokinetic stability by blocking the potential sites of metabolic activity with a fluorine 
or a hydroxyl group.224,225 
In order to expand the SAR studies, we were encouraged to investigate the effect of 
the different substitution around the C-9 position of the benzo-homoadamantane polycycle 
that may lead to more metabolically stable compounds. Similar to the adamantane group, 
the benzo-homoadamantane scaffold is easily functionalized at the tertiary positions, 
allowing subsequent substitutions with other functionalities.  
Hitherto, we have synthesized a few C-9-substituted derivatives thanks to the large 
exploration carried out during the preparation of amine 23. Specifically, the different 
synthetic routes have led us to obtain in sufficient amounts the chloro 42, hydroxyl 46, and 
bromo 47 derivatives (Fig. 31). 
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Chiou, W. J.; Pan, L.; Deng, X.; Chovan, L. E.; Ramaiya, A.; Mullally, M.; Henry, R. F.; Stolarik, D. F.; Imade, 
H. M.; Marsh, K. C.; Beno, D. W. A.; Fey, T. A.; Droz, B. A.; Brune, M. E.; Camp, H. S.; Sham, H. L.; Frevert, 
E. U.; Jacobson, P. B.; Link, J. T. J. Med. Chem. 2007, 50, 149-164. 
225 Jasys, V. J.; Lombardo, F.; Appleton, T. A.; Bordner, J.; Ziliox, M.; Volkmann, R. A. J. Am. Chem. Soc. 
2000, 122, 466-473. 
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Fig. 31. Amines prepared from the previous synthetic routes. 
The high instability observed in amine 47 prompted its exclusion for the screening as 
potential antagonist of the NMDA receptor.  
In accordance to the most common strategy for the blockade of potential sites of 
metabolic activity, i.e. the introduction of a fluorine atom, we contemplated the formation 
of fluorinated compound 48 (Fig. 32). 
 
Fig. 32. New fluorinated derivative to prepare. 
Incorporation of a fluorine atom has become in the last years a key designer 
component in the structure of modern biologically active compounds, agrochemicals and 
functional materials.226,227,228,229 As fluorine is the most electronegative and the second-
smallest atom in the periodic table, fluorine-containing molecules display different 
chemical, physical and biological properties from their parent compounds. Hence, the high 
carbon-fluorine bond strength (C-F bond: 105.4 kcal mol-1; C-H bond: 98.8 kcal mol-1)230 
provides the molecule high thermal and oxidative stability. Moreover, some fluorine effects 
are of special interest in pharmaceutical sciences: the increased lipophilicity enhances 
bioavailability, fluorine can block key metabolic positions and it can mimic enzyme 
substrates.231 Because of its characteristics, fluorine is considered as a bioisostere of 
hydrogen.232 
Taking into account the intrinsic characteristics of fluorine, it is plain to recognize that 
its introduction is in need of sophisticated synthetic procedures far from the conventional 
organic synthetic methods. During the last decade, organic chemists have developed new 
strategies to create carbon-fluorine (C-F) bonds on aromatic and aliphatic molecules.233 In 
most cases, a single fluorine is successfully introduced using either nucleophilic agents, such 
                                                          
226 Hagmann, W. K. J. Med. Chem. 2008, 51, 4359-4369. 
227 Müller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881-1886. 
228 Furuya, T.; Kamlet, A. S.; Ritter, T. Nature 2011, 473, 470-477. 
229 Jeschke, P. ChemBioChem 2004, 5, 570-589. 
230 O’Hagan, D. Chem. Soc. Rev. 2008, 37, 308-319. 
231 ChemBioChem 2004, 5, 557-726 (special issue: Fluorine in Life Sciences). 
232 Meanwell, N. A. J. Med. Chem. 2011, 54, 2529-2591. 
233 Shimizu, M.; Hiyama, T. Angew. Chem. Int. Ed. Engl. 2004, 44, 214-231. 
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as (diethylamino)sulfur trifluoride (DAST)234 or bis(2-methoxyethyl) aminosulfur trifluoride 
(Deoxofluor),235 or electrophilic agents, such as 1-chloromethyl-4-
fluorodiazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor)236,237 (Fig. 33).  
 
 
Fig. 33. Efficient nucleophilic and electrophilic fluorinating agents. 
Following the procedure described by Johnson,238 we first tested our chances in the 
preparation of amine 48 via nucleophilic substitution of the hydroxyl group of 46 using 
DAST as fluorinating agent. DAST is an aminosulfurane reagent that selectively exchanges 
hydroxyl groups for fluorine, and has proven highly applicable since its discovery in 1970.239 
The main advantage of DAST over previous fluorinating agents is that it is easily handled 
and versatile, unlike the more classical gaseous sulphur tetrafluoride. Luckily enough, we 
managed to obtain the desired fluorinated amine 48 in 44% yield under these conditions. 
The reaction goes through a deoxyfluorination mechanism where the oxygen atom of the 
substrate reacts with the sulfur, with elimination of a hydrogen fluoride molecule. The 
alkoxyaminosulfur difluoride intermediate eliminates a fluoride ion that attacks the 
sulfanylidene intermediate either by an SN1 or SN2 pathway, affording the desired product 
(Scheme 20). If the SN2 mechanism prevails over the SN1, chiral alcohols predominantly 
suffer from the Walden inversion of configuration. Obviously, due to steric issues, in our 
case only a SN1 pathway can operate.  
                                                          
234 Middleton, W. J. J. Org. Chem. 1975, 40, 574-578. 
235 Lal, G. S.; Pez, G. P.; Pesaresi, R. J.; Prozonic, F. M.; Cheng, H. J. Org. Chem. 1999, 64, 7048-7054. 
236 Lal, G. S.; Pez, G. P.; Syvret, R. G. Chem. Rev. 1996, 96, 1737-1756. 
237 Sodeoka, M. Science 2011, 334, 1651-1652. 
238 Johnson, A. L. J. Org. Chem. 1982, 47, 5220-5222. 
239 Singh, R. P.; Shreeve, J. M. Synthesis 2002, 2561-2578. 
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Scheme 20. Deoxyfluorination of alkanolamine 46 with DAST. 
As in the case of unsubstituted amine 23 and its dimethylated analogue 24, the chloro 
42, hydroxy 46, and fluoro 48 derivatives were subjected to reductive alkylation conditions 
to obtain their corresponding dimethylated tertiary amines 49, 50 and 51, respectively 
(Scheme 21). 
 
Scheme 21. Dimethylation of earlier amines by reductive alkylation. 
For the purpose of further inspecting the effect of the substitution on the C-9 position, 
and bearing in mind the intrinsic characteristic of enone 25 in relation to the 1,4-
conjugated-like addition, our next goal was the synthesis of methoxy derivative 52, which 
would add one extra group in our array of compounds (Fig. 34). 
 
Fig. 34. The methoxy derivative closes this family of compounds. 
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Thus, enone 25 was submitted to the 1,4-conjugated-like addition of methanol with p-
toulenesulfonic acid, as reported by Bishop et al.165 The reaction provided alcohol 53 which 
was transformed to the corresponding chloroacetamide 54 in 31% yield via the already 
mentioned Ritter reaction (Scheme 22). In this case, the procedure entails the protonation 
of the bridgehead hydroxyl group, formation of a tertiary carbocation and later addition of 
the nitrile nitrogen. The mechanism continues as indicated in scheme 7. Likewise, the 
methoxy group was prone to elimination and chloroacetamide 34 was recovered in 37% 
yield. Furthermore, with the purification by column chromatography the starting material 
was recovered in 16% yield. 
 
Scheme 22. Formation of alcohol 53 followed by the Ritter reaction, affording a mixture of 54, 
34 and the starting material. 
The pure methoxy derivative 54 was deprotected under the previous conditions with 
thiourea and glacial acetic acid in absolute ethanol, to get final amine 52 in 59% yield 
(Scheme 23).  
 
Scheme 23. Synthesis of amine 52 with thiourea under acid conditions.  
To sum up, scheme 24 discloses the synthetic routes followed for the new derivatives. 
Globally, we have prepared unsubstituted amines 23 and 24, along with C-9 substituted 
benzo-homoadamantanes bearing different substituents (hydroxyl and methoxy groups, 
and chloro and fluoro atoms). 
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2. Pharmacological evaluation of new benzo-homoadamantane derivatives 
2.1 Assessment of the NMDAR antagonistic activity  
The synthesized compounds were first evaluated as NMDAR antagonists by the 
determination of their respective half-maximal inhibitory concentration or IC50. The IC50 
represents the concentration of a drug that is required to produce 50% inhibition of an 
enzymatic reaction at a specific substrate concentration.240 This work was carried out by the 
research group of Dr. Francesc Xavier Sureda (University Rovira i Virgili, Reus, Spain). 
The group of Dr. Sureda is highly specialized in testing the ability of a given ligand to 
prevent neurodegenerative changes in several animal models of AD, both in vivo and in 
vitro. Specifically, to demonstrate the interactions of the new analogues with glutamate 
physiological actions, Dr. Sureda evaluated the competence of the compounds to block the 
increase of intracellular calcium evoked by NMDA in cultured rat cerebellar granule cells 
(CGC). Since the 1990s, different protocols for the determination of the intracellular 
calcium concentration have been established. Most part of the glutamatergic receptors are 
coupled to signal transduction processes that are dependent on the levels of this secondary 
messenger. In consequence, the study of its modulation is a valuable tool for the assessment 
of new molecules as NMDAR agonists or antagonists.  
The assay involves the addition of Fura-2-acetoxymethyl ester (Fura-2 AM) to the 
cultured CGCs, as previously reported.241 Fura-2 AM is a membrane-permeable analogue 
of the ratiometric fluorescent probe calcium indicator Fura-2.242 Once Fura-2 AM enters 
the cell, it is hydrolysed by nonspecific cytoplasmic esterases to Fura-2, which binds to free 
intracellular calcium and whose fluorescence depends on the concentration levels of the 
latter (Fig. 35). Both calcium-bound and calcium-free species fluoresce quite strongly, at 
340 and 380 nm respectively, and the ratio of emissions at those wavelengths is directly 
related to the amount of intracellular calcium. Regardless of the levels of Ca2+, Fura-2 emits 
fluorescence at 510 nm.243 
 
 
 
 
                                                          
240 Yung-Chi, C.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099-3108. 
241 Verdaguer, E.; García-Jordà, E.; Jiménez, A.; Stranges, A.; Sureda, F. X.; Canudas, A. M.; Escubedo, E.; 
Camarasa, J.; Pallàs, M.; Camins, A. Br. J. Pharmacol. 2002, 135, 1297-1307. 
242 Grynkiewicz, G.; Poenie, M.; Tsien, R. Y. J. Biol. Chem. 1985, 260, 3440-3450. 
243 Life technologies web page. Ion indicators & ionophores: Fura-2. 
https://www.lifetechnologies.com/order/catalog/product/F1200 (accessed on 14th June 2015). 
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Fig. 35. Hydrolysis of Fura-2 AM to Fura-2. 
Therefore, the determination of the calcium levels is based on the measurement of the 
fluorescence at 510 nm when excited at 340 (F340) and 380 (F380) nm, followed by the 
calculation of the ratio F340/F380 (R). 
For the assessment of the effect of the newly synthesized compounds against glutamate-
induced Ca2+ mobilization, the procedure is as follows. A single administration of the 
agonists glutamate (100 µM) and glycine (10 µM) leads to a significant increase in R value. 
After this stimulation, increasing cumulative concentrations of the compound to be tested 
are added, represented in blue arrows in figure 36. 
 
Fig. 36. Fluorescence detection after addition of the agonists glutamate and glycine prior 
administration of increasing concentrations of a given antagonist. 
Final adjustment of the data to a concentration-response sigmoidal curve using a non-
linear regression curve fitting (variable slope) gives the percentage of inhibition at every 
tested concentration of each compound, which in turn can be used for the calculation of 
the IC50 values.  
It is worth to highlight that the use of glutamate as agonist in the assay may lead to a 
calcium mobilization originated from the activation of other receptors different from the 
NMDAR, such as kainate. Therefore, for a better estimation of the effect of a plausible 
NMDAR antagonist, in most assays NMDA is used as the stimulator, allowing a 100% 
inhibition to be possible.  
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Evaluation of the ability of the new compounds to block the NMDAR by this 
technique revealed some interesting results. The data shown in table 11 are means of IC50 
values ± SEM of at least three separate experiments carried out on three different batches 
of cultured cells. Amantadine and memantine were used as standard controls. 
Table 11. IC50 values (µM) for 5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-
amines as NMDAR antagonists. 
  
 
Comp. R1 R2 IC50 (NMDA 100 µM) 
23 H H 0.70 ± 0.12 
24 H Me 2.30 ± 0.10 
42 Cl H 4.99 ± 1.53 
49 Cl Me 17.0 ± 9.3 
46 OH H 16.2 ± 3.3 
50 OH Me 71.1 ± 9.9 
48 F H 1.93 ± 0.21 
51 F Me 16.5 ± 2.4 
52 OMe H 24.3 ± 2.0 
19 Me H 13.6 ± 3.4 
Amantadine - - 92 ± 29 
Memantine - - 1.5 ± 0.1 
 
As aforementioned, the IC50 values were obtained by the measure of the antagonistic 
activity at varied concentrations of each compound, providing a concentration-response 
semi-logarithmic curve with the familiar sigmoidal shape. The plot in figure 37 includes the 
most potent compounds. 
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Fig. 37. IC50 curves of compounds 23 and 48 and their dimethylated analogues 24 and 51 
respectively, compared with memantine as a standard. 
Gratifyingly, rationalisation of the results shown in table 11 led to some attractive 
outcomes and a SAR could be established around the C-9 substitution: 
 All the new compounds have IC50 values lower than that of amantadine, with 
amines 23, 42, 24 and 48 in the low micromolar range.  
 Confirming our first hypothesis, compound 23 was the most potent 
compound with an IC50 lower than that of memantine (0.70 and 1.5 µM, 
respectively). Pleasingly, primary amine 23 and its bioisostere 48 (1.93 µM) 
were clearly more potent than our previous synthesized families I and II (Fig. 
38). Of note, the observed trend of going from 23 to its methylated analogue 
19 (13.6 µM) is the opposite of the one observed in going from amantadine to 
its dimethylated derivative memantine.  
 Considering solely primary amines, smaller substituents such as a hydrogen 
(23) or a fluorine (48) are better tolerated than larger groups, like hydroxyl (46), 
methoxy (52) or methyl (19). Particularly, either polar (46 or 52), or lipophilic 
electron-donating groups (EDG) as in the previously reported methylated 
compound 19 led to a significant reduction of the activity. Introduction of the 
electron-withdrawing chlorine (42) and fluorine (48) resulted in an increase on 
the potency compared with compounds bearing an EDG.  
 Interestingly, within this novel series of benzo-homoadamantanes, all the 
tertiary amines were clearly less potent than the corresponding primary amines 
(23 vs 24, 42 vs 49, 46 vs 50, 48 vs 51), in contrast to the behaviour observed 
in former families I and II. 
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Fig. 38. Confirmation of our first hypothesis from the former families. 
These results suggest that the combination of the size, the ability to form specific 
interactions, such as hydrophobic interactions or hydrogen bonds, and the inductive effects 
of the substituted group, alters greatly the activity as NMDAR antagonist of the molecule. 
The lack of a crystal structure of the ion channel resolved with an antagonist renders 
difficult the reasoning of the observed trends.  
2.2 Electrophysiological measurements  
In order to appraise if the new NMDA antagonists displayed a similar blocking mode 
to that of memantine, i.e. characterized by rapid and strongly voltage-dependent kinetics, 
Dr. David Soto from IBIDELL, performed a patch-clamp experiment with the more 
promising compounds, 23 and 48. 
Briefly, the patch-clamp technique permits the study of membrane current 
contributions of individual ionic channels from cells of any size and particularly the study 
of small cells in culture.244 It consists of the insertion of a micro-pipette into the cell 
membrane in a way that the connection is sealed. This tight seal isolates the membrane 
patch electrically, which means that all ions passing through the ion channels flow into the 
pipette. An electrode connected to a highly sensitive differential amplifier can record 
currents flowing through the membrane patch (Fig. 39). This technique has been widely 
used for NMDAR blockers.245,246,247,248,249 
 
 
 
 
 
                                                          
244 Sakmann, B.; Neher, E. Ann. Rev. Physiol. 1984, 46, 455-472. 
245 Chen, H. S.; Pellegrini, J. W.; Aggarwal, S. K.; Lei, S. Z.; Warach, S.; Jensen, F. E.; Lipton, S. A. J. Neurosci. 
1992, 12, 4427-4436. 
246 Parsons, G. R.; Gruner, R.; Rozental, J.; Millar, J.; Lodge, D. Neuropharmacol. 1993, 32, 1337-1350. 
247 Blanpied, T. A; Clarke, R. J.; Johnson, J. W. J. Neurosci. 2005, 25, 3312-3322. 
248 Gilling, K.; Jatzke, C.; Wollenburg, C.; Vanejevs, M.; Kauss, V.; Jirgensons, A.; Parsons, C. G. J. Neural 
Transm. 2007, 114, 1529-1537. 
249 Koller, M.; Urwyler, S. Expert Opin. Ther. Pat. 2010, 20, 1683-1702. 
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                    B 
 
Fig. 39. (A) Schematic representation of the patch-clamp principle and (B) image of a patch 
pipette attached to the membrane of a neuron.250 
During the experiment, the ion channels undergo different stages, which affect the 
current that flows through the membrane patch: 
1. Baseline conditions: voltage of  -60 mV with the ion channels closed. 
2. Addition to the media of agonists (glutamate and glycine): ion channels are 
now open with the entrance of cations until normalization. Reduction on the 
intensity. 
3. Addition of antagonist to the former media: some ion channels are now 
blocked. Increase on the intensity. 
4. Application of a positive pulse of +60 mV: release of the blockers. 
5. Stop of the positive pulse and addition of agonists + antagonist: recovery of 
the state in step 3. 
                                                          
250 Science Lab website. The patch-clamp technique. http://www.leica-microsystems.com/science-
lab/the-patch-clamp-technique/ (accessed on 18th September 2015). 
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6. Withdrawal of the antagonist, but with agonists: recovery of the state in step 
2. 
7. Application of a positive pulse of +60 mV: to check if the antagonist is an 
open-channel blocker or, in other words, voltage-dependent blocker. If the 
intensity of the second positive pulse is higher than the first one, it means that 
the antagonist is a non-voltage-dependent blocker. 
Following thus this protocol, amine 23 and 48 were assayed along with memantine for 
comparison (Fig. 40).  
 
 
Fig. 40. Results from electrophysiological studies with (A) memantine, (B) amine 48 and (C) 
amine 23. 
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As shown in figure 40, amine 48, which bears a fluorine atom in its structure, compares 
well with memantine, with a similar kinetic profile after running the experiment. However, 
this is not the case for amine 23, which presents a low-binding kinetic profile. Specifically, 
when 23 enters in the media, there is a rapid blockade of the NMDARs, and this blockade 
is slightly more intense than for the other two antagonists. In contrast, the recovery of the 
baseline levels is slower than memantine and amine 48. Altogether, the data suggests that 
amine 23 shows a similar association rate constant (kon) but a smaller dissociation rate 
constant (koff) than memantine. On the other hand, when applying the second positive 
pulse, the intensity in this case is higher than the one from the first pulse. This fact indicates 
that actually amine 23 is a non-voltage-dependent and non-open channel blocker. 
Therefore, amine 23 and 48, despite containing two bioisostere groups, bind to the 
channel in a distinct way. One hypothesis is that amine 23 behaves as a high-affinity NMDA 
receptor antagonist. At the time of writing this thesis, work is still ongoing in order to 
further study the electrophysiological behaviour of our NMDAR antagonists.  
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In this first part of the thesis, 12 new compounds, revolving around the benzo-
homoadamantane structure, have been synthesized and fully characterized by their 
spectroscopic and analytical data. Among them, 10 were pharmacologically evaluated as 
NMDA receptor antagonists. 
From the data of the first chapter of this dissertation, we can conclude the following: 
1. Amine 23 was prepared following a radical dehalogenation in low yield, after 
several synthetic attempts.  
2. A SAR study has been developed around the substitution pattern at the C-9 
position, with polar and non-polar substituents, partly thanks to the synthetic 
exploration performed for the synthesis of amine 23. 
3. The activity displayed by compound 23 confirmed our first hypothesis that an 
unsubstituted benzo-homoadamantane would exhibit a higher activity than the 
previous series of compounds. Indeed, amine 23 displayed the lowest IC50 
value ever described to date for the benzo-homoadamantane scaffold as 
surrogate of the adamantane group of memantine (IC50 of 0.70 µM for 23 vs 
1.5 µM for memantine, Fig. 41). 
 
Fig. 41. Best compound identified from this family of benzo-
homoadamantanes. 
4. The second most active structure discovered with this series of compounds was 
the fluoro derivative 48, bioisostere of 23 and with an equipotent activity 
compared with memantine (IC50 of 1.93 µM). 
5. Halides were better tolerated than hydroxyl and methoxy groups. Thus, 
compounds bearing a fluorine (48, IC50 of 1.93 µM) or a chlorine (42, IC50 of 
4.99 µM) were more potent as NMDA receptor antagonists than compounds 
with a hydroxyl (46, IC50 of 16.2 µM) or a methoxy (52, IC50 of 24.3 µM). 
6. All the tertiary amines were less active than their corresponding primary 
amines. 
7. Electrophysiological studies revealed that amine 48 possessed a similar kinetic 
profile than memantine in a patch-clamp assay, with a voltage-dependent 
binding mode, whereas amine 23 tended to stay longer time within the 
channel, in a non-voltage-dependent mode. Hence, amine 23 could not be 
considered as an open-channel blocker but, probably, as a high-affinity 
antagonist. 
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1. 11β-HSD1 inhibition by adamantane-based derivatives 
The following section will discuss the glucocorticoid effects in the organism and the 
regulation of these stress hormones by the 11β-HSD1 enzyme, which has been found to be 
relevant in the development of multiple diseases, such as the metabolic syndrome (MetS), 
inflammation and cognitive dysfunction. A brief disclosure of the developed 11β-HSD1 
inhibitors will be covered. Particularly, the adamantane-based compounds will be studied 
in order to understand their binding mode in the active site of the enzyme as well as their 
progress throughout the drug discovery process.  
1.1 The glucocorticoid system and its physiological actions 
Glucocorticoids (GCs) are well-known ubiquitous hormones playing a key role in 
modulating immune and inflammatory responses, regulating energy metabolism and 
cardiovascular homeostasis and the body’s responses to stress. Opposing the action of 
insulin, GCs promote gluconeogenesis, inhibit β-cell insulin secretion and peripheral 
glucose uptake. Moreover, GCs contribute to lipolysis, with subsequent fatty acid 
mobilization, and proteolysis. Thus, overall, GCs prompt catabolic states.251,252  
The active human GC cortisol, is synthesized by the adrenal cortex with a strong 
circadian rhythm. Its secretion is controlled by the hypothalamic-pituitary-adrenal (HPA) 
axis and induced in stressful conditions. Serum cortisol readily passes cell membranes and 
exerts its intracellular functions by binding to GC receptors (GRs), which are ligand-
activated nuclear receptors. GRs regulate, directly or indirectly, the expression of a plethora 
of genes involved in various physiological processes, including peroxisome proliferator-
activated receptor γ (PPAR-γ), CCAAT enhancer-binding protein and nuclear factor-κB 
(NF-κB), inter alia.253,254 Furthermore, GCs bind to mineralocorticoid receptors (MRs), 
which regulate blood pressure and sodium balance in the kidney.255 
1.1.1 GC regulation by 11β-HSD enzymes 
Along with the HPA axis, GC’s homeostasis is controlled by the 11β-HSD enzyme. 
Two isoforms of this enzyme, 11β-HSD type 1 (11β-HSD1) and type 2 (11β-HSD2), catalyse 
the interconversion between active 11-hydroxy forms (cortisol in humans, and 
corticosterone in rodents) and inert 11-ketosteroids (cortisone in humans, and 11-
dehydrocorticosterone in rodents), with the concomitant conversion of NADPH cofactor 
to NAD+ (Fig. 42). 11β-HSD1 is anchored to the membrane of the endoplasmic reticulum 
(ER) by the N-terminus, with the catalytic domain located within the lumen of the ER. 
                                                          
251 Dallman, M. F.; Strack, A. M.; Akana, S. F.; Bradbury, M. J.; Hanson, E. S.; Scribner, K. A.; Smith, M. Front. 
Neuroendocrinol. 1993, 14, 303-347. 
252 Sapolsky, R. M.; Romero, L. M.; Munck, A. U. Endocr. Rev. 2000, 21, 55-89. 
253 Rosen, E. D.; MacDougald, O. A. Nat. Rev. Mol. Cell Bio. 2006, 7, 885-896. 
254 Smoak, K. A.; Cidlowski, J. A. Mech. Ageing Dev. 2004, 125, 697-706. 
255 Arriza, J. L.; Weinberger, C.; Cerelli, G.; Glase, T. M.; Handelin, B. L.; Housman, D. E.; Evans, R. M. Science 
1987, 237, 268-275. 
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Hexose-6-phosphate dehydrogenase, also located in the ER, is thought to supply adequate 
concentrations of NADPH cofactor, which favour the behaviour of the 11β-HSD1 as a 
reductase in vivo.256,257 Besides, the higher affinity of 11β-HSD1 for cortisone than cortisol 
enhances this oxoreductive activity. In in vitro conditions, though, 11β-HSD1 is 
bidirectional and can also act as a dehydrogenase.  
 
 
Fig. 42. Interconversion of cortisone to cortisol in humans catalyzed by 11β-HSD enzyme. 
 
11β-HSD1 is mainly expressed in liver, adipose tissue, bone, pancreas, vasculature and 
brain, whilst 11β-HSD2 is found chiefly in mineralocorticoid target tissues such as the 
kidney, colon, pancreas and the salivary gland.258 In mineralocorticoid tissues, the MR have 
the same binding affinity for cortisol as aldosterone; 11β-HSD2 protects the MR from 
inappropriate activation by cortisol and allows aldosterone to act as the ligand, by 
inactivating cortisol to cortisone.259 Figure 43 summarizes what has been commented 
hitherto.  
                                                          
256 Dzyakanchuk, A. A.; Balázs, Z.; Nashev, L. G.; Amrein, K. E.; Odermatt, A. Mol. Cell. Endocrinol. 2009, 
301, 137-141. 
257 Atanasov, A. G.; Nashev, L. G.; Gelman, L.; Legeza, B.; Sack, R.; Portmann, R.; Odermatt, A. Biochim. 
Biophys. Acta 2008, 1783, 1536-1543. 
258 Hardy, R. S.; Seibel, M. J.; Cooper, M. S. Curr. Opin. Pharmacol. 2013, 13, 440-444. 
259 Edwards, C. R.; Stewart, P. M.; Burt, D.; Brett, L.; McIntyre, M. A.; Sutanto, W. S. de Kloet, E. R.; Monder, 
C. Lancet 1988, 2, 986-989. 
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Fig. 43. Biosynthesis of cortisol by adrenal gland under HPA axis control, and tissue-specific 
metabolism of GC by 11β-HSD enzymes. CRH: corticotropin-releasing hormone; ACTH: 
adrenocorticotrophic hormone.260,261 
It is worth to highlight that cortisone is not the only substrate of 11β-HSD1, but several 
additional substrates have been identified such as 7-oxygenated steroids, 7-ketocholesterol 
and non-steroidal unspecific carbonyl compounds, thus endowing the enzyme with an 
important role in the detoxification of exogenous substances.262,263,264 
1.2 11β-HSD1 as a pleiotropic therapeutical target 
The rationale for the inhibition of 11β-HSD1 came from the striking resemblances 
between the phenotype of hypercortisolism, also known as Cushing’s syndrome, and the 
symptoms of the MetS. The Cushing’s syndrome reveals a set of phenotypical characteristics 
such as insulin resistance, hypertension, dyslipidaemia, and osteoporosis (Fig. 44).265 While 
the Cushing’s syndrome is rare, it does exemplify the pathological effects associated with 
imbalances in circulating cortisol levels.  
                                                          
260 Hollis, G.; Huber, R. Diabetes Obes. Metab. 2011, 13, 1-6. 
261 Staab, C. A; Maser, E. J. Steroid Biochem. Mol. Biol. 2010, 119, 56-72. 
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265 Gathercole, L. L.; Lavery, G. G.; Morgan, S. A; Cooper, M. S.; Sinclair, A. J.; Tomlinson, J. W.; Stewart, P. 
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Fig. 44. The pleiotropic effects of GC excess in Cushing’s syndrome. 
Endogenous GC production and metabolism have been highlighted as having a pivotal 
role in the aetiology of several disorders. While this production underlies the attractiveness 
of pharmacological inhibition of 11β-HSD1 to modulate local GC action, it requires to 
inhibit selectively this specific isoform to avoid undesired effects associated with the 
binding to 11β-HSD2, or other hydroxysteroid dehydrogenase enzymes, such as 17β-
HSD.266 It has been demonstrated that a deficient 11β-HSD2 activity (as a result of gene 
mutation, or by inhibition of this isoform) results in an impaired cortisol inactivation and 
apparent mineralocorticoid excess, leading to hypokalemia and hypernatremia, eventually 
inducing hypertension and related cardiovascular problems.265,267 On the other hand, 
inhibition of 17β-HSD affects local estrogen metabolism. Worth to note is that 11β-HSD1 
is also expressed in areas of the brain relevant to metabolic control.268 Although it has been 
demonstrated that 11β-HSD1 activity in brain does not contribute to systemic 
cortisol/cortisone turnover,269 inhibition of 11β-HSD1 must be considered with caution 
since it may result in the risk of compensatory cortisol production via up-regulation of the 
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HPA axis.270 11β-HSD1 is considered as a pre-receptor target since it controls the binding 
of active cortisol to GR by modulating its metabolism.  
In recent years, there has been a rapid growth in publications concerning 11β-HSD1 
as a promising target.271 Many research groups in academia and in the pharmaceutical 
industry have put forth great efforts to determine the role of 11β-HSD1 in the development 
of multiple diseases, and hence to discover suitable inhibitors to overcome these disorders. 
As just seen, selectivity and tissue-targeting specificity are the ultimate criteria in the 
discovery of potent 11β-HSD1 inhibitors.  
1.2.1 11β-HSD1 inhibition and type 2 diabetes mellitus, obesity and metabolic syndrome 
Type 2 diabetes mellitus (T2DM) is characterized by increased cellular insulin 
resistance with an initial phase of enhanced insulin secretion followed by pancreatic β-cell 
failure. Regarding obesity, a person with a body mass index of 30 or more is considered 
obese, entailing health risks. T2DM and obesity are considered as first-world epidemics and 
are nowadays great healthcare challenges in the developed countries. According to the 
World Health Organization (WHO), in 2014, 9% of the worldwide adult population had 
diabetes.272 That same year, the percentage of total health expenditure in T2DM reached 
US $ 612 billion. The expected increase on the diabetic population by 2035 is about 205 
million, which will elevate the total health cost still higher.273 Concerning obesity, in 2014 
more than 1.9 billion adults were overweight, and of these, 600 million were obese.274 
From another standpoint, the MetS is a cluster of metabolic disorders and it is 
diagnosed in a given patient if visceral obesity and two or more risk factors are present, 
including elevated fasting plasma glucose, elevated triglycerides, elevated blood pressure 
and reduced high-density lipoprotein (HDL), as it has been recently redefined by the 
International Diabetes Foundation (Fig. 45). Conversely, the WHO was the first to tie 
together the key components of insulin resistance, obesity, dyslipidaemia and 
hypertension.275,276  
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Fig. 45. Combination of the above risk factors leads to the MetS. 
Currently, the predominant therapeutic strategy for preventing or managing T2DM 
and MetS is the individual treatment of the set of risk factors instead of treating the disorder 
as a whole. The increase in the prevalence of T2DM and MetS over the last few decades in 
the developed countries has propelled a growing need for the development of novel 
therapies to treat MetS and its associated disorders.  
 Unlike the Cushing’s syndrome, where elevated circulating cortisol levels cause the 
phenotypic changes, in MetS circulating GC levels are not usually elevated, despite the fact 
that, until recently, the extended belief was that the major contributor to the 
symptomatology was the level of free cortisol in plasma and the densities of GR and MR in 
target tissues. Therefore, it has been speculated that inter- and intracellular local levels of 
GC regulated by the 11β-HSD enzyme are responsible for metabolic abnormalities.  
 The impact of tissue-specific GC activation by 11β-HSD1 in metabolic homeostasis 
has been examined using several transgenic mouse models. Experiments in mice with 
adipose tissue-targeted 11β-HSD1 overexpression developed a phenotype similar to the one 
of Cushing’s syndrome, including insulin resistance, visceral obesity, dyslipidaemia and 
hypertension, without an increase in the GC plasmatic levels.277,278 On the other hand, 
overexpression of 11β-HSD1 in liver tissue led to the appearance of MetS but without 
impaired glucose tolerance and obesity.279 In contrast, 11β-HSD1 knock-out [11β-HSD1(-/-
)] mice had reduced triglyceride and non-esterified fatty acids, improved glucose tolerance 
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and higher HDLs on a high-fat diet.280,281,282 Parallelly, overexpression of adipose-specific 
11β-HSD2 resulted in reduced fat mass, and increased glucose tolerance and insulin 
sensitivity.283     
 Several studies have appeared over the recent years proving the relationship between 
tissue-specific alterations in 11β-HSD1 expression in human T2DM, obesity and MetS.284 
For instance, the expression of 11β-HSD1 in human adipose tissue is positively correlated 
with the degree of obesity.285,286,287 In view of all these studies, it is likely that an aberrant 
11β-HSD1 expression/activity in several key metabolic tissues underlies the pathogenesis 
of these diseases (Fig. 46).288 
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Fig. 46. Role of 11β-HSD1 in the pathogenesis of the MetS and related disorders. 
 Hence, modulation of 11β-HSD enzyme, and in particular inhibition of 11β-HSD1 in 
adipose tissue and liver, are of special interest as pharmacotherapeutic strategies in the 
medical treatment of the MetS and associated disorders.289,290,291 
1.2.2 11β-HSD1 inhibition and inflammation 
 The anti-inflammatory effects of pharmacological levels of GCs are well known and 
widely exploited.292 Short-term therapy with GCs, chiefly cortisone, is broadly described to 
treat acute inflammation. However, endogenous GCs are immunomodulatory rather than 
simply anti-inflammatory agents.293,294 GCs both enhance or suppress immune responses 
depending on concentration and timing, by affecting the migration of immune cells, their 
differentiated states, and the production of a range of inflammatory cytokines.288 
Ultimately, GCs shape an ongoing inflammatory response as it progresses, depending on 
the local environment. With respect to11β-HSD1, it is expressed in certain immune cells, 
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such as the differentiated monocytes and in most lymphocyte populations.295 Regulation of 
11β-HSD1 at this cellular level provides a further mechanism to fine-tune cellular immune 
responses.  
 In chronic inflammatory processes, such as rheumatoid arthritis, atherosclerosis and 
rhinitis, there is an imbalance on the expression/activity of the two isoforms of the 11β-
HSD.296,297,298 It has been suggested that dysregulation of the normal reciprocal control of 
11β-HSD1 and 11β-HSD2 may contribute to the failure of resolution during chronic 
inflammatory states. Therefore, the control of GC’s bioavailability within immune cells by 
11β-HSD1 provides a checkpoint for the attenuation of unwanted immune responses.299,300 
Hence, modulation of 11β-HSD1 expressed in immune cells may offer an alternative 
approach for the treatment of rheumatoid arthritis, rhinitis and atherosclerosis, diseases 
highly linked to MetS. Of note, metabolic disorders such as obesity and T2DM are 
associated with a dysregulated immune response,301 thereby underpinning the potential of 
the inhibition of 11β-HSD1 as a new therapeutic strategy for such conditions.  
1.2.2 11β-HSD1 inhibition and cognitive dysfunction with aging 
 The hippocampus region of the brain is an area that plays an important role in the 
formation of long-lasting memories and wields an executive level of control over the HPA 
axis.300,302 In this particular region, 11β-HSD1 but not 11β-HSD2 is greatly expressed, 
together with GRs and MRs. As already discussed, GCs are known to deeply influence 
metabolism, immune system and neuronal function.292 Bearing in mind the phenotype of 
Cushing’s syndrome depicted in figure 3, deficient regulation of the HPA axis with 
resultant chronically elevated levels of GCs exerts deleterious effects on specific areas of the 
brain, eventually resulting in cognitive dysfunction. Specifically, excessive GC 
concentrations in the brain enhance neuronal death due to a series of conditions such as 
increase of the levels of amyloid precursor protein, hypoxia and excitotoxic concentrations 
of glutamate (therefore connected with the previous chapter).303,304 There is mounting 
evidence from human and rodent studies that this GC-related cognitive decline is apparent 
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with aging.305,306,307 Indeed, GCs are strongly implicated in the pathogenesis of age-related 
cognitive impairment and AD.308,309,310 It is believed that low intracellular concentration of 
GCs in hippocampus activates MRs, whose stimulation lead to increased memory, whilst 
high concentration of GCs saturates MRs and over-activates GRs, thus affecting memory 
processes.311 Moreover, inhibition of 11β-HSD1 reduces Aβ plaque burden and plasma Aβ 
in AD animal models.312,313 
 In a similar way as for the previous disorders, influence on the metabolism of GCs 
within target tissues may offer a route for tissue-selective control of GC exposure. In this 
sense, 11β-HSD1 inhibition may assist in keeping the GC levels low throughout life, which 
may prevent the appearance of cognitive deficits with aging. This fact has been confirmed 
in aged [11β-HSD1(-/-)] mice, which are protected from GC-associated hippocampal 
dysfunction with aging.314 In contrast to aged wild type mice, [11β-HSD1(-/-)] counterparts 
learn as young mice, avoiding the normal cognitive decline seen with aging. On the other 
hand, it has been demonstrated that inhibition of 11β-HSD1 ameliorates age-related 
cognitive impairments in mice, suggesting that 11β-HSD1 is a potential target for the 
treatment of cognitive dysfunction.315,316 A study carried out by Seckl and co-workers proved 
that the use of a non-selective 11β-HSD inhibitor for 4-6 weeks improved the cognitive 
functions in healthy and diabetic elderly.305 T2DM is a risk factor of dementia, whose 
pathogenesis is triggered by an overactivation of the HPA axis.317  
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1.2.3 11β-HSD1 inhibition for other diseases   
 11β-HSD1 inhibition has been investigated also for other indications, such as 
glaucoma,318 osteoporosis,319 wound healing and age-associated skin damage.320,321 For the 
sake of brevity, these disorders are not discussed any further, the reader is referred to the 
titled references if desired. 
   
 
Fig. 47. Plausible therapeutic indications arising from 11β-HSD1 inhibition.271 
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 With the data provided so far, it would be logical to consider 11β-HSD1 inhibition as 
a potential panacea for the most prevalent diseases of the developed countries originated 
by HPA axis overactivation and subsequent chronically elevated GCs. In the light of the 
current insights of the role of 11β-HSD1 in tissue-specific reactivation of cortisone to 
cortisol and the pathological effects of an excess of GCs, perhaps we are in a position to re-
evaluate the use of cortisone as anti-inflammatory agent for the treatment of arthritis and 
other inflammatory conditions, which was the subject of the Noble Prize in Physiology and 
Medicine in 1950.322 
1.3 Crystal structure of 11β-HSD1 and its binding site  
11β-HSD1 is a 34 kD protein of 292 amino acids that forms homodimers and 
tetramers in solution, which are believed to be the functional unit in vivo.323,324 The enzyme 
is comprised of 4 main regions, i.e. (i) a transmembrane domain at the N-terminus linked 
to the ER membrane; (ii) a cofactor binding domain, characterized by a Rossman fold; (iii) 
a cluster of key residues that constitute the catalytic site; and (iv) a region essential for 
enzyme dimerization at the C-terminus. 
The Rossman fold is highly conserved in the so-called short-chain 
dehydrogenase/reductase family of enzymes, whereof 11β-HSD1 is member. This 
particular three-dimensional structure consists of seven-stranded parallel β-sheets flanked 
by three α-helices on the left and right sides each.325 In 11β-HSD1, the cofactor-binding site 
is placed in between the Rossman fold, and close to the location of the catalytic site of the 
substrate (Fig. 48).  
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Fig. 48. X-ray crystal structure of 11β-HSD1 bound to cofactor NADPH and a novel inhibitor. 
PDB code: 3CH6.326 
The substrate catalytic site shows the amino acid sequence Tyr-X-X-X-Lys (specifically 
Tyr183 and Lys187, wherein X-X-X is a certain combination of amino acids). The X-X-X 
motif often includes a conserved serine residue (Ser170), that participates in ligand 
binding, stabilizes the orientation of the substrate within the catalytic site, and catalyses the 
proton transfer to and from reduced and oxidized intermediates.327 In contrast, Lys187 
forms hydrogen bonds with the nicotinamide ribose of NADP(H) and lowers the pKa of the 
hydroxyl group of the neighbouring Tyr183, which also binds to the substrate and cofactor. 
The also known as catalytic triad Tyr183 – Ser170 – Lys187, interacts thus with the 
substrate and promotes the proton transfer to the reactive keto-oxygen of cortisone to 
furnish the active GC cortisol (Fig. 49).  
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Fig. 49. Binding mode of a steroid ligand (carbenoxolone) and cofactor NADPH with key 
residues highlighted similar to the endogenous substrate. PDB code: 2BEL.328  
Despite the residues that establish key hydrogen bond interactions, the catalytic pocket 
is largely hydrophobic.329 Furthermore, both ends of the catalytic site are open to the 
solvent, thus ligands that are too long to fit within the pocket can extend out of it and 
contact with surface residues.  
The distinctive binding site of the steroid substrate and the conformational flexibility 
in crystal structures assert 11β-HSD1 as an ideal target for rational drug design. It has been 
suggested that the murine structure can provide a reliable model for the design of inhibitors 
for the human enzyme.330 Notwithstanding that, the preferred structure for the computer-
aided drug design is the human protein, as it can be seen in most resolved crystal structures 
so far. 
1.4 11β-HSD1 inhibitors in development 
 
Since the discovery of 11β-HSD1, there has been a rapid growth in small molecules 
that inhibit this enzyme as potential therapeutics for the treatment of multiple conditions. 
Many pharmaceutical companies have pursued development programmes targeting 11β-
HSD1, which still represent an important area. The patent literature surrounding the 
development of novel 11β-HSD1 inhibitors has been extremely rich in the last decade, with 
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more than 250 patent applications published, as well as several publications from academia 
and industry covering biologically active inhibitors.331,332,333,334,335 
1.4.1 Non-selective 11β-HSD1 inhibitors as tools 
The Tibetan remedy liquorice root was used for the treatment of disorders in 
respiratory and digestive systems, biliary tracts and kidneys, paralysis with nervous origin, 
anaemia and as antidote in snake and wild dog bites.336 More than 250 active molecules 
have been identified from the extracts of this ancient medicine, and among them, the 18β-
glycyrrhetinic acid was isolated. This naturally occurring steroid is a potent, non-selective 
inhibitor of 11β-HSDs with IC50 values in the nano-molar range (Fig. 50).337 Interestingly, 
structural modification of the 18β-glycyrrhetinic acid led to inhibitors with a reverse 
selectivity towards 11β-HSD2.338,339 Later on, its hemisuccinate ester derivative 
carbenoxolone, which also inhibits both 11β-HSD1 and 11β-HSD2, was approved in the 
1960s in UK for the treatment of gastric ulcers and inflammation.340   
 
Fig. 50. Structure of 18β-glycyrrhetinic acid and its synthetically derived carbenoxolone, a 
clinically used inhibitor of 11β-HSDs. 
Despite inhibiting both isoforms, carbenoxolone has been used in animal and human 
studies as a proof-of-concept during the target validation of 11β-HSD1. Several studies have 
confirmed the increase of hepatic insulin sensitivity in humans with carbenoxolone, and 
                                                          
331 Webster, S. P.; Pallin, T. D. Expert Opin. Ther. Pat. 2007, 17, 1407-1422. 
332 Hughes, K. A.; Webster, S. P.; Walker, B. R. Expert Opin. Investig. Drugs 2008, 17, 481-496. 
333 St. Jean Jr., D. J.; Wang, M.; Fotsch, C. Curr. Top. Med. Chem. 2008, 8, 1508-1523. 
334 Boyle, C. D.; Kowalski, T. J. Expert Opin. Ther. Pat. 2009, 801-826. 
335 Scott, J. S.; Goldberg, F. W.; Turnbull, A. V. J. Med. Chem. 2014, 57, 4466-4486. 
336 Pavlova, S. I.; Uteshev, B. S.; Sergeev, A. V. Pharm. Chem. J. 2003, 37, 314-317. 
337 Bühler, H.; Perschel, F. H.; Hierholzer, K. Biochim. Biophys. Acta 1991, 1075, 206-212. 
338 Su, X.; Lawrence, H.; Ganeshapillai, D.; Cruttenden, A.; Purohit, A.; Reed, M. J.; Vicker, N.; Potter, B. V. 
L. Bioorg. Med. Chem. 2004, 12, 4439-4457. 
339 Pandya, K.; Dietrich, D.; Seibert, J.; Vederas, J. C.; Odermatt, A. Bioorg. Med. Chem. 2013, 21, 6274-
6281. 
340 Wang, M. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy, in Diabetes – 
Perspectives in Drug Therapy, Handbook of Experimental Pharmacology, 203, Springer-Verlag Berlin 
Heidelberg, 2011. 
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attenuation of the symptoms of MetS and atherogenesis in obese mice.341,342,343 Moreover, 
carbenoxolone improved cognitive function in healthy elderly men and type 2 diabetics, as 
commented before.305 However, the therapeutical potential of carbenoxolone is limited due 
to the hypokalemia and hypertension derived from 11β-HSD2 inhibition.   
1.4.2 Studies with selective 11β-HSD1 inhibitors 
Since the discovery of the latter dual inhibitors of 11β-HSDs, the surge of research and 
clinical interest in this area has resulted in many companies and academic groups 
developing selective 11β-HSD1 inhibitors from a variety of structural classes. The large 
majority of 11β-HSD1 inhibitors feature a hydrogen bond acceptor functionality such as 
amides, lactams, ureas, carbamates, sulphones, sulphonamides or heterocycles flanked by 
bulky lipophilic radicals such as cyclohexanes, adamantanes or benzene rings. A great part 
of the candidates can be sorted in a few groups: arylsulphonamides, triazoles, piperazine 
sulphonamides, piperidine carboxamides, thiazolones, heterocyclic and adamantyl amides, 
ureas, etc. From the available X-ray crystal structures of different inhibitors resolved with 
the protein,344 a few points can be drawn for the assistance when designing potential 
ligands:  
 the H-bond acceptor unit mimics the reducible keto function of the 
endogenous substrate cortisone by interacting with the residues of the active 
site. 
 The bulky lipophilic groups fit the buried hydrophobic pockets of the catalytic 
site, generally near the binding region of the nicotinamide unit of NADP(H) 
or the steroid substrate.  
 The catalytic site is open to the solvent region, which allows the binding pocket 
to accommodate extended ligands. In this area, tyrosine 177 plays an important 
role in interacting with the hydrophobic regions of the molecules. 
                                                          
341 Walker, B. R.; Connacher, A. A.; Lindsay, R. M.; Webb, D. J.; Edwards, C. R. J. Clin. Endocrinol. Metab. 
1995, 80, 3155-3159. 
342 Andrews, R. C.; Rooyackers, O.; Walker, B. R. J. Clin. Endocrinol. Metab. 2003, 88, 285-291. 
343 Nuotio-Antar, A. M.; Hachey, D. L.; Hasty, A. H. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E1517-
E1528. 
344 PDB codes: 2BEL, 3D4N, 3D3E, 2ILT, 3BYZ, 3CZR, 3CH6, among others. See also reference 329 for a 
detailed analyses of the crystal structures of 11β-HSD1.  
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Table 12 includes the most relevant candidates that have reached clinical trials in the 
last few years.345,346,347,348,349 The positive data from human studies validate 11β-HSD1 as a 
target for the treatment of T2DM, MetS, related disorders and AD.   
Table 12. List of drug candidates that have achieved clinical trials as inhibitors of the 11β-HSD1. 
Compound Company Status 
 
MK-0916 
Merck 
No longer in company 
pipeline (achieved 
Phase II in 2004) 
 
MK-0736 
Merck 
No longer in company 
pipeline (achieved 
Phase II in 2005) 
 
 
PF-915275 
Pfizer 
Discontinued Phase II 
(2007) 
                                                          
345 Stefan, N.; Ramsauer, M.; Jordan, P.; Nowotny, B.; Kantartzis, K.; Machann, J.; Hwang, J.H.; Nowotny, 
P.; Kahl, S.; Harreiter, J.; Hornemann, S.; Sanyal, A. J.; Stewart, P. M.; Pfeiffer, A. F.; Kautzky-Willer, A.; 
Roden, M.; Häring, H. U.; Fürst-Recktenwald, S. Lancet Diabetes Endocrinol. 2014, 2, 406-416. 
346 Siu, M.; Johnson, T. O.; Wang, Y.; Nair, S. K.; Taylor, W. D.; Cripps, S. J.; Matthews, J. J.; Edwards, M. P.; 
Pauly, T. A; Ermolieff, J.; Castro, A.; Hosea, N. A; LaPaglia, A.; Fanjul, A. N.; Vogel, J. E. Bioorg. Med. Chem. 
Lett. 2009, 19, 3493-3497. 
347 Feig, P. U.; Shah, S.; Hermanowski-Vosatka, A; Plotkin, D.; Springer, M. S.; Donahue, S.; Thach, C.; Klein, 
E. J.; Lai, E.; Kaufman, K. D. Diabetes Obes. Metab. 2011, 13, 498-504. 
348 Shah, S.; Hermanowski-Vosatka, A.; Gibson, K.; Ruck, R. A.; Jia, G.; Zhang, J.; Hwang, P. M. T.; Ryan, N. 
W.; Langdon, R. B.; Feig, P. U. J. Am. Soc. Hypertens. 2011, 5, 166-176. 
349 Clinical trials web site. 11β-HSD1. https://www.clinicaltrials.gov/ (accessed on 28th July 2015).  
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HSD-016 
Wyeth 
Discontinued Phase I 
(2008) 
 
AMG-221/BVT-83370 
Amgen/Biovitrum 
Discontinued Phase I 
(2011) 
 
AZD-8329 
AstraZeneca 
Discontinued Phase I 
(2011) 
INCB13739 
Structure not released yet 
Incyte Phase I completed 
RO5093151 
Structure not released yet 
Hoffman-La Roche Phase I completed 
 
BI 135585 
Boehringer Ingelheim Phase I completed 
 
BMS-770767 
Bristol-Myers Squibb Phase II completed 
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ABT-384 
Abbott Phase II completed 
P2202 
Structure not released yet 
Eli Lilly & Piramal Phase II completed 
 
AZD-4017 
AstraZeneca Phase II (recruiting) 
UE2343 
Structure not released yet 
University of Edinburgh - 
Actinogen 
Phase II (recruiting) 
ASP3662 
Structure not released yet 
Astellas Pharma Phase II (recruiting) 
 
 
 In the interest of this project, 11β-HSD1 inhibitors that are adamantane-based 
compounds will be discussed in more detail.  
1.4.3 Adamantane-based inhibitors of 11β-HSD1  
 The adamantyl group appears to be a privileged scaffold present in many 11β-HSD1 
inhibitors disclosed in the patent and scientific literature, and a few of them have reached 
clinical trials (see Table 12). As in the previous examples, the inhibitors bearing an 
adamantane moiety feature an H-bond acceptor functionality attached at one end to an 
adamantane group, which fits one of the hydrophobic pockets of the catalytic site. Despite 
of these general binding characteristics, different subclasses of adamantane-based 
compounds have been revealed, from amides and ureas to triazoles and thiazolones. A brief 
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compilation of the most significant adamantanyl 11β-HSD1 inhibitors is contained in 
figure 51.350.351,352,353,354,355,356,357,358,359,360 
                                                          
350 Cheng, H.; Hoffman, J.; Le, P.; Nair, S. K.; Cripps, S.; Matthews, J.; Smith, C.; Yang, M.; Kupchinsky, S.; 
Dress, K.; Edwards, M.; Cole, B.; Walters, E.; Loh, C.; Ermolieff, J.; Fanjul, A.; Bhat, G. B.; Herrera, J.; Pauly, 
T.; Hosea, N.; Paderes, G.; Rejto, P. Bioorg. Med. Chem. Lett. 2010, 20, 2897-2902. 
351 Johansson, L.; Fotsch, C.; Bartberger, M. D.; Castro, V. M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, 
C.; Hickman, D.; Homan, E.; Jordan, S. R.; Komorowski, R.; Li, A.; McRae, K.; Moniz, G.; Matsumoto, G.; 
Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J. J. Med. Chem. 2008, 51, 2933-2943. 
352 Tice, C. M.; Zhao, W.; Xu, Z.; Cacatian, S. T.; Simpson, R. D.; Ye, Y. J.; Singh, S. B.; McKeever, B. M.; 
Lindblom, P.; Guo, J.; Krosky, P. M.; Kruk, B. A; Berbaum, J.; Harrison, R. K.; Johnson, J. J.; Bukhtiyarov, Y.; 
Panemangalore, R.; Scott, B. B.; Zhao, Y.; Bruno, J. G.; Zhuang, L.; McGeehan, G. M.; He, W.; Claremon, D. 
A. Bioorg. Med. Chem. Lett. 2010, 20, 881-886. 
353 Olson, S.; Aster, S. D.; Brown, K.; Carbin, L.; Graham, D. W.; Hermanowski-Vosatka, A.; LeGrand, C. B.; 
Mundt, S. S.; Robbins, M. A; Schaeffer, J. M.; Slossberg, L. H.; Szymonifka, M. J.; Thieringer, R.; Wright, S. 
D.; Balkovec, J. M. Bioorg. Med. Chem. Lett. 2005, 15, 4359-4362. 
354 Rohde, J. J.; Pliushchev, M. A.; Sorensen, B. K.; Wodka, D.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K. M.; 
Chiou, W. J.; Pan, L.; Deng, X.; Chovan, L. E.; Ramaiya, A.; Mullally, M.; Henry, R. F.; Stolarik, D. F.; Imade, 
H. M.; Marsh, K. C.; Beno, D. W. A.; Fey, T. A.; Droz, B. A.; Brune, M. E.; Camp, H. S.; Sham, H. L.; Frevert, 
E. U.; Jacobson, P. B.; Link, J. T. J. Med. Chem. 2007, 50, 149-164. 
355 Richards, S.; Sorensen, B.; Jae, H.-S.; Winn, M.; Chen, Y.; Wang, J.; Fung, S.; Monzon, K.; Frevert, E. U.; 
Jacobson, P.; Sham, H.; Link, J. T. Bioorg. Med. Chem. Lett. 2006, 16, 6241-6245. 
356 Venier, O.; Pascal, C.; Braun, A.; Namane, C.; Mougenot, P.; Crespin, O.; Pacquet, F.; Mougenot, C.; 
Monseau, C.; Onofri, B.; Dadji-Faïhun, R.; Leger, C.; Ben-Hassine, M.; Van-Pham, T.; Ragot, J. L.; Philippo, 
C.; Farjot, G.; Noah, L.; Maniani, K.; Boutarfa, A.; Nicolaï, E.; Guillot, E.; Pruniaux, M. P.; Güssregen, S.; 
Engel, C.; Coutant, A. L.; de Miguel, B.; Castro, A. Bioorg. Med. Chem. Lett. 2013, 23, 2414-2421. 
357 Webster, S. P.; Ward, P.; Binnie, M.; Craigie, E.; McConnell, K. M. M.; Sooy, K.; Vinter, A.; Seckl, J. R.; 
Walker, B. R. Bioorg. Med. Chem. Lett. 2007, 17, 2838-2843. 
358 Okazaki, S.; Takahashi, T.; Iwamura, T.; Nakaki, J.; Sekiya, Y.; Yagi, M.; Kumagai, H.; Sato, M.; Sakami, 
S.; Nitta, A.; Kawai, K. J. Pharmacol. Exp. Ther. 2014, 351, 181-189. 
359 Ryu, J. H.; Kim, S.; Lee, J. A.; Han, H. Y.; Son, H. J.; Lee, H. J.; Kim, Y. H.; Kim, J.-S.; Park, H. Bioorg. Med. 
Chem. Lett. 2015, 15, 1679-1683. 
360 Kim, Y. H.; Kang, S. K.; Lee, G. Bin; Lee, K. M.; Kumar, J. A.; Kim, K. Y.; Rhee, S. D.; Joo, J.; Bae, M. A.; Lee, 
W. K.; Ahn, J. H. Med. Chem. Commun. 2015, 6, 1360-1369. 
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Fig. 51. Selection of adamantane-based inhibitors of 11β-HSD1 in development. 
The preponderance of the adamantane ring in many 11β-HSD1 inhibitors suggests 
that this precious polycycle forms tight-binding interactions within the hydrophobic 
binding pockets. Regardless of the good match that the adamantane moiety exerts in the 
binding site of the enzyme, the high lipophilicity furnished by the adamantane leads to 
potential solubility and metabolic stability problems, as seen in the introductory part of the 
present thesis. The initial pharmacological results imply that increasing the hydrophobicity 
of the inhibitors generally entails an improvement of 11β-HSD1 inhibitory potency, but 
this progression is often counterbalanced by a poor performance in the PD assay. With the 
goal of improving PK and PD profiles, academic and industrial research groups have carried 
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out different approaches. On one hand, the introduction of polar groups at key positions, 
such as amides, sulphonamides and hydroxyl groups, with diverse orientations on the ring 
stabilize the hydrophobic ring from metabolism and increase water solubility. On the other 
hand, replacement of the adamantane group by other scaffolds, such as 
bicyclo[2.2.2]octane, provides candidates that possess excellent PK and PD profiles in target 
tissues. Merck followed this strategy in a development programme with success, leading to 
MK-0736 (see table 12).361,362,363 These findings suggest that it is possible to optimize the 
lipophilic adamantane moiety effectively for clinical administration targeting the promising 
11β-HSD1 enzyme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
361 Waddell, S. T.; Balkovec, J. M.; Kevin, N. J.; Gu, X. Preparation of triazoles derivatives as inhibitors of 
11β-hydroxysteroid dehydrogenase-1. WO 2007047625.  
362 Wang, H.; Robl, J. A.; Hamann, L. G.; Simpkins, L. M.; Golla, R.; Li, X.; Seethala, R.; Zvyaga, T.; Gordon, 
D. A.; Robl, J. A.; Li, J. L. Bioorg. Med. Chem. Lett. 2011, 21, 4146-4149. 
363 Bauman, D. R.; Whitehead, A.; Contino, L. C.; Cui, J.; Garcia-Calvo, M.; Gu, X.; Kevin, N.; Ma, X.; Pai, L.; 
Shah, K.; Shen, X.; Stribling, S.; Zokian, H. J.; Metzger, J.; Shevell, D. E.; Waddell, S. T. Bioorg. Med. Chem. 
Lett. 2013, 23, 3650-3653. 
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At the time of the present dissertation, no 11β-HSD1 inhibitor had reached the market, 
what illustrates the difficultness of developing drug candidates with optimal PK and PD 
profiles and the need for discovering new active pharmaceutical ingredients (API) that may 
overcome these issues.  
From the available data drawn from the X-ray crystal structures of different inhibitors 
bound to the 11β-HSD1 catalytic site, a general trend can be deduced. For the most part, 
two hydrophobic moieties are linked by an H-bond acceptor, which fill the buried 
hydrophobic pockets and interact with the key residues of the catalytic site, respectively. 
These crucial pieces constitute the pharmacophore of the 11β-HSD1 inhibitors. From this 
observation, we hypothesized that different scaffolds can be placed as hydrophobic moieties 
instead of the adamantane group in order to achieve structures with more appropriate 
profiles.  
Taking advantage of the extended expertise of our research group in the synthesis of 
polycyclic scaffolds, we started a new project related to the discovery of novel 11β-HSD1 
inhibitors bearing adamantane-like scaffolds as hydrophobic counterparts. We 
hypothesized that the substitution of the adamantane moiety for other polycyclic cage 
structures may offer compounds with improved PK and PD profiles whilst keeping good 
binding affinity to the target. Under these premises, we determined the following goals of 
this chapter: 
1. Synthesis and pharmacological evaluation of a family of compounds with the general 
structure of the benzo-homoadamantane IV (Fig. 52). This scaffold, already seen in 
the previous chapter of the present thesis, embodies a phenyl ring in its structure 
and lets the introduction of different substituents at the C-9 position, which may 
alter the binding mode along with PK properties. 
 
Fig. 52. Replacement of the adamantane group by a scaffold with general structure IV. RHS: 
right-hand side. 
2. Synthesis and pharmacological evaluation of a family of compounds with general 
structure V (Fig. 53). This hexacyclic structure provides a larger lipophilic scaffold 
than the adamantane group. Derived from the synthetic route, both dienes and 
alkanes can be prepared. We aimed to determine the effect of an expanded 
adamantane analogue in the binding affinity of the new compounds. 
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Fig. 53. Incorporation of hexacycles V as surrogates of the adamantane moiety. 
In order to test our polycycles we designed the compounds based on the literature. In 
this manner, we chose as the right-hand side of the molecules a diversity of already proven 
subunits stemming from the work of a few pharmaceutical companies (Fig. 54).350,351,352,355 
 
Fig. 54. Right-hand sides (RHS) applied in the synthesis of the new compounds. 
  
  
 
 
 
 
 
 
 
 
 
 
Results & Discussion 
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1. Application of the benzopolycyclic scaffold as an adamantane analogue for 11β-HSD1 
inhibition 
1.1 Synthesis of the C-9 substituted 6,7,8,9,10,11-hexahydro-5,7:9,11-dimethano-5H-
benzocyclononen-7-yl derivatives 
For the design of the new compounds, we have adopted a hybrid strategy whereby the 
inhibitor is partitioned into a hydrophobic adamantane-like unit (left-hand side of the 
molecule) and a cyclic structure (right-hand side), linked by an amido- or urea-like unit (Fig. 
55). The adamantane moiety has been replaced by the benzo-homoadamantane polycycle 
IV. This strategy obeys a twofold purpose. First, the introduction of the phenyl ring, 
together with polar and non-polar groups attached to the polycycle (OH, OMe, F, Me) is 
intended to modify the PK properties of the compounds, and particularly the metabolism 
at specific ring positions. Second, the incorporation of the phenyl moiety is expected to 
establish new binding interactions in the hydrophobic cage. In addition, this insertion 
involves a size expansion of the carbocyclic structure. At this point, it is worth noting that 
the active site of the enzyme seems to be wide enough as to accommodate this polycycle, as 
suggested upon inspection of the available X-ray structures. On the other hand, a series of 
carbocyclic and heterocyclic subunits previously tested as 11β-HSD1 inhibitors are 
integrated into the final polar moiety as the RHS. Finally, the amido- or urea-like unit 
present in the linker should enable the formation of key hydrogen bonds at the binding 
site. 
 
Fig. 55. Design of the new 11β-HSD1 inhibitors with general structure IV. 
 The selection of the different moieties as the RHS was in accordance to a balance 
between the ease on their synthesis and the reasonable inhibitory activity. 350,351,352,355 Figure 
56 includes the IC50 values of the parent inhibitors. Worth to consider is the fact that the 
IC50 of Vitae’s inhibitor was determined in an enzymatic assay, which may differ from the 
value obtained by a cellular assay (not available). Thus, a direct comparison cannot be made 
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with the rest of the IC50 values, but it provides some indications of how potent is the 
compound. 
 
Fig. 56. Biological activity of the 11β-HSD1 inhibitors taken as templates. 
   Moreover, we decided to reduce the complexity of the Amgen’s analogue by placing 
two identical substituents in C-5 position, i.e. two methyl groups as shown in figure 55. In 
this manner, any stereochemistry derived from the substitution pattern is avoided.   
 Taking advantage of the C-9-substitution patterns obtained from the previous chapter 
of the thesis, we sought to explore the different combinations derived from the substitution 
at the C-9 position of the adamantane-like polycycle and each one of the selected polar 
units as RHS. First, we decided to use four of our amines as starting points (Fig. 57). Amine 
23 was not included due to its low-yielding synthetic procedure. 
 
Fig. 57. Amines 46, 19, 48 and 52 used as left-hand side of the putative new 11β-HSD1 
inhibitors. 
 Amine 19 preparation was similar to the synthesis of hydroxyl derivative 46. Likewise, 
Prins-Ritter transannulation of diene 29 with chloroacetonitrile and sulphuric acid in neat 
glacial acetic acid, followed by thiourea-mediated deprotection of the chloroacetamide 
group gave the desired intermediate, amine 19, in 56% yield (two steps) (Scheme 25). 
Scheme 25. Prins-Ritter transannular cyclization of 29, followed by thiourea-mediated 
deprotection of chloroacetamide. 
 To optimize the synthesis, we applied the following strategy to detect the perfect match 
between the C-9 substituent and the polar unit: 
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 Explore the effects on the C-9 substitution, essentially with polar and non-polar 
groups. We chose piperidine-1-carboxamide as the right-hand side of the 
molecule due to the ease of preparation of the final compounds. 
 Identify the polar unit from figure 55 that performs best with the scaffold at 
issue. To do so, we used amines 46 and 19 featuring a hydroxyl and a methyl 
group, respectively, so as to have one polar and one non-polar substituent to 
compare. 
With this in mind, the compounds that needed to be synthesized are depicted in figure 
58. 
 
Fig. 58. Compounds to be made to assess the effect of the different substitutions in benzo-
homoadamantane as a scaffold for 11β-HSD1 inhibitors. 
 Compound 60, which contains a cyclohexyl amide attached to the polycyclic structure, 
was also included in the list of polar units. We intended to analyse whether the replacement 
of a urea by an amide, a common functional group in most 11β-HSD1 inhibitors, might 
affect the inhibitory activity. This structure was previously tested by our group in a different 
series of compounds.364 
 The syntheses will be organized according to the different functionalities of the core 
moiety. 
                                                          
364 Leiva, R.; Seira, C.; McBride, A.; Binnie, M.; Luque, F. J.; Bidon-Chanal, A.; Webster, S. P.; Vázquez, S. 
Bioorg. Med. Chem. Lett. 2015, 25, 4250-4253. 
Exploration of 
the right-hand 
side 
Identification 
of the best C-9 
substituent 
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1.1.1 Preparation of amide compounds 
 Chemical reactions for the formation of amide bonds are among the most executed 
transformations in organic and medicinal chemistry.365 The current methods for amide 
formation are remarkably general but at the same time widely regarded as expensive and 
inelegant.366 Acylation of amines with activated carboxylic acids is the most frequent 
reaction performed in the synthesis of pharmaceuticals and in peptide chemistry, 
representing more than 70% of all acylations and related processes executed in medicinal 
chemistry (Scheme 26).367,368 
 
Scheme 26. Carboxylic acid activation for subsequent amine attack and final amide bond 
formation. 
 Based on the success and broad use of the activating or coupling agents, the titled 
amides were prepared following two different procedures. In these cases, the acylating agent 
is generated in situ from the acid in presence of the amine, by the addition of a coupling 
agent. The first approach implied the use of carbodiimides as coupling agents, which were 
the first activating reagents to be used in synthesis.369 Different carbodiimides are currently 
employed, such as dicyclohexyl carbodiimide (DCC), diisopropyl carbodiimide (DIC) and 
1-ethyl-3-(3’-dimethylaminopropyl)carbodiimide (EDC), each of one showing its own pros 
and cons. As for the reaction mechanism, the first step of the process involves the attack of 
the carboxylic acid to the carbodiimide to form O-acylisourea 66. This intermediate can 
yield a number of different products, depending on which species reacts with it: i) 
formation of the desired amide 67 via coupling with the amine; ii) formation of anhydride 
68, which can lead to amide 67 after attack of the amine (it requires two equivalent of the 
carboxylic acid); and iii) generation of N-acylurea 69 by rearrangement of the common 
intermediate. To exemplify the mechanism of this coupling it is represented in scheme 27 
using EDC. This carbodiimide was selected as the coupling agent due to its high water 
solubility, facilitating its removal by aqueous washes. 
                                                          
365 Roughley, S. D.; Jordan, A. M. J. Med. Chem. 2011, 54, 3451-3479. 
366 Pattabiraman, V. R.; Bode, J. W. Nature 2011, 480, 471-479. 
367 Montalbetti, C. A. G. N.; Falque, V. Tetrahedron 2005, 61, 10827-10852. 
368 Valeur, E.; Bradley, M. Chem. Soc. Rev. 2009, 38, 606-631. 
369 Sheehan, J. C.; Hess, G. P. J. Am. Chem. Soc. 1955, 77, 1067-1068. 
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Scheme 27. One-pot coupling of carboxylic acids with amines using EDC. 
 Inasmuch as part of the acid partner is lost with the formation of the N-acylurea 69, it 
was reasoned that the addition of a selected nucleophile that reacted faster than the 
competing acyl transfer, generating an intermediate still active enough to couple with the 
amine might avoid this side reaction. Hydroxybenzotriazole or HOBt is one of those 
nucleophiles.370 Hence, the established procedures consist in the addition of EDC as 
coupling agent, HOBt as additive, as shown in scheme 28. 
 
Scheme 28. Avoidance of the formation of N-acylurea 69 by addition of HOBt. 
                                                          
370 Chan, L. C.; Cox, B. G. J. Org. Chem. 2007, 72, 8863-8869. 
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 As the evolution in the coupling agents progressed, novel activators appeared with the 
purpose of preventing the use of two reagent species and increasing the reactivity. Onium 
salts based upon 7-aza-1-hydroxybenzotriazole (HOAt) have replaced the predominant 
carbodiimide and HOBt technique.371,372 Among them, 1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) has become one 
the most popular coupling agent. When first reported, HATU was described as an uronium 
salt (O-isomer), but X-ray crystal structure revealed that the preferred state is as guanidinium 
salt (N-isomer) (Fig. 59).373 However, there is an equilibrium between the two forms in 
solution.  
 
Fig. 59. Different isomers of HATU, the N-isomer being the predominant form in the crystal 
structure. 
 The coupling mechanism entails first the generation of both an activated O-acylisourea 
70 and a HOAt unit. The negatively charged oxygen atom of this same benzotriazole reacts 
with the activated acid in a similar manner to the previous mechanism. Elimination of 
tetramethylurea, prior to the coupling of the amine to the highly reactive ester-like species, 
affords the desired amide compound (Scheme 29). The generation of the urea by-product 
is the driving force of the reaction.  
                                                          
371 Carpino, L. A. J. Am. Chem. Soc. 1993, 115, 4397-4398. 
372 Albericio, F.; Bofill, J. M. El-Faham, A.; Kates, S. A. J. Org. Chem. 1998, 63, 9678-9683. 
373 Carpino, L. A.; Imazumi, H.; El-Faham, A.; Ferrer, F. J.; Zhang, C.; Lee, Y.; Foxman, B. M.; Henklein, P.; 
Hanay, C.; Mügge, C.; Wenschuh, H.; Klose, J.; Beyermann, M.; Bienert, M. Angew. Chem. Int. Ed. 2002, 
41, 441-445. 
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Scheme 29. Activation process of carboxylic acids using uronium/guanidinium type coupling 
agents. 
 Despite the high efficiency of HATU, especially in difficult sterically hindered 
couplings, the amine can react with the coupling agent to give a guanidinium by-product 
as a side reaction (Scheme 30).  
 
Scheme 30. Possible guanidinium side-product when using HATU. 
 Having introduced these two approaches, i.e. the use of EDC/HOBt or HATU as 
coupling agents, starting from amines 46, 19, 48 and 52, the synthetic procedure towards 
the obtaining of final amides is outlined in scheme 31. 
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Scheme 31. Amide coupling of amines 46, 19, 48 and 52 and selected carboxylic acids applied 
in this thesis. 
The first attempt was using HATU as the activating reagent, because of the known 
high efficiency of this agent in difficult sterically hindered couplings. Beginning with the 
preparation of proline derivative 56, the synthetic route started with the amide coupling 
between amine 46 and the commercially available N-Boc-D-proline (Scheme 32). A slightly 
excess of the amine was used over the non-natural amino acid, in order to prevent the 
guanidinium side reaction, as well as for HATU and the base. The reaction afforded the 
desired Boc-protected pyrrolidine 71 in 50% yield after purification by column 
chromatography. 
 
Scheme 32. Coupling of amine 46 with N-Boc-D-proline gave amide 71. 
The synthetic sequence towards amide 56 continued with the deprotection of the t-
butyl carbamate group following the procedure reported by Li et al.374 The method 
consisted in the use of aqueous phosphoric acid, which is an acid whose conjugate base is 
non-nucleophilic. This hampers the dehydration of the hydroxyl group at the tertiary 
position and subsequent introduction of the conjugate base. After neutralization of the 
media, deprotected pyrrolidine 72 was secured in 87% yield as a free base (Scheme 33). 
These two simple steps furnished the first compound for pharmacological testing that was 
also central to access the next final compound. 
                                                          
374 Li, B.; Bemish, R.; Buzon, R. A.; Chiu, C. K. F.; Colgan, S. T.; Kissel, W.; Le, T.; Leeman, K. R.; Newell, L.; 
Roth, J. Tetrahedron Lett. 2003, 44, 8113-8115. 
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Scheme 33. Deprotection of boc-protected pyrrolidine 71 to afford free amine 72. The reaction 
entails the formation of isobutene and carbon dioxide. 
With amine 72 in hand, we proceeded to the reductive alkylation following our 
previously mentioned methodology. We treated the free amine with acetaldehyde and 
sodium cyanoborohydride under the same conditions as scheme 19 (NMDA chapter), but 
regrettably no alkylated amine was observed (Scheme 34), and the starting material was fully 
recovered. 
 
Scheme 34. Attempt of reductive alkylation of amine 72 with acetaldehyde and NaBH3CN. 
 Unhappy with the result, we applied the procedure described in the literature for the 
preparation of PF-877423 derivative, which involved the N-alkylation with ethyl bromide 
in the presence of a base and potassium iodide. The latter was used in catalytic amounts in 
order to displace the bromide in an SN2 fashion and promote the attack of the amine to 
the alkylating agent, transformation known as Finkelstein reaction (Scheme 35). Pleasingly, 
amide 56 was obtained in 72% yield without need of column chromatography. 
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Scheme 35. N-alkylation of amine 72 with ethyl iodide after halogen displacement. 
 Once hydroxyl derivative 56 was prepared, we next moved to the synthesis of its C-9 
methylated analogue 57. Despite the avoidance of extra additives when using HATU as 
coupling agent, the moderate yield obtained in the preparation of 71 (50% yield) showed 
a partial success of the reaction. In consequence, we essayed the peptide-like coupling using 
EDC and HOBt as activating agents. Based on standard protocols,375,376,377 we subjected 
amine 19 to a coupling process with 1.5 equivalents of both agents, along with TEA as a 
base in ethyl acetate (Scheme 36). After several aqueous washes, pure amide 73 was 
obtained in 84% yield without any purification needed. 
 
Scheme 36. Formation of an amide bond with EDC and HOBt. 
Amide 73 was in turn submitted to Boc-deprotection with 85% aqueous ortho-
phosphoric acid to provide free amine 74 in quantitative yield. Primary amine 74 was 
purified and fully characterized for pharmacological evaluation. Last, N-alkylation with 
                                                          
375 Dragovich, P. S.; Prins, T. J.; Zhou, R.; Johnson, T. O.; Hua, Y.; Luu, H. T.; Sakata, S. K.; Brown, E. L.; 
Maldonado, F. C.; Tuntland, T.; Lee, C. A.; Fuhrman, S. A.; Zalman, L. S.; Patick, A. K.; Matthews, D. A.; Wu, 
E. Y.; Guo, M.; Borer, B. C.; Nayyar, N. K.; Moran, T.; Chen, L.; Rejto, P. A.; Rose, P. W.; Guzman, M. C.; 
Dovalsantos, E. Z.; Lee, S.; McGee, K.; Mohajeri, M.; Liese, A.; Tao, J.; Kosa, M. B.; Liu, B.; Batugo, M. R.; 
Gleeson, J. P. R.; Wu, Z. P.; Liu, J.; Meador, J. W.; Ferre, R. A. J. Med. Chem. 2003, 46, 4572-4585. 
376 Nikitenko, A.; Alimardanov, A.; Afragola, J.; Schmid, J.; Kristofova, L.; Evrard, D.; Hatzenbuhler, N. T.; 
Marathias, V.; Stack, G.; Lenicek, S.; Potski, J. Org. Process Res. Dev. 2009, 13, 91-97. 
377 Sasaki, N. A.; Garcia-Álvarez, M. C.; Wang, Q.; Ermolenko, L.; Franck, G.; Nhiri, N.; Martin M. T.; Audic, 
N.; Potier, P. Bioorg. Med. Chem. 2009, 17, 2310-2320. 
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ethyl bromide, KI and TEA afforded final compound 57 in moderate yield (44%), which 
was isolated as the L-(+)-tartrate salt after column chromatography (Scheme 37). Previous 
attempts to precipitate the resulting amine as its hydrochloride salt yielded a hygroscopic 
solid, which did not meet the required physical properties for pharmacological evaluation. 
 
Scheme 37. Boc-deprotection and N-alkylation reaction to provide 57·tartrate. 
In line with our objectives, aryl amides 58 and 59 were synthesized according to the 
best conditions obtained for the amide coupling, that is the combination of EDC and 
HOBt (84% vs 50% yield with HATU). Therefore, a slightly excess of amines 46 and 19 
were added to a mixture of commercially available 4-amino-3,5-dichlorobenzoic acid, EDC, 
HOBt and TEA in ethyl acetate to produce the corresponding final amides 58 and 59 in 
95% and 53% yield, respectively (Scheme 38). The significant differences in the yields 
indicate that the substitution on the C-9 position may affect directly the reactivity of the 
amine group, or indirectly by changes in solubility. 
 
Scheme 38. Amide coupling between amines 46 and 19 with 4-amino-3,5-dichlorobenzoic acid. 
The synthesis of the last amide 60 was performed by the same protocol, in this case 
with cyclohexanecarboxylic acid. Satisfyingly, reaction with amine 19 furnished the 
corresponding final amide 60 in excellent yield (Scheme 39). 
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Scheme 39. Reaction of amine 19 with cyclohexanecarboxylic acid under amide coupling 
conditions provided 60 in 96% yield. 
1.1.2 Synthesis of the thiazolone scaffold 
 The 2-amino-1,3-thiazol-4(5H)-one skeleton was built following the described 
procedures.378,379 Starting from amine 19, the intermediate thiourea 76 was prepared via a 
two-step protocol. First, treatment with benzoyl isothiocyanate provided benzamide 75 that 
was subsequently hydrolysed under basic conditions to give 76 in 52% overall yield (Scheme 
40). 
 
Scheme 40. Transformation of amine 19 to thiourea 76 after reaction with benzoyl 
isothiocyanate and later basic hydrolysis. 
 The construction of the thiazolone ring system was accomplished by a 
substitution/cyclization reaction between thiourea 76 and ethyl 2-bromoisobutyrate in the 
presence of N,N’-diisopropylethylamine (DIPEA) under microwave irradiation (Scheme 
41). Researchers from Biovitrum found that this process required long reaction times (3-8 
days) heating to 90-105 ºC by conventional methods. Nevertheless, the reaction time was 
substantially reduced by microwave-assisted heating to 130 ºC, but at the expense of 
lowering the yield (13%). 
                                                          
378 Jean, D. J. S.; Yuan, C.; Bercot, E. A; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R. W.; 
Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. J. Med. Chem. 2007, 50, 429-432. 
379 Johansson, L.; Fotsch, C.; Bartberger, M. D.; Castro, V. M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, 
C.; Hickman, D.; Homan, E.; Jordan, S. R.; Komorowski, R.; Li, A.; McRae, K.; Moniz, G.; Matsumoto, G.; 
Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J. J. Med. Chem. 2008, 51, 2933-2943. 
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Scheme 41. Substitution/cyclization sequence to assemble the thiazolone ring with a thiourea and 
an α-bromoester. For the sake of clarity, the proton exchanges have been omitted. 
1.1.3 Urea group formation 
 Different approaches have been described for the synthesis of the urea moiety of many 
11β-HSD1 inhibitors, from direct coupling of amines with isocyanates to the use of amine-
activating agents such as triphosgene or carbonyldiimidazole (CDI).380,381 Some of them will 
be reviewed in the last chapter of the thesis.  
 Alternatively, another method to install a urea functionality concerns the reaction of 
an amine with a carbamoyl chloride in the presence of a base, in a similar way than with 
an isocyanate.382 Since we aimed to prepare a urea embodied in a piperidine ring, we 
pursued its synthesis following this last approach, where amines 46, 19, 48 and 52 were 
reacted with 1-piperidinecarbonyl chloride in TEA to afford the corresponding final ureas 
62-65 in low to medium yields (Scheme 42). In all cases, the final compounds were purified 
by column chromatography and/or crystallization in order to eliminate the excess of the 
starting material. The reaction mechanism is simple, and entails the addition of the amine 
to the carbonyl, with the subsequent elimination of the chloride, which is trapped by the 
base as the hydrochloride salt. 
 
                                                          
380 Tice, C. M.; Zhao, W.; Xu, Z.; Cacatian, S. T.; Simpson, R. D.; Ye, Y.J.; Singh, S. B.; McKeever, B. M.; 
Lindblom, P.; Guo, J.; Krosky, P. M.; Kruk, B. A; Berbaum, J.; Harrison, R. K.; Johnson, J. J.; Bukhtiyarov, Y.; 
Panemangalore, R.; Scott, B. B.; Zhao, Y.; Bruno, J. G.; Zhuang, L.; McGeehan, G. M.; He, W.; Claremon, D. 
A. Bioorg. Med. Chem. Lett. 2010, 20, 881-886. 
381 Claremont, D. A.; Zhuang, L.; Ye, Y.; Singh, S. B.; Tice, C. M. Carbamate and urea inhibitors of 11beta-
hydroxysteroid dehydrogenase 1. US 2011/0112062 A1. 
382 Jimenez, H. N.; Ma, G.; Li, G.; Grenon, M.; Doller, D. Adamantyl amide derivatives and uses of same. 
WO 2011/087758 A1. 
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Scheme 42. Formation of ureas 62-65 via reaction of amine 46, 19, 48 and 52 with a carbamoyl 
chloride. 
1.2 Pharmacological evaluation of the C-9 substituted 6,7,8,9,10,11-hexahydro-5,7:9,11-
dimethano-5H-benzocyclononen-7-yl derivatives 
 A preliminary in vitro screening was performed to evaluate if the synthesized 
compounds were able to inhibit human 11β-HSD1. The research group of Dr. Scott 
Webster at the University of Edinburgh (United Kingdom) carried out these assays. 
Screening for 11β-HSD1 potency was accomplished using a functional scintillation 
proximity assay or SPA employing microsomes isolated from human embryonic kidney 
cells (HEK 293) overexpressing human 11β-HSD1. We should clarify at this point that 
this procedure measures the blockade of 11β-HSD1 isoform exclusively. 
  The SPA is a well-stablished high throughput screening assay for the evaluation of 
the ligand binding affinity to 11β-HSD1.383,384 The principle of this technique consists of 
microscopic beads that contain scintillant compounds. There are two types of beads: i) 
plastic beads such as polyvinyl toluene (PVT) beads; ii) crystalline beads such as yttrium 
silicate beads. In the PVT beads, the more common ones, the scintillator is 
diphenylanthracine.385 This molecule emits light when radiolabelled cortisol (3H-cortisol) 
binds to specific anti-cortisol antibodies that are exposed in the surface of the bead. The 
generation of light comes from the activation of the scintillator through energy transfer 
derived from the emitted radiation after binding. The amount of light is proportional to 
the amount of [3H]-cortisol molecules that binds to the beads. The emitted light is 
quantified by a scintillation detector and converted into concentration of cortisol present 
in the media. Thus, the assay measures the production of [3H]-cortisol from [3H]-cortisone 
by the action of 11β-HSD1 contained in the microsomes. Figure 60 illustrates the SPA 
principle. 
                                                          
383 Mundt, S.; Solly, K.; Thieringer, R.; Hermanowski-Vosatka, A. Assay Drug Dev. Technol. 2005, 3, 367-
375. 
384 Solly, K.; Mundt, S. S.; Zokian, H. J.; Ding, G. J.; Hermanowski-vosatka, A.; Strulovici, B.; Zheng, W. Assay 
Drug Dev. Technol. 2005, 3, 377-384. 
385 PerkinElmer website. Radiometric assays and detection, SPA bead Technology. 
http://www.perkinelmer.com/Resources/TechnicalResources/ApplicationSupportKnowledgebase/radio
metric/spa_bead.xhtml#top (accessed on 11th August 2015). 
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Fig. 60. Schematic representation of the SPA procedure.  
 When an inhibitor is added in the media in high concentrations, the production of 
[3H]-cortisol is reduced with a resultant decrease on the amount of emitted light from the 
SPA beads.  
 In order to assess the binding affinity of each inhibitor, a first screening was carried 
out with a fixed concentration of every inhibitor (10 µM). Compounds with 70% or 
higher of inhibition were then further evaluated by determination of their IC50 values. 
The enzyme activity was measured with increasing concentrations of each compound, 
providing a dose-response plot obeying a Langmuir isotherm. Normalization to the signal 
from the activity with no inhibitor added and further mathematical calculations furnished 
the IC50 values, which are included in table 13. 
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Table 13. Percentage of inhibition of the tested compounds at 10 µM and the IC50 value of 
amide 57. ND: not determined. PF-877423 was used as a standard.  
 
 
Comp. R RHS % inhibition at 10 µM IC50 (µM) 
72 OH 
 
15 ND 
56 OH 
 
24 ND 
74 Me 
 
57 ND 
57 Me 
 
77 1.0 ± 0.3 
58 OH 
 
31 ND 
59 Me 
 
36 ND 
60 Me 
 
52 ND 
61 Me 
 
35 ND 
62 OH 
 
30 ND 
63 Me 36 ND 
64 F 62 ND 
65 OMe 41 ND 
PF-877423 - - 93 0.004 
 
 From the above results, some conclusions can be tentatively drawn for this first series 
of compounds: 
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 Four compounds (74, 57, 60 and 64) were found to have an inhibitory effect 
larger than 50% at a single dose of 10 µM.  
 Comparing the C-9-methylated derivatives, the N-ethyl-D-proline subunit 
behaved better than the other tested right-hand sides. Within this family of 
compounds, the alkylation of the proline ring led to an increase in the inhibitory 
activity (compare 72 vs 56; 74 vs 57). 
 The replacement of the nitrogen atom in 63 by a methine group in 60 caused an 
enhancement of the potency against 11β-HSD1.  
 The introduction of a polar group at the C-9 position (hydroxyl in 72, 56, 58 and 
62; or methoxide in 65) was deleterious for the inhibitory activity, whereas 
lipophilic groups (methyl in 74, 57, 59, 60, 61, and 63; or fluorine in 64) were 
generally better tolerated. Thus, the inhibitory activity improved as the 
lipophilicity increased. For a better understanding of this fact, compare 56 vs 57, 
and 62 vs 65. 
 Considering the urea compounds 62-65, the fluorinated derivative 64 displayed 
the higher percentage of inhibition compared to the rest of substituents.  
 The substitution of the adamantane ring in PF-877423 by the benzo-
homoadamantane scaffold in 56 and 57 was detrimental to the inhibitory activity, 
with a 250-fold lower affinity.  
 
Taking into account the aforementioned, we identified the N-ethyl-D-proline subunit 
as the best right-hand side for the new scaffold (compound 57) when considering only the 
C-9-methylated derivatives. On the other hand, the introduction of a fluorine atom at the 
C-9 position performed better in the assay than the other substitution patterns. According 
to that, we hypothesized that the compound featuring both substituents would afford an 
inhibitor with improved potency (Fig. 61). This highlights the relevant role played by the 
polar moiety at the right-hand side as well as by the C-9 substituent. 
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Fig. 61. Compound 77 combines the best findings from the previous series of analogues. 
1.3 Synthesis of the fluoro-benzohomoadamantane analogue of PF-877423 
 For the preparation of the fluorinated analogue 77 the same synthetic route as for the 
compounds 56 and 57 was applied. The amide coupling reaction of amine 48 with (R)-
pyrrolidine-2-carboxylic acid under EDC and HOBt conditions afforded the desired Boc-
protected pyrrolidine 78 in 92% yield (Scheme 43). Next, the product was subjected to 
deprotection with aqueous phosphoric acid to provide proline 79 in quantitative yield. 
Final N-alkylation of the free amine with ethyl bromide under the already described 
conditions produced the final amide 77 in moderate yield. Similar to compound 57, the 
hydrochloride salt produced a hydroscopic solid. In order to have a compound suitable for 
characterization and pharmacological evaluation, PF-877423’s analogue 77 was prepared as 
its L-(+)-tartrate salt. 
From the 
exploration of 
the right-hand 
side 
From the 
identification 
of the best C-9 
substituent 
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Scheme 43. Full synthetic route for the preparation of amide 77 from intermediate 48. 
1.4 Pharmacological evaluation of the fluoro-benzohomoadamantane derivative of PF-
877423 
 The research group of Dr. Scott Webster (University of Edinburgh) tested the (R)-
proline 77 as an 11β-HSD1 inhibitor in the SPA. At a concentration of 10 µM, the 
compound inhibited 76% of the total enzyme, not far away from the percentage of 
inhibition of its methylated analogue 57 (Table 14). Pleasingly, in the IC50 determination, 
the threefold reduction on its value confirmed our first assumption, that the compound 
bearing a fluorine atom at the C-9 position and the N-ethyl-D-proline as the polar unit 
would result in an 11β-HSD1 inhibitor with enhanced potency, compared to the previous 
series of compounds. 
Table 14. Results of the pharmacological evaluation of amide 77 and its comparison with the 
methylated analogue 57 and the standard PF-877423.  
 
 
Comp. R % inhibition at 10 µM IC50 (µM) 
57 Me 77 1.0 ± 0.3 
77 F 76 0.35 ± 0.20 
PF-877423 - 93 0.004 
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However, compound 77 is around ~100-fold less potent than the adamantyl analogue 
PF-877423. Therefore, it can be argued that the substitution of the adamantane moiety by 
the size-expanded benzopolycycle might be detrimental for the binding to the enzyme. To 
check this hypothesis, molecular modelling studies were performed.  
1.5 Computational studies of the first family of 11β-HSD1 inhibitors 
 To gain insight on the mode of inhibition of the most potent compounds 57 and 77, 
the research group of Prof. Dr. F. Javier Luque of the University of Barcelona examined 
the binding of both prolines 57 and 77 on the 11β-HSD1 enzyme through docking and 
molecular dynamics simulations.  
 Preliminary docking calculations performed with Glide supported the ability of the 
ring-expanded benzopolycycle to fill the binding cavity of human 11β-HSD1.386 The 
docking scores of 57 (-8.1 kcal/mol) and 77 (-8.2 kcal/mol) compared well with PF-877423 
(-7.8 kcal/mol). Moreover, the best scored poses of both inhibitors indicated that, on one 
hand, the polar units mimicked the binding mode of PF-877423, retaining the hydrogen 
bond formed between the amide carbonyl oxygen and the hydroxyl group of Ser170. On 
the other hand, the hydrophobic cage filled the site occupied by the adamantane unit in 
PF-877423.  
 Despite the tolerable binding of new compounds 57 and 77 observed in the docking 
studies, we aimed to investigate further the reason for that difference on the inhibitory 
activity. With this in mind, the structural integrity of the best poses of compounds 57 and 
77 was explored by means of molecular dynamics (MD) simulations. Three independent 
50 ns MD simulations were run for each ligand-receptor complex, yielding the following 
characteristics: 
 All the simulations were stable, as noted in the root-mean square deviation profiles 
ranging from 1.5 to 2.4 Å for the protein backbone, and from 2.5 to 3.5 Å for the 
residues in the binding site. This fact reflected the enhanced flexibility of the loops 
that enclose the binding pocket.  
 The ligand pose was preserved along the simulations. Particularly, the hydrogen 
bond formed between the inhibitor and Ser170 residue was maintained in all cases, 
with an average distance of 2.8 ± 0.2 Å (Fig. 62).  
 The relative binding affinities were estimated from solvent interaction energy 
calculations, which revealed that compounds 57 and 77 should be stronger binders, 
by 0.5 and 1.1 kcal/mol, respectively, than PF-877423. 
                                                          
386 Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, 
P. C.; Mainz, D. T. J. Med. Chem. 2006, 49, 6177-6196. 
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Fig. 62. Representative snapshots taken from the MD simulations of the complexes 
between human 11β-HSD1 and compounds PF-877423 (top; green sticks) and 77 (bottom; 
pink sticks). Residues Tyr183 and Ser170 are shown as gray sticks, the NADP cofactor as 
yellow-based sticks and the protein backbone as blue cartoon. For the sake of clarity only 
polar hydrogens are shown. The shape of the binding cavity is shown as a white contour. 
 While the preceding results support the assumption that the insertion of a phenyl ring 
should lead to an enhanced binding affinity, the reduction of inhibitory potency may 
alternatively be ascribed to a lower effective concentration due to the increase in the 
hydrophobicity of the polycycle. In order to confirm this hypothesis, the log P was 
determined using quantum mechanical IEF/MST calculations for the most favourable 
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conformations of compounds 57, 77 and PF-877423.387 The study indicated that the 
introduction of a phenyl ring in the polycyclic structure increases the log P value by 1.5 
units for amide 57 and 0.9 units for amide 77 relative to the adamantyl parent compound 
PF-877423. 
 Taken together, the in silico results suggest that the ring-expansion strategy performed 
with the benzopolycyclic scaffold might lead to effective inhibitors of human 11β-HSD1 
enzyme. Nevertheless, the data from log P calculations along with the pharmacological 
results have demonstrated that a proper balance of hydrophobicity, furnished chiefly by the 
adamantane-like scaffold, is necessary to attain an optimum pharmacological profile.  
2. Application of the hexacyclic scaffold as an adamantane analogue in 11β-HSD1 
inhibitors  
Before starting with this section, it is worth to mention that the work presented 
henceforth was developed simultaneously with the previous family of compounds. 
Consequently, an iterative process could not be achieved to reshape the design of the new 
family of compounds.  
2.1 Synthesis of the 3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane derivatives 
Following the analogy-based approach applied in the former section, and bearing in 
mind the flexibility of the binding pocket of the 11β-HSD1 protein arisen from the 
available X-ray data, we pursued the preparation of a new family of compounds featuring a 
size-expanded ring in lieu of the adamantane group. Specifically, we decided to assemble 
the pentacyclic pyrrolidine scaffold V and amido- or urea-like units so as to assess the effect 
of this hydrophobic adamantane-like structure in the inhibition of 11β-HSD1 (Fig. 63). 
The polar groups attached to this polycycle consisted of the already tested moieties, again 
referred as right-hand sides (RHS). These functionalities should enable the formation of 
key hydrogen bonds at the binding site, whilst the polycyclic structure should fill one of the 
hydrophobic pockets of the catalytic site. 
                                                          
387 Curutchet, C.; Orozco, M.; Luque, F. J. J. Comput. Chem. 2001, 22, 1180-1193. 
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Fig. 63. Design of the new 11β-HSD1 inhibitors with general structure V. 
  The preparation of the hexacycles V has been described and applied multiple times 
by our research group.90,164,172 The synthetic pathway started with an elegant domino Diels-
Alder reaction between 9,10-dihydrofulvalene and dimethyl acetylenedicarboxylate, 
originally published by two independent groups; L. A. Paquette and E. Hedaya.388,389 In the 
first step, cyclopentadiene (prior to distillation from commercially available 
dicyclopentadiene) was deprotonated with sodium hydride, whose anion 80 self-coupled 
through low-temperature iodine-promoted oxidation, to generate in situ 9,10-
dihydrofulvalene 81 (Scheme 44). The latter underwent a double Diels-Alder reaction after 
the addition of one equivalent of dimethyl acetylenedicarboxylate, yielding a mixture of 
monoadducts 82 and 83, which are referred as pincer and domino products, respectively.390 
Along with them, diadducts 84 and 85 were formed as side-products.  
                                                          
388 Paquette, L. A.; Wyvratt, M. J. J. Am. Chem. Soc. 1974, 42, 4671-4673. 
389 McNeil, D.; Vogt, B. R.; Sudol, J. J.; Theodoropulos, S.; Hedaya, E. J. Am. Chem. Soc. 1974, 96, 4673-
4674. 
390 Domingo, L. R.; Arnó, M.; Andrés, J. Tetrahedron Lett. 1996, 37, 7573-7576. 
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Scheme 44. Domino Diels-Alder reaction of 9,10-dihydrofulvalene 81 and dimethyl acetylenedicarboxylate. 
The earlier procedures applied a tedious purification that implied difficult distillations. 
Fortunately, a few years later a more straightforward purification method appeared, 
allowing the separation of the pair of monoadducts from the pair of diadducts.391 Taking 
advantage of the solubility properties of the products, 82 and 83 were isolated by 
precipitation of the side-products 84 and 85 with diethyl ether and subsequent filtration. 
This experimental-related improvement permitted to scale-up the reaction up to 40 g of 
final mixture.  
Separation of monoadducts 82 and 83 was achieved by selective hydrolysis of the less 
sterically hindered diester 83. Treatment with aqueous potassium hydroxide solution in 
methanol at room temperature for a short period of time afforded diacid 87, which was 
                                                          
391 Taylor, R. T.; Pelter, M. W.; Paquette, L. A. Org. Synth. Coll. Vol. VIII 1993, 298-302. 
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isolated from the intact diester 82 in the aqueous work-up (Scheme 45). In this way, we 
prepared 20 g of the desired pentacyclic diester 82 in 7% overall yield.  
 
Scheme 45. Selective hydrolysis of 83 vs 82 due to steric hindrance. 
Employing harsher conditions, diester 82 could be hydrolysed providing its 
corresponding pentacyclic diacid 88 in 81% yield (Scheme 46). Next, diacid 88 was 
subjected to imide formation with neat urea at 220 ºC to afford imide 89 in 86% yield. At 
this temperature, the already melt urea undergoes thermal decomposition to supply cyanic 
acid and ammonia, which is the actual nucleophile that adds to each one of the carboxylic 
acids.392  
 
Scheme 46. Basic hydrolysis of diester 82 and later imide formation. 
Afterwards, the imide was transformed to the corresponding pentacyclic pyrrolidine 
90 based on the protocol formerly described by our research group.393 Unlike the more 
common reductive agents, such as lithium aluminium hydride, sodium bis(2-
methoxyethoxy)aluminium hydride (Vitride® or Red-Al®) is soluble in most of the common 
organic solvents, which facilitates the handling of the substance, and reacts less strongly 
with water than LiAlH4, although it is still moisture sensitive.394 Besides, Red-Al® is highly 
efficient in the reduction of multiple functional groups, such as nitriles, isocyanates and 
sulfonamides, inter alia. Thus, imide 89 was reduced with Red-Al® to produce secondary 
amine 90 in 92% yield (Scheme 47). 
                                                          
392 For further study on the pyrolysis of urea: Schaber, P. M.; Colson, J.; Higgins, S.; Thielen, D.; Anspach, 
B.; Brauer, J. Thermochim. Acta 2004, 424, 131-142. 
393 Rey-Carrizo, M. Ph.D. Dissertation, University of Barcelona, 2014. 
394 Gugelchuk, M.; Silva, L. F. Jr.; Vasconcelos, R. S.; Quintiliano, S. A. P. e-EROS 2007, 1-8. 
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Scheme 47. Imide reduction with Red-Al®. 
With key intermediate 90 in hand, we proceeded to the coupling of this pentacyclic 
pyrrolidine to the different polar units showed in figure 63. Applying the same procedures 
as in section 1, we started with the amide coupling with N-Boc-D-proline using EDC and 
HOBt as activating agents to provide hexacyclic amide 91 in 90% yield (Scheme 48). 
 
Scheme 48. Amide bond formation with (R)-N-boc-pyrrolidine-2-carboxilyc acid. 
Regrettably, when the Boc-protected pyrrolidine 91 was subjected to acid conditions 
for its deprotection, only a complex was obtained, from which the desired amine 92 was 
could not be isolated. Illustrative computational studies revealed the feasibility that one 
part of the product might have been lost in the intramolecular attack of the amine to one 
of the double bonds of the polycyclic system, giving compound 94 as a plausible side-
product (Scheme 49).395  
 
Scheme 49. Possible explanation for the absence of desired amine 92. 
                                                          
395 Data from computational studies is not shown. 
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To avoid this issue, we decided to reduce the olefinic double bonds prior to the amide 
coupling, even though it meant to skip the no preparation of the final compound 93. For 
the provision of saturated pentacyclic pyrrolidine 95 for further uses, diene 90 was 
hydrogenated under atmospheric pressure and at room temperature for 4 hours, 
whereupon amine 95 was recovered after filtration of the catalyst in 86% yield (Scheme 
50). 
 
Scheme 50. Catalytic hydrogenation of pentacyclo 90 at atmospheric pressure. 
Starting now from saturated pentacyclo pyrrolidine 95, final ethylated proline 98 was 
synthesized after amide bond formation with N-Boc-D-proline, followed by deprotection of 
the carbamate group with aqueous phosphoric acid and subsequent N-alkylation with ethyl 
bromide and catalytic amounts of potassium iodide, as shown in the scheme below. Of 
note were the requirement of column chromatography after the acid deprotection affording 
compound 97 in 36% yield, and the isolation of the final amide 98 as tartrate salt for its 
full characterization and pharmacological evaluation. 
 
Scheme 51. Synthetic pathway for the preparation of amide 98 from saturated pyrrolidine 95. 
The substituted phenyl analogue 99 and its saturated derivative 100 were prepared 
applying the same conditions as before, i.e. amide coupling with EDC and HOBt, and 
 
144   CHAPTER 2: 11β-HSD1 inhibition 
catalytic hydrogenation with palladium on carbon, affording the corresponding products 
in 47% and 89% yield, respectively (Scheme 52).  
 
Scheme 52. Amide coupling between diene 90 with 4-amino-3,5-dichlorobenzoic acid, then 
hydrogenation at 1 atm. 
Similarly, the pair of cyclohexyl amides 101 and 102 were obtained under the same 
procedures in moderate and excellent yields, respectively (Scheme 53).  
 
Scheme 53. Synthesis of saturated and unsaturated cyclohexyl amides 101 and 102. 
 Next, we moved to the hexacyclic derivatives bearing a urea unit as the polar core of 
the molecule. In analogy with the previous benzopolycyclic scaffold, secondary amine 90 
was reacted with 1-piperidinecarbonyl chloride in the presence of a base to provide 
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unsaturated urea 103 in 71% yield (Scheme 54). Albeit multiple attempts to purify the 
product, from different gradient elution systems in column chromatography to several 
solvent mixtures in crystallization techniques, urea 103 did not achieve the adequate purity 
for pharmacological testing. Because of that, diene 103 was subjected to catalytic 
hydrogenation, furnishing 104 in 72% yield and pure enough for its biological evaluation.  
 
Scheme 54. Urea formation with a carbamoyl chloride prior to reduction of the double bonds. 
For the synthesis of the last analogue of this family, which featured a thiazolone ring 
in the right-hand side of the molecule, pyrrolidine 90 was reacted with benzoyl 
isothiocyanate in chloroform to give carbonyl thiourea derivative 105 in quantitative yield 
(Sheme 55). Basic hydrolysis with potassium carbonate and water did not afford the desired 
thiourea 106, and the starting material was fully recovered. An alternative for the formation 
of thiourea 106 was adapted from the literature and consisted in the hydrazine-promoted 
debenzoylation under solvent-free conditions at room temperature.396 Worth the mention 
is the fact that if the reaction was carried out in chloroform at reflux, triazole-ring formation 
takes place instead of the debenzoylation. Nevertheless, neither thiourea 106 nor the 
corresponding triazole ring were formed, but again the starting material was recovered. We 
reasoned the lack of reactivity was coming from the steric hindrance furnished by the ring-
expanded scaffold.  
                                                          
396 Kodomari, M.; Suzuki, M.; Tanigawa, K.; Aoyama, T. Tetrahedron Lett. 2005, 46, 5841-5843. 
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Scheme 55. Conversion of pyrrolidine 90 to benzoylthiourea 105, and failed attempts of 
hydrolysis. 
 In the end, this family of hexacyclic derivatives comprehended 6 new compounds that 
were tested as 11β-HSD1 inhibitors.  
2.2 Pharmacological evaluation and computational studies of the 3-
azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane derivatives 
 Compounds 98-102 and 104 were tested, using the SPA technique, by Dr. Scott 
Webster in the University of Edinburgh. As for the previous family, compounds with a 
percentage of inhibition of 70% or higher at 10 µM were further evaluated with their IC50 
determination (Table 15). 
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Table 15. Inhibition of the 11β-HSD1 by the new hexacyclic compounds. ND: not determined. 
PF-877423 was used as a standard.  
 
 
Comp. No. of double 
bonds 
RHS % inhibition at 10 µM IC50 (µM) 
98 0 
 
56 ND 
99 2 
 
98 2.77   
100 0 
 
98 0.414  
101 2 
 
95 1.076  
102 0 
 
103 0.289  
104 0 
 
101 0.320  
PF-877423 - - 93 0.004 
  
 These data allowed us to deduce the following: 
 Five compounds (98-102 and 104) inhibited almost totally the 11β-HSD1 enzyme 
in the SPA at 10 µM concentration. 
 Generally, aliphatic amides 101-102 and urea 104 were slightly more potent than 
aromatic amides 99-100.  
 In contrast with the previous benzopolycyclic family, the PF-877423’s analogue 98 
showed the lowest activity for this series of compounds.  
 As a common trend, saturated pentacyclic pyrrolidines were more potent that their 
parent unsaturated analogues (compare 100 vs 99 and 102 vs 101). 
 The replacement of the methine group in 102 by a nitrogen atom in 104 did not 
greatly improved the activity, unlike the previous family. 
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 The substitution of the adamantane ring in PF-877423 for the hexacyclic scaffold 
led to a significant reduction in the inhibitory activity. 
The fact that proline derivative 98 was the least potent compound of this series, but 
the most potent analogue for the benzo-homoadamantane series, reflected that the 
lipophilic scaffold oriented the polar units in a way that could alter their binding mode 
within the catalytic site. Thus, a specific right-hand side should not necessarily behave 
similarly for any given scaffold. Consequently, for each scaffold a screening of polar 
subunits should be performed in order to identify the best combination of fragments. In 
order to shed light on the reasoning of the binding mode of the new structures, Prof. Luque 
performed preliminary MD studies of the most active compounds 102 and 104, and 
simultaneously, the adamantane derivative 107, synthesized by our group, was evaluated 
(Fig. 64).364 
 
Fig. 64. Three selected compounds for MD simulations. 
From the preliminary results, two main conclusions are depicted: 
 The hexacyclic scaffold occupies a larger space than the adamantane, being 
practically the upper-limit the size the lipophilic scaffold can reach. In other 
words, the scaffold is too big to properly fit within the hydrophobic pocket 
(Fig. 65). 
 There is no significant difference between 102 and 104 in their binding mode. 
Thus, the nitrogen does not seem to affect the potency, as reflected by their 
very similar IC50 values.  
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Fig. 65. Representative snapshots taken  
from the MD simulations of the complexes 
 between human 11β-HSD1 and  
compounds 102 (top left; purple sticks),  
104 (top right, yellow sticks) and 107  
(bottom; blue sticks). Residues Tyr183  
and Ser170 are shown as green sticks,  
the NADP cofactor as orange-based sticks  
and the protein backbone as green cartoon.  
For the sake of clarity only polar hydrogens  
are shown. The shape of the binding  
cavity is shown as a white contour. 
 
As a final remark, the larger inhibitory potency of saturated compounds 100 and 102 
(also 104, although it was not possible to test its parent compound 103) could also reflect 
the increase in hydrophobicity resulting from saturation of the double bonds in 99 and 
101, respectively, as expected from the higher hydrophobicity of ethane relative to ethylene 
(experimental log P of 1.8 and 1.1, respectively).397  
The decreased activity of the benzopolycyclic and hexacyclic compounds compared to 
the adamantyl analogue underlined the requirement of both a perfect match and the 
reduction of the overall lipophilicity of a bulky group in this pocket to achieve high potency. 
Hence, the incorporation of nuclei with enhanced polarity and reduced size appears to be 
a suitable strategy for developing novel inhibitors. 
                                                          
397 Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR: Hydrophobic, Electronic and Steric Constants, 
American Chemical Society, Washington, DC, 1995. 
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It is worth to mention that taking advantage of the conclusions drawn from the two 
sets of compounds reported in this manuscript, the Ph.D. student Rosana Leiva, in her 
thesis, has synthesized novel 11β-HSD1 inhibitors with low nanomolar IC50 values.   
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In the second chapter of the thesis, 19 new final compounds were prepared and 
thoroughly characterized by means of spectroscopic and analytical techniques. Concretely, 
the families prepared in this work and the conclusion derived from them are: 
 6,7,8,9,10,11-hexahydro-5,7:9,11-dimethano-5H-benzocyclononen-7-yl 
derivatives: 
1. From the synthetic point of view: since the intermediate scaffolds were 
already prepared in the previous chapter, only procedures described in 
the literature were followed for the final reactions. 
2. From a pharmacological activity point of view: only two derivatives, 57 
and 77, displayed enough percentage of inhibition at 10 µM (77 and 
76%, respectively) for their IC50 determination (Fig. 66). The methylated 
compound 57 showed low inhibitory activity in the SPA (IC50 of 1.0 
µM), and this activity was slightly improved with the fluorinated 
analogue 77 (IC50 of 0.35 µM). None of the others benzo-
homoadamantane compounds were active as 11β-HSD1 inhibitors. The 
substitution of the adamantane group for the benzo-homoadamantane 
nucleus is unfavourable. 
 
Fig. 66. Active compounds from the first family. 
3. From a computational point of view: docking and MD simulations 
revealed that the insertion of a phenyl ring in the bulky group should 
not be detrimental for the activity, compared with the standard PF-
877423. However, the lack of inhibitory activity of the benzo-
homoadamantane derivatives may be due to an improper balance of 
lipophilicity. 
 3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane derivatives: 
1. From the synthetic point of view: their preparation entailed the 
synthesis first of the scaffold, through a 5-step sequence, implying an 
elegant domino Diels-Alder reaction. The subsequent reaction 
conditions were taken from the previous family of compounds. 
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However, not all the reactions were efficient, and a few of the targeted 
products were abandoned. 
2. From a pharmacological activity point of view: except for compound 98, 
all the tested compounds were active as inhibitors of the 11β-HSD1, 
showing moderate potency. Of note is the increase on the potency with 
the saturation of the double bonds, resulting in the most potent 
compounds of the series 100, 102 and 104 (IC50 of 0.414, 0.289 and 
0.320 µM, respectively) (Fig. 67). The different RHSs do not alter 
significantly the activity between them. The substitution of the 
adamantane ring for the hexacylic nucleus is unfavourable.  
 
Fig. 67. Active compounds from the second family. 
3. From a computational point of view: preliminary MD simulations of 
102 and 104 revealed that the hexacyclic scaffold fills the hydrophobic 
cavity to a larger extent than the adamantane standard 107, diminishing 
the activity. No significant difference was observed between the binding 
mode of 102 and 104. Finally, the increase on the activity with saturated 
compounds 100, 102 and 104 can be due to changes on the lipophilicity 
from their parent compounds. 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 3:  
sEH inhibition 
 
  
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 Introduction   159 
1. sEH inhibition by adamantane-based derivatives 
The last chapter of the present thesis will deal with the discovery of sEH as a pleiotropic 
target for drug development, as well as the manifold therapeutic benefits that its inhibition 
may lead. A summary of the sEH inhibitors that are currently in development will be 
included, most of which integrate an adamantane ring as the bulky moiety. Finally, the 
issues that have arisen over the drug discovery process will be discussed in order to 
comprehend the current needs for the development of future drug candidates. 
1.1 Epoxyeicosatrienoic acids and their biological role 
1.1.1 Oxidative pathways of arachidonic acid metabolism 
 One of the principal metabolic pathways in the organism is the arachidonate cascade, 
which revolves around the arachidonic acid (ARA), an ω-6, 20-carbon polyunsaturated fatty 
acid that is produced from membrane phospholipids of activated cells upon various 
stimuli.398 ARA is transformed to lipid chemical mediators with pro-inflammatory 
properties, such as prostaglandins (PGs) and leukotrienes (LKTs), by the action of 
cyclooxygenase (COX) and lipoxygenase (LOX) enzymes respectively, which are well-known 
drug targets against inflammation (Fig. 68).399 The most recently discovered cytochrome 
P450 (CYP450) branch of the cascade, which has not been exploited as a pharmaceutical 
target yet, also generates physiologically important eicosanoids.400 Among them, 
epoxyeicosatrienoid acids (EETs) are formed after epoxidation of ARA by mainly CYP2C 
and CYP2J, and possess an opposite effect than their counterpart products from COX and 
LOX metabolism.401 Detailed discussions on each of these three pathways are beyond the 
scope of this thesis.  
                                                          
398 Harizi, H.; Corcuff, J. B.; Gualde, N. Trends Mol. Med. 2008, 14, 461-469. 
399 Funk, C. D. Science 2001, 294, 1871-1875. 
400 Zeldin, D. C. J. Biol. Chem. 2001, 276, 36059-36062. 
401 Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Science 1999, 285, 
1276-1279. 
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Fig. 68. Three metabolic pathways of ARA: the COX, LOX and CYP450 enzymatic routes, resulting 
in an array of chemical mediators involved in inflammatory processes. Inhibitors of COX (COX-1 
and COX-2) (NSAIDs) are used for the treatment of pain and inflammation. Leukotriene 
antagonists are indicated in asthmatic and allergic states. NSAIDs: nonsteroidal anti-inflammatory 
drugs.  
1.1.2 Biological relevance of EETs and importance of the sEH management 
Generally, EETs are lipid mediators that move biological processes towards a 
homeostatic or status quo condition. EETs are autocrine and paracrine endothelium-derived 
factors that display attractive effects particularly in vascular and renal systems. To begin 
with, EETs are potent vasodilatory and anti-inflammatory agents.402 The vasodilatory 
properties of EETs are associated with an increased open-state probability of calcium-
activated potassium channels, which lead to hyperpolarization of the vascular smooth 
muscle.403 Of note, EETs seem to encourage the resolution of inflammation rather than 
prevent it via inhibition of the nuclear factor κB (NF-κB), activation of subfamilies of 
nuclear peroxisome proliferator-activated receptors (PPARs), and decreasing the expression 
                                                          
402 Morisseau, C.; Hammock, B. D. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 37-58. 
403 Fleming, I. Circ. Res. 2001, 89, 753-762. 
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of inducible COX-2. Besides, EETs exhibit other beneficial effects on biological systems, 
such as analgesic, anti-hypertensive, anti-platelet aggregation, fibrinolytic, pro-angiogenic 
and anti-apoptotic effects.404,405 In addition, some metabolic events are mediated by EETs, 
such as control of insulin release and modulation of insulin sensitivity.406,407 Taken 
together, EETs are considered important chemical mediators that interact with a plethora 
of proteins to generate a set of wholesome effects. Experimental studies have revealed that 
EETs act through an intracellular mechanism by binding to fatty-acid-binding proteins and 
PPARs, inter alia.408 However, the cascade processes derived from the action of EETs are 
still unknown for some of the abovementioned effects. For the moment, an EET receptor 
has yet to be identified. Figure 69 includes a schematic representation of the potential 
mechanism for the anti-inflammatory, cardiovascular and analgesic effects of EETs.409 
  
Fig. 69. Plausible mode of action of EETs in cardiovascular system, inflammation and pain. 
GPCR: G protein-coupled receptor; cAMP: cyclic adenosine monophosphate.  
The metabolic fate of the EETs is under control of the sEH, an enzyme that belongs 
to the α/β hydrolase family and facilitates the addition of water to an epoxide, leading to 
the formation of a vicinal diol.410 Thus, EETs are subjected to epoxide-ring opening to 
                                                          
404 El-Sherbeni, A. A.; El-Kadi, A. O. S. Arch. Toxicol. 2014, 88, 2013-2032. 
405 Duflot, T.; Roche, C.; Lamoureux, F.; Guerrot, D.; Bellien, J. Expert Opin. Drug Discov. 2014, 9, 1-15. 
406 Falck, J. R.; Manna, S.; Moltz, J.; Chacos, N.; Capdevila, J. Biochem. Biophys. Res. Commun. 1983, 114, 
743-749. 
407 Skepner, J. E.; Shelly, L. D.; Ji, C.; Reidich, B.; Luo, Y. Prostaglandins Other Lipid Mediat. 2011, 94, 3-8. 
408 Imig, J. D.; Hammock, B. D. Nat. Rev. Drug Discov. 2009, 8, 794-805. 
409 Pillarisetti, S. Inflamm. Allergy - Drug Targets 2012, 11, 143-158. 
410 Harris, T. R.; Hammock, B. D. Gene 2013, 526, 61-74. 
 
162   CHAPTER 3: sEH inhibition 
afford dihydroeicosatrienoic acids (DHETs), whereby the biological effects of EETs are 
diminished, eliminated or altered (Fig. 70).411   
 
 
 
Fig. 70. Transformation of active EETs to inactive DHETs through the sEH enzyme. 
Consequently, since the discovery of the biological role of EETs and their metabolism, 
sEH has emerged as a promising therapeutic strategy for the treatment of multiple 
conditions. Inhibition of sEH stabilizes the levels of EETs for the maintenance of the 
cellular homeostasis. Because other metabolic routes different from the sEH have been 
described that ensure the control of EETs’ concentration in plasma and tissues even in the 
absence of sEH activity, EETs levels can only increase moderately with the inhibition of 
sEH.412 Hence, limited target-related side effects are predicted with the administration of 
potent sEH inhibitors. 
1.2 Targeting sEH: an overview of its pharmacology  
Over the past decade, the appreciation of the importance of EETs and their regulation 
by sEH has greatly accelerated due to the huge therapeutical potential derived from the 
inhibition of sEH. Since the first studies performed 30 years ago, the value of the sEH 
inhibition in various animal models of diseases has been demonstrated. The contribution 
of these studies will be covered in order to understand the beneficial outcomes from sEH 
inhibition. 
1.2.1 Regulation of inflammation by sEH inhibitors  
The anti-inflammatory role of EETs has been demonstrated using multiple strategies 
including overexpression of CYP450, deletion of sEH in animal models or use of sEH 
                                                          
411 Morisseau, C.; Hammock, B. D. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 311-333. 
412 Imig, J. D. Physiol. Rev. 2012, 92, 101-130. 
Epoxyeicosatrienoic acids 
(EETs) 
Dihydroxyeicosatrienoic 
acids (DHETs) 
 
 Introduction   163 
inhibitors and directly monitoring EET effects.413,414,415 Reduced activation of the NF-κB is 
a key event in the anti-inflammatory activity of EETs, specially of 11,12-EET and 14,15-
EET, as previously indicated. This reduction seems to follow three complementary cellular 
mechanisms (Fig. 71): i) decrease of the activation of NF-κB induced by tumor necrosis 
factor-α (TNF-α); ii) activation of PPAR-γ activity; iii) reduction of the prostaglandin E2 
(PGE2).402,416 
 
Fig. 71. Action of epoxy-fatty acids (EpFAs) in the inflammatory process. PLA2: phospholipase 
A2. FAs: fatty acids. DiHFAs: dihydroxy-fatty acids. IKK: inhibitor of κB kinase. iNOS: 
inducible nitric oxide synthase. VCAM-1: vascular cell adhesion molecule 1. IL: interleukin. 
NO: nitric oxide. 
Furthermore, the agents that elevate cAMP are known to be anti-inflammatory, also by 
inhibiting NF-κB transcription.417 Thus, it is likely that the elevation of cAMP, prior 
activation of GPCR, is another major mechanism behind the anti-inflammatory effects of 
EETs.  
All in all, these data indicate that sEH is an emerging therapeutic target in a number 
of diseases that have inflammation as a common underlying cause. 
 
                                                          
413 Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Science 1999, 285, 
1276-1279. 
414 Schmelzer, K. R.; Kubala, L.; Newman, J. W.; Kim, I.; Eiserich, J. P.; Hammock, B. D. Proc. Natl. Acad. Sci. 
USA 2005, 102, 9772-9777. 
415 Deng, Y.; Edin, M. L.; Theken, K. N.; Schuck, R. N.; Flake, G. P.; Kannon, M. A.; DeGraff, L. M.; Lih, F. B.; 
Foley, J.; Bradbury, J. A.; Graves, J. P.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C.; Lee, C. R. FASEB J. 2011, 25, 
703-713. 
416 Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T. S.; Fang, X.; Zhu, Y.; Spector, A. A.; Gill, S.; Morisseau, C.; 
Hammock, B. D.; Shyy, J. Y. J. Proc. Natl. Acad. Sci. USA 2005, 102, 16747-16752. 
417 Ollivier, V.; Parry, G. C. N.; Cobb, R. R.; de Prost, D.; Mackman, N. J. Biol. Chem. 1996, 271, 20828-20835. 
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1.2.2 Effects of sEH inhibitors on pain 
Neuropathic pain is a component of many disease states, such as T2DM, and there is 
no current treatment to suppress it. Despite the intensive efforts and resulting gains in 
understanding the mechanisms underlying neuropathic pain, limited success in therapeutic 
approaches has been attained. A recently identified, non-channel, non-neurotransmitter 
therapeutic target for pain is the enzyme sEH.418 Given the effectiveness in reducing 
inflammation in some rodent models, it was not surprising that the inhibition of sEH also 
reduced inflammatory and neuropathic pain. This effect has been subsequently detected in 
multiple animal models of pain in which sEH inhibitors and EETs reduced pain 
perception.419,420 The mechanism by which the sEH intervenes in the nociception process 
has been confirmed to imply opioid and GABAergic pathways, as well as PPARs.421 As it 
will be discussed later on, the sEH has also been associated with the endoplasmic reticulum 
(ER) stress, a causative agent of neuropathic pain.422,423 
Interestingly, the sEH inhibitors are more effective than the opioid morphine in 
relieving some pain conditions, with no change in behaviour or sedation, unlike many 
opiates. Some studies have demonstrated that the co-administration of sEH inhibitors and 
NSAIDs produced a valuable analgesic and anti-inflammatory effect with a reduction of 
cardiovascular toxicity derived from the NSAID treatment.424 The efficacy of sEH inhibitors 
against diabetic neuropathic pain is noteworthy because of its potential to address the 
unmet therapeutic need of relieving this chronic pain condition.  
1.2.3 sEH and cardiovascular disease  
 Another therapeutic area of interest for sEH inhibitors is cardiovascular diseases. EETs 
are putative endothelium-derived hyperpolarizing factors (EDHP) that increase open-state 
frequency of calcium ion channels leading to vasodilatation of vascular smooth muscle by 
activation of potassium channels, through a cAMP/protein kinase A-dependent 
mechanism that involves the intracellular translocation of transient receptor potential 
channels.425 The identification of their vasodilatory properties suggested a role of the sEH 
in blood pressure regulation. EETs also promote natriuresis, regulating indirectly the blood 
                                                          
418 Hammock, B. D.; Wagner, K.; Inceoglu, B. Pain Manag. 2011, 1, 383-386. 
419 Wagner, K.; Inceoglu, B.; Dong, H.; Yang, J.; Hwang, S. H.; Jones, P.; Morisseau, C.; Hammock, B. D. Eur. 
J. Pharmacol. 2013, 700, 93-101. 
420 Sing, K.; Lee, S.; Liu, J.; Wagner, K. M.; Pakhomova, S.; Dong, H.; Morisseau, C.; Fu, S. H.; Yang, J.; Wang, 
P.; Ulu, A.; Mate, C. A.; Nguyen, L. V; Hwang, S. H.; Edin, M. L.; Mara, A. A.; Wul, H.; Newcomer, M. E.; 
Zeldin, D. C.; Hammock, B. D. J. Med. Chem. 2014, 57, 7016-7030. 
421 Pillarisetti, S.; Khanna, I. Drug Discov. Today 2015, In press. DOI: 10.1016/j.drudis.2015.07.017. 
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Acad. Sci. USA 2015, 112, 9082-9087. 
424 Schmelzer, K. R.; Inceoglu, B.; Kubala, L.; Kim, I.; Jinks, S. L.; Eiserich, J. P.; Hammock, B. D. Proc. Natl. 
Acad. Sci. USA 2006, 103, 13646-13651. 
425 Fleming, I.; Rueben, A.; Popp, R.; Fisslthaler, B.; Schrodt, S.; Sander, A.; Haendeler, J.; Falck, J. R.; 
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pressure.426 This hypothesis has been confirmed in several studies using inhibitors of sEH, 
which led to an increase in the EETs’ levels, resulting in a reduction of blood pressure in 
angiotensin-driven hypertensive rodent models.427   
 Ulu et al. showed that inhibition of sEH in a mammalian model of atherosclerosis by an 
orally administered agent reduced the formation of aortic plaques.428 A recent study 
performed with mice treated with a sEH inhibitor revealed a reduction in the size of 
atherosclerotic plaques, along with an improvement in the cholesterol levels.429 Numerous 
studies with sEH inhibitors have also shown cardiovascular-protective effects in cerebral 
and cardiac ischaemia, arrhythmia, hypertrophy and blood clotting, 430,431,432,433 proving once 
more the great potential of the sEH as a cardiovascular regulator.  
 The data regarding the cardiovascular effects of sEH inhibition has been compiled in 
several reviews.408,412,434,435 These finding encourage the use of sEH inhibitors in patients 
who have cardiovascular problems. 
1.2.4 Role of sEH in the development of diabetes and metabolic syndrome. Involvement of ER stress 
Metabolic processes are coordinately regulated by lipids, where EETs display a 
significant role in the pathophysiology of the endocrine system in relation to glucose 
homeostasis.406 Whilst EETs and sEH inhibitors do not alter the levels of glucose and 
insulin in healthy patients, they have proven efficient in the regulation of glycemic states 
in some models of diabetes and MetS. Luo et al. demonstrated that sEH inhibitors or sEH 
knockout [EHPX2(-/-)] control glucose homeostasis in streptozotocin-treated mice. 
Specifically, they observed reduction of the glycemic levels, increase of insulin secretion 
and islet apoptosis reduction.436 These alterations of the pancreatic islets and the 
improvement of the glucose homeostasis have been also confirmed in an animal model of 
insulin resistance.437  
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EETs also regulate the levels of lipids and adipogenesis by activation of PPARs.438 In 
addition, the diet-induced MetS in rats was ameliorated with the administration of sEH 
inhibitors, with a notable reduction of the blood pressure and the body weight gain, an 
increase of the insulin sensitivity and an improvement of the inflammation markers.439 
Moreover, sEH has been related to the ER stress in liver and adipose tissue, whose 
dysfunction is a contributor to metabolic diseases.422 Perturbation of the ER function and 
chronic ER stress are also associated with many other pathologies ranging from 
neurodegenerative diseases to cancer and inflammation.440 ER stress will be covered in 
more depth later on in the present chapter. 
The (patho)physiological importance of the sEH in the glucose and lipid homeostasis 
indicates that treatment with sEH inhibitors may address major comorbidities of diabetes, 
obesity and MetS. 
1.2.5 sEH inhibition for other potential clinical applications 
The inhibition of the sEH has been studied for other conditions with positive results. 
In brief, inhibitors of the sEH display a protective effect on renal damage induced by 
hypertension or inflammation.441,442 Furthermore, the inhibition of sEH has resulted 
effective in the treatment of chronic obstructive pulmonary disease, especially when 
cigarette smoke is a risk factor, and pulmonary fibrosis.443,444,445 On the other hand, because 
of the structural similarity of some inhibitors of sEH with sorafenib, the only FDA-
approved small molecule used for the treatment of advanced hepatocellular carcinoma, 
their cytotoxicities were also similar to sorafenib in various human cancer cell lines.446,447 
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Besides, schizophrenia, seizures and hepatic fibrosis has been recently related to 
sEH.448,449,450 The potential clinical indications of sEH inhibitors are shown in Figure 72.  
 
 
 
 
 
 
 
Fig. 72. Potential clinical indications for the use of sEH inhibitors. 
1.3 sEH: crystal structure, catalytic mechanism, tissue expression and regulation  
There are several mammalian epoxide hydrolases, including microsomal EH (mEH) 
and sEH, which are named according to their subcellular location. They can be also 
differentiated by their substrate specificity. Whereas mEH activity is focused on the 
metabolism of xenobiotics, where it degrades preferentially epoxides on cyclic systems, such 
as arenes, sEH is prone to hydrolyze endogenous epoxide-fatty acids, such as the oxidation 
products of linoleic acid, linolenic acid or the EETs themselves.451 14,15-EET is the 
preferred substrate of sEH with the highest Vmax and lowest Km, followed by 11,12-EET, 8,9-
EET and 5,6-EET.405 Other epoxide hydrolases have been identified and studied, such as 
cholesterol and hepoxilin epoxide hydrolases, but they are beyond the purpose of the 
present thesis.452 
The EPHX-2 gene, located on the short arm of chromosome 8, with nearly 45 kb and 
19 axons, encodes the sEH.410 Human sEH is a homodimer formed by two ~ 62 kDa 
monomeric subunits arranged in an anti-parallel fashion and separated by a short proline-
rich linker (Fig. 73).453 The epoxide hydrolase activity resides in the C-terminal domain, 
whereas the N-terminal domain exhibits a phosphatase activity that apparently acts on 
lysophosphatidic acids.454 
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A prerequisite for the development of potent and selective inhibitors is the 
understanding of the sEH mechanism of action. The catalytic mechanism of the sEH has 
been elucidated in the last few years with the aim of defining the key residues involved in 
the hydrolysis. As a result, X-ray crystallographic data has revealed that the hydrolase 
catalytic pocket consists of two tyrosine residues (Tyr382 and Tyr465) which act as 
hydrogen bond donors to promote epoxide-ring opening by the backside attack via an SN2-
type reaction of an aspartic acid residue (Asp334) to form a hydroxyl alkyl-enzyme 
intermediate (Fig. 74).411 In this step, the nucleophilic Asp334 is oriented and activated by 
a histidine residue (His523). Then, different proton shifts, which have yet to be proven, 
occur and a water molecule attacks the intermediate releasing the diol product and the 
original enzyme.  
 
Fig. 74. Schematic representation of the polarization of the epoxide by the two tyrosine 
residues and subsequent attack of the aspartic acid residue. Catalytic triad (blue), long branch 
(purple) and short branch (green).  
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Fig. 73. X-ray crystal structure of the sEH homodimer. PDB code: 1S80.455 
 
 Introduction   169 
Extensive enzymological and structural 
studies revealed an “L”-shaped hydrophobic 
tunnel of the binding site, whose branches 
measure 10 and 15 Å, respectively, and with the 
catalytic triad placed between them (Fig. 75). 
Albeit being largely hydrophobic, each branch of 
the pocket features residues that are involved in 
specific interactions, such as hydrogen bonds, 
Van der Waals and π-stacking interactions, and 
are open to the solvent.  
Fig. 75. Overview of the catalytic pocket, with 
representative fragments bound to each site 
(catalytic triad: cyan; long branch: purple; short 
branch: orange).456 
Although at different levels, sEH is expressed in all organs and tissues and differs from 
the expression of mEH. The specific activity of sEH is highest in the liver, followed by 
kidney, heart, lung and brain.457,458 In a lesser extent, sEH activity has been detected in 
spleen, adrenals, intestine, urinary bladder, vascular endothelium and smooth muscle, 
placenta, skin, mammary gland, testicles and leucocytes.451 Concerning the regulation of 
the sEH, both PPAR-α and PPAR-γ agonists, e.g. fibrates and glitazones, have proven to 
alter sEH expression, underlying the close relationship between PPARs and sEH.416,459,460 
Angiotensin II and homocysteine, which appears to depend on activating transcription 
factor 6 (ATF6), are inducers of sEH.461,462 
1.4 Discovery of sEH inhibitors  
In an effort to explore sEH inhibition as an avenue for the development of therapeutic 
agents, many academic and industrial groups have entered the arena of the discovery of 
potent sEH inhibitors. The research group of Prof. Dr. Hammock has been the major 
contributor to sEH inhibitors.463,464 A detailed understanding of the catalytic mechanism 
of the enzyme and later multiple crystal structures helped in the identification of a diversity 
of functional groups that can be considered for the ligand design. The structural types of 
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sEH inhibitors are extremely broad, which is consistent with the wide binding pocket of 
the enzyme. 
From a historical point of view, the first generation of sEH inhibitors were potent 
competitive epoxide molecules and included chalcone oxides and trans-3-phenylglycidols 
(Fig. 76).465,466 These compounds were generally transient inhibitors with low turnover rates. 
Also, these substrates were rapidly inactivated by glutathione transferases, rendering them 
ineffective in in vitro and in vivo assays. 
 
Fig. 76. Early inhibitors of sEH bearing an epoxide moiety. R and R’ are various substituents. 
Just to mention, heavy metals such as Zn, Hg, Cu and Cd have been reported also to 
inhibit sEH activity via interactions with the phosphatase domain.467 
Since the early 2000s, several pharmacophores have emerged and major advances in 
the potency and pharmacokinetic properties of the inhibitors have been made. It was 
demonstrated that functional groups such as ureas, carbamates, amides, thioesters, 
carbonates, esters, thioureas, guanidines, inter alia, fit well into the active site and display a 
similar binding to that of endogenous epoxides.468,469,470,471 Therefore, in recent years there 
has been a significant and rapid development of compounds featuring mainly a urea or 
amide group as reversible sEH inhibitors. The urea group, which is the most exploited 
functionality for the design of sEH inhibitors, mimics the endogenous epoxide substrate 
by binding to the key residues of the catalytic triad. Thus, the carbonyl oxygen is involved 
in a hydrogen bonding interaction with both tyrosines, Tyr382 and Tyr465, whereas the 
NH groups act as hydrogen bond donors to the aspartic acid residue Asp334 (Fig. 77).472 
These specific interactions are responsible for their consideration as tight-binding sEH 
inhibitors, referred as “transition state competitive inhibitors”.473 
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Figure 77. General binding mode of urea-based sEH inhibitors and key residues of the binding 
pocket of sEH: catalytic triad (blue), long branch (purple) and short branch (green). LHS: left-
hand side; RHS: right-hand side. 
1,3-Disubstituted ureas have undergone a remarkable evolution since their discovery. 
The earliest symmetrical N,N’-disubstituted ureas displayed good inhibitory activities. Their 
design was based on the fact that the catalytic triad is in between two hydrophobic pockets, 
which could be filled with cycloalkyl groups for the establishment of Van der Waals-like 
interactions. Thus, the side chains of the urea were selected according to these premises 
and DCU (N,N’-dicyclohexylurea) appeared as a promising inhibitor with proven efficacy 
lowering blood pressure in hypertensive rats.474 Other carbocyclic substituents were 
introduced, such as phenyl, cyclooctyl and adamantyl groups.475 Despite the fact that this 
type of compounds showed potent inhibitory activities, they lacked optimal 
physicochemical properties for good oral absorption. These dialkylureas had high crystal 
lattice energies as indicated by their high melting points, and limited solubility in water.  
From this first series of compounds, the adamantane nucleus afforded a superior 
enzyme inhibition. Taking into account the characteristics of the binding site of sEH and 
the overall high hydrophobicity of the tunnel, the introduction of an adamantane ring has 
proven a successful strategy for the space-filling of the cavity. Thus, several sEH inhibitors 
incorporate an adamantane moiety on the LHS exhibiting high affinity and potency. Since 
the bulky adamantane ring can occupy one of two sides of the active site tunnel, it is 
possible that 1-adamantyl-urea-based inhibitors bind in the active site of human sEH with 
different orientations.476 Figure 78a highlights the binding mode of an adamantane-based 
inhibitor. In the present introduction, only the adamantane-based sEH inhibitors will be 
examined, despite the fact that further development has been done regarding other 
scaffolds, mainly substituted phenyl rings (Fig. 78b).477,478  
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a)                                                                      b) 
 
 
Figure 78. (a) Crystal structure of t-AUCB (vide infra) bound to sEH. PDB code: 3WKE;456 (b) 
Structure of GlaxoSmithKline’s candidate that entered phase I clinical trials in 2013.444,473 
Structural refinement of the first generation of inhibitors led to the discovery of 
adamantyl ureas attached to long alkyl chains featuring a terminal polar functionality, so as 
to resemble the carboxylic acid in a putative endogenous substrate, in an attempt to render 
these compounds more druggable. In this manner, N-adamantanyl-N’-dodecanoic acid urea 
(AUDA) emerged as an improved inhibitor with excellent inhibition of murine and human 
sEH and enhanced water solubility.479 AUDA has been extensively used as a tool molecule 
to validate efficacy in models of hypertension, cardio-protection and inflammation.431,480,481 
Addition of polar ethylene glycol linkers in the alkyl chain afforded new compounds with 
similar properties as AUDA, such as N-adamantanyl-N’-(5-(2-(2-
ethoxyethoxy)ethoxy)pentyl)urea (AEPU).482 Although improving water solubility, these 
compounds were rapidly metabolized through β-oxidation of the alkyl chain.483  
To avoid this issue, the incorporation of a conformationally restricted unit on the RHS 
of the molecule, such as an heterocycle or a phenyl ring, led to sEH inhibitors with 
improved metabolic stability whilst maintaining the potency.484,478 Here is where came into 
play the “pharmacophore model”, which may consist of three parts, the “primary 
pharmacophore or PP”, the “secondary pharmacophore or SP” and the “tertiary 
pharmacophore or TP” (Fig. 79).485,486 PP refers to the urea, amide, carbamate, … group 
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bearing the bulky hydrophobic adamantane nucleus on one side. SP is a polar group, e.g. 
ester, ether, amide, sulphonamide, alcohol or ketone, normally positioned approximately 
7 Å from the carbonyl group of the PP.479,487 In addition, a polar TP such as ester, ether, 
carboxylic acid, or amide that is 13 atoms or ~ 17 Å away from the urea carbonyl has also 
been identified and applied. Hydrophobic linkers join the PP to the SP, and the SP to the 
TP, where the presence of cyclic groups seem to increase oral bioavailability compared to 
linear alkyl chains.488 Apart from improving the metabolic stability of the RHS, the 
incorporation of the SP and TP enhanced the water solubility and lowered the melting 
points. 
 
Figure 79. Representation of the “pharmacophore model”. 
Table 16 summarizes the evolution of the adamantane-based sEH inhibition over the 
course of their development.  
Table 16. Representative adamantane-based sEH inhibitors and their evolution in chronological 
order. 
sEH inhibitor 
Pharmacophore 
model & 
Structural 
features 
Characteristics 
 
N-adamantyl-N’-cyclohexylurea (ACU) 
PP; two 
hydrophobic side 
chains 
High potency, 
low solubility, 
poor PK 
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AUDA 
“PP”; long carbon 
chain with a 
terminal 
carboxyclic acid 
High potency, 
improved 
solubility, poor 
PK 
 
AEPU 
“PP”; long carbon 
chain with 
ethylene glycol 
units 
High potency, 
improved 
solubility, poor 
PK 
 
4-(3-adamantan-1-yl-ureido)-2-hydroxyl-benzoic 
acid methyl ester (AUSM) 
SP; benzoic acid 
methyl ester 
High potency, 
improved 
solubility, 
enhanced PK 
 
N-(1-acetylpiperidin-4-yl)-N’-adamantylurea 
(APAU, AR9281) 
SP; 
conformationally 
restricted amide 
High potency, 
improved 
solubility, 
enhanced PK 
 
1-adamantan-1-yl-3-(4-(3-
morpholinopropoxy)cyclohexyl)urea (AMCU) 
TP; ether and 
morpholine ring 
groups as 
pharmacophores 
High potency, 
improved 
solubility, 
enhanced PK 
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trans-4-[4-(3-adamantan-1-
ylureido)cyclohexyloxy]benzoic acid (t-AUCB) 
TP; ether and 
carboxylic acid 
groups as 
pharmacophores 
High potency, 
improved 
solubility, 
enhanced PK 
 
 
Among these compounds, APAU or AR9281, developed by Arête Therapeutics, was 
the only adamantane-based sEH inhibitor that reached phase II clinical trials. It showed a 
high level of safety but failed to show efficacy in early-stage hypertension and impaired 
glucose tolerance. This failure was attributed to poor PK properties or variable effects of 
the inhibitor.405,489 
Regardless of the efforts made to procure drug candidates, it still remains a significant 
challenge to develop sEH inhibitors with excellent inhibitory activities and optimum 
solubility and PK profiles. A vast number of sEH inhibitors in development enclose an 
adamantane moiety, which possess particular properties that determine the behaviour of 
the future drug candidates: 
 Its pronounced lipophilicity compromises negatively the overall water 
solubility of the molecule, which is an important physicochemical parameter 
in the early stages of drug discovery.490,491 In addition, the general stability of 
the adamantyl compounds’ crystal structures, indicated by their high melting 
points, leads to a general lack of solubility even in organic solvents. 
 Besides, the adamantane nucleus is prone to rapid metabolism in vivo giving 
rise to a variety of inactive, hydroxylated derivatives and leading to low drug 
concentrations in blood and short in vivo half-life. 
 Again, the high lipophilicity of the inhibitors furnished chiefly by the 
adamantyl unit results in an increased likelihood of binding to multiple targets, 
leading to apparent toxicity.492  
Considering the above mentioned, it seems evident that the adamantane ring does not 
possess the optimal properties as a scaffold for sEH inhibition. A decrease in the overall 
lipophilicity will lead to more soluble and metabolically stable compounds, which will 
therefore be more “drug-like”.29-30 In this sense, there is an urgent need for the development 
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491 Di, L.; Fish, P. V; Mano, T. Drug Discov. Today 2012, 17, 486-495. 
492 Leeson, P. D.; Springthorpe, B. Nat. Rev. Drug Discov. 2007, 6, 881-890. 
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of new scaffolds that provide compounds with more optimal physicochemical properties to 
avoid attrition in later stages of the drug discovery process. 
  
 
 
 
 
 
 
 
 
 
 
Objetives 
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Regardless of the gigantic effort made from academic and industrial research groups 
in the development of drug candidates, only a few sEH inhibitors have entered into clinical 
trials. At the time of writing the present dissertation, no sEH inhibitor had got into the 
market, and only two compounds have reached human clinical trials, one of which contains 
an adamantane group, as mentioned previously. This points out that the drug discovery 
process of sEH inhibitors is complex and highly challenging. Some development limitations 
are: inappropriate physicochemical properties, especially high lipophilicity and low water 
solubility, and chemical and metabolic instability. Therefore, there is a demand for the 
development of new sEH inhibitors that, having an acceptable inhibitory activity, will 
overcome these issues.  
The adamantane nucleus seems to be a privileged scaffold in sEH inhibitors since it is 
the most exploited bulky group when designing a new drug candidate. This precious ring, 
together with the urea group as primary pharmacophore, fits into one of the hydrophobic 
pockets of the catalytic site of the enzyme. However, considering that the adamantane does 
not possess the optimum properties (i.e. lipophilicity, water solubility, etc…) for a urea-
based sEH inhibitor, we hypothesized that the replacement of the adamantane moiety by 
other polycyclic cage structures may afford compounds with improved PK and PD profiles 
by changes in the physicochemical properties, whilst maintaining a good binding affinity 
for the target. 
In line with the previous chapter of the thesis, and taking advantage of the extended 
expertise of our research group in the synthesis of polycyclic scaffolds, we started a new 
project related to the discovery of novel sEH inhibitors bearing adamantane-like scaffolds 
as hydrophobic counterparts. Thus, these were the main goals of this chapter: 
1. Synthesis of a variety of scaffolds, including ring-contracted, ring-expanded and oxa-
derivatives of the adamantane group, attached to an already reported substituted 
urea (Fig. 80).  
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Fig. 80. Replacement of the adamantane group by a variety of scaffolds.  
2. Pharmacological evaluation of these scaffolds to provide useful information of the 
threshold of tolerance of the catalytic site to accept a diversity of structures. 
Determination of water solubility as well as calculation of clog P of each new 
compound to assess the changes in physicochemical properties. 
 
3. Determination of the ability to ameliorate the ER stress in human hepatocytes of 
selected inhibitors, according to the results from 2. With the in vitro assays, the cell 
permeation and cytotoxicity will be also evaluated. 
 
  
 
 
 
 
 
 
 
 
 
 
Results & Discussion 
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1. Scaffold-hopping approach for the development of new sEH inhibitors  
 From the available data regarding sEH and its inhibition by small molecules, we 
identified a few relevant issues: 
 The adamantane ring is predominantly chosen as the bulky group for the space-
filling of the hydrophobic pockets of the sEH catalytic site.  
 On the other hand, the adamantane group provides a remarkable increase in the 
overall lipophilicity of the molecule, compromising the water solubility and the 
pharmacokinetic profile.  
 From the crystal structure of sEH, it has been suggested that, while the catalytic 
tunnel is restricted around the catalytic residues, it enlarges as one moves away from 
the site of reaction to yield relatively large cavities. These structural features show 
that the enzyme can accommodate larger groups on both sides of the urea moiety.  
 Additionally, polar groups can be incorporated into one of the alkyl substituents 
without loss of activity if they are placed at an appropriate distance from the urea 
function. 
Considering the aforementioned, we aimed to pursue a small and medium-step 
scaffold-hopping approach via the replacement of the adamantane nucleus by diverse 
polycycles that possess different physicochemical properties and varied shapes and sizes 
(Fig. 81). Scaffold-hopping is a strategy widely applied in medicinal chemistry whose purpose 
is to identify novel structures that are active against a given target with acceptable 
pharmacological properties defined by marketed drugs.493  
 
Fig. 81. Design of new sEH inhibitors by scaffold-hopping approach. 
                                                          
493 Sun, H.; Tawa, G.; Wallqvist, A. Drug Discov. Today 2012, 17, 310-324. 
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 The design of these compounds was carefully studied in order to fulfil most of the 
established criteria (potency, molecular weight and lipophilicity), wherein the adamantane-
like ring plays a crucial role. Because of the shape and size of the active site tunnel as well 
as its hydrophobicity, varying the polycyclic cages may affect how the urea moiety of the 
molecule sits within the tunnel, thereby affecting inhibition. Bearing in mind the existence 
of residues capable of establishing hydrogen bonds and π-stacking interactions in the long 
branch of the binding site of sEH, we hypothesized that the introduction of an heteroatom, 
such as an oxygen atom, and/or an aromatic ring on the polycyclic structure may be 
tolerated. In addition, the size and shape of that branch may assist the adjustment of the 
dimensions of the lipophilic group. Table 17 outlines the selected scaffolds, including their 
structural contributions and antecedent applications in medicinal chemistry. 
Table 17. Selected polycycles for the design of novel sEH inhibitors. CB: cannabinoid receptor. 
Entry Scaffold Structural features 
Previous uses 
in medicinal 
chemistry 
1 
 
Replacement of a methylene group by an 
oxygen atom at C-2 position. Introduction 
of non-polar groups at C-3 position 
NMDA 
receptor 
antagonism, 
anti-
trypanosome,95 
CB 
agonism,494 
cancer495  
2  
Replacement of a methylene group by an 
oxygen atom at C-5 position 
No described 
                                                          
494 Dixon, D. D.; Sethumadhavan, D.; Benneche, T.; Banaag, A. R.; Tius, M. A.; Thakur, G. A.; Bowman, A.; 
Wood, K. T.; Makriyannis, A. J. Med. Chem. 2010, 53, 5656-5666. 
495 Wang, L.; Doherty, G.; Wang, X.; Tao, Z. F.; Brunko, M.; Kunzer, A. R.; Wendt, M. D.; Song, X.; Frey, R.; 
Hansen, T. M.; Sullivan, G. M.; Judd, A.; Souers, A. 8-Carbamoyl-2-(2,3-disubstitutedpyrid-6-yl)-1,2,3,4-
tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune 
and autoimmune disease. WO 2013055897 A1.  
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3 
 
“Bird cage”, similar shape to adamantane. 
Incorporation of an oxygen atom. 
Racemic mixture 
NMDA 
receptor 
antagonism496 
4  
Double ring-contraction of adamantane 
group. Addition of methyl groups to 
increase molecular volume and/or a small 
linker to space out the urea moiety from 
the bulky group 
NMDA 
receptor 
antagonism, 
anti-
trypanosome,95 
M2 channel 
blocker91 
5  Single ring-contraction of rimantadine 
M2 channel 
blocker, 
NMDA 
receptor 
antagonism 95 
6 
 
Ring-expansion and rearrangement of 
adamantane nucleus. Presence of double 
bonds 
M2 channel 
blocker90 
7  
Insertion of a phenyl ring into the 
adamantane-like group. Introduction of a 
methyl group, and possibility to replace 
bridged methylene by an oxygen atom 
NMDA 
receptor 
antagonism, 
anti-
trypanosome97, 
98 
 
 
 In order to assess the effect of each new scaffold in the sEH inhibition, we placed them 
as the left-hand side (LHS) of the urea group and a selected unit from the literature was 
chosen as the right-hand side (RHS) (Fig. 82). Particularly, 2,3,4-trifluorophenyl group was 
selected due to its facile synthesis and high inhibitory activity against sEH. In fact, both 1-
(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea 108 and 1-(2-adamantyl)-3-(2,3,4-
trifluorophenyl)urea 109 were firstly reported as anti-tuberculosis agents whose mechanism 
                                                          
496 Geldenhuys, W. J.; Malan, S. F.; Bloomquist, J. R.; Marchand, A. P.; Van der Schyf, C. J. Med. Res. Rev. 
2005, 25, 21-48. 
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of action consists in the inhibition of the epoxide hydrolase family of enzymes 
(Mycobacterium tuberculosis epoxide hydrolases B and E, but also human sEH).497,498  
 
Fig. 82. 2,3,4-Trifluorophenyl unit as RHS. 
1.1 Synthesis of N-adamantane-like-N’-(2,3,4-trifluorophenyl)ureas 
 The synthetic plan of the final ureas was simple and straightforward, and consisted in 
the coupling of an amine with an isocyanate. Because of the handy experience of our 
research group in the preparation of polycyclic cage amines, and that 2,3,4-trifluorophenyl 
isocyanate was commercially available, we prepared the adamantyl-based ureas as showed 
in scheme 56. 
 
Scheme 56. General procedure for the preparation of adamantyl-like ureas. 
 In order to save time and resources, in certain cases we started the synthesis from 
intermediate amines already prepared by former group members or myself in earlier time 
(Fig. 83).  
                                                          
497 Brown, J. R.; North, E. J.; Hurdle, J. G.; Morisseau, C.; Scarborough, J. S.; Sun, D.; Korduláková, J.; 
Scherman, M. S.; Jones, V.; Grzegorzewicz, A.; Crew, R. M.; Jackson, M.; McNeil, M. R.; Lee, R. E. Bioorg. 
Med. Chem. 2011, 19, 5585-5595. 
498 Scherman, M. S.; North, E. J.; Jones, V.; Hess, T. N.; Grzegorzewicz, A. E.; Kasagami, T.; Kim, I. H.; 
Merzlikin, O.; Lenaerts, A. J.; Lee, R. E.; Jackson, M.; Morisseau, C.; McNeil, M. R. Bioorg. Med. Chem. 2012, 
20, 3255-3562. 
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Fig. 83. Intermediate amines formerly synthesized by the group. 
 The rest of the amines were prepared from different intermediates, and some of them 
starting from scratch (Fig. 84). 
 
Fig. 84. Intermediate amines to prepare. 
1.1.1 Preparation of intermediate scaffolds 
 1.1.1.1 Synthesis of (2-oxaadamantan-1-yl)amine, 120: 
 The oxa-derivative of amantadine 120 was prepared following the procedure firstly 
described by Gagneux and Meier in 1969 and broadly applied by our research 
group.499,500,501 Starting from known diketone 125, a transannular reductive amination took 
place affording compound 126 in 57% yield (Scheme 57). In this step, reaction with 
benzylamine yielded an imine intermediate, which was reduced following a 1,4-conjugated-
like mechanism upon the addition of a hydride source in a one-pot fashion. This 
intramolecular attack is possible due to the presence of a π-homoconjugated system, similar 
to that of 25. 
                                                          
499 Geigy A. G. Derivatives of 2-oxa-adamantane. GB 1123609. 
500 Gagneux, A. R.; Meier, R. Tetrahedron Lett. 1969, 10, 1365-1368. 
501 Duque, M. D.; Camps, P.; Profire, L.; Montaner, S.; Vázquez, S.; Sureda, F. X.; Mallol, J.; López-Querol, 
M.; Naesens, L.; De Clercq, E.; Prathalingam, S. R.; Kelly, J. M. Bioorg. Med. Chem. 2009, 17, 3198-3206. 
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Scheme 57. Formation of benzylamine 126 from diketone 125 and subsequent precipitation as 
the hydrochloride salt. The proton shifts have been avoided for the sake of clarity. 
 With benzylamine 126 in hand, hydrogenolysis of the benzyl group led to hemiaminal 
120 in quantitative yield, isolated as its hydrochloride salt (Scheme 58).  
 
Scheme 58. Deprotection of the benzyl group by catalytic hydrogenation at atmospheric 
pressure. 
1.1.1.2 Preparation of (4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodec-3-yl)amine, 121: 
 The synthesis of oxahexacyclo derivative 121 was based on the work of Govender and 
co-workers, and started by using the so-called Cookson’s dione 127.502 Analogously to the 
latter intermediate, 127 was subjected to a reductive amination with benzylamine. In this 
procedure, azeotropic distillation with toluene led the dehydration of the reaction 
intermediate to afford imine 128, which was then reduced with sodium borohydride. 
Subsequent catalytic hydrogenation provided deprotected amine 121 in 30% overall yield 
(Scheme 59).  
                                                          
502 Onajole, O. K.; Coovadia, Y.; Kruger, H. G.; Maguire, G. E. M.; Pillay, M.; Govender, T. Eur. J. Med. Chem. 
2012, 54, 1-9. 
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Scheme 59. Preparation of oxahexacyclo amine 121 starting from  
commercially available diketone 127. 
   
 In accordance to what was described in chapter 1 (see page 66), the formation of aza-
cage compound 130 was reported by Marchand and co-workers from the selective reduction 
of the imine with sodium cyanoborohydride instead of the ketone in compound 128.503 
The resulting amine attacked the carbonyl group providing a hydroxyl-aza-bridged 
compound (Scheme 60). To avoid this, sodium borohydride is needed. Thus, the ketone is 
first reduced, releasing a hydroxyl function ready to add to the imine moiety, and finally 
affording the desired “bird-cage” compound 129. 
 
Scheme 60. Selective reduction of keto-imine 128. 
 1.1.1.3 Synthesis of (tricyclo[3.3.0.03,7]oct-1-yl)amines 122 and 123: 
 Amines 122 and 123 were prepared following a long and tedious synthetic pathway 
inspired from the previous work of the group. The key step of the route revolves around 
an intramolecular enolate homocoupling of diesters 131 and 132, which can lead to the 
desired amines after classical synthetic transformations (Fig. 85). Diester 132 was taken 
from previously prepared samples by former group members. 
                                                          
503 Marchand, A. P.; Arney, B. E. Jr.; Dave, P. R.; Satyanarayana, N. J. Org. Chem. 1988, 53, 2644-2647. 
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Fig. 85. Planned synthesis of amine 122 and 123 from diester 131 and 132, respectively. 
For the preparation of diester 131, the first step was the synthesis of diketone 133 
through a Weiss-Cook condensation in a multigram scale. Following the procedure 
reported in Organic Syntheses, 504 two equivalents of 1,3-dimethyl-acetondicarboxylate were 
condensed with glyoxal in the presence of sodium hydroxide as a base (Scheme 61). After 
neutralization of disodium salt 134, dienol-tetraester 135 was obtained in 55% yield. The 
reaction mechanism is analogous to that from scheme 3 in chapter 1, and consisted in a 
double aldol condensation prior to a double Michael addition.  
  
Scheme 61. Weiss-Cook condensation of 1,3-dimethyl-acetondicarboxylate and glyoxal. 
Without further purification, tetraester 135 was treated with acidic aqueous solution 
for the hydrolysis of the ester group and concomitant decarboxylation of the resulting β-
keto carboxylic acids, giving diketone 133 in 71% yield (Scheme 62). 
 
Scheme 62. β-decarboxylation of tetraester 135 to yield dione 133 after acid hydrolysis. 
The synthesis continued with the reaction of diketone 133 with sodium cyanide and 
sulphuric acid.505 In this step, the slow addition of 40% H2SO4 solution to sodium cyanide 
in aqueous media supplied in situ-formed cyanide ions that added to the carbonyl groups 
of 133, giving a stereoisomeric mixture of bis-cyanohydrins 136 (Scheme 63). 
                                                          
504 Bertz, S. H.; Cook, J. M.; Gawish, A.; Weiss, U. Org. Synth. Coll. Vol. VII 1990, 50-56. 
505 Camps, P.; Iglesias, C.; Rodríguez, M. L.; Grancha, M. D.; Gregori, M. E.; Lozano, R.; Miranda, M. A.; 
Figueredo, M.; Linares, A. Chem. Ber. 1988, 121, 647-654. 
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Scheme 63. Double addition of cyanide to diketone 133 for obtaining a mixture of bis-
cyanohydrins 136. 
Bis-cyanohydrins 136 were transformed into vinyl cyanides in the presence of thionyl 
chloride and pyridine under reflux. Under these conditions, dehydration of 136 led to a 
regioisomeric mixture of dinitriles 137 and 138 in 44% yield (Scheme 64). The reaction 
begins with the addition of the oxygen atom of the hydroxyl group to SOCl2 and later 
elimination of a chloride ion. The base subtracts the α-proton to form the vinyl system, 
eliminating sulphur dioxide and eventually hydrochloric acid, which is trapped by the base. 
 
Scheme 64. Dehydration of bis-cyanohydrins 136 with thionyl chloride in the presence of 
pyridine. 
Following the procedure, the syn- and anti-mixture of both vinyl cyanides 137 and 138 
was submitted to a very slow catalytic hydrogenation due to the steric encumbrance around 
the double bonds. After 3 days at 27 atm of hydrogen, a complex stereoisomeric mixture 
of saturated nitriles 139 was obtained in a ratio of 2:1.3:1; (1α,3α,5α,7α), (1α,3β,5α,7β) 
and (1α,3α,5α,7β) respectively, in 87% yield (Scheme 65). 
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Scheme 65. Formation of the stereoisomeric mixture 139 after hydrogenation of 137 and 138. 
The next step was the hydrolysis of the nitrile groups with potassium hydroxide and 
water, followed by a Fischer esterification with anhydrous methanol and conc. H2SO4, 
providing a mixture of dimethyl esters 141 in 62% yield (2 steps) (Scheme 66).506 
 
Scheme 66. Hydrolysis of dinitriles 139 and esterification of 140 to 141. 
The next step can be consider as the most important transformation of the whole 
synthetic route, consisting of the intramolecular homocoupling of enolates to build the 
tricyclic system (Fig. 86).  
 
Fig. 86. Intramolecular cyclization of 141. 
Many different procedures have been reported since the first dimerization of enolates 
was described in 1935, where Ivanoff et al. published the generation of the enolate of a 
carboxylic acid with a Grignard reagent for the posterior treatment with bromine to give 
the desired dimer.507 Later on, similar methods for the homo- and heterocoupling of 
enolates appeared, all of them with common features: use of a strong base for the α-
deprotonation, such as lithium N-(tert-butyl)cyclohexanamide or lithim diisopropylamide 
                                                          
506 Méndez, N. M.S. Thesis, University of Barcelona, 1997. 
507 Ivanoff, D.; Spassoff, A. Bull. Soc. Chim. Fr. 1935, 2, 76-78. 
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(LDA),  and an oxidant agent, such as copper(II) bromide or chloride, iron(III) chloride, 
titanium(IV) chloride or iodine.508,509,510,511,512,513,514 
Despite these alternatives, we decided to apply the method already employed by the 
group.515,506 The tricyclic system of 131 was thus formed starting from the stereoisomeric 
mixture of diesters 141 by an oxidative homocoupling with iodine as oxidant and LDA as 
base (formed in situ from diisopropylamine and n-butyllithium) in 36% yield (Scheme 67). 
The actual mechanism of this reaction is still unclear, albeit different studies have been 
performed to understand it.516 It is believed that the treatment of diesters 141 with LDA 
generates enolates A that can undergo two different reaction pathways: i) reaction with 
iodine by a single electron transfer (SET) to give diradical B (path a), which can collapse to 
directly provide the ring-closed diester 131; ii) formation of iodide C by an ionic mechanism 
(path b), which can be displaced in an intramolecular SN2-type reaction. The steric 
hindrance of the dianions plays an important role in determining the reaction pathway.  
                                                          
508 Rathke, M. W.; Lindert, A. J. Am. Chem. Soc. 1971, 93, 4605-4606. 
509 Ito, Y.; Konoike, T.; Saegusa, T. J. Am. Chem. Soc. 1975, 97, 2912-2914. 
510 Frazier, R. H. Jr.; Harlow, R. L. J. Org. Chem. 1980, 45, 5408-5411. 
511 Kise, N.; Tokioka, K.; Aoyama, Y.; Matsumura, Y. J. Org. Chem. 1995, 60, 1100-1101. 
512 Paquette, L. A.; Bzowej, E. I.; Branan, B. M.; Stanton, K. J. J. Org. Chem. 1995, 60, 7277-7283. 
513 Baran, P. S.; DeMartino, M. P. Angew. Chem. Int. Ed. Engl. 2006, 45, 7083-7086. 
514 DeMartino, M. P.; Chen, K.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 11546-11560. 
515 Camps, P.; Luque, F. J.; Orozco, M.; Pérez, F.; Vázquez, S. Tetrahedron Lett. 1996, 37, 8605-8608. 
516 Renaud, P.; Fox, M. A. J. Org. Chem. 1988, 53, 3745-3752. 
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Scheme 67. Intramolecular oxidative homocoupling of diester 141. 
At this point, the syntheses of amines 122 and 123 were concurrently run. With the 
goal of achieving these monoamines from diesters 131 and 132, we needed to differentiate 
the ester functions in order to selectively eliminate one of them (Scheme 68). For this 
purpose, diesters 131 and 132 were hydrolysed under basic conditions to furnish the 
corresponding carboxylic acids 142 and 143 in quantitative yields. Afterwards, the 
treatment of the aforementioned with neat acetic anhydride produced anhydrides 144 and 
145 in 72% and quantitative yield, respectively. Then, the anhydride unit was opened in 
the presence of sodium methoxide and methanol to give hemiesters 146 and 147 in low 
yields due to the presence of adventitious water from the solvent. In both cases, diacids 142 
and 143 were recovered.  
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Scheme 68. Functional group differentiation of 131 and 132. 
Next, hemiesters 146 and 147 were converted to the corresponding monoesters 148 
and 149 through a Barton radical decarboxylation.517,518 The procedure consists in the 
protodecarboxylation of a carboxylic acid 150 in the presence of a suitable hydrogen bond 
donor (H-donor) to furnish the corresponding hydrocarbon 151. Fundamental to the 
Barton decarboxylation protocol is the alkyl thiohydroxamic ester 152, also known as 
Barton ester, which is readily prepared from the reaction of an activated carboxylic acid 
and the sodium salt of 1-hydroxypyridine-2(1H)-thione.519,520 By means of applying light and 
heat, the Barton ester undergoes rapid homolytic decomposition yielding the 
corresponding alkyl acyloxy radical 153, which is subjected to decarboxylation. The 
remaining alkyl radical 154 intercepts a proton from the H-donor, whereupon 151 is 
recovered (Scheme 69). 
 
Scheme 69. Mechanism of reaction of the Barton decarboxylation. 
                                                          
517 Barton, D. H. R.; Crich, D.; Motherwell, W. B. J. Chem. Soc. Chem. Commun. 1983, 939-941. 
518 Barton, D. H. R.; Hervé, Y.; Potier, P.; Thierry, J. J. Chem. Soc. Chem. Commun. 1984, 1298-1299. 
519 Barton, D. H. R.; Crich, D. Motherwell, W. B. Tetrahedron 1985, 41, 3901-3924. 
520 Barton, D. H. R.; Samadi, M. Tethahedron 1992, 48, 7083-7090. 
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Former protocols of the Barton decarboxylation applied by our group entailed the use 
of 2,2’-dithiobis(pyridine-N-oxide) as precursor of the Barton ester and n-tributylphosphine 
for its pre-activation.172 As H-donor, t-butylthiol was the preferred proton source, despite 
the fact that its use implied that the reaction should be set up in a special laboratory for 
highly smelly and toxic reactions.  
On the other hand, the utility of chloroform as both solvent and H-donor in Barton 
decarboxylation has been recently demonstrated.521,522 Taking advantage of this finding, we 
performed the reaction under t-butylthiol-free conditions within chloroform (Scheme 70). 
Pleasingly, hemiesters 146 and 147 were easily transformed to their corresponding 
monoesters 148 and 149 (86% yield for 149). Because of the high volatility of 148, the 
solvents were distilled off after the work up to give the monoester along with reaction by-
products. The crude was used in next step without any purification. 
 
Scheme 70. Barton decarboxylation of hemiesters 39 and 40 with chloroform as H-donor. 
The decarboxylation was followed by a basic hydrolysis of monoesters 148 and 149 to 
monoacids 155 and 156 in 73% and 61% yield (2 steps), respectively (Scheme 71). 
 
Scheme 71. Basic hydrolysis of monoesters 148 and 149. 
The last step for the preparation of monoamines 122 and 123 involved a Curtius 
rearrangement, which led to the one-step functional interconversion of a carboxylic acid to 
a primary amine with concomitant loss of one carbon atom through an acyl azide 
intermediate. In this transformation, the thermal decomposition of carboxylic azides 
produces an isocyanate, which can be hydrolysed to yield the corresponding amine. In our 
case, we applied the Yamada’s modification of the Curtius reaction, which employs 
diphenylphosphoryl azide (DPPA) as the azide source.523,95 Thus, addition of DPPA to a 
                                                          
521 Ko, E. J.; Savage, G. P.; Williams, C. M.; Tsanaktsidis, J. Org. Lett. 2011, 13, 1944-1947. 
522 Ho, J.; Zheng, J.; Meana-Pañeda, R.; Truhlar, D. G.; Ko, E. J.; Savage, G. P.; Williams, C. M.; Coote, M. L.; 
Tsanaktsidis, J. J. Org. Chem. 2013, 78, 6677-6687. 
523 Ninomiya, K.; Shioiri, T.; Yamada, S. Tetrahedron 1974, 30, 2151-2157. 
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solution of both monoacids 155 and 156 supplied finally amines 122 and 123 in 31% and 
quantitative yield, respectively (Scheme 72).  
 
Scheme 72. Curtius rearrangement with DPPA. 
1.1.2 Preparation of pentacyclic urea 157 
M. D. Duque in her doctoral thesis observed that unsaturated amine 124 was unstable 
under her reaction conditions.164 Several attempts to isolate desired amine 124 were 
fruitless, probably due to a high reactivity of the olefin bonds in the acidic media. Lest the 
same quandary, for the preparation of the final ring-expanded urea 157 we decided to swap 
functionalities so as to react the 2,3,4-trifluoroaniline with the corresponding isocyanate as 
the LHS (Scheme 73).  
 
Scheme 73. Inverted procedure for the preparation of urea 157. 
Consequently, we envisioned the preparation of isocyanate 158 from unsaturated 
monoacid 159 through a Curtius rearrangement, which in turn can be prepared from the 
already seen diacid 88 (Scheme 74). 
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Scheme 74. Retrosynthetic scheme for urea 157. 
 Starting from the pentacyclic diacid 88, we produced monoacid 159 using a synthetic 
sequence previously described by our group, analogous to the synthetic route for amines 
122 and 123 (Scheme 75).524,90 Accordingly, diacid 88 was subjected to anhydride formation 
with neat acetic anhydride to give compound 160 in 88% yield, which was treated with 
sodium methoxide in anhydrous methanol for the functional group differentiation. Thus, 
hemiester 161 was obtained in 60% yield, recovering part of diacid 88 after purification by 
column chromatography. Barton reductive decarboxylation with 2,2’-dithiobis(pyridine-N-
oxide) in chloroform, the latter acting as a solvent and H-donor, afforded monoester 162 
in 59% yield, which is lower than the reported value of 91%. This reduction in the yield 
can be attributed to a lower reactivity of the chloroform as H-donor than t-BuSH for this 
specific alkyl radical. Finally, basic hydrolysis of monoester 162 furnished monoacid 159 
in 31% yield.  
 
Scheme 75. Synthetic route for the preparation of monoacid 159 from diacid 88. 
Our wide experience with these kind of polycycles warned us that isocyanate 158 might 
be highly volatile, a property that makes it difficult to isolate. This volatility is attributed to 
the low molecular weight of the scaffold (12 carbon atoms) and to the planarity around the 
sp2 atoms of the isocyanate group, whereupon no stable intermolecular interaction can be 
formed. With this in mind, we first explored the proposed synthetic route in scheme 76 
                                                          
524 Camps, P.; Lukach, A. E.; Rossi, R. A. J. Org. Chem. 2001, 66, 5366-5373. 
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using the adamantane derivative as template, since the pentacyclic scaffold is more valuable 
in terms of synthetic effort than adamantane, which is commercially available. Thus, we 
applied classical chemical transformations to produce acyl azide 164 from 1-
adamantanecarboxylic acid. Treatment of the latter with thionyl chloride afforded acyl 
chloride 163 in quantitative yield, which was then subjected to an addition-elimination 
reaction with sodium azide to give 164 in quantitative yield. Both interconversions were 
controlled by infrared (IR) spectroscopy.  
 
Scheme 76. Functional group interconversion of 1-adamantanecarboxylic acid. 
In order to avoid any type of isolation of isocyanate 165, we aimed to form it in situ 
through a Curtius rearrangement upon heating 164, for the subsequent addition to the 
media of 2,3,4-trifluoroaniline and final formation of desired urea 166 (Scheme 77). 
Following the conditions reported by Lee and co-workers,525 we in situ-formed isocyanate 
165, whose formation was monitored by IR spectroscopy, for later adding the aniline and 
triethylamine as base. Unfortunately, no product was recovered but the starting materials, 
despite of the long reaction time. 
 
Scheme 77. Intended formation of urea 166 with TEA as base. 
In the hope of optimizing the reaction and assuming that the base was the variable to 
adjust, we next explored the effectiveness of n-butyllithium as base. As the published 
procedure indicated,525 the reaction mixture was stirred for 1 hour at room temperature 
and quenched with methanol. Alas, no product was again recovered but, in this case, 
methyl carbamate 167. The formation of this side-product came from the attack of 
methanol to isocyanate 165. This fact illustrated that longer reaction times were needed. 
Therefore, when the reaction was performed overnight, desired urea 166 was obtained with 
no further purification (Table 18).  
                                                          
525 North, E. J.; Scherman, M. S.; Bruhn, D. F.; Scarborough, J. S.; Maddox, M. M.; Jones, V.; Grzegorzewicz, 
A.; Yang, L.; Hess, T.; Morisseau, C.; Jackson, M.; McNeil, M. R.; Lee, R. E. Bioorg. Med. Chem. 2013, 21, 
2587-2599. 
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Table 18. Preparation of urea 166 with n-BuLi as base. 
  
 
Entry Time (h) 166 167  
1 1    
2 18    
  
Once the optimum conditions identified, we proceeded to the preparation of 
pentacyclic derivative 157 (Scheme 78). Hence, monoacid 159 was converted to acyl 
chloride 168 with thionyl chloride in quantitative yield, followed by the reaction with an 
excess of sodium azide to furnish acyl azide 169 in 88% yield. Their structures were 
confirmed also by IR spectroscopy. Then, Curtius reaction took place upon heating 169, 
providing isocyanate 158 that was trapped by 2,3,4-trifluoroaniline, and finally achieving 
desired unsaturated urea 157 in 25% overall yield after purification by column 
chromatography.  
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Scheme 78. Synthetic pathway for the preparation of urea 157. Transformation from 169 to 
157 was in one-pot. 
1.1.3 Synthesis of final ureas 170-183 
 After the quest and preparation of intermediate amines 110-123, we progressed in our 
goal to synthesize the 2,3,4-trifluorophenyl ureas for their testing as sEH inhibitors. As 
described earlier, our synthetic strategy consisted in the coupling between intermediate 
amines 110-123 with 2,3,4-trifluorophenyl isocyanate, using triethylamine as base and 
anhydrous dichloromethane as solvent. Satisfyingly, ureas 170-183 were produced in 
variable yields (Scheme 79). Apart from them, 1-adamantanyl, 108, and 2-adamantanyl, 
109, ureas were synthesized as standard compounds for comparison. 
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Scheme 79. Final ureas and their yields. 
  Just to mention that the low yield achieved for compound 182 was attributed to the 
low purity of the sample used as the starting amine.  
1.2 Pharmacological evaluation of final ureas. IC50 determination  
 As part of the research project, we pursued the measurement of the inhibitory activity 
of new ureas 157 and 170-183 by means of determining their IC50 values. Prior to entering 
into details of the IC50 evaluation, a brief introduction of the enzymatic assays will be 
disclosed. 
1.2.1 A little of background 
 The appearance of the sEH as potential therapeutic target, and the discovery of large 
libraries of small molecules as inhibitors of this enzyme, urged the finding of an enzymatic 
assay that needed to fulfil critical requirements, such as robustness and sensitivity. The 
availability of homogenous, recombinant sEH from human and model species have been 
crucial for the development of the screening assays.  
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 The screening assays have evolved in the last years as the demand of assays that could 
distinguished among the most potent inhibitors increased over time: 
1. Earlier rapid kinetic spectrophotometric assays employed recombinant sEH and 
epoxy esters or carbonates as substrates. The most used substrates were trans-stilbene 
oxide (t-SO), trans-diphenyl-propene oxide (t-DPPO) and 4-nitrophenyl-trans-2,3-
epoxy-3-phenylpropyl carbonate (NEPC).526 These substrates cyclize spontaneously 
upon or during hydrolysis of the epoxide functionality by sEH, releasing an alcohol 
that can be directly detected by UV-vis spectrophotometry, or after a second 
reaction with them (Scheme 80).  
Scheme 80. Hydrolysis of NEPC by sEH and detection of 4-nitrophenol by UV 
spectrophotometry. 
However, these assays became ineffective because they were not sensitive enough to 
differentiate among the best compounds based on their IC50 values. Moreover, the 
aqueous instability of these photometric substrates required short incubation times. 
Thus, they could not be employed in long-term assay systems as it is often the case 
in the screening of large compound libraries.  
2. Several radiochemical and chromatographic assays were developed to overcome the 
limitations of the previous procedures.527 The most used radiolabelled substrates 
are [3H]-t-SO and [3H]-t-DPPO, which represent the first-rate surrogates that are 
employed in radiometric assays. These assays are based on differential partitioning 
between the epoxide substrate, the 1,2-diol product, and (if necessary) glutathione 
conjugates, and thus need two different solvent systems for the selective extraction 
(Scheme 81).528 Despite of the improvement with respect to former techniques, they 
are too slow, costly and labour intensive to screen larger amounts of compounds. 
                                                          
526 Dietze, E. C.; Kuwano, E.; Hammock, B. D. Anal. Biochem. 1974, 216, 176-187. 
527 Borhan, B.; Mebrahtu, T.; Nazarian, S.; Kurth, M. J.; Hammock, B. D. Anal. Biochem. 1995, 231, 188-
200. 
528 Morisseau, C.; Hammock, B. D. Curr. Protoc. Toxicol. 2007, Suppl. 33, 4.23.1-4.23.18. 
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Moreover, unlike [3H]-t-SO, [3H]-t-DPPO is not commercially available and needs to 
be prepared prior to assaying.  
 
Scheme 81. Different polarity of [3H]-t-DPPO and its hydrolyzed product. 
3. Fluorescent substrates appeared as an alternative with higher sensitivities and rapid 
responses.529 These substrates combine the decomposition mechanism of NEPC 
with the latent fluorophore of α-cyanoesters and α-cyanocarbonates. After 
hydrolysis of the epoxide by sEH, O-deacylation liberates a cyanohydrin 
intermediate that rapidly decomposes to the highly fluorescent 6-methoxy-2-
naphthaldehyde, which is characterized by a large Stoke’s shift (Scheme 82). Among 
all the known fluorescent substrates, CMNPC (cyano(2-methoxynaphthalen-6-
yl)methyl (3-phenyloxiran-2-yl)methyl carbonate) and PHOME ((3-phenyl-oxiranyl)-
acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester) are the most employed 
due to their high sensitivity and improved aqueous stability and solubility. Thus, 
this type of substrates have been widely applied in high-throughput screening (HTS) 
assays with long incubation times. They required, however, the use of purified 
enzyme or at least a preparation free of competing enzymes activities (e.g. esterases 
and glutathione-S-transferase). 
Scheme 82. Hydrolysis of the epoxide moiety of PHOME by sEH, followed by an 
intramolecular cyclization, resulting in the release of a cyanohydrin, which decomposes into 
a cyanide ion as well as the highly fluorescent 6-methoxy-2-naphthaldehyde. 
                                                          
529 Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Anal. Biochem. 2005, 
343, 66-75. 
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4.   The last developed assays consist in the use of natural epoxides, which are neither 
UV-absorbent nor fluorescent, and are not available in a radioactive form. For their 
detection, an LC-MS/MS method was developed by Newman et al.530 Although 
providing an alternative, this technique is less sensitive than the previous ones and 
a challenge remains to distinguish among inhibitors with picomolar IC50 values. 
However, they are recommended to verify the activity of lead inhibitors.464 
 
1.2.2 Tune-up of the screening assay 
 Since it was the first time that our research group dealt with the pharmacological 
evaluation of small molecules, in particular of sEH inhibitors, we first explored the different 
available alternatives for the determination of the IC50 values. To our delight, a sEH 
inhibitor screening assay using fluorescent substrates was commercially available from 
Cayman Chemical Company (from now on referred as Cayman).531 This ready-to-use assay 
kit utilizes PHOME as substrate, and provides the necessary items to run the assay, i.e. 96-
wells black plate, 25 mM 2{bis[2-hydroxyethyl(imino)-2-(hydroxymethyl]}-1,3-propanediol 
(bis-Tris) assay buffer (pH 7.0), human recombinant sEH and the assay protocol.  
Thus, we decided first to test the ability to run the assay with both standards 108 and 
109 at their reported IC50 (0.4 nM for both).497 For the fluorescence reading, we used a 
BMG FLUOstar optima microplate reader at an excitation wavelength of 337 nm and an 
emission wavelength of 460 nm. Following the established procedure, we managed to 
obtain a few times around 50% of inhibition for both standards at 0.4 nM. Unfortunately, 
several attempts to repeat these positive results were unsuccessful, and we were not able to 
reproduce our first data set.  
Thanks to the personal advises from the research group of Prof. Hammock and Dr. 
Morisseau in University of California Davis (United States of America), we identified the 
key elements that were altering our results. From the available data, we considered different 
causes:  
 Cayman includes in the kit the substrate already dissolved in DMSO in an 
adequate amount for running more than one plate. That means that the 
PHOME solution was frozen and thawed several times in between assays, 
compromising its stability. This fact was reflected in the signal-to-noise ratio, 
where the fluorescence of 100% activity (wells with sEH enzyme and substrate 
but without inhibitor) was too close to that of the background activity (wells 
with PHOME but without sEH enzyme and inhibitor). Calculation of the Z’ 
value, which is a statistical parameter that evaluates and validates HTS assays, 
                                                          
530 Newman, J. W.; Watanabe, T.; Hammock, B. D. J. Lipid Res. 2002, 43, 1563-1578. 
531 Cayman Chemical Company website. Soluble epoxide hydrolase inhibitor screening assay kit. 
https://www.caymanchem.com/app/template/Product.vm/catalog/10011671 (accessed on 13th 
September 2015) 
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showed to be less than 0.5, indicating that it was not possible to discern 
inhibition potency because of the spontaneous hydrolysis of the substrate (data 
not shown).532  
 The final concentration of the substrate [S] in each well was 0.25 µM, which is 
below the estimated Km value of 1.5 µM by Cayman. Nevertheless, experts on 
the field have published a Km much larger (272 µM) for this particular 
substrate.533  
The Michaelis-Menten is a theory of enzyme kinetics that helped us to understand how 
the assay works. The Michaelis-Menten parameters Km and Vmax characterize enzyme-
substrate interactions regarding substrate turnover.534 The relation between these two 
parameters is expressed in the following equation 1, which relates the reaction rate (ν) to 
[S]:  
ν =
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 + [𝑆]
 Equation 1 
The graphic bellow represents this relationship (Fig. 87). 
 
Fig. 87. Schematic plot of initial reaction rate ν vs substrate concentration [S] following the 
theory of Michaelis-Menten. Vmax: maximal velocity; Km: Michaelis-Menten constant or the [S] at 
which the ν is half the Vmax. 
At high substrate concentration, substrate turnover rates are more stable. Under such 
conditions, small variations in enzyme amount or other assay conditions such as 
temperature or pH should not influence the velocity significantly, resulting in a 
reproducible and stable assay. If the [S] is very low with respect to Km, any variation in the 
assay will affect greatly the activity. With lower [S], one gains in sensitivity but lose in 
reproducibility and stability. For competitive inhibitors, the IC50 is dependent upon the 
[S], where the IC50 value will increase with the [S]. 
                                                          
532 Zhang, J. H.; Chung, T. D. Y.; Olderburg, K. R. J. Biomol. Screen. 1999, 4, 67-73. 
533 Wolf, N. M.; Morisseau, C.; Jones, P. D.; Hock, B.; Hammock, B. D. Anal. Biochem. 2006, 355, 71-80. 
534 Reuveni, S.; Urbakh, M.; Klafter, J. Proc. Natl. Acad. Sci. USA 2014, 111, 4391-4396. 
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All the aforementioned indicated that we needed to increase the [S] in order to have a 
stable and robust assay, as well as to use a freshly prepared solution of PHOME lest its 
hydrolysis. In fact, Hammock studied the kinetics of PHOME and human sEH and found 
that the optimized concentrations of both were 50 µM and 3 nM, respectively. Using these 
concentrations, they were able to ensure a linear substrate hydrolysis over a long period of 
time. However, our supplier of pure human recombinant sEH, Cayman, did not provide 
information on the final concentration of the enzyme which they considered confidential. 
Nevertheless, we performed a Bradford assay to quantify the amount of protein present in 
a sample, determining a concentration of 1.56 nM.  
Knowing the approximate concentration of the sEH, we carried out a screening of 
substrate concentration in a checkboard experiment in which [PHOME] varied from 0.25 
to 20 µM (0.25, 2.5, 5, 10 and 20 µM). The solutions of PHOME in DMSO were freshly 
prepared from a solid stock. The best results were the ones using PHOME at 5 µM, with 
the highest and most consistent inhibition. 
Simultaneously, we decided to prepare ourselves the assay buffer. Cayman sells a pre-
mixture of the assay buffer that needed to be diluted with HPLC-grade water to achieve a 
final concentration of 25 mM of bis-Tris, pH 7.0. So, we prepared the assay buffer according 
to the protocol from Cayman. Sadly, we could not reach the same levels of inhibition when 
testing ureas 108 and 109. In these cases, once again, the signal-to-noise ratio was too small 
to differentiate any inhibition. Reviewing the literature, most part of the reported assays 
included bovine serum albumin (BSA) in the buffer.528,533 The role of the BSA in the assay 
is double: 
i. The BSA helps the substrate to be more soluble. Thus, the [S] that the enzyme 
encounters is higher, improving the signal-to-noise ratio. 
ii. Inhibitors can bind lousily to BSA through hydrophobic interactions. Hence, 
adding BSA is a simple way to eliminate low-potency inhibitors.  
Having considered the aforementioned, we finally achieved the optimum conditions 
as follows: 
 In situ prepared PHOME solution at a final concentration of 5 µM. 
 Self-prepared assay buffer with 25 mM bis-Tris containing 0.1 mg/mL BSA. 
 Human recombinant sEH from Cayman, with a likely concentration of 1.56 nM. 
 Total volume was 200 µL with a final DMSO concentration of 1% (v/v). 
 Assay reaction time was less than 20 minutes. 
 Assay performed at room temperature (23 ± 2 ºC). 
 96-wells black plate from Greiner Bio-one (Fig. 88). 
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Fig. 88. Drawing of the used microplate and its dimensions in mm. 
1.2.3 IC50 determination of ureas 157 and 170-183 
With the optimized conditions in hand, we proceeded to determine the IC50 of the 
new sEH inhibitors. For each measure, it was necessary to have at least two wells designated 
as background, three wells designated as 100% activity, and three wells for each one of the 
inhibitor concentrations to test. The assay was performed as indicated below: 
1. Addition of assay buffer to each well. 
2. Addition of DMSO to background and 100% activity wells. 
3. Addition of inhibitors to the corresponding wells. 
4. Addition of sEH to 100% activity and inhibitors wells. 
5. Addition of PHOME to all the wells. 
6. Incubation of 5 minutes at room temperature and fluorescence detection 
during the next 15 minutes. 
The curve was generated from 5 different concentrations of inhibitor, ranging from 
0.05 to 20 nM. The IC50 was calculated from at least three separate runs. The IC50 values 
of the new compounds are disclosed in table 19. The obtained values should be directly 
compared with our data for standard ureas 108 and 109, and not with the reported values, 
since assay conditions may violate Michaelis-Menten assumptions, and it is difficult to 
compare inhibitor potencies among laboratories.  
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Table 19. Inhibition of the sEH by the new compounds. Ureas 108 and 109 were used as 
standards. SE: standard error. 
 
Comp. LHS IC50 ± SE (nM) Comp. LHS IC50 ± SE (nM) 
108 
 
7.74 ± 0.06 177 
 
14.1 ± 4.2 
109 
 
4.04 ± 0.45 178 
 
0.86 ± 0.31 
170 
 
2.58 ± 0.28 179 
 
4.16 ± 1.06 
171 
 
21.3 ± 5.4 180 
 
10.3 ± 1.6 
172 
 
8.08 ± 3.16 157 
 
37.1 ± 10.2 
173 
 
17.6 ± 3.6 181 
 
25.5 ± 11.5 
174 
 
21.3 ± 4.3 182 
 
0.80 ± 0.13 
175 
 
47.4 ± 11.4 183 
 
25.7 ± 1.2 
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176 
 
31.4 ± 3.2    
 
Satisfyingly, all the new adamantyl-like ureas were potent sEH inhibitors, with IC50 
values ranging from 0.80 to 47.4 nM. Outstanding are compounds 170, 178 and 182, with 
IC50 values lower than the adamantyl standards. In general, some trends could be deduced 
from these data: 
 Replacement of a methylene in the adamantane by an oxygen atom led to an 
increase in the inhibitory activity (compare 108 (IC50 = 7.74 nM) vs 170 (IC50 
= 2.58 nM)). These data indicated that the insertion of an oxygen atom is 
tolerated, far from what was observed by Nishi and co-workers with a series of 
cycloalkylamides bearing a polar group such as hydroxyl or carbonyl,535 and by 
Rose et al. when replacing a benzene by a phenol ring.478 
 Position of the oxygen atom within the adamantane ring is significant for the 
activity, with the highest inhibition when the oxygen atom is in C-2 position 
and not in C-5 (compare 170 (IC50 = 2.58 nM) vs 175 (IC50 = 47.4 nM)). 
 Regarding the (2-oxaadamantan-1-yl)ureas 170-174, it seemed that the bulkier 
the substituent in C-3 position, the worse the inhibitory activity. Methyl 
derivative 171 (IC50 = 21.3 nM) escaped a little bit this trend, with a higher 
IC50 value than the next larger compound 172 (IC50 = 8.08 nM). This fact can 
be reasoned by a worse performance in the assay of 171, probably 
underpinning a lower solubility. It is likely that bulky groups disrupt the 
binding of the inhibitor within the catalytic pocket of the enzyme. 
 The use of the “bird-cage” scaffold in 176 was detrimental for the activity, with 
an IC50 of 31.4 nM. However, 176 was prepared and tested as a racemic 
mixture, and thus the data has to be taken with a pinch of salt. 
 Ring-contracted scaffolds 177-179 also exhibited good inhibitory activities. 
Worth to highlight, the introduction of methyl substituents in 178 (IC50 = 0.86 
nM) and 179 (IC50 = 4.16 nM) significantly improved the activity compared 
with the bisnoradamantane compound 177 (IC50 = 14.1 nM). This increase in 
the activity reflected the better space-filling of 178-179 than 177 thanks to the 
methyl groups, which could provide a most favourable interaction within the 
catalytic site of sEH. Of note, it is compound 178 with a lower IC50 value than 
the adamantyl standards 108 (IC50 = 7.74 nM) and 109 (IC50 = 4.04 nM).  
                                                          
535 Kim, I.; Park, Y.; Hammock, B. D.; Nishi, K. J. Med. Chem. 2011, 54, 1752-1761. 
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 On the other hand, ring-contracted rimantadine analogue 180 showed good 
inhibitory potency, even though it was assayed also as a racemate. 
 Ring-expanded compounds 157 and 181 displayed lower activities compared 
with the standards, although showing good potency (IC50 of 37.1 and 25.5 nM, 
respectively). No significant difference was observed in the transition from 
unsaturated 157 to saturated pentacyclo 181.  
 Finally, benzo-homoadamantane scaffolds were also permitted. A first 
observation was that the replacement of the bridged methylene in 182 (IC50 = 
0.80 nM) by and oxygen atom in 183 (IC50 = 25.7 nM) conduced to a decrease 
in the activity, a trend observed in the previous scaffolds (except for compound 
170). Nevertheless, the introduction of a phenyl group in the molecule gave 
the most potent compound of the series (182 with an IC50 of 0.80 nM), being 
useful for enhancing inhibitory potency. This suggests that larger scaffolds than 
the adamantane nucleus are well tolerated. In addition, the benzene ring may 
establish discrete interactions with specific residues in the catalytic site. 
Thus, in terms of sEH inhibition, the most promising compounds were 170, 178 and 
182 (Fig. 89). The structural variety of the scaffolds below indicates that the catalytic pocket 
of sEH is largely flexible.  
 
Fig. 89. Most potent compounds identified with a fluorescence screening assay. 
1.3 Water solubility determination  
It is well known that the solubility profile can be improved by salt/solid form selection 
and formulation, as well as through chemical structure modification, the latter being our 
approximation.536 To further assess the ability of the new scaffolds to surrogate the 
adamantane group, we aimed to measure the water solubility of our new sEH inhibitors. 
Solubility is a physical parameter that plays an important role in all phases of drug 
discovery and development. Solubility is central in in vivo assays (affecting the ADME 
process) and in vitro screenings (affecting reproducibility and reliability).537 Among the five 
                                                          
536 Sugano, K.; Okazaki, A.; Sugimoto, S.; Tavornvipas, S.; Omura, A.; Mano, T. Drug Metab. Pharmacokinet. 
2007, 22, 225-254. 
537 Bhattachar, S. N.; Deschenes, L. A; Wesley, J. A. Drug Discov. Today 2006, 11, 1012-1018. 
 
212   CHAPTER 3: sEH inhibition 
key physicochemical properties in early compound screenings (pKa, solubility, 
permeability, stability and lipophilicity), poor solubility is on the top list of undesirable 
compound properties. Attrition in later stages of the drug discovery process are partly due 
to solubility issues.538 
In a broad sense, solubility may be defined as the amount of a substance that dissolves 
in a given volume of solvent at a specified temperature. Various solubility assays are 
performed routinely in many pharmacological companies, and three major types of 
solubilities have been identified depending on the incubation time: 
- Equilibrium or thermodynamic solubility: maximum amount of compound that can 
remain in solution in a given volume of the solvent under equilibrium conditions (days). 
- Apparent or semi-equilibrium solubility: long incubation time with intention of 
reaching equilibrium (hours to one day). 
- Kinetic solubility: solubility of a given compound measured regardless of the 
incubation time. Normally, after the addition of the sample into an aqueous media 
(minutes to a few hours). 
Since the thermodynamic solubility is more time-consuming, and needs pure samples 
of the compounds, kinetic solubility is applied as HTS in early stages of drug discovery 
throughout the development process. Yet, both measurements are not interchangeable 
since they rely on fundamentally different physical properties. 
Likewise, the solubility assays can be classified as: 
- Solubility measurement using a DMSO stock solution of the compound (anti-solvent 
precipitation method). 
- Solubility measurement using powder material (dissolution method). 
After looking up the literature related to the discovery of sEH inhibitors, different 
procedures reached our hands describing how to measure water solubility. Since our 
research group was completely inexperienced with water solubility determinations, we 
turned once again to the group of Prof. Hammock in order to get some advises regarding 
these protocols. Kindly, they suggested following the method described by Tsai et al., which 
consisted of an apparent or semi-equilibrium solubility measurement.539 Starting off with a 
powdered sample of each compound, sodium phosphate buffer (pH 7.4) was added and 
the suspension was equilibrated during 24 h of shaking at room temperature (23 ± 2 ºC). 
After extraction, the amount of each compound dissolved in buffer was determined by 
HPLC (fully protocol described in Material & Methods). Figure 90 includes an example of 
a solubility assay followed by Roche, and similar to our procedure. 
                                                          
538 Di, L.; Fish, P. V; Mano, T. Drug Discov. Today 2012, 17, 486-495. 
539 Tsai, H. J.; Hwang, S. H.; Morisseau, C.; Yang, J.; Jones, P. D.; Kasagami, T.; Kim, I. H.; Hammock, B. D. 
Eur. J. Pharm. Sci. 2010, 40, 222-238. 
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Fig. 90. Example of assay applied in a pharmaceutical company.540 
Table 20 compiles the solubility data of compounds 157 and 170-183, and of the 
standard 109. 
Table 20. Water solubility of the new compounds. Urea 109 was used as standard. S: solubility, SD: 
standard deviation. 
 
Comp. LHS S ± SD (µg/mL) Comp. LHS S ± SD (µg/mL) 
109 
 
1.66 ± 0.20 177 
 
8.03 ± 1.46 
170 
 
16.1 ± 3.5 178 
 
5.50 ± 0.40 
171 
 
3.01 ± 0.87 179 
 
3.74 ± 2.14 
 
                                                          
540 Alsenz, J.; Kansy, M. Adv. Drug Deliv. Rev. 2007, 59, 546-567. 
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172 
 
4.18 ± 2.76 180 
 
2.36 ± 0.39 
173 
 
2.57 ± 0.53 157 
 
3.19 ± 0.22 
174 
 
7.26 ± 0.83 181 
 
5.77 ± 1.39 
175 
 
5.67 ± 0.97 182 
 
4.26 ± 0.69 
176 
 
2.19 ± 0.10 183 
 
2.52 ± 0.17 
Examination of the data included in table 20 allowed us to identify a few structure-
solubility relationships: 
 All the new scaffolds were slightly more soluble than the adamantyl standard 
109 with small differences between them. 
 With reference to the oxaadamantyl series, unsubstituted compound 170 was 
10-times more soluble than 109 (16.1 µg/mL vs 1.66 µg/mL). 
 Concerning the bisnoradamantane compounds, an appealing trend was 
detected with a decrease in the water solubility as the number of carbon atoms 
increased. Thus, the smaller compound 177 showed the largest solubility for 
this series (8.03 µg/mL), followed by the dimethylated 178 (5.50 µg/mL) and 
the elongated 179 (3.74 µg/mL). However, this trend was not observed in the 
oxaadamantyl series. 
 Surprisingly, benzo-homoadamantane 182 was more soluble than its 
corresponding oxa-derivative 183 (4.26 µg/mL vs 2.52 µg/mL). 
The disparity on the data points out that it should be carefully considered, because of 
two main reasons: 
1. The crystal form affects the solubility of a compound, and amorphous material 
is usually more soluble than crystalline material. As indicated in Material & 
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Methods, some of the new sEH inhibitors were crystallized for purity, whereas 
others came from column chromatography prior to evaporation of solvents 
using rotary-vacuum, which often generates amorphous material. 
2. The establishment of intermolecular interactions determines the molecular 
packing, which directly affects solubility.  
 Although the increase in the water solubility is not remarkable, if we consider that our 
strategy has been the modulation of only one part of the molecule (LHS) so far, and that 
that modulation has been around the introduction of adamantane-like scaffolds, we can 
say that small changes on the molecule can affect substantially the solubility. For instance, 
just the replacement of a methylene group by an oxygen atom means a 10-fold increase in 
water solubility, which is significant when it comes to developing drug candidates. 
An indirect approach to test the solubility is by means of the melting point. The 
melting point provides a reasonable indication of the strength of intermolecular solute-
solute interactions in the solid material. In general, high melting points are an indication 
of high crystal lattice energies, which lead to a lack of solubility both in organic solvents 
and in water, as just seen.541 Taking into account this, we determined the melting points of 
the new ureas, with the values in table 21. 
Table 21. Melting points of the new compounds. Ureas 108 and 109 were used as standards.497 
mp: melting point. 
 
Comp. LHS mp (ºC) Comp. LHS mp (ºC) 
108 
 
216-219 177 
 
185-186 
109 
 
229-230 178 
 
174-175 
170 
 
196-198 179 
 
133-134 
                                                          
541 Morisseau, C.; Newman, J. W.; Tsai, H. J.; Baecker, P. A.; Hammock, B. D. Bioorg. Med. Chem. Lett. 
2006, 16, 5439-5444. 
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171 
 
195-197 180 
 
148-150 
172 
 
165-166 157 
 
217-219 
173 
 
193-195 181 
 
> 220 dec. 
174 
 
150-152 182 
 
206-207 
175 
 
211-213 183 
 
257-259 
176 
 
152-154    
 
 Except for compounds 157, 181 and 183 that did not alter or reduce somewhat the 
value with respect to the standards, the new scaffolds provided compounds with lower 
melting points. This observation is in accordance to the overall increase in the water 
solubility from table 20. 
1.4 Lipophilic ligand efficiency: a new metric for drug discovery 
The strong relationship between solubility and lipophilicity is often discussed in the 
literature, and unsurprisingly as clog P increases, solubility on average decreases.84 
Compounds may be less water soluble if i) they are lipophilic and/or ii) they form cohesive, 
stable crystalline lattices. Indeed, Banerjee et al. suggested an empirical equation that relates 
solubility, melting point and log P [log P = 6.5 – 0.89(log S) – 0.015mp].542 Hence, these 
three characteristics are interrelated. In consequence, fine-tuning of lipophilicity is one of 
the most applied strategies for improving water solubility, and eventually refining the “drug-
                                                          
542 Banerjee, S. Environ. Sci. Technol. 1980, 14, 1227-1229. 
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likeness”. 27,536 In fact, this has been our approach with the modulation of adamantane’s 
structure (scaffold-hopping), thus affecting log P, as it will be discussed later on. 
In the last few years, novel metrics different from the traditional Lipinski’s rule of five 
have appeared, and are employed to expedite the optimization process by combining several 
of these factors into guidelines for medicinal chemists.543,544,545 All of them are designed to 
define the “drug-like” space. Among them, ligand efficiency (LE) is one of the most 
important and commonly employed metrics in drug discovery, first published by Kuntz in 
1999 and redefined by Hopkins in 2004.546,547 LE quantifies the average contribution of a 
heavy atom to the binding (Equation 2). As the name suggests, it measures the efficiency of 
the ligand in the potency.  
LE = ∆G / number of heavy atoms  
or  
LE = pIC50 (or pKi) / number of heavy atoms 
Equation 2 
 
Another major metric is the lipophilic ligand efficiency (LLE or LipE), which is an 
estimate of the specificity of a molecule in binding to the target relative to lipophilicity. In 
other words, LipE normalizes potency relative to log P.548 It is calculated by applying a 
relative simple equation 3.  
LipE = – log (Ki or IC50) – log D (or clog P) Equation 3 
It reasserts the principle of minimal hydrophobicity, which states that “without 
convincing evidence to the contrary, drugs should be made as hydrophilic as possible 
without loss of efficacy”.549 Increasing LipE is likely to be associated with better selectivity, 
efficient polar atom ligand-protein contacts, and specific hydrophobic binding.83 Based on 
the properties of an average oral drug, with a clog P of ~2.5–3.0 and potency in the range 
of ~1–10 nM, an ideal LipE value for an optimized drug candidate is ~5–7 units or greater. 
Negative LipE values are clearly unfavourable. Many oral drugs occupy optimal combined 
ligand efficiency space for their specific targets, showing the importance of balancing 
biological activity, size, and lipophilicity in lead optimization. 
In order to assess the changes on the clog P, and hence on the LipE, as a result of our 
scaffold-hopping strategy, we first calculated the clog P using Bio-Loom® software, and then 
we applied equation 3. The results are summarized in table 22. 
                                                          
543 Meanwell, N. A. Chem. Res. Toxicol. 2011, 24, 1420-1456. 
544 Abad-Zapatero, C.; Champness, E. J.; Segall, M. D. Future Med. Chem. 2014, 6, 577-593. 
545 Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. Nat. Rev. Drug Discov. 2014, 13, 
105-121. 
546 Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. Proc. Natl. Acad. Sci. USA 1999, 96, 9997-10002. 
547 Hopkins, A. L.; Groom, C. R.; Alex, A. Drug Discov. Today 2004, 9, 430-431. 
548 Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W. Future Med. Chem. 2013, 5, 113-115. 
549 Hansch, C.; Björkroth, J. P.; Leo, A. J. Pharm. Sci. 1987, 76, 663-687. 
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Table 22. Values of clog P and LipE for the new sEH inhibitors. Ureas 108 and 109 were used 
as standards.  
 
Comp. LHS clog P LipE Comp. LHS clog P LipE 
108 
 
4.04 4.07 177 
 
2.93 4.92 
109 
 
5.08 3.31 178 
 
3.96 5.11 
170 
 
2.71 5.58 179 
 
5.36 3.02 
171 
 
3.23 4.44 180 
 
5.19 2.80 
172 
 
3.76 4.33 157 
 
2.59 4.84 
173 
 
5.26 2.50 181 
 
3.55 4.04 
174 
 
4.27 3.40 182 
 
5.48 3.62 
175 
 
2.14 5.18 183 
 
4.21 3.38 
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176 
 
1.67 5.83     
 
 
 Some interesting aspects could be deduced from the evaluation of the clog P values: 
 The clog P varied with every different scaffold, with values ranging from 1.67 to 
5.48. Since adamantyl standards 108 and 109 showed clog P values of 4.04 and 
5.08, respectively, most part of the new compounds lowered the lipophilicity, 
whilst others increased moderately the clog P. 
 Compounds bearing an oxygen atom 170-176 displayed a significant reduction in 
the clog P, except for compounds 173 and 174 (clog P of 5.26 and 4.27, 
respectively), which contain bulkier hydrophobic substituents. Outstanding are 
ureas 170, 175 and 176 (clog P of 2.71, 2.14 and 1.67, respectively) with a clog P 
value < 3 and 1 to 2 log units less than adamantyl ureas 108 and 109 (clog P of 
4.04 and 5.08, respectively). 
 For both 2-oxaadamantan-1-yl and tricyclo[3.3.0.03,7]oct-1-yl families, the 
lipophilicity was enhanced as the number of atoms increased, as expected. 
 Among the ring-contracted scaffolds, compounds 177 and 178 (clog P of 2.93 and 
3.96, respectively) lowered the clog P significantly compared with 1-adamantyl-urea 
108. 
 Surprisingly, enlarged pentacyclic ureas 157 and 181 (clog P of 2.59 and 3.55, 
respectively) reduced lipophilicity around 0.5-2.5 log units when compared to 
standards 108 and 109 (clog P of 4.04 and 5.08, respectively).  
 Finally, scaffolds featuring a phenyl ring 182 and 183 (clog P of 5.48 and 4.21, 
respectively) displayed a larger clog P than the adamantyl ureas 108 and 109 
because of their expanded hydrocarbon skeleton. Besides, the insertion of a 
heteroatom in 183 reduced the lipophilicity compared with its analogue 182. 
 
Evaluation of the LipE values led us to the identification of three different situations: 
 
 Enhanced LipE with a reduction of both IC50 and clog P values: this is case of 
compounds 170 and 178 (LipE of 5.58 and 5.11, respectively).   
 Enhanced LipE because of a remarkable reduction in the lipophilicity: here are 
included compounds 171 (LipE of 4.44), 172 (LipE of 4.33), 175 (LipE of 5.18), 
176 (LipE of 5.83), 177 (LipE of 4.92), 157 (LipE of 4.84) and 181 (LipE of 4.04). 
 Reduced LipE due to loss in the inhibitory activity and to an increase in the 
lipophilicity: this behaviour is showed in compounds 173 (LipE of 2.50), 174 (LipE 
of 3.40), 179 (LipE of 3.02), 180 (LipE of 2.80) and 183 (LipE of 3.38). 
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A special case is urea 182 (LipE of 3.62), with a LipE in between both standards 108 
and 109 (LipE of 4.07 and 3.31, respectively), which despite of the dramatic gain in the 
lipophilicity (clog P of 5.48), is more efficient than the adamantyl analogues in the binding, 
as it is reflected in its IC50 (0.80 nM). 
This last observation, along with the former statements, showed that the adamantane 
ring is not the most efficient bulky hydrophobic group as LHS of sEH inhibitors, and that 
a variety of scaffolds may replace it with properties that are more appropriate.  
2. New ureas with selected scaffolds  
In order to confirm the ability of the new scaffolds to surrogate the adamantane in 
sEH inhibitors, we aimed to build a second batch of compounds with the more promising 
scaffolds. The selection of the polycycles were in accordance to the overall performance in 
the inhibition assay, solubility measurement and LipE calculation, but also to the ease on 
the synthesis of the scaffold. Figure 91 resumes the selected scaffolds. 
 
Fig. 91. Selection of scaffolds from the previous series of compounds. 
 We applied the scaffolds from compounds 170, 176 and 178 to the synthesis of further 
ureas with the aim of proving the efficiency of these structures as lipophilic groups in the 
design of sEH inhibitors. In this case, we selected the RHS of the known inhibitors t-AUCB 
and APAU. Both compounds display potent activities against sEH (IC50 values of 1.3 nM 
and 7 nM, respectively) and improved physicochemical properties (Fig. 92).484,483 
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Fig. 92. New approach for the synthesis of new ureas. 
2.1 Synthesis of new ureas with selected scaffolds 
 For the preparation of the next ureas, we could not apply the synthetic approach used 
for the previous batch, since no required isocyanate was commercially available. In the 
exploration of the different strategies to build ureas groups, two procedures stood out: i) 
formation of an intermediate isocyanate with triphosgene from the first amine, and 
subsequent attack of the second amine, or ii) use of the coupling agent carbonyldiimidazole 
(CDI) (Scheme 83). Both routes implied the use of a transfer reagent, which functionalized 
one of the amine counterparts in order to react with the other one.550 
 
Scheme 83. Two alternatives to form a urea functionality. 
 To test the feasibility of both protocols in our scaffolds, we applied both conditions 
for the preparation of the N-(1-acetylpiperidin-4-yl)-N’-(oxaadamantan-1-yl)urea 184, 
analogue to APAU. We decided to make first the corresponding isocyanate 185 from the 
treatment of (2-oxaadamantan-1-yl)amine 120 with triphosgene, a source of the highly toxic 
                                                          
550 Pdiya, K. J.; Gavade, S.; Kardile, B.; Tiwari, M.; Bajare, S.; Mane, M.; Gaware, V.; Varghese, S.; Harel, D.; 
Kurhade, S. Org. Lett. 2012, 14, 2814-2817. 
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phosgene.551,552,553 Triphosgene has the advantage of being safer than phosgene when 
working with the substance since it is a solid crystal, as opposed to phosgene that is a gas. 
Its name came from the idea that triphosgene contains three molecules of phosgene, which 
are released upon reaction. Thus, the reaction mechanism starts with the attack of the 
nucleophilic amine to the triphosgene carbonyl, liberating one molecule of phosgene and 
the carbamate intermediate 186. This intermediate eliminates another molecule of 
phosgene to give the desired isocyanate 185 in 86% yield (Scheme 84). The two in situ-
formed molecules of phosgene can react with the starting amine 120. Hence, only a third 
of the equivalents of triphosgene is enough for the reaction to be efficient.  
 
Scheme 84. Formation of an isocyanate via the reaction of an amine with triphosgene. 
 Next, isocyanate 185 was reacted with 1-acetyl-4-aminopiperidine under the same 
conditions used for the preparation of the former trifluorophenyl ureas. In this manner, 
urea 184 was produced in 52% yield after purification by column chromatography (Scheme 
85).  
 
Scheme 85. Reaction of oxaadamantyl isocyanate 185 with a commercially available amine. 
 For the second alternative, we proceeded to the synthesis of the corresponding 
imidazole carboxamide 187 by reacting CDI with 1-acetyl-4-aminopiperidine in 1,2-
dichloroethane (Scheme 86).554 The titled compound 187 was obtained in 75% yield, and 
fully characterized. 
                                                          
551 Sciuto, A. M.; Hurt, H. H. Inhal. Toxicol. 2004, 16, 565-580.  
552 Ichikawa, Y.; Matsukawa, Y.; Nishiyama, T.; Isobe, M. Eur. J. Org. Chem. 2004, 2004, 586-591. 
553 Davis, M. C.; Dahl, J. E. P.; Carlson, R. M. K. Synth. Commun. 2008, 38, 1153-1158. 
554 Rawling, T.; McDonagh, A. M.; Tattam, B.; Murray, M. Tetrahedron 2012, 68, 6065-6070. 
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Scheme 86. Preparation of the intermediate 187 through an addition-elimination reaction 
mechanism. 
 Then, imidazole carboxamide 187 was subjected to the attack of (2-oxaadamantan-1-
yl)amine 120 to afford the desired urea 184 in 53% yield, comparable to the previous 
procedure with triphosgene (Scheme 87).  
 
Scheme 87. Synthesis of final urea 184 following the protocol with CDI as the transfer reagent. 
 With these two syntheses, we concluded that both alternatives were comparable in 
terms of yield. Nevertheless, the procedure with CDI as transfer reagent needed harsher 
conditions (long reaction times while heating). Accordingly, we applied the triphosgene 
route, whenever possible, for the preparation of the following ureas.  
 Analogously, oxaahexacyclo derivative 188 was built by means of the preparation of its 
corresponding isocyanate 189 in quantitative yield from amine 121, and subsequent 
transformation to urea 188 with the addition of 1-acetyl-4-aminopiperidine in 26% yield 
(Scheme 88). 
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Scheme 88. Synthetic sequence for the preparation of urea 188. 
 In the case of the analogues of the sEH inhibitor t-AUCB, the corresponding amine 
190 was not commercially available. So, we followed the reported methodologies by Hwang 
et al. for the construction of the RHS of the molecule.483,555 The synthetic pathway consisted 
in the nucleophilic aromatic substitution of fluorobenzonitrile by trans-4-
aminocyclohexanol, and consecutive hydrolysis of nitrile 191 to carboxylic acid 190 under 
basic conditions in 44% overall yield (Scheme 89). The success of the nucleophilic aromatic 
substitution was due to the presence of an EWG in para-position (nitrile). 
 
Scheme 89. Nucleophilic aromatic substitution and basic hydrolysis for the preparation of 
intermediate amine 190 as its hydrochloride salt. 
                                                          
555 Hwang, S. H.; Wecksler, A. T.; Zhang, G.; Morisseau, C.; Nguyen, L. V; Fu, S. H.; Hammock, B. D. Bioorg. 
Med. Chem. Lett. 2013, 23, 3732-3737. 
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 Once intermediate amine 190 was prepared in sufficient amounts, ureas 192 and 193 
were obtained in 24 and 50% yield, respectively, from the corresponding isocyanates 185 
and 189 (Scheme 90). 
 
Scheme 90. Attack of the primary amine of 190 to each one of the isocyanates to provide final 
ureas 192 and 193. 
  Special cases were the ring-contracted analogues with general structure VI, the last 
scaffold to prepare (Fig. 93).  
 
Fig. 93. Bisnoradamantane ureas to prepare. 
  For the synthesis of these particular ureas, we encountered two handicaps: 
1. We envisioned that the corresponding isocyanate 194 should be volatile under the 
reaction conditions and posterior work-up procedure (Fig. 94). This volatility may 
be due to the small molecular weight (177.12 Da) and to the lack of strong 
intermolecular interactions. 
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Fig. 94. We hypothesized the volatility of isocyanate 194. 
2. Because of the low-yielding synthetic route to construct the bisnoradamantane 
scaffold, we had only enough amounts of starting amine 123 to prepare a single 
derivative. 
All in all, we pursued the synthesis of APAU’s derivative 195 implementing the 
procedure that entailed CDI as transfer reagent. In this sense, amine 123 was reacted with 
the imidazole carboxamide 187 in the presence of triethylamine to furnish final urea 195 
in 77% yield (Scheme 91).  
 
Scheme 91. Synthesis of the last derivative of the series. 
2.2 Pharmacological evaluation of new ureas with the selected scaffolds 
 The five new ureas were tested as sEH inhibitors under our optimized screening assay 
(Fig. 95). 
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Fig. 95. New ureas to test as sEH inhibitors. 
 We performed the inhibitory screening assay under the previous conditions for the 
determination of the IC50 values, using the commercially available t-AUCB as standard 
(Table 23). 
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Table 23. Inhibition of the sEH by the new ureas. t-AUCB was used as standard.483,484  
 
 
Comp. LHS RHS IC50 ± SE (nM) 
t-AUCB 
 
 
1.87 ± 0.14 
(reported 1.3 
nM) 
APAU 
 
 
reported 7 nM 
184 
  
19.8 ± 6.2 
188 
  
50.8 ± 11.9 
192 
 
 
13.4 ± 4.0 
193 
 
 
40.6 ± 8.9 
195 
  
8.41 ± 0.59 
 
According to the above data, the following conclusions may be drawn for this second 
batch of ureas: 
 Any new scaffold improved the inhibitory activity of the standard t-AUCB 
under the assay conditions. 
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 Among the three different scaffolds tested, bisnoradamantane 195 (IC50 of 
8.41 nM) was the most potent inhibitor compared with other structures. 
 Regarding the oxa-derivatives, oxaadamantyl ureas 184 and 192 (IC50 of 19.8 
and 13.4 nM, respectively) displayed lower IC50 values than oxahexacyclic ureas 
188 and 193 (IC50 of 50.8 and 40.6 nM, respectively). 
 Between the two different RHSs assayed (when a direct comparison was 
possible), APAU derivatives showed lower inhibitory potency than t-AUCB 
derivatives; compare 184 with 192 (IC50 of 19.8 and 13.4 nM, respectively) and 
188 and 193 (IC50 of 50.8 and 40.6 nM, respectively). 
 
Although showing higher IC50 values than the adamantyl standard, the potent activity 
of the selected scaffolds as sEH inhibitors underpinned their ability to surrogate the 
adamantane nucleus in this kind of bioactive molecules. 
Taking into account the excellent potency of the ring-contracted APAU derivative 195 
(IC50 of 8.41 nM), and that the inhibitors bearing the RHS from t-AUCB displayed higher 
activities, it seems logical that the missing piece of this puzzle is the corresponding ring-
contracted t-AUCB derivative 196 (Fig. 96). Unfortunately, there was not enough time 
during the present thesis to prepare this promising compound. 
 
Fig. 96. Urea to prepare to combine the best findings from table 23. 
2.3 Water solubility, melting points and LipE 
 To further assess the new sEH inhibitors, we aimed to determine some 
physicochemical properties as in the case of the former series of compounds. Thus, we 
measured the water solubility, determined the melting points, and calculated the clog P 
and the LipE in order to compare these structures with the adamantyl standards (Table 24). 
 Worth to mention is that, in the case of compounds 184, 188 and 195, which lack a 
chromophore group and therefore showed lower absorbance in the HPLC measurement, 
a mathematical adjustment was required in order to extrapolate the values to the calibration 
curve (see Materials & Methods). 
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Table 24. Water solubility, melting points, clog P and LipE of the new ureas. t-AUCB was used as 
standard.483 mp: melting point. ND: not determined. 
 
 
Comp. LHS RHS S ± SD 
(µg/mL) 
mp (ºC) clog P LipE 
t-AUCB 
 
 
reported    
> 200 
250-255 4.84 3.89 
APAU 
 
 
reported    
> 200 
205-206 0.77 7.38 
184 
 
 
232.9 ± 
12.1 
172-173 -0.37 8.07 
188 
  
258.1 ± 
17.4 
164-166 -1.41 8.70 
192 
 
 
72.1 ± 2.9 255-257 3.70 4.17 
193 
  
138.6 ± 3.5 254-256 2.67 4.72 
195 
  
295.9 ± 
26.6 
165-167 0.69 7.39 
  
The data shown in table 24 revealed interesting features: 
 Although we could not afford to determine the water solubility of the standards 
under our procedure, all the prepared ureas displayed good solubility values, 
better suited than the previous ones for a possible pharmaceutical. 
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 Compound 195 showed the highest water solubility (295.9 µg/mL), whereas 
tAUCB derivatives 192 and 193 exhibited the worst results (72.1 and 138.6 
µg/mL, respectively). This is in accordance with the high melting points for 
these two ureas. Presumably, the extraordinary energy lattices of the crystal 
structure of these compounds affects significantly their water solubility. 
 clog P values extremely decreased when 1-acetylpiperidine was placed as the 
RHS (compounds 184, 188 and 195), to a level that they were no longer 
considerable as drug candidates (-1.41 to 0.69). Because of this, LipE values 
were remarkably high for these type of structures.  
 t-AUCB derivatives 192 and 193 showed a more “drug-like” profile with 
acceptable water solubilities, optimum clog P values, and appropriate LipE. 
 Compiling the data obtained so far, we have identified some scaffolds as excellent 
surrogates of the adamantane nucleus in sEH inhibitors, a few of them with remarkable 
physicochemical properties. From this point, the next step was the evaluation of these new 
sEH inhibitors in in vitro studies, so as to assess their ability to inhibit the sEH enzyme in a 
cellular level. Because of the close relationship of the sEH in the development of the 
endoplasmic reticulum (ER) stress (vide infra), we aimed to test a few of our more promising 
compounds in ER stress studies. Consequently, we selected three compounds that 
displayed a perfect balance between inhibitory activity and clog P (expressed in the LipE) 
and that entailed easy synthetic routes for the preparation of the scaffolds. The latter point 
was envisioning that these structures would progress throughout the drug discovery process. 
The selected molecules are disclosed in figure 97.  
 
Fig. 97. Selected compounds for in vitro studies. 
3. ER stress amelioration with selected sEH inhibitors. In vitro studies 
 The ER is a membranous network that functions in the synthesis, folding and 
maturation of newly secretory and membrane proteins, and is highly responsive to nutrients 
and energy status of the cell. When certain pathological stress conditions disrupt ER 
homeostasis, such as nutrient excess or deficiency, stress, inflammation, hypoxia or 
infection, the folding capacity of the ER is exceeded and consequently misfolded proteins 
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accumulate and lead to the so-called ER stress.556 For instance, obesity is a chronic stimulus 
for ER stress in peripheral tissues, and is a core mechanism involved in triggering insulin 
resistance and T2DM.557 In addition, obese individuals exhibit increased expression of 
multiple markers of ER stress.558 On the other hand, ER stress also provides several links 
with the emergence of inflammatory processes, mainly by activation of both c-Jun amino-
terminal kinase (JNK) and inhibitor of κ β kinase (IKK), both related to the development 
of insulin resistance.559,560 Taken together, the effector arms of ER stress and the associated 
stress responses are tightly linked to inflammatory pathways at many levels that are crucial 
for insulin action and metabolic homeostasis. Thus, understanding the role of ER stress 
may be of therapeutic potential for the treatment of metabolic diseases, specially obesity 
and T2DM.301,561 In addition, ER stress is a key piece to the pathogenesis of other diseases 
such as neurodegenerative disorders and cancer. 440 
 In response to the accumulation of unfolded proteins in the ER, a sequential process 
takes place; the rate of general translation initiation is attenuated, the expression of ER 
resident protein chaperones and protein foldases is induced, the ER compartment 
proliferates, and ER-associated degradation (ERAD) is activated to eliminate irreparable 
misfolded proteins.556,562 If these survival mechanisms fail to facilitate ER homeostasis, ER-
stress triggers apoptotic processes.563,564 The adaptive mechanisms to mitigate ER stress and 
to restore homeostasis are collectively termed as the unfolded protein response (UPR), 
which consists of a signal transduction system linking the ER lumen with the cytoplasm 
and nucleus.565 UPR signalling consists of three branches initiated by the ER 
transmembrane proteins PKR-like ER-regulated kinase (PERK), inositol-requiring enzyme 
1 (IRE1), and activating transcription factor 6 (ATF6).559,566,567 These sensor proteins 
respond to changes in protein folding status in the ER and convey information to activate 
distinct and sometimes overlapping pathways, leading to diverse developmental and 
metabolic processes. PERK phosphorylates the α-subunit of eukaryotic translation 
initiation factor 2 (eIF2) at Ser51, leading to rapid and transient attenuation of protein 
                                                          
556 Schröder, M.; Kaufman, R. J. Annu. Rev. Biochem. 2005, 74, 739-789. 
557 Ozcan, U.; Cao, Q.; Yilmaz, E.; Lee, A. H.; Iwakoshi, N. N.; Ozdelen, E.; Tuncman, G.; Görgün, C.; Glimcher, 
L. H.; Hotamisligil, G. S. Science 2004, 306, 457-461. 
558 Sharma, N. K.; Das, S. K.; Mondal, A. K.; Hackney, O. G.; Chu,W. S.; Kern, P. A.; Rasouli, N.; Spencer, H. 
J.; Yao-Borengasser, A.; Elbein, S. C. J. Clin. Endocrinol. Metab. 2008, 93, 4532-4541. 
559 Hummasti, S.; Hotamisligil, G. S. Circ. Res. 2010, 107, 579-591. 
560 Hotamisligil, G. S. Int. J. Obs. 2008, 32, S52-S54. 
561 Eizirik, D. L.; Cardozo, A. K.; Cnop, M. Endocr. Rev. 2008, 29, 42-61. 
562 Wu, J.; Kaufman, R. J. Cell Death Differ. 2006, 13, 374-384. 
563 Zinszner, H.; Kuroda, M.; Wang, X.; Batchvarova, N.; Lightfoot, R. T.; Remotti, H.; Stevens, J. L.; Ron, D. 
Genes Dev. 1998, 12, 982-995. 
564 Nishitoh, H.; Matsuzawa, A.; Tobiume, K.; Saegusa, K.; Takeda, K.; Inoue, K.; Hori, S.; Kakizuka, A.; Ichijo, 
H. Genes Dev. 2002, 16, 1345-1355. 
565 Pluquet, O.; Pourtier, A.; Abbadie, C. Am. J. Physiol. Cell Physiol. 2015, 308, C415-C425. 
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synthesis to decrease protein influx into the ER lumen.568,569 eIF2α promotes the activating 
transcription factor 4 (ATF4), which induces genes involved in ER function, ER-induced 
apoptosis, and an inhibitory feedback to prevent hyperactivation of the UPR, among other 
effects.570,571 IRE1 activation leads to the unconventional splicing of X-box-binding protein 
1 (XBP1) mRNA, leading to the synthesis of a nuclear XBP1 form that induces the 
transcription of genes encoding ER chaperones and ERAD.572,573,574 The third canonical 
branch includes ATF6, which, upon ER stress, traffics to the Golgi apparatus, where it is 
cleaved to liberate a fragment that translocates to the nucleus to induce genes encoding ER 
chaperones and ERAD functions, independently or synergistically with XBP1 and 
ATF4.575,576  
 The master initiator of the UPR is the immunoglobulin-heavy-chain-binding protein 
or BiP, which is a negative effector of the UPR, known as well as 78 kDa glucose-regulated 
protein (GRP78). In physiological states, this chaperone is known to be expressed 
constitutively and binds to the luminal domains of PERK, IRE1, and ATF6 in their inactive 
forms.577 Under conditions that promote accumulation of misfolded proteins, GRP78 is 
overexpressed and preferentially binds to hydrophobic regions of unfolded/misfolded 
proteins that accumulate in the ER lumen.578 Consequently, BiP is sequestered and 
dissociates from the ER stress sensors to allow their signalling.579,580,581 
As stated before, chronic or severe ER stress activates the UPR leading to apoptosis. 
Persistent activation of PERK-eIF2α-ATF4 and ATF6 pathways culminates in the induction 
of the CCAAT enhancer-binding protein (C/EBP) homologous protein (CHOP or 
GADD153), which up-regulates apoptosis-related genes.563,582,583  
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Figure 98 summarizes what has been discussed so far. 
 
Fig. 98. UPR activation in response to the ER stress. 
The machinery concerning ER stress is thus intricate and complex. Although still 
unknown to some extent, different proteins have been identified to play a trivial role in the 
development of the ER stress. Among them, activating transcription factor 3 (ATF3) is an 
ER stress marker whose expression is increased in such conditions. It is related to insulin 
signalling and lipogenesis.584 
Over the multiple studies that have been performed in relation to the ER stress, 
different ER stress-inducers have been identified. Among them, the saturated fatty acid 
palmitate,585,586,587 followed by thapsigargin (by depletion of Ca2+ from the ER), tunicamycin 
(by blockade of protein glycosylation in the ER)588 and borrelidin.589 On the other hand, 
several substances have emerged as restorers of ER stress, such as unsaturated fatty acids 
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(oleate and linolate),590,591 the PPARα agonist fenofibrate,592 and the chemical chaperon 4-
phenyl butyric acid (PBA),593 and tauroursodeoxycholic acid (TUDCA).594  
 In 2013, sEH was identified as a key regulator of the ER stress.595 Epoxy fatty acids 
have proven to be upstream modulators of ER stress pathways.596,597 In consequence, 
attenuation or inhibition of sEH leads to an amelioration of the ER stress, therefore 
reasserting its potential as a therapeutic target for obesity-related comorbidities. Taken 
together these studies and due to the wide expertise of the research group of Dr. Manuel 
Vázquez Carrera in the study of the ER stress in skeletal muscle and in animal models of 
insulin resistance,590,598 we envisioned that our sEH inhibitors would be able to attenuate 
the ER stress when produced by a stimuli.  
For our studies, human hepatocytes, from the cell line Huh-7,599 were chosen because 
of their availability and ease to maintain for cell cultures, coupled with the fact that sEH is 
widely expressed in liver, as seen in the introductory part of this chapter. Cells were treated 
with palmitate prior to conjugation of this fatty acid with BSA, as previously described by 
the group.590 Based on our experience in ER stress and the reported studies, we proceeded 
to run the in vitro assays in a single final concentration of each inhibitor (170, 176 and 192) 
and palmitate (1 µM/L and 0.5 mM/L, respectively) during 48 hours. After the treatment, 
samples were recovered for RNA and total protein extraction. We used again urea 109 as 
standard for comparison. Worth to note is the fact that adamantyl urea 109 has not been 
tested in human cell cultures prior to our studies.  
 To assess the resolution of ER stress with our sEH inhibitors, we examined their effects 
on the expression of the ER stress markers Bip/Grp78, Chop and Atf3. Levels of mRNA of 
the three genes were determined by Real Time-PCR with GAPDH as housekeeping gene. 
Human Huh-7 hepatocytes exposed to 0.5 mmol/L palmitate showed an increase in 
Bip/Grp78, Chop and Atf3 mRNA levels compared with cells exposed only to BSA (Fig. 99). 
Interestingly, co-incubation of cells with palmitate (0.5 mmol/L) and each one of the 
inhibitors (1 µmol/L) considerably blocked the effects of the saturated fatty acid, with a 
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significant reduction of the mRNA levels for the three markers. This trend was more 
remarkable for Atf3 (Fig. 99C). 
A                                                                    B 
 
                                 C 
 
Fig. 99. Assessment by quantitative real-time RT-PCR of mRNA abundance of Bip/Grp78 (A), 
Chop (B) and Atf3 (C). Huh-7 hepatocytes were incubated for 48 h in the absence (Control, 
CT) or in the presence of 0.5 mmol/L palmitate (PAL) and the compounds tested. Data are 
presented as the mean ± SD (n = 6 per group). ***: P < 0.001 vs control. #: P < 0.05, ##: P < 
0.01 and ###: P < 0.001 vs palmitate-exposed cells. 
In agreement with the changes in Chop mRNA levels, CHOP protein levels were only 
increased in cells exposed to palmitate (Fig. 100). 
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               A  
B  
 
Fig. 100. Levels of protein of CHOP (A) and their quantification (B). Huh-7 hepatocytes were 
incubated for 48 h in the absence (Control, CT) or in the presence of 0.5 mmol/L palmitate 
(PAL) and the compounds tested. Data are presented as the mean ± SD (n = 3 per group).    
***: P < 0.001 vs control. ##: P < 0.01 and ###: P < 0.001 vs palmitate-exposed cells. 
 
 The reduction of the mRNA and protein levels of BiP, CHOP and ATF3 markers 
resulting from the sEH inhibition from our three tested compounds prompted the 
following conclusions:   
 In general, sEH inhibition at a low concentration provided a remarkable protection 
against palmitate-induced ER stress and reduced the levels of theses markers to 
those present in control cells. 
 Except for compound 192, new inhibitors 170 and 176 led to an extremely 
significant reduction of the ER stress comparable with the adamantyl standard 109. 
 Addition of compound 192, although providing less benefit than the other tested 
compounds, resulted in a very significant recovery of the ER stress. 
 Only in mRNA levels, compound 170 showed a better behaviour preventing 
palmitate-induced ER stress than the adamantane analogue 109. 
 The positive outcomes of these in vitro studies showed that the four sEH inhibitors 
are able to cross cell membrane and are not cytotoxic. 
 As a whole, the findings of this study show that sEH inhibition contributes to the 
prevention of palmitate-induced ER stress, and that our scaffolds compare well with the 
adamantane nucleus. 
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 To our delight, these experiments with sEH inhibitors in Huh-7 cell line are, to date 
and to the best of our knowledge, the first in vitro studies concerning sEH and ER stress 
performed under this new protocol. 
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This chapter involves the synthesis of 20 new ureas with 15 different adamantane-like 
polycycles through a scaffold-hopping approach; none of them had been previously 
described in the literature. The new structures have been thoroughly characterized by 
spectroscopic and analytical means. None of the scaffolds had been previously applied in 
the design and synthesis of sEH inhibitors.  
The pharmacological evaluation was carried out, and entailed the optimization of the 
assay conditions, followed by the determination of the IC50 values of each new compound. 
Furthermore, an unexplored method for the water solubility measurement was applied, 
and the values of solubility were used for the assessment of each scaffold. Finally, the 
lipophilic ligand efficiency of each new sEH inhibitor was calculated from the IC50 and clog 
P data.  
As the main conclusions of this chapter, in chronological order: 
1. All the 15 polycyclic scaffolds were potent sEH inhibitors, with IC50 values 
ranging from 0.80 to 50.8 nM. 
2. Three different structures were identified with higher inhibitory activities than 
the adamantanyl standards 108 and 109 (IC50 of 7.74 and 4.04 nM, 
respectively) (Fig. 101).  
 
Fig. 101. Most potent compounds found in this chapter. 
3. According to the results obtained from water solubility and LipE, and taking 
into account the ease in the synthesis of each structure, three scaffolds were 
selected for the preparation of optimized sEH inhibitors (Fig. 102). 
 
Fig. 102. Selected scaffolds as adamantane surrogates for the second batch of 
compounds. 
4. Five new ureas were prepared following described methods, in order to test 
their in vitro potency against human sEH. Albeit showing higher IC50 values 
than the standard t-AUCB, all of them were potent sEH inhibitors (from 8.41 
to 50.8 nM). 
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5. After the determination of their water solubility and LipE, these scaffolds have 
proven to be efficient surrogates of the adamantane ring for this specific target, 
with more appropriate physicochemical properties than the adamantane group. 
6. In vitro cellular studies have demonstrated their ability to cross cell membrane 
and to attenuate ER stress induced by palmitate, without promoting cell death. 
These experiments with the human Huh-7 cell line are, to date, the first ever 
reported that link sEH and ER stress under this protocol. 
This work has been focused on investigating structure-activity relationships of 
adamantane-like derivatives as human sEH inhibitors, which provided an important base 
for developing valuable compounds that are not only highly potent inhibitors but show 
improved physicochemical properties. 
 
 
As a general conclusion of this dissertation, we have demonstrated that the 
adamantane nucleus is not necessarily the perfect lipophilic bullet, and that a fine-tuning is 
required in order to optimize the binding mode of the molecule for each specific target as 
well as to adjust its physicochemical properties. Exploration around adamantane-like 
scaffolds for the discovery of improved drug candidates is still an underexploited research 
area. 
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General Methods 
Melting points were determined in open capillary tubes with a MFB 59510M 
Gallenkamp or a Büchi B – 540 melting point apparatuses. 
300 MHz 1H NMR spectra, 400 MHz 1H/100.6 MHz 13C NMR spectra, and 500MHz 
1H/125.7 MHz 13C NMR spectra were recorded on Varian Gemini 300, Varian Mercury 
400, and Varian Inova 500 spectrometers, respectively. The chemical shifts are reported in 
ppm (δ scale) relative to internal tetramethylsilane, or to solvent peak, and coupling 
constants are reported in Hertz (Hz). The used abbreviations were: s, singlet; d, doublet; t, 
triplet; q, quadruplet; m, multiplet; or combinations thereof.  
IR spectra were run on FTIR Perkin-Elmer Spectrum RX I spectrophotometer using 
potassium bromide (KBr) pellets or attenuated total reflectance (ATR) technique. 
Absorption values are expressed as wavenumbers (cm-i); only significant absorption bands 
are given. 
The GC/MS analyses were carried out in an inert Agilent Technologies 5975 gas 
chromatograph equipped with a DB-5MS (30 m x 25 mm) capillary column with a 
stationary phase of phenylmethylsilicon (5% diphenyl-9% dimethylpolysoloxane), using the 
following conditions: initial temperature of 50 ºC ( 1 min), with a gradient of 15 ºC/min 
up to 300 ºC, and a temperature in the source of 230 ºC. solvent decay of 3 minutes and 
pressure of 7.5 psi. The electron impact (70 eV) or chemical ionization (CH4) techniques 
were used. Only significant ions are given, those with higher relative ratio, except for the 
ions with higher m/z values. 
The accurate mass analyses were carried out at Unitat d’Espectrometria de Masses dels 
Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB), Faculty of 
Chemistry, using a LC/MSD-TOF spectrophotometer. 
The elemental analyses were carried out in a Flash 1112 series Thermofinnigan 
elemental microanalyzator (A5) to determine C, H, and N, and in a tiroprocessor Methrom 
808 to determine Cl, at the Servei de Microanàlisi of IIQAB (CSIC) of Barcelona. 
To concentrate solvents in vacuo a Büchi GKR-50 rotavapor was used. 
Column chromatography was perfomed on either silica gel 60 Å (35-70 mesh, SDS), 
or on aluminium oxide, neutral, 60 Å (50-200 µm, Brockmann I). 
Thin-layer chromatography was performed with aluminium–backed sheets with either 
silica gel 60 F254 or aluminum oxide 60 Å, and spots were visualized with UV light, 1% 
aqueous solution of KMnO4 and/or iodine. 
All new compounds that were subjected to a pharmacological evaluation, possessed a 
purity ≥ 95% as evidenced by their analytical data, if possible. 
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Solvent purification was carried out following the procedures described in: Perrin, D. 
D.; Armarego, W. L. F. Purification of Laboratory Chemicals, 4th Edition, Butterworth-
Heinemann: Oxford, 1996. 
The NMR data and the synthetic procedure of all the compounds synthesized for the 
first time in our laboratory are included in the current manuscript. Regarding the 
compounds described previously in the literature, the synthetic procedure is described 
along with the reference corresponding with their preparation. 
A complete characterization of all the new compounds synthesized in this thesis, was 
carried out including 1H and 13C, IR, elemental analysis or accurate mass and GC/MS. All 
1H and 13C NMR signlas were assigned by reason of homocorrelation 1H/1H (COSY and 
NOESY) and heterocorrelation 1H/13C (HSQC) experiments. 
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Preparation of 5,6,8,9-tetrahydro-5,9-propanebenzocycloheptane-7,11-dione, 27 and 
7,11-epoxi-6,7,8,9-tetrahydro-5,9-propane-5H-benzocycloheptane-7,11-diol, 28168 
 
a) Tetraester’s formation: 
To a solution of o-phthaldialdehyde (9.80 g, 73.1 mmol) and dimethyl 1,3-
acetonedicarboxylate (25.9 g, 149 mmol) in methanol (200 mL) were added 15 drops of 
diethylamine, and the solution was heated at reflux for 1.5 hours. Then 12 drops more of 
diethylamine were added and the mixture was cooled to 4 ºC overnight. The resulting 
precipitated was filtered in vacuo and washed with cold methanol (25 mL) to give the 
intermediate tetraester as white crystals (22.2 g, 68% yield). 
b) Preparation of the diketone 27 and its hydrate 28: 
 To a round bottom flask containing the intermediate tetraester prepared in the last 
step (22.2 g, 49.8 mmol), glacial acetic acid (125 mL) and conc. HCl (35 mL) were added 
and the mixture was heated at reflux for 12 hours. The acids were then removed under 
vacuo and the resulting solid was digested with diethyl ether (150 mL) for 15 minutes and 
cooled to 4 ºC overnight. Filtration in vacuo gave a mixture of diketone 27 and hydrate 28 
with a 1:3 ratio as a white solid (10.5 g). Dehydration of the mixture by a Dean-Stark system 
with toluene (250 mL) as the solvent gave the pure diketone 27 (9.8 g, 93% yield), whose 
spectroscopic data matched with those previously published. 
 
Preparation of 5,6,8,9-tetrahydro-5,9-propanebenzocycloheptane-11-ene-7-one, 25165  
 
 A suspension of sodium hydride, 60% dispersion in mineral oil (1.00 g, 25.17 mmol) 
in anh. DMSO (50 mL) was heated to 75 ºC for 45 minutes under N2 atmosphere. After 
the reaction mixture was tempered, a solution of triphenylmethylphophonium iodide 
(10.55 g, 25.17 mmol) in anh. DMSO (60 mL) was added and the resulting yellow solution 
was stirred at room temperature for 20 minutes. Then a suspension of diketone 27 (4.31 g, 
20.14 mmol) in anh. DMSO (50 mL) was added and the obtained solution was heated to 
75 ºC overnight. The resulting black solution was allowed to cool to room temperature and 
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then poured into water (150 mL). Hexane (50 mL) was added and the phases were 
separated. The aqueous phase was extracted with further hexane (2 x 50 mL) and the 
combined organic phases were washed with brine (50 mL), dried over anh. Na2SO4, filtered 
and concentrated in vacuo to give a white solid (3.93 g). Purification by packing the solid 
with silica gel and extracting with 10% petroleum ether/diethyl ether mixture gave 25 (3.34 
g, 84% yield) as a white solid. The spectroscopic data were identical to those previously 
published. 
 
Preparation of 2-chloro-N-(9-hydroxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)acetamide, 34  
 
 
 To a solution of enone 25 (2.09 g, 9.86 mmol) in DCM (15 mL) was added 
chloroacetonitrile (0.62 mL, 9.86 mmol) and the mixture was cooled to 0-5 ºC with an ice 
bath. Then conc. H2SO4 (0.79 mL, 14.82 mmol) was added dropwise without reaching a 
temperature greater than 10 ºC. After the addition, the reaction mixture was allowed to 
reach room temperature and stirred overnight. Then to the resulting solution was added 
ice (25 g) and the mixture was stirred at room temperature for few minutes. DCM (30 mL) 
was added, the phases were separated and the aqueous phase was extracted with further 
DCM (2 x 30 mL). The combined organic phases were dried over anh. Na2SO4, filtered 
and evaporated in vacuo to give a white solid (2.68 g). Purification by column 
chromatography (Al2O3, 0-5% methanol/DCM) gave 34 (1.46 g, 49% yield) as a white solid. 
Analytical and spectroscopic data of compound 34: 
Melting point: 184 – 185 ºC. 
IR (ATR) ν: 3300 – 2800 (3315, 3247, 3217, 3065, 3021, 2925, 2851), 1911, 1664, 1560, 
1494, 1441, 1413, 1361, 1300, 1224, 1202, 1151, 1107, 1037, 911, 757, 668, 571, 512, 471 
cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.78 [d, J = 12.8 Hz, 2 H, 10(13)-Hb], 1.97 [m, 2 H, 10(13)- 
Ha], 2.04 [d, J = 12.8 Hz, 2 H, 6(12)- Hb], 2.12 (s, 2 H, 8-H2), 2.19 [m, 2 H, 6(12)- Ha], 3.21 
[t, J = 6.4 Hz, 2 H, 5(11)-H], 3.93 (s, 2 H, CH2Cl), 6.36 (s, 1 H, NH), 7.08 [m, 2 H, 1(4)-H], 
7.13 [m, 2 H, 2(3)-H]. 
13C-NMR (100.6 MHz, CDCl3) δ: 38.2 [CH2, C6(12)], 39.9 [CH, C5(11)], 42.4 [CH2, 
C10(13)], 42.8 (CH2, CH2Cl), 47.9 (CH2, C8), 57.3 (C, C7), 70.7 (C, C9), 126.8 [CH, 
C2(3)], 128.1 [CH, C1(4)], 144.9 [C, C4a(C11a)], 164.6 (C, CO). 
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MS (EI), m/z (%); significant ions: 307 (10), 305 (M·+, 30), 270 [(M-35Cl)+, 12], 212 (100), 
197 (17), 194 (22), 179 (26), 169 (13), 155 (58), 142 (25), 129 (32), 115 (26), 91 (7), 77 (9), 
65 (2), 55 (4), 49 (4). 
HRMS-ESI+ m/z [M+H]+ calcd for [C17H20ClNO2+H]+: 306.1255, found: 306.1249. 
 
Preparation of 9-amino-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-ol hydrochloride, 46·HCl 
  
 
 To a solution of chloroacetamide 37 (710 mg, 2.32 mmol) in abs. ethanol (40 mL) 
were added thiourea (0.212 g, 2.79 mmol) and glacial acetic acid (1.4 mL) and the mixture 
was heated at reflux overnight. The resulting suspension was then tempered to room 
temperature, water (20 mL) was added and the pH adjusted to ~12 with 5 N NaOH 
solution. DCM (20 mL) was added, the phases were separated and the aqueous phase was 
extracted with further DCM (2 x 20 mL). The combined organic phases were dried over 
anh. Na2SO4, filtered and concentrated in vacuo to give 46 as a white solid. Its 
hydrochloride was obtained by adding an excess of Et2O·HCl to a solution of the amine in 
DCM, followed by filtration of the white precipitated (602 mg, quantitative yield). The 
analytical sample was obtained by crystallization with methanol/diethyl ether. 
Analytical and spectroscopic data of compound 46·HCl: 
Melting point: > 315 ºC (dec.). 
IR (ATR) ν: 3273, 2902, 2872, 2638, 2569, 2088, 1633, 1531, 1493, 1441, 1355, 1314, 1272, 
1106, 1094, 1015, 972, 902, 764, 640, 580 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.75 [d, J = 12.5 Hz, 2 H, 6(12)-Hb], 1.81 [d, J = 13.0 Hz, 2 
H, 10(13)- Hb], 1.89 (s, 2 H, 8-H2), 1.98 [m, 2 H, 6(12)- Ha], 2.05 [m, 2 H, 10(13)- Ha], 3.30 
[tt, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 7.13 (m, 4 H, Ar-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 39.0 [CH2, C10(13)], 40.7 [CH, C5(11)], 42.8 [CH2, 
C6(12)], 47.9 (CH2, C8), 57.5 (C, C7), 70.9 (C, C9), 128.3 [CH, C2(3)], 129.3 [CH, C1(4)], 
145.7 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 229 (M·+, 100), 214 (10), 196 (C15H16·+, 10), 187 (37), 186 
(16), 172 (14), 171 (11), 170 (23), 168 (18), 158 (11), 157 (20), 156 (29), 155 (12), 144 (49), 
143 (47), 129 (28), 128 (32), 115 (26), 110 (33), 96 (29). 
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Elemental analysis: 
Calculated for C15H20ClNO:                     C  67.79%    H  7.58%   Cl13.34%    N  5.27% 
Calculated for C15H20ClNO·0.20H2O:      C  66.87%   H  7.63%   Cl  13.16%   N  5.20%                                             
Found:                                  C  66.87%   H  7.71%   Cl  13.08%   N  4.98% 
 
Preparation of 9-(dimethylamino)-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-ol hydrochloride, 50·HCl  
  
 
 To a solution of amine 46 (250 mg, 1.09 mmol) in methanol (8 mL) were added 
formaldehyde (0.25 mL, 37% wt in aqueous solution, 3.32 mmol), glacial acetic acid (0.23 
mL) and sodium cyanoborohydride (206.2 mg, 3.12 mmol) and the mixture was stirred at 
room temperature for 7 hours. Then further NaBH3CN (206.2 mg, 3.12 mmol) and 
formaldehyde (0.25 mL, 37% wt in aqueous solution, 3.32 mmol) were added and the 
solution was stirred at room temperature overnight. The reaction mixture was then 
evaporated to dryness in vacuo and the resulting residue partitioned between water (5 mL) 
and EtOAc (5 mL). The pH was adjusted to ~12 with 5 N NaOH solution and the phases 
were separated. The aqueous phase was extracted with further EtOAc (2 x 5 mL) and the 
combined organic layers were dried over anh. Na2SO4, filtered and concentrated in vacuo. 
The residue was taken in DCM and the amine 50 was precipitated as its hydrochloride 
(104.9 mg, 33% yield) by adding an excess of Et2O·HCl. The analytical sample was obtained 
by crystallization with methanol/diethyl ether.  
Analytical and spectroscopic data of compound 50·HCl: 
Melting point: 241-242 ºC. 
IR (ATR) ν: 3424, 3224, 2956, 2855, 2533, 2429, 1665, 1487, 1451, 1412, 1361, 1348, 1310, 
1211, 1183, 1141, 1094, 1078, 990, 978, 969, 908, 769, 702, 621, 591 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.74 [d, J = 14.0 Hz, 2 H, 6(12)-Hb], 1.96-2.02 [m, 6 H, 
10(13)-Hb, 8-H2, 6(12)-Ha], 2.14 [m, 2 H, 10(13)-Ha], 2.83 (s, 6 H, N-CH3), 3.38 [tt, J = 6.5 
Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 7.14 (s, 4 H, Ar-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 34.1 [CH2, C10(13)], 37.5 (CH3, N-CH3), 40.5 [CH, 
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C5(11)], 42.6 [CH2, C6(12)], 45.5 (CH2, C8), 69.0 (C, C7), 71.6 (C, C9), 128.3 [CH, C2(3)], 
129.3 [CH, C1(4)], 145.6 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 257 (M·+, 100), 242 (16), 240 (20), 215 (43), 214 (14), 198 
(14), 187 (54), 184 (19), 172 (18), 155 (16), 138 (18), 129 (19), 128 (22), 127 (12), 124 (23), 
115 (19), 85 (17). 
Elemental analysis: 
Calculated for C17H24ClNO:                    C  69.49%   H  8.23%   Cl  12.07%  N  4.77% 
Calculated for C17H24ClNO·0.50H2O:     C 67.42%   H 8.32%     Cl 11.71%   N 4.63%                                                      
Found:                                 C  67.70%   H  8.51%   Cl  11.80%  N  4.44% 
 
Preparation of 9-bromo-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine, 47 
  
 
To a solution of amine 46 (700 mg, 3.06 mmol) in toluene (23mL) and few drops of 
DCM was added thionyl bromide (7 mL, 90.05 mmol). The resulting orange solution was 
stirred at room temperature for 1.5 hours. The reaction mixture was then concentrated to 
dryness in vacuo. Toluene (50 mL) was added and the resulting solution concentrated in 
vacuo. The procedure was repeated five times more until it was obtained an orange solid 
(1.33 g). The crude was partitioned between DCM (15 mL) and saturated aqueous 
NaHCO3 solution (15 mL) and the phases were separated. The aqueous layer was extracted 
with further DCM (2 x 15 mL) and the combined organic layers were dried over anh. 
Na2SO4, filtered and concentrated in vacuo to give the amine 47 (709.5 mg, 79% yield) as 
a brown solid. The product was used in next steps without further purification or 
characterization.  
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Preparation of 5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-
amine hydrochloride, 23·HCl  
  
 
To a solution of amine 47 (700 mg, 2.54 mmol) in dry and deoxygenated toluene (14.2 
mL) under N2 atmosphere were added tri-n-butyltin hydride (1.2 mL, 4.56 mmol) and 2,2’-
azobisisobutyronitrile (AIBN) (62.5 mg, 0.38 mmol). The resulting solution was heated to 
95 ºC for 1 hour. After addition of further AIBN (62.5 mg, 0.38 mmol) the solution was 
kept to 95 ºC for 90 minutes. The reaction mixture was then cooled to room temperature 
and concentrated to dryness in vacuo. The residue was partitioned between DCM (15 mL) 
and 2 N HCl solution (15 mL). The phases were separated and the organic layer was 
extracted with further 2 N HCl solution (2 x 10 mL). The combined aqueous phases were 
basified to pH ~12 with 10 N NaOH solution and then extracted with DCM (3 x 15 mL). 
The combined organic layers were dried over anh. Na2SO4, filtered and concentrated in 
vacuo to give a yellow oil (236 mg). The residue was taken in DCM and the amine 23 was 
precipitated as its hydrochloride (72.9 mg, 12% yield) by adding an excess of Et2O·HCl. 
Analytical and spectroscopic data of compound 23·HCl: 
Melting point: > 330 ºC (dec.). 
IR (ATR) ν: 3426, 2987, 2903, 2856, 2633, 2545, 2159, 2050, 1604, 1506, 1493, 1446, 
1371, 1312, 1273, 1220, 1119, 1092, 1059, 1006, 954, 752, 611 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.79 [dm, J = 14.0 Hz, 2 H, 10(13)-Hb], 1.91 [d, J = 13.0 
Hz, 2 H, 6(12)- Hb], 1.97 (s, 2 H, 8-H2), 2.01 [m, 2 H, 10(13)-Ha], 2.13 [m, 2 H, 6(12)- Ha], 
2.45 [m, 1 H, 9-H], 3.17 [tt, J = 6.0 Hz, J’ = 2.0 Hz, 2 H, 5(11)-H], 7.09 (broad s, 4 H, Ar-
H).  
13C-NMR (125.7 MHz, CD3OD) δ: 32.2 (CH, C9), 34.7 [CH2, C10(13)], 39.9 [CH2, 
C6(12)], 40.5 (CH2, C8), 41.8 [CH, C5(11)], 54.0 (C, C7), 127.9 [CH, C2(3)], 129.3 [CH, 
C1(4)], 146.8 [C, C4a(C11a)].  
MS (EI), m/z (%); significant ions: 213 (M·+, 90), 198 (20), 172 (15), 171 (91), 170 (30), 157 
(21), 156 (100), 155 (15), 144 (28), 143 (21), 141 (31), 130 (19), 129 (27), 128 (34), 115 
(34), 94 (26), 77 (11), 57 (12). 
Elemental analysis:  
Calculated for C15H20ClN:                       C  72.13%   H  8.07%   Cl  14.19%   N  5.61% 
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Calculated for C15H20ClN·0.60H2O:       C  69.14%    H  8.20%   Cl  13.60%  N 5.38% 
Found:                                C  68.85%     H  7.91%    Cl  13.68%   N  5.417% 
 
Preparation of N,N-dimethyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine hydrochloride, 24·HCl  
  
 
 To a solution of amine 23 (140 mg, 0.55 mmol) in methanol (4 mL) were added 
formaldehyde (0.13 mL, 37% wt in aqueous solution, 1.71 mmol), glacial acetic acid (0.12 
mL) and sodium cyanoborohydride (107 mg, 1.62 mmol) and the mixture was stirred at 
room temperature for 8 hours. Then further NaBH3CN (107 mg, 1.62 mmol) and 
formaldehyde (0.13 mL, 37% wt in aqueous solution, 1.71 mmol) were added and the 
solution was stirred at room temperature overnight. The reaction mixture was then 
evaporated to dryness in vacuo and the resulting residue partitioned between water (5 mL) 
and DCM (5 mL). The pH was adjusted to ~12 with 10 N NaOH solution and the phases 
were separated. The aqueous phase was extracted with further DCM (2 x 5 mL) and the 
combined organic phases were dried over anh. Na2SO4, filtered and concentrated in vacuo. 
An excess of Et2O·HCl was added to a solution of the amine 24 in DCM to form its 
hydrochloride, followed by evaporation to dryness in vacuo (101.4 mg, 69 yield). 
Analytical and spectroscopic data of compound 24·HCl: 
Melting point: 253 - 255 ºC. 
IR (ATR) ν: 3414, 3014, 2930, 2904, 2850, 2599, 2473, 2151, 1635, 1491, 1447, 1416, 1377, 
1309, 1287, 1272, 1220, 1188, 1156, 1089, 1046, 1011, 957, 902, 756, 631, 608 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.78 [broad d, J = 14.0 Hz, 2 H, 6(12)-Hb], 2.00-2.09  [m, 
6 H, 6(12)-Ha, 8-H, 10(13)-Hb], 2.19 [dm, J = 12.5 Hz, J’ = 6.5 Hz, 2 H, 10(13)-Ha], 2.53 [m, 
1 H, 9-H], 2.80 [s, 6 H, N-CH3], 3.26 [broad t, J = 6.5 Hz, 2 H, 5(11)-H], 7.10 (m, 4 H, Ar-
H). 
13C-NMR (125.7 MHz, CD3OD) δ: 32.8 (CH, C9), 34.6 [CH2, C6(12)], 35.0 [CH2, 
C10(13)], 37.0 (CH3, N-CH3), 37.8 (CH2, C8), 41.8 [CH, C5(11)], 65.6 (C, C7), 128.0 [CH, 
C2(3)], 129.2 [CH, C1(4)], 146.7 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 241 (M·+, 84), 226 (21), 200 (18), 199 (100), 198 (33), 
184 (39), 172 (21), 171 (16), 170 (15), 155 (30), 141 (43), 129 (30), 128 (35), 122 (20), 115 
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(33), 108 (21), 85 (43), 84 (14), 71 (16), 70 (21), 58 (18). 
Elemental analysis:  
Calculated for C17H24ClN:                             C 73.49%  H 8.71%  Cl 12.76%  N 5.04% 
Calculated for C17H24ClN·1.3H2O·0.15HCl: C 66.57%  H 8.79%  Cl 13.29%  N 4.57%  
Found:                                      C 66.51%  H  8.52%  Cl 13.08%  N 4.60% 
 
Preparation of 2-chloro-N-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)acetamide, 40  
  
 
 A solution of chloroacetamide 37 (500 mg, 1.64 mmol) in thionyl chloride (20.5 mL) 
was heated at reflux for 1 hour. The reaction mixture was then tempered to room 
temperature and evaporated to dryness in vacuo. Toluene (25 mL) was added and the 
resulting solution concentrated in vacuo. The procedure was repeated twice more to give a 
yellow oil (592mg). Purification by column chromatography (Al2O3, 0-10% 
methanol/DCM) gave 40 (297 g, 56% yield) as a white solid. The analytical sample was 
obtained by crystallization with methanol/diethyl ether.  
Analytical and spectroscopic data of compound 40: 
Melting point: 195 - 197 ºC. 
IR (ATR) ν: 3292, 3074, 2947, 2910, 2856, 1654, 1552, 1492, 1450, 1426, 1359, 1331, 1307, 
1281, 1251, 1206, 1153, 1091, 1044, 998, 941, 892, 803, 756, 734, 692, 676 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 2.05 [d, J = 13.2 Hz, 2 H, 6(12)- Hb], 2.18 [d, J = 13.2 Hz, 2 
H, 10(13)- Hb], 2.27  [m, 2 H, 6(12)-Ha], 2.40 [m, 2 H, 10(13)-Ha], 2.55 [s, 2 H, 8-H], 3.28 
[tt, J = 6.8 Hz, J’ = 1.6 Hz, 2 H, 5(11)-H], 3.94 [s, 2 H, 14-H], 6.35(s, 1 H, NH), 7.07 [m, 2 
H, 2(3)-H], 7.13 [m, 2 H, 1(4)-H]. 
13C-NMR (100.6 MHz, CDCl3) δ: 37.8 [CH2, C6(12)], 41.0 [CH, C5(11)], 42.8(CH2, C14), 
44.3 [CH2, C10(13)], 49.6 (CH2, C8), 56.7 (C, C9), 68.7 (C, C7), 127.0 [CH, C2(3)], 128.2 
[CH, C1(4)], 144.4 [C, C4a(C11a)], 164.6 (C, C14). 
MS (EI), m/z (%); significant ions: 327 [M·+ (37Cl2), 5], 325 [M·+ (35Cl37Cl), 20], 323 [M·+ 
(35Cl2), 32], 290 [(C17H1937ClNO)·+, 13], 288 [(C17H1935ClNO)·+, 34], 233 (14), 232 (42), 231 
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(40), 230  [(C15H1535Cl)·+, 100], 207 (21), 196 (19), 195 [(C15H15)·+, 88), 194 (23), 181 (28), 
179 (24), 175 (23), 165 (24), 155 (36), 153 (24), 141 (41), 129 (24), 128 (31), 115 (33), 77 
(15). 
HRMS-ESI+ m/z [M+H]+ calcd for [C17H19Cl2NO+H]+: 324.0916, found: 324.0913. 
 
Preparation of 9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine hydrochloride, 42·HCl  
  
 
 To a solution of chloroacetamide 40 (350 mg, 1.08 mmol) in abs. ethanol (23 mL) 
were added thiourea (98mg, 1.29 mmol) and glacial acetic acid (0.75 mL) and the mixture 
was heated at reflux overnight. The resulting suspension was then tempered to room 
temperature, water (10 mL) was added and the pH adjusted to ~12 with 5 N NaOH 
solution. DCM (10 mL) was added, the phases were separated and the aqueous phase was 
extracted with further DCM (2 x 10 mL). The combined organic phases were dried over 
anh. Na2SO4, filtered and concentrated in vacuo to give 42 as a yellow solid. An excess of 
Et2O·HCl was added to a solution of the amine in DCM to form its hydrochloride, 
followed by filtration of the white precipitated (230.3 mg, 73 yield). The analytical sample 
was obtained by crystallization with methanol/diethyl ether.  
Analytical and spectroscopic data of compound 42·HCl: 
Melting point: > 315 ºC (dec.). 
IR (ATR) ν: 2906, 2850, 2673, 2559, 2176, 1601, 1509, 1494, 1452, 1361, 1309, 1297, 1213, 
1170, 1090, 1070, 1036, 1007, 967, 945, 877, 804, 756 cm-1. 
1H-RMN (500 MHz, CD3OD) δ: 1.87 [d, J = 13 Hz, 2 H, 10(13)-Hb], 2.10-2.17 [complex 
signal, 4 H, 10(13)-Ha, 6(12)-Hb], 2.35 (s, 2 H, 8-H2), 2.41 [m, 2 H, 6(12)- Ha], 3.33 [tt, J = 
6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 7.12-7.17 (complex signal, 4 H, Ar-H). 
13C-RMN (125.7 MHz, CD3OD) δ: 38.3 [CH2, C10(13)], 41.8 [CH, C5(11)], 45.0 [CH2, 
C6(12)], 50.0 (CH2, C8), 56.9 (C, C7), 68.4 (C, C9), 128.5 (CH) and 129.4 (CH) [C1(4) 
and C2(3)], 145.1 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 248 [(M+H)·+, 12], 214 (52), 213 [(M-Cl+H)·+, 100], 212 
(62), 158 (16), 157 (27), 156 (21), 155 (19), 152 (10), 129 (12), 128 (14), 115 (15). 
HRMS-ESI+ m/z [M+H]+ calcd for [C15H18ClNO+H]+: 248.1021, found: 248.1202. 
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Elemental analysis:  
Calculated for C15H19Cl2N:                      C  63.39%   H  6.74%    N  4.93% 
Calculated for C15H19Cl2N·0.50H2O:       C  61.44%   H  6.87%    N  4.78% 
Found:                                 C  61.37%   H  6.61%    N  4.78% 
 
Preparation of N,N-dimethyl-9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine hydrochloride, 49·HCl  
  
 
 To a solution of amine 42 (200 mg, 0.80 mmol) in methanol (6 mL) were added 37% 
formaldehyde solution (0.19 mL, 2.48 mmol), glacial acetic acid (0.17 mL) and sodium 
cyanoborohydride (155 mg, 2.35 mmol) and the mixture was stirred at room temperature 
for 6 hours. Then further NaBH3CN (155 mg, 2.35 mmol) and 37% formaldehyde solution 
(0.19 mL, 2.48 mmol) were added and the solution was stirred at room temperature 
overnight. The reaction mixture was then evaporated to dryness in vacuo and the resulting 
residue partitioned between water (5 mL) and EtOAc (5 mL). The pH was adjusted to ~12 
with 5 N NaOH solution and the phases were separated. The aqueous phase was extracted 
with further EtOAc (2 x 5 mL) and the combined organic phases were dried over anh. 
Na2SO4, filtered and concentrated in vacuo. Purification by column chromatography 
(Al2O3, 0-2% methanol/DCM) gave 49 (75.2 g, 57% column yield) as a white solid. The 
purified product was taken in DCM and the amine 49 was precipitated as its hydrochloride 
(44.4 mg, 19.6% overall yield) by adding an excess of Et2O·HCl.  
Analytical and spectroscopic data of compound 49·HCl: 
Melting point: 265 - 270 ºC. 
IR (ATR) ν: 3484, 3415, 2937, 2867, 2553, 2441, 1481, 1467, 1449, 1367, 1316, 1252, 1218, 
1177, 1158, 1143, 1091, 1048, 1012, 975, 936, 900, 822, 802, 783, 764, 737, 632 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 2.02 [d, J = 12.5 Hz, 2 H, 6(12)-Hb], 2.13 [d, J = 13.5 Hz, 
2 H, 10(13)-Hb], 2.23 [m, 2 H, 6(12)-Ha], 2.44 [m, 2 H, 8-H, 10(13)-Ha], 2.47 (s, 2 H, 8-H2), 
2.85 [s, 6 H, N(CH3)2], 3.41 [t, J = 7 Hz, 2 H, 5(11)-H], 7.16 (s, 4 H, Ar-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 33.6 [CH2, C6(12)], 37.7 [CH3, N(CH3)2], 41.6 [CH, 
C5(11)], 44.9 [CH2, C10(13)], 47.2 (CH2, C8), 68.2 (C, C7), 69.2 (C, C9), 128.6 (CH) and 
 
 CHAPTER 1 259 
129.4 (CH) [C1(4) and C2(3)], 145.0 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 275 (M·+, 18), 240 [(M-Cl)·+, 100], 233 (11), 184 (17). 
HRMS-ESI+ m/z [M+H]+ calcd for [C17H23ClN+H]+: 276.1514, found: 276.1514. 
Elemental analysis:  
Calculated for C17H23Cl2N:                        C  65.39%   H  7.42%   Cl 22.70%     N  4.49% 
Calculated for C17H23Cl2N·0.80MeOH:    C  63.27%   H  7.81%   Cl 20.98%     N   4.16% 
Found:                                  C  63.12%   H  7.54%    Cl 20.74%    N  4.16% 
 
Preparation of 9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine hydrochloride, 48·HCl  
 
 
 A solution of amine 46 (400 mg, 1.75 mmol) in DCM (6 mL) was cooled to -30 ºC 
with a dry ice in acetone bath. Then (diethylamino)sulfur trifluoride (DAST) (0.97 mL, 
6.98 mmol) was added and the reaction mixture was stirred with the dry ice in acetone bath 
overnight. To the resulting solution was added water (10 mL) and the pH adjusted to ~12 
with a 1 N NaOH solution. The phases were separated and the aqueous phase was extracted 
with further DCM (2 x 8 mL), and the combined organic phases were dried over anh. 
Na2SO4, filtered and concentrated in vacuo to about 5 mL. An excess of Et2O·HCl was 
added and the amine 48·HCl was recovered by filtration in vacuo (205.5 mg, 44% yield) as 
a white solid.  
Analytical and spectroscopic data of compound 48·HCl: 
Melting point: 280 ºC (dec.). 
IR (ATR) ν: 3280, 2934, 2854, 2701, 2649, 2580, 1626, 1542, 1493, 1453, 1367, 1326, 
1259, 1218, 1094, 998, 900, 860, 757, 708, 594, 577 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.85 [broad d, J = 15 Hz, 2 H, 6(12)-Hb], 1.89 [broad d, J 
= 10 Hz, 2 H, 10(13)-Hb],  2.10-2.15  [m, 4 H, 6(12)-Ha, 8-H2], 2.19 [m, 2 H, 10(13)-Ha], 3.39 
[m, 2 H, 5(11)-H], 7.15 (s, 4 H, Ar-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 38.7 [CH2, s, C6(12)], 40.2 [CH, d, 3JC-F = 12.8 Hz, 
C5(11)], 40.6 [CH2, d, 2JC-F = 20.5 Hz, C10(13)], 45.9 (CH2, d, 2JC-F = 20.5 Hz, C8), 58.2 (C, 
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d, 3JC-F = 10.7 Hz, C7), 94.5 (C, d, 1JC-F = 179.1 Hz, C9), 128.5 [CH, s, C2(3)], 129.4 [CH, s, 
C1(4)], 145.2 [C, s, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 231 (M·+, 100), 216 (17), 211 (11), 196 (20), 190 (12), 189 
(73), 188 (12), 170 (34), 169 (18), 168 (56), 159 (13), 156 (44), 155 (13), 144 (18), 141 (14), 
129 (17), 128 (24), 115 (26), 112 (25).  
HRMS-ESI+ m/z [M+H]+ calcd for [C15H18FN+H]+: 232.1496, found: 232.1496. 
Elemental analysis:  
Calculated for C15H19ClFN:                     C  67.28%   H  7.15%   Cl 13.24%    N  5.23% 
Calculated for C15H19ClFN·0.75H2O:     C  64.05%   H  7.35%   Cl  12.60%   N  4.98% 
Found:                                C  63.61%   H  7.32%   Cl 13.11%     N  4.75% 
 
Preparation of 9-fluoro-N,N-dimethyl-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine hydrochloride, 51·HCl  
  
 
 To a solution of amine 48 (228 mg, 0.99 mmol) in methanol (8 mL) were added 
formaldehyde (0.23 mL, 37% wt in aqueous solution, 3.01 mmol), glacial acetic acid (0.21 
mL) and sodium cyanoborohydride (189.2 mg, 2.86 mmol) and the mixture was stirred at 
room temperature for 6 hours. Then further NaBH3CN (189.2 mg, 2.86 mmol) and 
formaldehyde (0.23 mL, 37% wt in aqueous solution, 3.01 mmol) were added and the 
solution was stirred at room temperature overnight. The reaction mixture was then 
evaporated to dryness in vacuo and the resulting residue partitioned between water (5 mL) 
and EtOAc (5 mL). The pH was adjusted to ~12 with 5 N NaOH solution and the phases 
were separated. The aqueous phase was extracted with further EtOAc (2 x 10 mL) and the 
combined organic phases were dried over anh. Na2SO4, filtered and concentrated in vacuo 
to about 5 mL. An excess of Et2O·HCl was added and the solvents were removed under 
vacuo to give the amine 51·HCl (67 mg, 23% yield).  
Analytical and spectroscopic data of compound 51·HCl: 
Melting point: 249 - 251 ºC. 
IR (ATR) ν: 3398, 3034, 2936, 2860, 2511, 2415, 1470, 1368, 1341, 1322, 1220, 1186, 1136, 
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1088, 1057, 983, 968, 929, 903, 882, 757, 656, 582 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.89 [d, J = 12.5 Hz, 2 H, 6(12)-Hb], 1.99 [d, J = 12 Hz, 2 
H, 10(13)-Hb], 2.19-2.24 [m, 6 H, 6(12)-Ha, 8-H2, 10(13)-Ha], 2.85 (s, 6 H, N-CH3), 3.47 [m, 
2 H, 5(11)-H], 7.17 (s, 4 H, Ar-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 33.9 [CH2, s, C6(12)], 37.8 (CH3, s, N-CH3), 39.9 [CH, 
d, 3JC-F = 12.8 Hz, C5(11)], 40.6 [CH2, d, 2JC-F = 20.5 Hz, C10(13)], 43.3 (CH2, d, 2JC-F = 21.6 
Hz, C8), 69.5 (C, d, 3JC-F = 10.7 Hz, C7), 94.8 (C, d, 1JC-F = 179.1 Hz, C9), 128.3 [CH, s, 
C2(3)], 129.3 [CH, s, C1(4)], 145.1 [C, s, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 259 (M·+, 100), 258 (18), 244 (13), 217 (55), 216 (13), 184 
(23), 173 (12), 159 (10), 141 (11), 140 (12), 128 (12), 115 (12), 85 (10). 
Elemental analysis:  
Calculated for C17H23ClFN:                               C 69.02% H 7.84%  Cl 11.98% N 4.73% 
Calculated for C17H23ClFN·0.30H2O·0.05HCl: C 67.38% H 7.87%  Cl 12.28% N 4.62%                                                                           
Found:                                          C  67.32% H 7.91% Cl 12.20%  N 4.67% 
 
Preparation of 9-methoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-ol, 53165  
  
 
 To a solution of enone 25 (500 mg, 2.36 mmol) in methanol (10 mL) was added p-
toluenesulfonic acid monohydrate (112 mg, 0.59 mmol) and the reaction mixture was 
stirred at room temperature overnight. To the resulting solution was then concentrated in 
vacuo and the obtained residue partitioned between DCM (10 mL) and saturated aqueous 
NaHCO3 solution (10 mL). The phases were separated and the aqueous one was extracted 
with further DCM (2 x 10 mL). The combined organic layers were dried over anh. Na2SO4, 
filtered and evaporated in vacuo to give a yellow gum (541.3 mg). Purification by column 
chromatography (Al2O3, DCM/methanol mixture) gave 53 (367.5 mg, 64% yield) as a white 
solid.  
Analytical and spectroscopic data of compound 53: 
Melting point: 97 - 98 ºC. 
 
262   Materials & Methods 
IR (ATR) ν: 3359, 2930, 2851, 1723, 1495, 1444, 1356, 1296, 1239, 1193, 1094, 1061, 
981, 900, 846, 758, 663 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.74 [dm, J = 12.0 Hz, 2 H, 10(13)-Hb], 1.78 [s, 2 H, 8-H2], 
1.81 [d, J = 13.0 Hz, 2 H, 6(12)-Hb], 1.90 [m, 4 H, 6(12)-Ha, 10(13)-Ha], 3.23 [tt, J = 6.4 Hz, 
J’ = 2.0 Hz, 2 H, 5(11)-H], 3.24 (s, 3 H, OCH3), 7.07-7.15 (m, 4 H, Ar-H).  
13C-NMR (100.6 MHz, CDCl3) δ: 37.8 [CH2, C10(13)], 39.6 [CH, C5(11)], 42.7 [CH2, 
C6(12)], 48.4 (CH3, OCH3), 48.9 (CH2, C8), 72.5 (C, C9), 76.5 (C, C7), 126.7 [CH, C2(3)], 
128.1 [CH, C1(4)], 145.1 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 244 (M·+, 100), 213 (42), 201 (17), 172 (22), 171 (30), 159 
(38), 158 (72), 157 (28), 155 (48), 154 (16), 153 (16), 144 (17), 143 (22), 141 (23), 132 (12), 
130 (12), 129 (63), 128 (52), 127 (19), 125 (40), 115 (48), 111 (25), 107 (12), 91 (13). 
HRMS-ESI+ m/z [M+H]+ calcd for [C16H19O+H; fragment]+: 227.1431, found: 227.1430. 
 
Preparation of 2-chloro-N-(9-methoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)acetamide, 54  
 
 
 To a solution of alcohol 53 (545 mg, 2.23 mmol) in DCM (5 mL) was added 
chloroacetonitrile (0,140 mL, 2.23 mmol) and the mixture was cooled to 0-5 ºC with an ice 
bath. Then conc. H2SO4 (0.180 mL, 3.38 mmol) was added dropwise without reaching a 
temperature greater than 10 ºC. After the addition, the reaction mixture was stirred at 
room temperature overnight. Then the resulting solution was poured into ice (10 g) and 
DCM (10 mL) was added. The phases were separated and the aqueous phase was extracted 
with further DCM (2 x 10 mL). The combined organic phases were dried over anh. Na2SO4, 
filtered and evaporated in vacuo to give a white gum (570 mg). Column chromatography 
(Al2O3, Hexane/EtOAc mixture) gave in order of elution 54 (222 mg, 31% yield), 34 (210 
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mg, 37% column yield) and 53 (91 mg, 16% column yield) as white solids. The product 
was used in next steps without further purification or characterization. 
 
Preparation of 9-methoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-amine, 52 
  
 
 
 To a solution of chloroacetamide 54 (136.8 mg, 0.43 mmol) in abs. ethanol (9 mL) 
were added thiourea (39.2 mg, 0.52 mmol) and glacial acetic acid (0.3 mL) and the mixture 
was heated at reflux overnight. The reaction mixture was then tempered to room 
temperature and concentrated in vacuo. The crude was partitioned between water (10 mL) 
and DCM (10 mL) and the aqueous phase was acidified to pH ~2 with 2 N HCl solution. 
The phases were separated, the pH adjusted to ~12 with 2 N NaOH solution and the 
aqueous phase was then extracted with DCM (3 x 10 mL). The combined organic phases 
were dried over anh. Na2SO4, filtered and concentrated in vacuo to give 52 (62 mg, 59% 
yield) as a white solid. 
Analytical and spectroscopic data of compound 52: 
Melting point: 71 – 73 ºC. 
IR (ATR) ν: 3500–2850 (3507, 3389, 3329, 3307, 3263, 3126, 3019, 2936, 2852), 1651, 
1605, 1490, 1441, 1360, 1210, 1113, 1059, 1047, 1010, 969, 947, 893, 847, 754, 666, 630, 
584 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.61-1.66 [m, 4 H, 6(12)-Hb, 8-H2], 1.77 [m, 2 H, 6(12)-Ha], 
1.83-1.90 [m, 4 H, 10(13)-H2], 3.19 [broad t, J = 6.0 Hz, 2 H, 5(11)-H], 3.23 (s, 3 H, OCH3), 
7.05-7.13 (m, 4 H, Ar-H). 
13C-NMR (100.6 MHz, CDCl3) δ: 37.8 [CH2, C10(13)], 40.2 [CH, C5(11)], 43.3 [CH2, 
C6(12)], 48.2 (CH3, OCH3), 49.5 (CH2, C8), 52.5 (C, C7), 75.4 (C, C9), 126.6 [CH, C2(3)], 
128.0 [CH, C1(4)], 145.4 [C, C4a(C11a)]. 
MS (EI), m/z (%); significant ions: 243 (M·+, 100), 228 (17), 212 (27), 201 (13), 200 (14), 
171 (20), 170 (18), 156 (23), 155 (14), 144 (20), 129 (15), 128 (19), 124 (28), 115 (18), 110 
(41).  
HRMS-ESI+ m/z [M+H]+ calcd for [C16H21O+H]+: 244.1696, found: 244.1704. 
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Preparation of 5,6,8,9-tetrahydro-5,9-propanebenzocycloheptane-7,11-diene, 29165 
 
 A suspension of sodium hydride, 60% dispersion in mineral oil (0.78 g, 19.64 mmol) 
in anh. DMSO (50 mL) was heated to 75 ºC for 45 minutes. After the reaction mixture was 
tempered, a solution of triphenylmethylphophonium iodide (8.2 g, 19.64 mmol) in anh. 
DMSO (70 mL) was added and the resulting yellow solution was stirred at room 
temperature for 20 minutes. Then a suspension of diketone 27 (2 g, 9.35 mmol) in anh. 
DMSO (20 mL) was added and the obtained solution was heated to 75 ºC overnight. The 
resulting black solution was allowed to cool to room temperature and then poured into 
water (150 mL). Hexane (100 mL) was added and the phases were separated. The aqueous 
phase was extracted with further hexane (3 x 50 mL) and the combined organic phases were 
washed with brine (50 mL), dried over anh. Na2SO4, filtered and concentrated in vacuo to 
give an orange gum (2.32 g).  Purification by packing the solid with silica gel and extracting 
with 100% petroleum ether gave 29 (1.56 g, 80% yield) as a white solid. The spectroscopic 
data were identical to those previously published. 
 
Preparation of N-(6,7,8,9,10,11-hexahydro-9-methyl-5,7:9,11-dimethano-5H-
benzocyclononen-7-yl)chloroacetamide, 5598 
 
A solution of diene 29 (5.02 g, 23.9 mmol) in chloroacetonitrile (6.05 mL, 95.6 mmol) 
and glacial acetic acid (15 mL) was cooled to 0-5 ºC with an ice bath. Then conc. H2SO4 
(7.6 mL, 143.4 mmol) was added dropwise without reaching a temperature greater than 10 
ºC. After the addition, the reaction mixture was stirred at room temperature overnight. 
Then the resulting solution was poured into ice (100 g) and DCM (40 mL) was added. The 
phases were separated and the aqueous phase was extracted with further DCM (2 x 40 mL). 
The combined organic phases were dried over anh. Na2SO4, filtered and evaporated in 
vacuo to give 55 (5.86 g, 81% yield) as a white solid, whose spectroscopic data were those 
corresponding to the previously published. 
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Preparation of 6,7,8,9,10,11-hexahydro-9-methyl-5,7:9,11-dimethano-5H-
benzocyclononen-7-amine, 1998 
 
To a solution of chloroacetamide 55 (5.86 g, 19.4 mmol) in abs. ethanol (150 mL) 
were added thiourea (1.76 g, 23.2 mmol) and glacial acetic acid (14 mL) and the mixture 
was heated at reflux overnight. The reaction mixture was then tempered to room 
temperature and concentrated in vacuo. The crude was partitioned between water (200 mL) 
and EtOAc (100 mL) and the aqueous phase was acidified to pH ~2 with 1N HCl solution. 
The phases were separated, the pH adjusted to ~12 with 5N NaOH solution and the 
aqueous phase was then extracted with EtOAc (4 x 100 mL). The combined organic phases 
were dried over anh. Na2SO4, filtered and concentrated in vacuo to give 19 (3.03 g, 69% 
yield) as a white solid. The spectroscopic data were identical to those previously published. 
 
Preparation of (2R)-tert-butyl 2-[(9-hydroxy-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)carbamoyl]pyrrolidine-1-carboxylate, 71 
   
 To a solution of amine 46 (500 mg, 2.18 mmol) in DMF (10 mL) were added Boc-D-
proline (445.8 mg, 2.07 mmol), HATU (328.4 mg, 2.18 mmol) and triethylamine (0.6 mL, 
4.36 mmol) and the resulting solution was stirred at room temperature overnight. The 
reaction mixture was then diluted with EtOAc/benzene (2:1, 25 mL) and washed with 0.5 
N HCl aqueous solution (2 x 25 mL), brine (25 mL), saturated NaHCO3 aqueous solution 
(2 x 25 mL) and brine (25 mL). The organic phase was separated, dried over anh. Na2SO4, 
filtered and concentrated in vacuo to give an orange oil (765 mg). Column chromatography 
(Al2O3, hexane/ethyl acetate mixture) gave 12 (438 mg, 50% yield) as a white solid. The 
analytical sample was obtained by crystallization from EtOAc/pentane. 
Analytical and spectroscopic data of compound 71: 
Melting point: 98 – 103 °C. 
IR (ATR) ν: 3408, 3327, 2975, 2927, 1677, 1538, 1451, 1400, 1366, 1300, 1247, 1163, 1119, 
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1088, 1045, 978, 922, 862, 758 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.45 [s, 9 H, OC(CH3)3], 1.73 (m, 2 H, 17-H), 1.76 [d, J = 
13.0 Hz, 2 H, 10(13)-Hb], 1.83 (broad signal, 1 H, 16-Ha), 1.93-2.31 [complex signal, 9 H, 
10(13)-Ha, 6(12)-H2, 8-H, 16-Hb], 3.17 [t, J = 6.5 Hz, 2 H, 5(11)-H],  3.37 (m, 2 H, 18-H), 4.21 
(m, 1 H, 15-H), 5.81 (broad s, 1 H, OH), 6.94 (broad s, 1 H, NH), 7.06 [m, 4 H, 1(4)-H], 
7.10 [m, 2 H, 2(3)-H]. 
13C-NMR (125.7 MHz, CDCl3) δ (mixture of two rotamers): 23.7 (CH2) and 24.1 (CH2) 
(two rotamers, C17), 28.4 [CH3, OC(CH3)3], 31.1 (broad CH2, C16), 38.4 [CH2, C6(12)], 
40.0 [CH, C5(11)], 42.4 [CH2, C10(13)], 47.1 (CH2, C18), 48.2 (CH2, C8), 56.6 (C, C7), 
61.2 (CH) and 61.9 (CH) (C15, two rotamers), 70.8 (C, C9), 80.4 (C, C20), 126.6 [CH, 
C2(3)], 128.1 [CH, C1(4)], 145.2 [d, C, C4a(C11a)], 154.7 (C) and 156.1 (C) (NCO, two 
rotamers), 170.9 (C) and 171.6 (C) (CO, two rotamers). 
HRMS-ESI+ m/z [M+H]+ calcd for [C25H34N2O4+H]+: 427.2591, found: 427.2593. 
 
Preparation of (2R)-N-(9-hydroxy-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)pyrrolidine-2-carboxamide, 72 
 
 A solution of Boc-protected pyrrolidine 71 (438.5 mg, 1.03 mmol) in DCM (5 mL) 
and 85% o-phosphoric acid (1.05 mL, 15.4 mmol) was stirred at room temperature for 3 
hours. To the reaction mixture was then added water (8 mL) and the pH was adjusted to 
~12 with 5 N NaOH solution. The phases were separated, the aqueous phase was extracted 
with further DCM (2 x 8 mL) and the combined organic phases were dried over anh. 
Na2SO4 and filtered. Evaporation in vacuo of the combined organic layers gave 72 (290.8 
mg, 87% yield) as a white solid. 
Analytical and spectroscopic data of compound 72: 
Melting point: 175 – 180 °C. 
IR (ATR) ν: 3441, 3368, 3262, 2945, 2863, 1639, 1521, 1507, 1475, 1434, 1401, 1378, 1361, 
1336, 1300, 1230, 1194, 1115, 1050, 887, 846, 799, 767, 731, 698, 552 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.66 (complex signal, 2 H, 17-H2), 1.78 [d, J = 13 Hz, 2 H, 
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10(13)-Hb], 1.85 (m, 1H, 16-Ha), 1.90-1.99 [complex signal, 4 H, 6(12)-Hb, 10(13)-Ha], 2.04-
2.11 (complex signal, 4 H, 8-H, 16-Hb), 2.15-2.25 [complex signal, 2 H, 6(12)-Ha], 2.83 (dt, J 
= 10.5 Hz, J’ = 6.5 Hz, 1 H, 18-Ha), 2.97 (dt, J = 10.5 Hz, J’ = 6.5 Hz, 1 H, 18-Hb), 3.17 [broad 
t, J = 6.5 Hz, 2 H, 5(11)-H], 3.59 (dd, J = 9 Hz, J’ = 5.5 Hz, 1 H, 15-H), 7.06 [m, 2 H, 1(4)-
H], 7.08 [m, 2 H, 2(3)-H], 7.60 (broad s, 1 H, NH). 
13C-NMR (125.7 MHz, CDCl3) δ: 26.1 (CH2, C17), 30.8 (CH2, C16), 38.5 (CH2) and 38.6 
(CH2) (C6 and C12), 40.1 [CH, C5(11)], 42.4 [CH2, C10(13)], 47.2 (CH2, C18), 48.1 (CH2, 
C8),  55.9 (C, C7), 61.0 (CH, C15), 70.7 (C, C9), 126.6 [CH, C2(3)], 128.1 [CH, C1(4)], 
145.3 [C, C4a(C11a)], 174.1 (C, CO). 
Elemental analysis: 
Calculated for C20H26N2O2:                      C  73.59%      H  8.03% N  8.58% 
Calculated for C20H26N2O2·0.15DCM:          C  71.36%      H  7.82% N  8.26% 
Found:                                      C  71.48%      H  7.78% N  8.07% 
 
Preparation of (2R)-1-ethyl-N-(9-hydroxy-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)pyrrolidine-2-carboxamide, 56 
 
 A solution of pyrrolidine 72 (170 mg, 0.52 mmol) in DMF (3 mL) was cooled to 5 °C 
with an ice bath. Then KI (8.64 mg, 0.052 mmol) and triethylamine (0.278 mL, 2.08 mmol) 
were added, followed by the dropwise addition of ethyl bromide (0.04 mL, 0.55 mmol). 
The reaction mixture was stirred at room temperature in an ice-water bath overnight. The 
resulting suspension was then filtered and the solids were washed with EtOAc (10 mL). 
The combined filtrates were washed with saturated aqueous NaHCO3 solution (10 mL) 
and brine (10 mL). The organic phase was separated, dried over anh. Na2SO4, filtered and 
concentrated in vacuo to give 56 (133 mg, 72% yield) as a white solid. The analytical sample 
was obtained by crystallization from EtOAc/pentane. 
Analytical and spectroscopic data of compound 56: 
Melting point: 150 – 152 °C. 
IR (ATR) ν: 3388, 2931, 2871, 1647, 1511, 1440, 1384, 1358, 1335, 1304, 1234, 1194, 1117, 
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1088, 1060, 761, 647 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.04 (t, J = 7.5 Hz, 3 H, NCH2CH3), 1.59-1.82 (complex 
signal, 3 H, 16-Ha, 17-H), 1.77 [d, J = 12.5 Hz, 2 H, 10(13)-Hb], 1.92 [d, J = 13 Hz, 2 H, 6(12)-
Hb], 1.97 [dd, J = 12.5 Hz, J’ = 6.5 Hz, 2 H, 10(13)-Ha], 2.02 (broad s, 1 H, OH), 2.11 (m, 1 
H, 16-Hb), 2.14 (s, 2 H, 8-H), 2.17-2.30 [complex signal, 3 H, 6(12)-Ha, 19-Ha], 2.45 (m, 1 H, 
18-Ha), 2.58 (m, 1 H, 18-Hb), 3.85 (dd, J = 10.0 Hz, J’ = 4.5 Hz, 1 H, 15-H), 3.12 (m, 1 H, 
19-Hb),  3.18 [dt, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 7.07 [m, 2 H, 1(4)-H], 7.11 [m, 2 H, 
2(3)-H], 7.45 (broad s, 1 H, NH). 
13C-NMR (125.7 MHz, CDCl3) δ: 14.8 (CH3, NCH2CH3), 24.1 (CH2, C17), 30.7 (CH2, 
C16), 38.6 (CH2) and 38.7 (CH2) (C6 and C12), 40.1 [CH, C5(11)], 42.4 [CH2, C10(13)], 
48.1 (CH2, C8), 49.7 (CH2, C18),  53.8 (CH2, NCH2CH3), 55.8 (C, C7), 67.8 (CH, C15), 
70.7 (C, C9), 126.6 [CH, C2(3)], 128.1 [CH, C1(4)], 145.3 [d, C, C4a(C11a)], 174.3 (C, 
CO). 
Elemental analysis: 
Calculated for C22H30N2O2:                        C  74.54%      H  8.53%     N  7.90% 
Calculated for C22H30N2O2·0.1EtOAc:         C  74.06%      H  8.55%    N  7.71% 
Found:                                    C  73.93%      H  8.64%    N  7.71% 
 
Preparation of (2R)-tert-butyl-2-[(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)carbamoyl]pyrrolidine-1-carboxylate, 73 
 
 Boc-D-proline (336 mg, 1.56 mmol), HOBt (316 mg, 2.34 mmol), EDC (363 mg, 2.34 
mmol) and triethylamine (0.48 mL, 3.43 mmol) were added to a solution of amine 19 (388 
mg, 1.71 mmol) in EtOAc (20 mL) and the mixture was stirred at room temperature 
overnight. To the resulting suspension was then added water (15 mL) and the phases were 
separated. The organic phase was washed with saturated aqueous NaHCO3 solution (15 
mL) and brine (15 mL), dried over anh. Na2SO4 and filtered. Evaporation in vacuo of the 
combined organic layers gave 73 (556 mg, 84% yield) as a white solid, that was washed with 
pentane for obtaining an analytical sample. 
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Analytical and spectroscopic data of compound 73: 
Melting point: 168 – 169 °C. 
IR (ATR) ν: 3296, 2917, 1706, 1684, 1657, 1560,  1450, 1385, 1363, 1287, 1238, 1179, 1161, 
1123, 1089, 1048, 1009, 982, 920, 756, 673, 574 cm-1. 
1H-NMR (400 MHz, CDCl3) δ (two rotamers): 0.91 (s, 3 H, C9-CH3), 1.46 [s, 9 H, 
OC(CH3)3], 1.53 [broad d, J = 13.5 Hz, 2 H, 10(13)-Hb], 1.65 [broad dd, J = 13.5 Hz, J’ = 6.5 
Hz, 2 H, 10(13)-Ha], 1.75-1.88 (complex signal, 4 H, 8-H, 17-H), 2.01 [broad d, J = 13 Hz, 2 
H, 6(12)-Hb], 2.13 [m, 2 H, 6(12)-Ha], 2.3 (very broad signal, 1 H, 16-Hb), 3.06 [t, J = 6 Hz, 
2 H, 5(11)-H],  3.39 (broad m, 2 H, 18-H), 4.11 (very broad signal, 1 H, 15-H), 6.77 (broad 
s, 1 H, NH), 7.05 [m, 4 H, Ar-H]. 
13C-NMR (100.6 MHz, CDCl3) δ (two rotamers): 24.2 (broad CH2, C17), 28.4 [CH3, 
C(CH3)3], 31.1 (broad CH2, C16), 32.2 (CH3, C9-CH3), 33.6 (C, C9), 38.9 and 39.0 [CH2, 
C6(12)], 41.0 and 41.1 [CH, C5(11)], 41.11 and 41.15 [CH2, C10(13)], 47.0 (CH2, C8), 47.2 
(broad signal, CH2, C18), 54.1 (C, C7), 60.6 and 61.9 (CH, C15), 126.2 [CH, C2(3)], 127.9 
[CH, C1(4)], 146.2 [broad C, C4a(C11a)], 170.8 (very broad C, CO). 
MS-DIP (EI), m/z (%); significant ions: 424 (M·+, <1), 211 (C16H19+, 14), 171 (22), 170 (14), 
155 (19), 140 (8), 115 (22), 114 (100), 70 (60), 57 (22). 
HRMS-ESI+ m/z [M+H]+ calcd for [C26H36N2O3+H+]: 425.2799, found: 425.2803. 
 
Preparation of (2R)-N-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)pyrrolidine-2-carboxamide, 74 
 
 A solution of Boc-protected pyrrolidine 73 (556.1 mg, 1.31 mmol) in DCM (6 mL) 
and 85% o-phosphoric acid (1.33 mL, 19.6 mmol) was stirred at room temperature for 18 
hours. To the reaction mixture was then added water (15 mL) and the aqueous phase was 
basified until pH ~12 with 5 N NaOH solution. The phases were separated and the aqueous 
phase was extracted with further DCM (2 x 10 mL). The combined organic layers were 
dried over anh. Na2SO4, filtered and evaporated in vacuo to give 74 (419.5 mg, quantitative 
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yield) as a white solid. The analytical sample was obtained by crystallization from 
EtOAc/pentane. 
Analytical and spectroscopic data of compound 74: 
Melting point: 116 – 119 °C. 
IR (ATR) ν: 3289, 3257, 3017, 2920, 2897, 2864, 2839, 1646, 1515, 1492, 1467, 1450, 1359, 
1345, 1307, 1245, 1208, 1153, 1135, 1110, 1090, 1046, 1006, 948, 914, 877, 856, 800, 754, 
700, 613, 644, 558, 488 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 0.91 (s, 3 H, C9-CH3), 1.53 [d, J = 13.0 Hz, 2 H, 10(13)-Hb], 
1.66 [complex signal, 4 H, 17-H, 10(13)-Ha], 1.86 (complex signal, 3 H, 8-H, 16-Ha), 1.99 
[dq, J = 13.0 Hz, J’ = 1.5 Hz, 2 H, 6(12)-Hb], 2.07 (m, 1 H, 16-Hb), 2.17 [m, 2 H, 6(12)-Ha], 
2.84 (dt, J = 10.5 Hz, J’ = 6.5 Hz, 1 H, 18-Ha), 2.97 (dt, J = 10.5 Hz, J’ = 6.5 Hz, 1 H, 18-Hb), 
3.06 [tq, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 3.60 (dd, J = 9.0 Hz, J’ = 5.5 Hz, 1 H, 15-H), 
7.02-7.08 [complex signal, 4 H, Ar-H], 7.50 (broad s, 1 H, NH). 
13C-NMR (125.7 MHz, CDCl3) δ: 26.1 (CH2, C17), 30.8 (CH2, C16), 32.2 (CH3, C9-CH3), 
33.5 (C, C9), 38.9 (CH2) and 39.0 (CH2) (C6 and C12), 41.0 [CH, C5(11)], 41.1 (CH2) and 
41.2 (CH2) (C10 and C13), 47.0 (CH2, C8), 47.2 (CH2, C18),  53.3 (C, C7), 61.1 (CH, C15), 
126.2 [CH, C2(3)], 127.9 [CH, C1(4)], 146.3 [d, C, C4a(C11a)], 173.9 (C, CO). 
MS (CI), m/z (%); significant ions: 324 (M·+, <1), 211 (C16H19·+, 1), 155 (4), 70 (100). 
Elemental analysis: 
Calculated for C21H28N2O:                  C  77.74%   H  8.70% N  8.63% 
Calculated for C21H28N2O·0.2EtOAc·0.15Pentane: C  76.75%   H  8.97% N  7.94% 
Found:                             C  76.78%   H  8.95% N  7.89% 
 
Preparation of (2R)-1-ethyl-N-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)pyrrolidine-2-carboxamide, 57·tartrate 
 
 A solution of pyrrolidine 74 (504 mg, 1.55 mmol) in DMF (10 mL) was cooled to 5 °C 
with an ice bath. Then KI (26 mg, 0.16 mmol) and triethylamine (0.87 mL, 6.2 mmol) were 
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added, followed by the dropwise addition of ethyl bromide (0.12 mL, 1.63 mmol). The 
reaction mixture was stirred at room temperature in an ice-water bath overnight. To the 
resulting solution was added EtOAc (5 mL) and water (20 mL). The phases were separated 
and the aqueous layer was extracted with further EtOAc (2 x 15 mL). The combined organic 
phases were washed with saturated aqueous NaHCO3 solution (15 mL) and brine (15 mL), 
dried over anh. Na2SO4, filtered and concentrated in vacuo to give a clear oil (446 mg). 
Column chromatography (Al2O3, hexane/EtOAc mixtures) gave 57 (255 mg, 44% yield) as 
a white solid. A solution of L-(+)-tartaric acid (108.8 mg, 0.72 mmol) in methanol (2 mL) 
was added to 57 directly. The solvents were removed under vacuo to give 57 as its tartrate 
salt. The analytical sample was obtained by crystallization from methanol/diethyl ether. 
Analytical and spectroscopic data of compound 57·tartrate: 
Melting point: 177-179 °C. 
IR (ATR) ν: 3426, 3250, 3023, 2915, 1694, 1667, 1573, 1453, 1361, 1306, 1243, 1217, 1116, 
1080, 948, 893, 800, 761, 666 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 0.94 (s, 3 H, C9-CH3), 1.27 (t, J = 7.5 Hz, 3 H, NCH2CH3), 
1.50 [d, J = 13.5 Hz, 2 H, 10(13)-Hb], 1.69 [dd, J = 13.0 Hz, J’ = 6.0 Hz, 2 H, 10(13)-Ha], 1.80 
(s, 2 H, 8-H2), 1.93-1.99 (complex signal, 3 H, 16-Ha, 17-H), 2.11 [m, 2 H, 6(12)-Ha], 2.17 [d, 
J = 13 Hz, 2 H, 6(12)-Hb], 2.46 (m, 1 H, 16-Hb), 3.08 [tt, J = 6.5 Hz, J’ = 2 Hz, 2 H, 5(11)-H], 
3.13 (m, 1 H, 18-Ha), 3.19 (q, J = 7.5 Hz, 2 H, NCH2CH3), 3.66 (m, 1 H, 18-Hb), 3.96 (dd, J 
= 9 Hz, J’ = 6.5 Hz, 1 H, 15-H), 4.41 (s, 2 H, tartrate-CH), 7.02-7.065 [complex signal, 4 H, 
Ar-H]. 
13C-NMR (125.7 MHz, CD3OD) δ: 11.5 (CH3, NCH2CH3), 24.0 (CH2, C17), 31.2 (CH2, 
C16), 32.8 (CH3, C9-CH3), 34.5 (C, C9), 39.5 (CH2) and 39.6 (CH2) (C6 and C12), 42.4 
[CH and CH2, C5(11), C10(13)], 48.0 (CH2, C8), 51.3 (CH2, NCH2CH3), 55.6 (CH2, C18),  
56.1 (C, C7), 68.6 (CH, C15), 74.1 (CH, tartrate-CH), 127.5 [CH, C2(3)], 129.0 [CH, 
C1(4)], 147.4 [C, C4a(C11a)], 168.6 (C, CO), 176.6 (C, tartrate-CO). 
MS (CI), m/z (%); significant ions: 393 (M+41, 7), 381 (M+29, 18), 354 (27), 353 (M+1, 
100), 211 (12), 98 (26). 
Elemental analysis: 
Calculated for C27H38N2O7:                 C 64.52% H  7.62% N  5.57% 
Calculated for C27H38N2O7·1H2O:       C 62.29% H  7.74% N  5.38% 
Found:                             C 62.50% H  7.50% N  5.13% 
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Preparation of 4-amino-3,5-dichloro-N-(9-hydroxy-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)benzamide, 58 
 
4-Amino-3,5-dichlorobenzoic acid (220.9 mg, 1.07 mmol), 1-hydroxybenzotriazole 
(HOBt) (216.7 mg, 1.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
(248.0 mg, 1.6 mmol) and triethylamine (0.327 mL, 2.2 mmol) were added to a solution of 
amine 46 (270 mg, 1.18 mmol) in EtOAc (15 mL) and DMF (1 mL) and the reaction 
mixture was stirred at room temperature for 21 hours. To the resulting suspension was 
then added water (20 mL) and the phases were separated. The organic phase was washed 
with 5% aqueous NaHCO3 solution (15 mL) and brine (15 mL), dried over anh. Na2SO4 
and filtered. Evaporation in vacuo of the combined organic phases gave 58 (422 mg, 95% 
yield) as a white solid. The analytical sample was obtained by crystallization from DCM. 
Analytical and spectroscopic data of compound 58: 
Melting point: 236 – 237 °C. 
IR (ATR) ν: 3362, 2923, 2853, 2160, 1976, 1643, 1606, 1547, 1519, 1492, 1452, 1321, 1299, 
1269, 1230, 1201, 1101, 1020, 864, 748, 570 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.58 (broad s, 1 H, OH), 1.81 [d, J = 12.5 Hz, 2 H, 10(13)-
Hb], 2.00 [m, 2 H, 10(13)-Ha], 2.12 [d, J = 13 Hz, 2 H, 6(12)-Hb], 2.19 (s, 2 H, 8-H), 2.27 
[ddd, J = 13.0 Hz, J’ = 6.5 Hz, J’’ = 1.0 Hz, 2 H, 6(12)-Ha], 3.23 [tt, J = 6.5 Hz, J’ = 1.5 Hz, 2 
H, 5(11)-H], 4.73 (broad s, 2 H, Ar-NH2), 5.72 (broad s, 1 H, CONH), 7.09 [m, 2 H, 1(4)-
H], 7.13 [m, 2 H, 3(2)-H], 7.54 [s, 2 H, 16(20)]. 
13C-NMR (125.7 MHz, CDCl3) δ: 38.6 [CH2, C6(12)], 40.0 [CH, C5(11)], 42.5 [CH2, 
C10(13)], 48.4 (CH2, C8), 57.4 (C, C7), 70.9 (C, C9), 118.9 [C, C17(19)], 125.4 (C, C15), 
126.7 [C, C16(20)], 126.8 [CH, C2(3)], 128.1 [CH, C1(4)], 142.6 (C, C18), 145.1 [d, C, 
C4a(C11a)], 164.2 (C, CO). 
MS (EI), m/z (%); significant ions: 418 (21), 416 (M·+, 32), 212 (43), 207 (36), 205 (46), 194 
(16), 190 (63), 188 (100), 179 (15), 160 (15), 155 (33), 154 (29), 142 (16), 141 (17), 129 (19), 
128 (20), 124 (16), 115 (16). 
Elemental analysis: 
Calculated for C22H22Cl2N2O2:              C  63.32%    H  5.31%      N  6.71% 
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Found:                         C  63.32%    H  5.35%     N  6.52% 
 
Preparation of 4-amino-3,5-dichloro-N-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)benzamide, 59 
  
 4-Amino-3,5-dichlorobenzoic acid (165 mg, 0.80 mmol), 1-hydroxybenzotriazole 
(HOBt) (162 mg, 1.2 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (186 
mg, 1.2 mmol) and triethylamine (0.25 mL, 1.76 mmol) were added to a solution of amine 
19 (200 mg, 0.88 mmol) in ethylacetate (10 mL) and DMF (1 mL) and the reaction mixture 
was stirred at room temperature for 22 hours. To the resulting suspension was then added 
water (20 mL) and the phases were separated. The organic phase was washed with 5% 
aqueous NaHCO3 solution (15 mL) and brine (15 mL), dried over anh. Na2SO4 and 
filtered. Evaporation in vacuo of the combined organic phases gave an orange solid (320 
mg). Column chromatography (Al2O3, 100% DCM) gave 59 (176.7 mg, 53% yield) as a 
white solid. The analytical sample was obtained washing the solid with n-pentane. 
Analytical and spectroscopic data of compound 59: 
Melting point: 173 – 175 °C. 
IR (ATR) ν: 3460, 3352, 2920, 2852, 1627, 1610, 1532, 1484, 1452, 1322, 1306, 1270, 1232, 
1126, 1091, 1049, 1006, 947, 908, 880, 837, 789, 757, 720, 695, 663, 581 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 0.95 (s, 3 H, C9-CH3), 1.58 [dt, J = 13.5 Hz, J’ = 1.5 Hz, 2 
H, 10(13)-Hb], 1.69 [ddm, J = 13.5 Hz, J’ = 6.5 Hz, 2 H, 10(13)-Ha], 1.93 (s, 2 H, 8-H), 2.15 
[dt, J = 13.0 Hz, J’ = 1.5 Hz, 2 H, 6(12)-Hb], 2.25 [ddm, J = 13.0 Hz, J’ = 6.5 Hz, 2 H, 6(12)-
Ha], 3.11 [tt, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 4.71 (broad s, 2 H, NH2), 5.68 (broad s, 
1 H, NH), 7.04-7.11 [complex signal, 4 H, 1(4)-H, 2(3)-H], 7.54 [s, 2 H, 16(20)]. 
13C-NMR (125.7 MHz, CDCl3) δ: 32.2 (CH3, C9-CH3), 33.7 (C, C9), 39.1 [CH2, C6(12)], 
41.0 [CH, C5(11)], 41.1 [CH2, C10(13)], 47.3 (CH2, C8), 55.0 (C, C7), 118.8 [C, C17(19)], 
125.7 (C, C15), 126.3 [CH, C2(3)], 126.6 [CH, C16(20)], 128.0 [CH, C1(4)], 142.4 (C, 
C18), 146.1 [d, C, C4a(C11a)], 164.1 (C, CO). 
MS (EI), m/z (%); significant ions: 416 (25), 415 (11), 414 (M·+, 38), 211 (20), 210 (100), 195 
(26), 190 (48), 188 (74), 182 (19), 181 (19), 160 (12), 156 (14), 155 (78), 154 (30), 143 (13), 
142 (14), 141 (18), 129 (18), 128 (19), 124 (15), 115 (14). 
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Elemental analysis: 
Calculated for C23H24Cl2N2O2:                   C  66.51%   H  5.82% N  6.74% 
Calculated for C23H24Cl2N2O2·0.1C5H12:           C  66.79%   H  6.01% N  6.63% 
Found:                                          C  66.82%   H  6.04% N  6.54% 
 
Preparation of N-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)cyclohexanecarboxamide, 60 
  
Cyclohexanecarboxylic acid (104.9 mg, 0.82 mmol), HOBt (166.1 mg, 1.23 mmol), 
EDC (190.5 mg, 1.23 mmol) and triethylamine (0.251 mL, 1.80 mmol) were added to a 
solution of amine 19 (204.8 mg, 0.90 mmol) in EtOAc (15 mL) and the reaction mixture 
was stirred at room temperature overnight. To the resulting suspension was then added 
water (15 mL) and the phases were separated. The organic phase was washed with saturated 
aqueous NaHCO3 solution (15 mL) and brine (15 mL), dried over anh. Na2SO4 and 
filtered. Evaporation in vacuo of the combined organic layers gave 60 (265 mg, 96% yield) 
as a white solid. The analytical sample was obtained by crystallization with EtOAc/pentane. 
Analytical and spectroscopic data of compound 60: 
Melting point: 197-198 °C. 
IR (ATR) ν: 3299, 3060, 2917, 2850, 1645, 1545, 1490, 1447, 1381, 1361, 1335, 1316, 1261, 
1214, 1091, 1047, 1005, 960, 942, 894, 753, 675, 665 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 0.91 (s, 3 H, 14-H), 1.15-1.27 [complex signal, 4 H, 18-H, 
17(19)-Ha], 1.37 [m, 2 H, 16(20)-Ha], 1.53 [broad d, J = 13.5 Hz, 2 H, 10(13)-Hb], 1.65 [m, 2 
H, 10(13)-Ha], 1.72-1.83 [m, complex signal, 4 H, 16(20)-Hb, 17(19)-Hb], 1.85 (s, 2 H, 8-H), 
1.93 (tt, J = 11.5 Hz, J’ = 3.5 Hz, 1 H, 15-H]), 1.97 [dt, J = 13 Hz, J’ = 1.5 Hz, 2 H, 6(12)-Hb], 
2.16 [ddm, J = 13.0 Hz, J’ = 6.5 Hz, 2 H, 6(12)-Ha], 3.06 [tt, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 
5(11)-H], 5.14 (broad s, 1 H, NH), 7.02-7.08 [complex signal, 4 H, Ar-H]. 
13C-NMR (125.7 MHz, CDCl3) δ: 25.7 [CH2, C17(19)], 25.8 (CH2, C18), 29.8 [CH2, 
C16(20)], 32.2 (CH3, C14), 33.6 (C, C9), 39.1 [CH2, C6(12)], 41.0 [CH, C5(11)], 41.1 [CH2, 
C10(13)], 46.4 (CH, C16), 47.2 (CH2, C8), 54.0 (C, C7), 126.2 [CH, C2(3)], 127.9 [CH, 
C1(4)], 146.2 [d, C, C4a(C11a)], 175.3 (C, CO). 
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MS (EI), m/z (%); significant ions: 338 (18), 337 (M·+, 68), 282 (49), 212 (22), 211 (92), 210 
(61), 169 (18), 156 (19), 155 (100), 154 (20), 143 (34), 141 (30), 129 (27), 128 (23), 83 (17), 
55 (22). 
Elemental analysis: 
Calculated for C23H31NO:                   C  81.85%   H  9.26% N  4.15% 
Found:                               C  81.82%   H  9.34% N  4.14% 
 
Preparation of N-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)thiourea, 76 
  
a) N-[(9-methyl-6,7,8,9,10,11-hexahydro-5,9:7,11-dimethano-5H-benzocyclononen-7-
yl)carbamothioyl]benzamide formation: 
 Benzoyl isothiocyanate (0.327 mL, 2.43 mmol) was added to a solution of amine 19 
(500 mg, 2.21 mmol) in CHCl3 (20 mL) and the reaction mixture was stirred at room 
temperature overnight. The resulting solution was concentrated in vacuo to give a brown 
gum (1.11 g).  
b) N-[(9-methyl-6,7,8,9,10,11-hexahydro-5,9:7,11-dimethano-5H-benzocyclononen-7-
yl)thiourea formation: 
 K2CO3 (1.97 g, 14.26 mmol) and water (10 mL) were added to a solution of the 
aforementioned benzamide (1.11 g, aprox. 2.85 mmol) in methanol (22 mL) and THF (10 
mL), and the mixture was stirred at room temperature overnight. The resulting suspension 
was filtered and the solids were washed with methanol (15 mL) to give 76 (330.3 mg, 52% 
overall yield) as a white solid. 
Analytical and spectroscopic data of compound 76: 
Melting point: 197-199 °C. 
IR (ATR) ν: 3481, 3209, 3135, 3097, 3012, 2916, 2840, 1618, 1529, 1491, 1450, 1359, 1302, 
1238, 1209, 1134, 1090, 1048, 1022, 941, 815, 799, 758, 719, 708, 643, 611 cm-1. 
1H-RMN (400 MHz, DMSO-d6) δ: 0.88 (s, 3 H, 14-H), 1.36 [broad d, J = 13.0 Hz, 2 H, 
10(13)-Hb], 1.61 [ddd, J = 13.0 Hz, J’ = 6.0 Hz, J’’ = 1.2 Hz, 2 H, 10(13)-Ha], 1.77 (s, 2 H, 8-
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H2), 2.06 [ddd, J = 12.0 Hz, J’ = 5.6 Hz, J’’ = 2.0 Hz, 2 H, 6(12)-Ha], 3.04 [m, 2 H, 5(11)-H], 
6.76 (broad s, 2 H, NH2), 7.02-7.09 (complex signal, 4 H, Ar-H), 7.31 (broad s, 1 H, NH). 
13C-RMN (100.6 MHz, DMSO-d6) δ: 32.1 (CH3, C14), 33.2 [CH2, C10(13)], 38.2 [CH, 
C5(11)], 41.0 [CH2, C6(12)], 47.5 (CH2, C8), 50.1 (C, C7), 55.0 (C, C9), 126.1 [CH, C2(3)], 
127.7 [CH, C1(4)], 146.2 [d, C, C4a(C11a)], 181.2 (C, CS). 
MS-DIP (EI), m/z (%); significant ions: 287 (15), 286 (M·+, 66), 285 (66), 212 (10), 211 
[(C16H19)+, 50], 210 (14), 169 (15), 156 (17), 155 (100), 154 (12), 153 (12), 143 (37), 141 (33), 
129 (29), 128 (24), 117 (11), 115 (24). 
HRMS-ESI+ m/z [M+H]+ calcd for [C17H22N2S+H+]: 287.1576, found: 287.1578. 
 
Preparation of 5,5-dimethyl-2-[(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)amino]thiazol-4(5H)-one, 61 
 
 
Thiourea 76 (300 mg, 1.05 mmol), ethyl 2-bromoisobutyrate (0.29 mL, 1.95 mmol), 
DIPEA (0.36 mL) and abs. ethanol (3.5 mL) were placed into a microwave vial. The white 
suspension was heated to 130 °C, 250 psi and 250 W for 3 hours. The solvents were then 
removed under vacuo and the resulting solid was partitioned between DCM (10 mL) and 
0.5 N HCl solution (10 mL) and the phases were separated. The aqueous phase was 
extracted with further DCM (3 x 10 mL), and the combined organic phases were dried over 
anh. Na2SO4 and filtered. Evaporation in vacuo of the combined organic layers gave a white 
solid (315 mg). Column chromatography (Al2O3, DCM/methanol mixtures) gave 61 (47 
mg, 13% yield) as a white solid. The analytical sample was obtained washing the solid with 
pentane. 
Analytical and spectroscopic data of compound 61: 
Melting point: 294 – 299 °C. 
IR (ATR) ν: 3223, 2906, 1673, 1586, 1540, 1505, 1458, 1376, 1361, 1293, 1281, 1255, 1235, 
1182, 1128, 1091, 1033, 1005, 951, 756, 651, 633, 602, 534 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 0.93 (s, 3 H, C-CH3), 1.53 [d, J = 13.5 Hz, 2 H, 10(13)-Hb], 
1.62 [s, 6 H, C(CH3)2], 1.67 [ddm, J = 12.5 Hz, J’ = 6.5 Hz, 2 H, 10(13)-Ha], 1.95 (s, 2 H, 8-
H), 2.17 [d, J = 12.5 Hz, 2 H, 6(12)-Hb], 2.29 [dd, J = 12.5 Hz, J’ = 6.5 Hz, 2 H, 6(12)-Ha], 
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3.09 [t, J = 6.5 Hz, 2 H, 5(11)-H], 5.75 (broad s, 1 H, NH), 7.04 [m,  H, 1(4)-H], 7.08 [m,  H, 
2(3)-H]. 
13C-NMR (125.7 MHz, CDCl3) δ: 27.9 [CH3, C(CH3)2], 32.0 (CH3, C-CH3), 33.9 (C, C9), 
38.9 [CH2, C6(12)], 40.8 [CH2, C10(13)], 40.9 [CH, C5(11)], 47.1 (CH2, C8), 59.4 (C, C7), 
61.0 [C, C(CH3)2], 126.5 [CH, C2(3)], 128.0 [CH, C1(4)], 145.7 [d, C, C4a(C11a)], 176.2 
(C, CN), 193.8 (C, CO). 
MS (EI), m/z (%); significant ions: 355 (24), 354 (M·+, 100), 285 (34), 211 [(C16H19)+, 35], 
210 (11), 169 (14), 156 (15), 155 (100), 154 (10), 143 (35), 141 (29), 129 (27), 128 (21), 117 
(11), 115 (18). 
Elemental analysis: 
Calculated for C21H26N2OS:                              C 71.15% H 7.39% N 7.90%  S  9.04% 
Calculated for C21H26N2OS·0.75CH3OH·0.1DCM: C 67.81%  H 7.60%  N 7.24%  S 8.28% 
Found:                                      C 67.98% H 7.22% N 7.29% S 7.88% 
 
Preparation of N-(9-hydroxy-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)piperidine-1-carboxamide, 62  
 
 1-Piperidinecarbonyl chloride (0.162 mL, 1.30 mmol) and triethylamine (0.328 mL, 
2.36 mmol) were added to a solution of amine 46 (270 mg, 1.18 mmol) in DCM (10 mL) 
and the reaction mixture was stirred at room temperature overnight. Saturated aqueous 
NaHCO3 solution (15 mL) was added and the phases were separated. The aqueous phase 
was extracted with further DCM (2 x 15 mL), and the combined organic phases were dried 
over anh. Na2SO4, filtered and concentrated in vacuo to give a yellow solid (472 mg). 
Column chromatography (Al2O3, DCM/methanol mixtures) gave 62 (288 mg, 64% overall 
yield) as a white solid, that was washed with pentane for obtaining an analytical sample. 
Analytical and spectroscopic data of compound 62: 
Melting point: 188 – 190 °C. 
IR (ATR) ν: 3419, 2934, 2899, 2852, 1635, 1502, 1444, 1414, 1375, 1356, 1334, 1291, 1249, 
1201, 1161, 1148, 1111, 1067, 1028, 992, 969, 907, 848, 762, 728, 625, 570, 544 cm-1. 
1H-RMN (500 MHz, CDCl3) δ: 1.48-1.59 [complex signal, 6 H, 16(18)-H2, 17-H2], 1.76 [d, J 
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= 13.0 Hz, 2 H, 10(13)-Hb], 1.90-2.02 [complex signal, 4 H, 6(12)-Hb, 10(13)-Ha], 2.09 (s, 2 
H, 8-H2), 2.17 [ddd, J = 13.0 Hz, J’ = 6.5 Hz, J’’ = 1.5 Hz, 2 H, 6(12)-Ha], 3.16 [tt, J = 6.5 Hz, 
J’ = 1.5 Hz, 2 H, 5(11)-H], 3.23 [m, 4 H, 15(19)-H2], 7.05 [m, 2 H, 1(4)-H], 7.09 [m, 2 H, 
3(2)-H]. 
13C-RMN (125.7 MHz, CDCl3) δ: 24.3 (CH2, C17), 25.5 [CH2, C16(18)], 39.4 [CH2, C6(12)], 
40.1 [CH, C5(11)], 42.4 [CH2, C10(13)], 44.9 [CH2, C15(19)], 49.1 (CH2, C8), 56.3 (C, C7), 
71.0 (C, C9), 126.5 [CH, C2(3)], 128.0 [CH, C1(4)], 145.4 [d, C, C4a(C11a)], 156.4 (C, 
CO). 
MS-DIP (EI), m/z (%); significant ions: 341 (11), 340 (M·+, 48), 255 (41), 212 (9), 157 (13), 
155 (22), 144 (13), 141 (13), 129 (35), 128 (33), 127 (43), 115 (21), 112 (20), 86 (19), 85 (70), 
84 (100), 69 (20), 57 (10), 56 (14). 
Elemental analysis: 
Calculated for C21H28N2O2:                    C  74.08%   H  8.29% N  8.23% 
Calculated for C21H28N2O2·0.45CH3OH·0.2C5H12:  C  73.01%   H  8.79% N  7.59% 
Found:                                  C  73.17%   H  8.43% N  7.23% 
 
Preparation of N-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)piperidine-1-carboxamide, 63 
  
 1-Piperidinecarbonyl chloride (0.247 mL, 1.98 mmol) and triethylamine (0.367 mL, 
2.64 mmol) were added to a solution of amine 19 (300 mg, 1.32 mmol) in DCM (15 mL). 
The reaction mixture was stirred at room temperature overnight. To the resulting mixture 
was added saturated aqueous NaHCO3 solution (15 mL) and the phases were separated. 
The aqueous phase was extracted with further DCM (2 x 15 mL), and the combined organic 
phases were dried over anh. Na2SO4, filtered and concentrated in vacuo to give a yellow 
solid (419 mg). Column chromatography (Al2O3, DCM/methanol mixtures) gave 63 (265 
mg, 59% yield) as a white solid. The analytical sample was obtained washing with pentane. 
Analytical and spectroscopic data of compound 63: 
Melting point: 170 – 171 °C. 
IR (ATR) ν: 3361, 2914, 2850, 1617, 1525, 1479, 1439, 1404, 1360, 1343, 1275, 1261, 1228, 
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1211, 1168, 1022, 978, 949, 852, 758, 576 cm-1. 
1H-RMN (500 MHz, CDCl3) δ: 0.91 (s, 3 H, C9-CH3), 1.49-1.59 [complex signal, 8 H, 
10(13)-Hb, 16(18)-H2, 17-H2], 1.65 [ddm, J = 13.5 Hz, J’ = 6.5 Hz, 2 H, 10(13)-Ha], 1.84 (s, 2 
H, 8-H), 2.00 [d, J = 13.0 Hz, 2 H, 6(12)-Hb], 2.16 [ddm, J = 13.0 Hz, J’ = 6.5 Hz, 2 H, 6(12)-
Ha], 3.06 [tt, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 3.22-3.25 [complex signal, 4 H, 15(19)-
H], 4.25 (s, 1 H, NH), 7.03 [m, 2 H, 1(4)-H], 7.06 [m, 2 H, 3(2)-H].  
13C-RMN (125.7 MHz, CDCl3) δ: 24.4 (CH2, C17), 25.6 [CH2, C16(18)], 32.3 (CH3, C9-
CH3), 33.7 (C, C9), 39.8 [CH2, C6(12)], 41.2 [CH, C5(11)], 41.3 [CH2, C10(13)], 44.9 [CH2, 
C15(19)], 48.0 (CH2, C8), 53.6 (C, C7), 126.1 [CH, C2(3)], 127.9 [CH, C1(4)], 146.4 [d, C, 
C4a(C11a)], 156.6 (C, CO). 
MS-DIP (EI), m/z (%); significant ions: 254 (18), 253 [(M-C5H11N)·+, 100], 238 (25), 195 
(10), 182 (14), 155 (32), 143 (13), 141 (15), 129 (17), 128 (15), 115 (15). 
Elemental analysis: 
Calculated for C22H30N2O:               C  78.06%   H  8.93%    N  8.28% 
Found:                           C  78.05%   H  9.11%    N  8.06% 
 
Preparation of N-(9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)piperidine-1-carboxamide, 64 
 
 1-Piperidinecarbonyl chloride (0.1 mL, 0.80 mmol) and triethylamine (0.213 mL, 1.54 
mmol) were added to a solution of amine 48 (177.5 mg, 0.79 mmol) in DCM (9 mL) and 
the reaction mixture was stirred at room temperature overnight. To the resulting mixture 
was added saturated aqueous NaHCO3 solution (10 mL) and the phases were separated. 
The aqueous phase was extracted with further DCM (2 x 10 mL), and the combined organic 
phases were dried over anh. Na2SO4, filtered and concentrated in vacuo to give a yellow 
gum (246.3 mg). Column chromatography (Al2O3, DCM/methanol mixtures) gave 64 (68 
mg, 26% yield) as a white solid. The analytical sample was obtained by crystallization with 
EtOAc/pentane. 
Analytical and spectroscopic data of compound 64: 
Melting point: 178 – 179 °C. 
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IR (ATR) ν: 3285, 2932, 2856, 1614, 1538, 1470, 1442, 1359, 1278, 1259, 1230, 1088, 1024, 
1005, 968, 915, 865, 851, 804, 756, 648, 605, 570 cm-1. 
1H-RMN (500 MHz, CDCl3) δ: 1.50-1.60 [complex signal, 6 H, 16(18)-H2, 17-H2], 1.91 [d, J 
= 12.5 Hz, 2 H, 10(13)-Hb], 2.03 [d, J = 13.5 Hz, 2 H, 6(12)-Hb], 2.12-2.22 [complex signal, 
4 H, 6(12)-Ha, 10(13)-Ha], 2.25 (d, JC-F = 6.5 Hz, 2 H, 8-H2), 3.20-3.27 [complex signal, 6 H, 
5(11)-H, 15(19)-H2], 4.32 (s, 1 H, NH), 7.07 [m, 2 H, 1(4)-H], 7.11 [m, 2 H, 3(2)-H].  
13C-RMN (125.7 MHz, CDCl3) δ: 24.4 (CH2, C17), 25.6 [CH2, C16(18)], 39.3 [CH2, C6(12)], 
39.6 [CH, d, 3JC-F = 13.3 Hz, C5(11)], 40.1 [CH2, d, 2JC-F = 20.1 Hz, C10(13)], 44.9 [CH2, 
C15(19)], 46.8 (CH2, d, 2JC-F = 17.8 Hz, C8), 51.1 (C, d, 3JC-F = 11.4 Hz, C7), 95.4 (C, d, 1JC-F 
= 173.2 Hz, C9), 126.8 [CH, C2(3)], 128.1 [CH, C1(4)], 144.9 [d, C, C4a(C11a)], 156.3 (C, 
CO). 
MS (EI), m/z (%); significant ions: 258 (17), 257 [(C16H16FNO)+, 100], 215 (12), 170 (10), 
159 (13), 155 (10), 141 (9), 129 (13), 128 (12), 115 (15). 
Elemental analysis: 
Calculated for C21H27FN2O:                     C  73.65%   H  7.95% N  8.18% 
Calculated for C21H27FN2O·0.1EtOAc:    C  73.17%   H  7.98% N  7.97% 
Found:                                 C  73.35%   H  8.06% N  7.93% 
 
Preparation of N-(9-methoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)piperidine-1-carboxamide, 65 
 
 1-Piperidinecarbonyl chloride (0.04 mL, 0.33 mmol) and triethylamine (0.09 mL, 0.62 
mmol) were added to a solution of amine 252(76 mg, 0.31 mmol) in DCM (3.5 mL) and 
the reaction mixture was stirred at room temperature overnight. To the resulting mixture 
was added saturated aqueous NaHCO3 solution (5 mL) and the phases were separated. The 
aqueous phase was extracted with further DCM (2 x 5 mL), and the combined organic 
phases were dried over anh. Na2SO4, filtered and concentrated in vacuo to give a yellow 
gum (201.4 mg). Column chromatography (Al2O3, DCM/methanol mixtures) gave 65 (42 
mg, 38% yield) as a white solid.  
Analytical and spectroscopic data of compound 65: 
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Melting point: 172 – 173 °C. 
IR (ATR) ν: 3293, 2926, 2850, 2820, 1616, 1540, 1491, 1441, 1409, 1383, 1360, 1344, 1265, 
1256, 1231, 1151, 1080, 1064, 1045, 1025, 994, 984, 969, 914, 848, 756, 638, 602 cm-1. 
1H-RMN (500 MHz, CDCl3) δ: 1.47-1.57 [complex signal, 6 H, 16(18)-H2, 17-H2], 1.43 [d, J 
= 13.0 Hz, 2 H, 10(13)-Hb], 1.96 [m, 2 H, 10(13)-Ha], 2.08 (s, 2 H, 8-H2), 2.07 [d, J = 13.5 
Hz, 2 H, 6(12)-Hb], 2.14 [m, 2 H, 6(12)-Ha], 3.18 [tt, J = 6.5 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 
3.23-3.27 [complex signal, 7 H, 15(19)-H, C9-OCH3], 4.31 (s, 1 H, NH), 7.05 [m, 2 H, 1(4)-
H], 7.09 [m, 2 H, 3(2)-H].  
13C-RMN (125.7 MHz, CDCl3) δ: 24.4 (CH2, C17), 25.5 [CH2, C16(18)], 38.3 [CH2, C6(12)], 
39.6 [CH2, C10(13)], 39.9 [CH, C5(11)], 44.9 [CH2, C15(19)], 45.4 (CH2, C8), 48.2 (CH3, 
OCH3), 56.1 (C, C7), 74.8 (C, C9), 126.5 [CH, C2(3)], 128.0 [CH, C1(4)], 145.5 [d, C, 
C4a(C11a)], 156.5 (C, CO).  
MS (EI), m/z (%); significant ions: 270 (18), 269 [(C17H19NO2)+, 100], 238 (36), 226 (12), 
195 (15), 182 (20), 171 (22), 159 (32), 158 (91), 155 (35), 153 (15), 150 (17), 141 (20), 129 
(26), 128 (30), 127 (13), 115 (32). 
Elemental analysis: 
Calculated for C22H30N2O2:                        C  74.54%   H  8.53%     N  7.90% 
Calculated for C22H30N2O2·0.1CH3OH:     C  74.21%   H  8.57%     N  7.83% 
Found:                                    C  74.11%   H  8.54%     N  7.67% 
 
Preparation of (2R)-tert-butyl-2-[(9-fluoro-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)carbamoyl]pyrrolidine-1-carboxylate, 78 
 
 Boc-D-proline (55 mg, 0.26 mmol), HOBt (52 mg, 0.38 mmol), EDC (59 mg, 0.38 
mmol) and triethylamine (0.14 mL, 1.02 mmol) were added to a solution of amine 48·HCl 
(75 mg, 0.28 mmol) in EtOAc (4 mL) and the mixture was stirred at room temperature 
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overnight. To the resulting suspension was then added water (5 mL) and the phases were 
separated. The organic phase was washed with saturated aqueous NaHCO3 solution (5 mL) 
and brine (5 mL), dried over anh. Na2SO4 and filtered. Evaporation in vacuo of the 
combined organic layers gave 78 (110 mg, 92% yield) as a beige solid. The product was used 
in next step without further purification or characterization. 
 
Preparation of (2R)-N-(9-fluoro-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)pyrrolidine-2-carboxamide, 79 
 
 A solution of Boc-protected pyrrolidine 78 (110 mg, 1.26 mmol) in DCM (2 mL) and 
85% o-phosphoric acid (0.26 mL, 3.90 mmol) was stirred at room temperature for 4 hours. 
To the reaction mixture was then added water (5 mL) and the aqueous phase was basified 
until pH ~12 with 5 N NaOH solution. The phases were separated and the aqueous phase 
was extracted with further DCM (2 x 5 mL). The combined organic layers were dried over 
anh. Na2SO4, filtered and evaporated in vacuo to give 79 (82 mg, quantitative yield) as a 
maroon gum. The product was used in next step without further characterization or 
purification. 
 
Preparation of (2R)-1-ethyl-N-(9-fluoro-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)pyrrolidine-2-carboxamide, 77·tartrate 
 A solution of pyrrolidine 79 (82 mg, 0.25 mmol) in DMF (1.5 mL) was cooled to 5 
°C with an ice bath. Then KI (4 mg, 0.03 mmol) and triethylamine (0.14 mL, 1.00 mmol) 
were added, followed by the dropwise addition of a solution of ethyl bromide (29 mg, 0.26 
mmol) in DMF (0.5 mL). The reaction mixture was stirred at room temperature in an ice-
water bath overnight. To the resulting solution was added EtOAc (5 mL) and water (5 mL). 
The phases were separated and the aqueous layer was extracted with further EtOAc (2 x 5 
mL). The combined organic phases were washed with saturated aqueous NaHCO3 solution 
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(5 mL) and brine (5 mL), dried over anh. Na2SO4, filtered and concentrated in vacuo to give 
an orange oil (74 mg). Column chromatography (SiO2, DCM/methanol mixtures) gave 77 
(33 mg, 35% yield) as a white solid. A solution of L-(+)-tartaric acid (11 mg, 0.07 mmol) in 
methanol (1 mL) was added to 77 directly. The solvents were removed under vacuo to give 
77 as its tartrate salt.  
Analytical and spectroscopic data of compound 77·tartrate: 
Melting point: 94-96 °C. 
IR (ATR) ν: 3500-2800 (3432, 3381, 3285, 3063, 2923, 2856), 2553, 2363, 2182, 1962, 
1721, 1667, 1563, 1441, 1395, 1358, 1341, 1301, 1235, 1118, 1074, 997, 863, 757, 663 cm-
1. 
1H-RMN (500 MHz, CD3OD) δ: 1.28 (t, J = 7.5 Hz, 3 H, NCH2CH3), 1.84 [d, J = 11.5 Hz, 
2 H, 10(13)-Hb], 1.99 (complex signal, 2 H, 16-Ha, 17-Ha), 2.08 [d, J = 13 Hz, 2 H, 6(12)-Hb], 
2.16 [complex signal, 6 H, 6(12)-Ha, 10(13)-Ha, 17-Ha], 2.24 (d, J = 6.5 Hz, 2 H, 8-H), 2.50 
(m, 1 H, 16-Hb], 3.17 (complex signal, 3 H, NCH2CH3, 18-Ha), 3.27 [m, 2 H, 5(11)-H], 3.68 
(m, 1 H, 18-Hb), 3.95 (dd, J = 8.5 Hz, J’ = 7 Hz, 1 H, 15-H),  4.45 (s, 2 H, tartrate-CH), 7.11 
[complex signal, 4 H, Ar-H].  
13C-RMN (125.7 MHz, CD3OD) δ: 11.4 (CH3, NCH2CH3), 24.0 (CH2, C17), 31.1 (CH2, 
C16), 39.1 [CH2, d, 4JC-F = 7.4 Hz, C6(12)], 40.9 [CH, d, 3JC-F = 12.9 Hz, C5(11)], 41.2 [CH2, 
d, 2JC-F = 20.1 Hz, C10(13)], 46.6 (CH2, d, 2JC-F = 18.9 Hz, C8), 51.4 (CH2, NCH2CH3), 55.6 
(CH2, C18), 59.3 (C, d, 3JC-F = 11.2 Hz, C7), 68.6 (CH, C15), 73.8 (CH, tartrate-CH), 94.6 
(C, d, 1JC-F = 177.6 Hz, C9), 128.1 [CH, C2(3)], 129.2[CH, C1(4)], 146.1 [C, C4a(C11a)], 
168.4 (C, CO), 176.9 (C, tartrate-CO).  
MS (DEPEI), m/z (%); significant ions: 99 (27), 98 (100), 97 (26), 96 (11), 76 (13), 71 (10), 
70 (34), 69 (14), 68 (11). 
HRMS-ESI+ m/z [M+H]+ calcd for [C22H29FN2O+H+]: 357.2337, found: 357.2338. 
 
  
 
 
 
 
 
 
 
 
 
 
Hexacyclic scaffolds 
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Preparation of dimethyl pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8,9-dicarboxylate, 
82391 
a) Formation of 9,10-dihydrofulvalene, 81: 
 
 In a 2 L reactor equipped with a mechanic stirrer, thermometer, gas inlet and pressure-
equalizing dropping funnel was prepared a suspension of 95% dry sodium hydride (50 g, 
2.08 mol) in anh. THF (1 L). The stirred suspension was cooled to ~0 ºC with an ice bath 
and then freshly distilled cyclopentadiene (137 g, 2.08 mol) was added dropwise over 70 
minutes avoiding excess foaming. After the addition, the cooling bath was removed and 
the resulting dark red colour suspension was stirred at room temperature for one hour. 
Aferwards, copper(I)-bromide-dimethyl sulphide complex (750 mg) was added and the 
mixture was cooled to -78 ºC with a dry ice in acetone bath. A solution of iodine (265 g, 
1.04 mol) in anh. THF (400 mL) was added dropwise over 2 hours without reaching a 
temperature greater than -40 ºC. The dark suspension was stirred at low temperature for 
15 minutes. 
b) Diels-Alder reaction of 81 with dimethyl acetylenedicarboxylate: 
 
 Dimethyl acetylenedicarboxylate (165 g, 1.16 mol) was added rapidly dropwise over 10 
minutes to the previous slurry. The mixture was kept at low temperature for 30 minutes 
and then allowed to reach room temperature with the stirring maintained for 4 hours. The 
reaction mixture was the filtered through a Celite™ pad and the solid was washed 
repeatedly with THF (1 L). The combined filtrates were concentrated under vacuo at a 
temperature not above 40 ºC with the obtaining of a dark oil, which was dissolved in diethyl 
ether (750 mL) and stirred at room temperature for 15 minutes. The mixture was again 
filtered through Celite™ pad and evaporated under vacuo without exceeding 40 ºC to give 
a mixture of diesters 82 and 83, which was stored at 0 ºC until next step. 
c) Selective hydrolysis and isolation of 82: 
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 In a 2 L reactor equipped with mechanical stirrer, thermometer, gas outlet and 
pressure-equalizing dropping funnel was dissolved the concentrated from part b in 
methanol (1 L) and the solution was cooled to -5 ºC by means of an ice/NaCl bath. Then 
a precooled (0 ºC) solution of potassium hydroxide (110 g, 85%, 1.67 mol) in water (200 
mL) was added dropwise at such a rate as to keep the reaction temperature below 10 ºC. 
The reaction mixture was stirred at 0 ºC for 2 hours and at room temperature for an 
additional 2 hours prior to the addition of glacial acetic acid (50 mL), followed by powder 
sodium carbonate until pH ~8. The resulting suspension was then filtered through Celite™ 
pad. The filtrate was concentrated at 40 ºC under vacuo to about 500 mL, the residue was 
diluted with water (1 L) and extracted with petroleum ether (6 x 300 mL). The combined 
organics were washed with 10% sodium thiosulfate solution (2 x 200 mL), dried over anh. 
Na2SO4, filtered and concentrated under reduced pressure at 40 ºC to give the diester 82 
as an orange solid (20.0 g, 7% overall yield), whose spectroscopic data were in agreement 
with those described in the bibliography. 
 
Preparation of pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8,9-dicarboxylic acid, 88391 
 
 To a solution of pentacyclic diester 82 (20.0 g, 73.4 mmol) in methanol (75 mL) was 
added a solution of potassium hydroxide (20 g, 85%, 0.30 mol) in water (75 mL). The 
reaction mixture was heated at reflux for 1 hour. The methanol was removed from the 
resulting brown solution under vacuo, water (145 mL) was added and the solution was 
heated for further 5 hours. Thereafter, activated charcoal (6 g) was added and the black 
suspension was stirred at room temperature overnight. Filtration through Celite™ pad was 
followed by cooling the filtrate with an ice bath. Conc. HCl was added dropwise until pH 
1 with the formation of a white solid, which was filtered under vacuo. The solid was 
dissolved in EtOAc (1 L), dried over anh. Na2SO4, filtered and concentrated under reduced 
pressure to give the diacid 88 as a white solid. In order to recover further amounts of desired 
product, the aqueous layer was extracted with EtOAc (3 x 50 mL) and the combined 
organics were dried over anh. Na2SO4, filtered and concentrated under vacuo to give a total 
amount of 14.5 g (81% yield) of diacid 88. The spectroscopic data were identical to those 
previously published.  
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Preparation of 3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-diene-2,4-dione, 
8990 
 
Pentacyclic diacid 88 (3.60 g, 14.8 mmol) and urea (4.44 g, 74.0 mmol) were placed in 
a round-bottom flask equipped with a magnetic stirrer, gas outlet and Liebig condenser 
apparatus. The mixture was heated slowly to fusion (150 ºC) and once melted, the resulting 
paste was heated at 220 ºC for 30 minutes. Then the reaction mixture was tempered, water 
(120 mL) was added and the suspension was extracted with DCM (7 x 50 mL). The 
combined organic phases were washed with brine (100 mL), dried over anh. Na2SO4 and 
filtered. Evaporation under vacuo gave the imide 89 as a white solid (2.85 g, 86% yield). 
The spectroscopic data matched with those described in the bibliography. 
 
Preparation of 3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-diene, 9090  
 
To a suspension of pentacyclic imide 89 (2.85 g, 12.6 mmol) in anh. toluene (90 mL) 
was added dropwise Red-Al® (17.9 mL, 63.4 mmol) under nitrogen, keeping the 
temperature lower than 35 ºC and with some gas releasing. The reaction mixture was 
heated at reflux for 48 hours, monitoring the starting material conversion by TLC. Then 
the solution was tempered to room temperature and quenched with 30 wt. % aqueous 
KOH solution (45 mL). The phases were separated and the aqueous layer was extracted 
with DCM (3 x 25 mL). The combined organic phases were dried over anh. Na2SO4, filtered 
and evaporated under vacuo to give a brown oil. In order to purify the crude, this was 
dissolved in DCM (20 mL) and extracted with 1 N HCl solution (2 x 15 mL). The pH of 
the combined aqueous phases was adjusted to 12 with 5 N NaOH solution and extracted 
with DCM (3 x 20 mL). The combined organic layers were dried over anh. Na2SO4, filtered 
and concentrated under vacuo to give the amine 90 as a brownish oil (2.28 g, 92% yield), 
its spectroscopic data and those previously published were identical. 
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Preparation of 3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane hydrochloride, 
95·HCl90 
 
A suspension of amine 90 (231 mg, 1.17 mmol) and 5 wt. % palladium on carbon 
(50% in water, 37 mg, 16% of the weight of 90) in abs. ethanol (37 mL) was stirred at room 
temperature and atmospheric pressure under hydrogen for 4 hours. The suspension was 
then filtered and the solids were washed with EtOH (15 mL). An excess of HCl/Et2O was 
added and the solvents were removed under vacuo to give the reduced amine 95·HCl (239 
mg, 86% yield) as white solid. The spectroscopic data matched with those described in the 
bibliography. 
 
Preparation of tert-butyl (R)-2-(3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]-pentadecane-3-
carbonyl)pyrrolidine-1-carboxylate, 96  
 
 To a solution of amine 95 (239 mg, 1.01 mmol) in ethylacetate (15 mL) were added 
Boc-D-Proline (197 mg, 0.92 mmol), HOBt (188 mg, 1.38 mmol), EDC (214 mg, 1.38 
mmol) and triethylamine (0.560 mL, 4.05 mmol) and the reaction mixture was stirred at 
room temperature overnight. To the resulting suspension was then added water (15 mL) 
and the phases were separated. The organic phase was washed with saturated aqueous 
NaHCO3 solution (15 mL) and brine (15 mL), dried over anh. Na2SO4 and filtered. The 
organic layer was concentrated under vacuo to give 96 along with reaction by-products (360 
mg, quantitative yield) as a clear oil. The product was used in the next step without further 
purification or characterization.  
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Preparation of 3-[(2R)-prolyl]-3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane, 97  
 
 A solution of Boc-protected pyrrolidine 96 (385 mg, 0.97 mmol) in DCM (5 mL) and 
85 wt. % o-phosphoric acid (1.00 mL, 14.5 mmol) was stirred at room temperature for 6 
hours. To the reaction mixture was then added water (10 mL) and the aqueous phase was 
basified until pH ~12 with 5 N NaOH solution. The phases were separated and the aqueous 
phase was extracted with further DCM (2 x 10 mL). The combined organic layers were 
dried over anh. Na2SO4, filtered and evaporated in vacuo to give a brown oil (202 mg). The 
crude was purified by column chromatography (Al2O3, DCM/methanol mixture). The 
appropriate fractions were combined and concentrated under reduced pressure to give 97 
(104 mg, 36% yield) as a white solid that was used in the next step without further 
purification or characterization. 
 
Preparation of 3-[(2R)-N-ethylprolyl]-3-
azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane, 98·tartrate 
 
 A solution of pyrrolidine 97 (98 mg, 0.33 mmol) in DMF (2 mL) was cooled to 5 ºC 
with an ice bath. Then potassium iodide (5.5 mg, 10% mmol) and triethylamine (0.180 
mL, 1.32 mmol) were added, followed by the slowly addition of ethyl bromide (37.6 mg, 
0.35 mmol). The reaction mixture was stirred at room temperature in an ice-water bath 
overnight. Then the resulting precipitated was filtered off and washed with EtOAc (5 mL). 
The filtrate was washed with saturated aqueous NaHCO3 solution (5 mL) and brine (5 mL), 
dried over anh. Na2SO4, filtered and concentrated in vacuo to give clear oil (90 mg). A 
solution of tartaric acid (41 mg, 0.28 mmol) in methanol (1 mL) was added to the crude 
directly. The solvents were removed under vacuo to give 98 as tartrate salt (106 mg, 68% 
yield).  
Analytical and spectroscopic data of compound 98·tartrate: 
Melting point: 184 - 185 ºC. 
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IR (ATR) ν: 3450-2800 (3453, 3038, 2931, 2868), 1712, 1632, 1463, 1424, 1355, 1227, 1201, 
1118, 1074, 1027, 893, 836, 678 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.31 (t, J = 7 Hz, 3 H, CH3CH2), 1.48-1.63 (complex signal, 
8 H, 7-H2, 8-H2, 13-H2, 14-H2), 2.03-2.14 (complex signal, 2 H, 3’-Ha, 4’-Ha), 2.16-2.26 
(complex signal, 5 H, 6-H, 9-H, 12-H, 15-H, 4’-Hb), 2.49 (m, 2 H, 10-H, 11-H), 2.66 (m, 1 
H, 3’-Hb), 3.20 (m, 1 H, 5’-Ha), 3.28 (complex signal, 4 H, 2-H2 or 4-H2, CH3CH2), 3.51 (m, 
2 H, 4-H2 or 2-H2), 3.78 (m, 1 H, 5’-Hb), 4.41 (s, 2.2 H, tartrate-CH), 4.53 (m, 1 H, 2’-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 11.4 (CH3, CH3CH2), 22.3 (CH2), 22.4 (CH2), 22.6 
(CH2), and 22.7 (CH2), (C7, C8, C13 and C14), 24.0 (CH2, C4’), 29.5 (CH2, C3’), 42.6 
(CH2, C2 or C4), 43.1 (CH2, C4 or C2), 50.6 (CH, C10 or C11), 51.2 (CH, C11 or C10), 
51.5 (CH2, CH3CH2), 55.5 (CH2, C5’), 55.8 (CH), 55.9 (CH), 56.3 (CH) and 56.5 (CH) 
(C6, C9, C12 and C15), 56.4 [d, CH, C12(15) or C6(9)], 58.8 (C, C1 or C5], 60.8 (C, C5 
or C1], 67.6 (CH, C2’), 74.1 (CH, tartrate-CH), 167.3 (C, CO), 176.6 (C, tartrate-CO). 
MS (CI), m/z (%); significant ions: 327 [(M·+)+1, 100], 325 (41), 258 (14), 230 (19), 98 (68). 
Elemental analysis: 
Calculated for C21H30N2O·1C4H6O6:             C 63.01% H 7.61% N 5.88% 
Calculated for C21H30N2O·1.25C4H6O6:  C 60.75% H 7.35% N 5.45% 
Found:                 C 61.03% H 7.51% N 5.19% 
 
Preparation of (4-amino-3,5-dichlorophenyl) (3-
azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-dien-3-yl)methanone, 99 
 
 To a solution of amine 90 (400 mg, 2.03 mmol) in EtOAc (30 mL) and DMF (2 mL) 
were added 4-amino-3,5-dichlorobenzoic acid (380 mg, 1.85 mmol), 1-hydroxybenzotriazole 
(HOBt) (375 mg, 2.78 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (430 
mg, 2.78 mmol) and triethylamine (0.560 mL, 4.07 mmol) and the reaction mixture was 
stirred at room temperature overnight. To the resulting suspension was then added water 
(20 mL) and the phases were separated. The organic phase was washed with saturated 
aqueous NaHCO3 solution (20 mL) and brine (20 mL), dried over anh. Na2SO4 and 
filtered. Evaporation in vacuo of the organic phase gave 677 mg of a yellow solid. The crude 
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was purified by column chromatography (Al2O3, DCM/methanol mixture). The 
appropriate fractions were combined and concentrated under vacuo to give compound 99 
as a white solid (332 mg, 47% yield).  
Analytical and spectroscopic data of compound 99: 
Melting point: 236 - 238 ºC. 
IR (ATR) ν: 3449, 3306, 3250, 3204, 2954, 2867, 2150, 1597, 1538, 1501, 1456, 1410, 
1384, 1342, 1316, 1295, 1244, 1225, 1192, 1054, 1002, 943, 896, 875, 791, 745, 733, 686, 
667, 643 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 2.61 [m, 2 H, 10(11)-H], 2.85 [broad s, 2 H, 6(12)-H or 9(15)-
H], 2.94 [broad s, 2 H, 9(15)-H or 6(12)-H], 3.13 (broad s, 2 H, 2-H or 4-H), 3.33 (broad s, 
2 H, 4-H or 2-H), 5.91 [m, 2 H, 7(13)-H or 8(14)-H], 6.03 [m, 2 H, 8(14)-H or 7(13)-H], 7.19 
(s, 2 H, Ar-H). 
13C-NMR (125.7 MHz, CDCl3) δ: 45.5 (CH2, C2 or C4), 49.9 (CH2, C4 or C2), 61.8 [CH, 
C6(12), C9(15)], 62.8 [CH, C10(11)], 68.8 (C, C1 or C5), 71.0 (C, C5 or C1), 118.7 (C, Ar-
Cmeta), 126.7 (C, Cipso), 127.1 (CH, Ar-Cortho), 132.9 [CH, C7(13) or 8(14)], 133.9 [CH, C8(14) 
or C7(13)], 141.3 (C, Ar-Cpara), 166.8 (C, CO). 
MS (EI), m/z (%); significant ions: 388 [(C21H1837Cl2N2O)·+, 2], 386 [(C21H1837Cl35ClN2O)·+, 
12], 384 [(C21H1835Cl2N2O)·+, 18], 192 [(C7H437Cl2NO)+, 10],, 190 [(C7H437Cl35ClNO)+, 63], 
188 [(C7H435Cl2NO)+, 100], 180 (12), 160 (12), 124 (16). 
HRMS-ESI+ m/z [M+H]+ calcd for [C21H18Cl2N2O+H]+: 385.0869, found: 385.0875. 
 
Preparation of (4-amino-3,5-dichlorophenyl) (3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15] 
pentadecan-3-yl)methanone, 100 
 
 
 To a solution of amide 99 (200 mg, 0.78 mmol) in abs. ethanol (24 mL) was added  
5 wt. % palladium on carbon (50% in water, 24 mg, 8% of the weight of 99) and the 
suspension was hydrogenated at room temperature and atmospheric pressure for 5 hours. 
The reaction mixture was then filtered, the solids were washed with EtOH (15 mL) and the 
solvent was removed under vacuo to give a yellow solid (207 mg). Column chromatography 
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(Al2O3, DCM/methanol mixture) gave the desired amide 100 (180 mg, 89% yield) as white 
solid. 
Analytical and spectroscopic data of compound 100: 
Melting point: 243 - 244 ºC. 
IR (ATR) ν: 3455, 3283, 3238, 3186, 2931, 2865, 1631, 1597, 1545, 1498, 1456, 1425, 1332, 
1307, 1269, 1232, 1216, 1118, 1070, 1035, 944, 895, 789, 769, 745, 693, 647, 629 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.43-1.60 [complex signal, 8 H, 7(13)-H2, 8(14)-H2], 2.04 
[broad s, 2 H, 6(12)-H or 9(15)-H], 2.12 [broad s, 2 H, 9(15)-H or 6(12)-H], 2.41 [m, 2 H, 
10(11)-H], 3.29 (s, 2 H, 2-H2 or 4-H2), 3.53 (s, 2 H, 4-H2 or 2-H2), 7.40 (s, 2 H, Ar-H). 
13C-NMR (125.7 MHz, CDCl3) δ: 21.5 [CH2, C7(13) or C8(14)], 21.8 [CH2, C8(14) or 
C7(13)], 40.8 (CH2, C2 or C4), 45.5 (CH2, C4 or C2), 49.6 [CH, C10(11)], 54.8 [broad 
CH, C6(12) and C9(15)], 57.9 (C, C1 or C5), 59.6 (C, C5 or C1), 118.8 (C, Ar-Cmeta), 126.9 
(C, Cipso), 127.2 (CH, Ar-Cortho), 141.4 (C, Ar-Cpara), 170.0 (C, CO). 
MS (EI), m/z (%); significant ions: 392 [(C21H2237Cl2N2O)·+, 8], 390 [(C21H2237Cl35ClN2O)·+, 
42], 388 [(C21H2235Cl2N2O)·+, 63], 200 (18), 192 [(C7H437Cl2NO)+, 11], 190 
[(C7H437Cl35ClNO)+, 64], 188 [(C7H435Cl2NO)+, 100],, 184 (33), 169 (13), 160 (12), 124 (13). 
Elemental analysis: 
Calculated for C21H22Cl2N2O:                     C  64.79%   H  5.70%   Cl  18.21%  N  7.20% 
Calculated for C21H22Cl2N2O·0.50H2O:     C  63.32%   H  5.82%   Cl  17.80%  N  7.03% 
Found:                                   C  63.23%   H  5.71%   Cl 17.82%   N 6.77% 
 
Preparation of (3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-dien-3-
yl)(cyclohexyl)methanone, 101 
 
 To a solution of amine 90 (400 mg, 2.03 mmol) in ethylacetate (30 mL) were added 
cyclohexanecarboxylic acid (237 mg, 1.85 mmol), HOBt (375 mg, 2.78 mmol), EDC (430 
mg, 2.78 mmol) and triethylamine (0.570 mL, 4.07 mmol) and the reaction mixture was 
stirred at room temperature overnight. To the resulting suspension was then added water 
(20 mL) and the phases were separated. The organic phase was washed with saturated 
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aqueous NaHCO3 solution (20 mL) and brine (20 mL), dried over anh. Na2SO4 and 
filtered. Evaporation in vacuo of the combined organic layers gave an orange oil (627 mg). 
The crude was purified by column chromatography (Al2O3, DCM/methanol mixture). The 
appropriate fractions were combined and concentrated under vacuo to give the desired 
amide 101 as a white solid (260 mg, 42% yield). The analytical sample was obtained by 
crystallization from tert-butanol. 
Analytical and spectroscopic data of compound 101: 
Melting point: 111 - 113 ºC. 
IR (ATR) ν: 2961, 2930, 2853, 1630, 1443, 1425, 1347, 1305, 1223, 1194, 1138, 1067, 998, 
897, 878, 830, 780, 749, 734, 696, 659, 646 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.17-1.24 [complex signal, 3 H, 4’-Hax, 3’(5’)-Hax], 1.43 
[complex signal, 2 H, 2’(6’)-Hax], 1.60-1.66 [complex signal, 3 H, 2’(6’)-Heq, 4’-Heq], 1.75-1.78 
[complex signal, 2 H, 3’(5’)-Heq], 2.13 (tt, J = 12.0 Hz, J’ = 3.5 Hz, 1 H, 1’-H), 2.67 [m, 2 H, 
10(11)-H], 2.98 [complex signal, 4 H, 6(12)-H, 9(15)-H], 3.18 (s, 2 H, 2-H2 or 4-H2), 3.19 (s, 
2 H, 4-H2 or 2-H2), 6.00 [ddd, J = 6 Hz, J’ = 3 Hz, J’’ = 1.5 Hz, 2 H, 7(13)-H or 8(14)-H], 6.04 
[ddd, J = 6 Hz, J’ = 3 Hz, J’’ = 1 Hz, 2 H, 8(14)-H or 7(13)-H]. 
13C-NMR (125.7 MHz, CDCl3) δ: 25.8 (CH2, C4’), 25.9 [CH2, C3’(5’)], 28.7 [CH2, C2’(6’)], 
42.5 (CH, C1’), 45.5 (CH2, C2 or C4), 46.7 (CH2, C4 or C2), 62.0 [CH, C6(12) and 
C9(15)], 62.8 [CH, C10(11)], 69.1 (C, C1 or C5), 70.8 (C, C5 or C1), 132.8 [CH, C7(13) 
or 8(14)], 134.1 [CH, C8(14) or C7(13)], 174.4 (C, CO). 
MS (EI), m/z (%); significant ions: 308 (20), 307 (M·+, 83), 252 (16), 242 (25), 198 (17), 197 
(100), 196 (C14H14N·+, 39), 182 (19), 181 (15), 180 (41), 179 (16), 168 (24), 167 (25), 166 (15), 
165 (38), 156 (21), 153 (23), 152 (27), 132 (64), 131 (100), 130 (64), 128 (17), 118 (19), 117 
(19), 115 (23), 91 (18), 83 [(C6H11)+, 85], 77 (15), 55 (72). 
HRMS-ESI+ m/z [M+H]+ calcd for [C21H25NO+H]+: 308.2009, found: 308.2003. 
 
Preparation of (3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane-3-
yl)(cyclohexyl)methanone, 102 
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To a solution of amide 101 (118 mg, 0.40 mmol) in abs. ethanol (13 mL) was added 5 
wt. % palladium on carbon (50% in water, 12.6 mg, 10% of the weight of 101) and the 
suspension was hydrogenated at room temperature and atmospheric pressure for 5 hours. 
The reaction mixture was then filtered, the solids were washed with EtOH (15 mL) and the 
solvents were removed under vacuo to give the amide 102 (94 mg, 78% yield) as white solid. 
The analytical sample was obtained by crystallization from DCM/diethyl ether. 
Analytical and spectroscopic data of compound 102: 
Melting point: 134 - 135 ºC. 
IR (ATR) ν: 2932, 2851, 1621, 1463, 1426, 1357, 1286, 1202, 1120, 1104, 1036, 1013, 969, 
925, 886, 860, 825, 768, 732, 702, 657, 627 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.25 [complex signal, 3 H, 4’-Hax, 3’(5’)-Hax], 1.48-1.57 
[complex signal, 10 H, 7(13)-H2, 8(14)-H2, 17(21)-Hax], 1.68 (m, 1 H, 4’-Heq), 1.75-1.82 
[complex signal, 4 H, 2’(6’)-Heq, 3’(5’)-Heq], 2.08 (broad signal, 4 H, 6(12)-H, 9(15)-H], 2.36 
(tt, J = 12 Hz, J’ = 3.5 Hz, 1 H, 1’-H), 2.41 [m, 2 H, 10(11)-H], 3.29 [s, 4 H, 2(4)-H2]. 
13C-NMR (125.7 MHz, CDCl3) δ: 21.5 [CH2, C7(13) or C8(14)], 21.8 [CH2, C8(14) or 
C7(13)], 25.8 (CH2, C4’), 25.9 [CH2, C3’(5’)], 29.0 [CH2, C2’(6’)], 40.7 (CH2, C2 or C4), 
42.0 (CH2, C4 or C2), 42.9 (CH, C1’), 49.6 [CH, C10(11)], 55.0 [CH, C6(12) or C9(15)], 
55.1 [CH, C9(15) or C6(12)], 57.5 (C, C1 or C5], 59.3 (C, C5 or C1], 175.1 (C, CO). 
MS (EI), m/z (%); significant ions: 312 (23), 311 (M·+, 100), 270 (14), 257 (19), 256 (99), 243 
(12), 228 [(C15H18NO)+ 13], 202 (12), 201 (30), 200 (13), 184 (29), 169 (11), 129 (15), 128 
(15), 91 (16), 83 [(C6H11)+, 24], 55 (25). 
Elemental analysis: 
Calculated for C21H29NO: C  80.98%   H  9.39%    N  4.50% 
Found:    C  80.76%   H  9.61%    N 4.33% 
 
Preparation of (3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-diene-3-
yl)(piperidin-1-yl)methanone, 103  
 
 To a solution of amine 90 (400 mg, 2.03 mmol) in DCM (18 mL) were added 1-
piperidinecarbonyl chloride (0.26 mL, 2.13 mmol) and triethylamine (0.56 mL, 4.06 mmol) 
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and the mixture was stirred at room temperature overnight. To the resulting mixture was 
added saturated aqueous NaHCO3 solution (20 mL) and the phases were separated. The 
aqueous phase was extracted with further DCM (2 x 10 mL), and the combined organic 
phases were dried over anh. Na2SO4, filtered and concentrated in vacuo to give a yellow oil 
(719 mg). Column chromatography (Al2O3, DCM/Methanol mixture) gave 103 (443 mg, 
71% yield) as a clear oil. Several attempts to crystallize this product met with failure. The 
product was used in the next step without further purification or characterization. 
MS (EI), m/z (%); significant ions: 308 (M·+, 46), 196 [(C14H14N)+, 17], 165 (14), 130 (15), 
112 [(C6H10NO)+, 100], 84 [(C5H10N)+, 17], 69 (41). 
 
Preparation of (3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca -3-yl)(piperidin-1-
yl)methanone, 104  
 
A suspension of urea 103 (235 mg, 0.76 mmol) and 5 wt. % palladium on carbon (50% 
in water, 24 mg, 10% of the weight of 103) in abs. ethanol (25 mL) was stirred at room 
temperature and atmospheric pressure under hydrogen for 3 hours. The suspension was 
then filtered and the solids were washed with EtOH (10 mL). The solvents were removed 
under vacuo to give the reduced urea 104 (171 mg, 72% yield) as white solid.  
Analytical and spectroscopic data of compound 104: 
Melting point: 124 - 126 ºC. 
IR (ATR) ν: 3457, 3291, 2936, 2867, 2839, 1615, 1538, 1461, 1415, 1370, 1332, 1304, 1252, 
1226, 1202, 1159, 1124, 1110, 1027, 991, 915, 882, 851, 767, 722, 632 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.47-1.58 [complex signal, 14 H, 7(8,13,14)-H2, 3’(5’)-H2, 4’-
H2], 2.05 [m, 4 H, 6(9,12,15)-H], 2.38 [m, 2 H, 10(11)-H], 3.19 [m, 8 H, 2(4)-H2, 2’(6’)-H2].  
13C-NMR (125.7 MHz, CDCl3) δ: 21.7 [CH2, C7(8, 13, 14)], 24.8 (CH2, C4’), 25.9 [CH2, 
C3’(5’)], 43.3 [CH2, C2(4)], 47.8 [CH2, C16(20)], 49.6 [CH, C10(11)], 54.8 [CH, C6(9, 12, 
15)], 58.8 [C, C1(5)], 163.3 (C, CO). 
MS (EI), m/z (%); significant ions: 312 (M·+, 100), 201 (15), 200 [(C14H18N)+, 82], 184 (33), 
129 (36), 112 [(C6H10NO)+, 54], 91 (16), 84 [(C5H10N)+, 59], 69 (28). 
Elemental analysis: 
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Calculated for C20H28N2O: C  76.88%   H  9.03%    N  8.97% 
Found:    C  76.60%   H  9.21%    N 8.74% 
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Preparation of N-benzyl(2-oxaadamantan-1-yl)amine hydrochloride, 126·HCl500  
 
In a three-necked round bottom flask equipped with a magnetic stirrer and gas inlet, 
benzylamine (4.36 mL, 40.3 mmol) was added to a solution of diketone 125 (6 g, 39.4 
mmol) in anh. THF (120 mL). The reaction mixture was heated at reflux for 0.5 hours. 
Afterwards the solution was cooled in an ice bath. In a separate flask, lithium aluminium 
hydride (3.16 g, 78.9 mmol) was added in small portions to anh. Et2O (80 mL). Then the 
cooled solution prepared before was added dropwise under vigorous stirring. After the 
addition, the suspension was heated to 40 ºC for 6 hours. The reaction mixture was 
tempered to room temperature and filtered through a Celite™ pad and the filtrate was 
evaporated under vacuo. The residue was partitioned between DCM (50 mL) and water (50 
mL) and the phases were separated. The aqueous layer was extracted with further DCM (3 
x 50 mL). The combined organic phases were washed with brine (100 mL), dried over anh. 
Na2SO4, filtered and concentrated under vacuo. To a solution of the residue in acetone 
(120 mL) was added an excess of conc. HCl. The formed precipitated was filtered under 
vacuo to give 126·HCl (6.25 g, 57% yield) as a white solid. The spectroscopic data was 
identical to those previously described. 
 
Preparation of (2-oxaadamantan-1-yl)amine hydrochloride, 120·HCl501  
 
 A suspension of benzilamine 126 (720 mg, 2.58 mmol) and 5% wt. palladium on 
carbon (55 mg) in abs. ethanol (80 mL) was hydrogenated at room temperature and 
atmospheric pressure until no further hydrogen consumption was observed. The 
suspension was then filtered and the solid washed with methanol (30 mL). An excess of 
Et2O·HCl was added and the solvent was evaporated under vacuo to give the amine 
120·HCl (466 mg, 96% yield) as a white solid. The spectroscopic data matched with those 
previously described.  
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Preparation of N-benzyl(4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodec-3-yl)amine, 129502 
 
In a three-necked round bottom flask equipped with a magnetic stirrer and gas inlet, 
Cookson’s diketone (5 g, 28.7 mmol) was dissolved in anh. THF (50 mL) and the solution 
was cooled to 5 ºC with an ice bath while stirring for 30 minutes under nitrogen. The 
resulting white solid (hydroxylamine) was filtered under vacuo and washed with cold THF 
(20 mL). The solid (11.25 g) was suspended in toluene (125 mL) and dehydrated under 
Dean-Stark conditions for one hour. The reaction mixture was tempered to room 
temperature and concentrated under vacuo to give the imine (6.95 g) as a yellow oil. Anh. 
THF (150 mL), anh. methanol (30 mL) and sodium borohydride (1.63 g, 43.1 mmol) were 
added and the suspension was stirred at room temperature for 24 hours. The reaction 
mixture was then evaporated under vacuo and the residue was partitioned between water 
(100 mL) and DCM (100 mL). The phases were separated and the aqueous layer was 
extracted with further DCM (3 x 50mL). The combined organic phases were dried over 
anh. Na2SO4, filtered and concentrated under vacuo to give a yellow solid (6.93 g). Column 
chromatography (SiO2, Hexanes/Ethyl acetate mixtures) gave 129 (2.67 g, 35% yield) as a 
white solid, whose spectroscopic data matched with those previously published. 
 
Preparation of 4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodec-3-yl)amine hydrochloride, 
121·HCl502 
 
 A suspension of benzilamine 129 (2.67 mg, 10.0 mmol) and 10 wt. % palladium on 
carbon (1.33 g) in methanol (100 mL) was hydrogenated at room temperature and 
atmospheric pressure until no further hydrogen consumption was observed. The 
suspension was then filtered and the solid washed with methanol (40 mL). An excess of 
Et2O·HCl was added and the solvent was evaporated under vacuo to give the amine 
121·HCl (1.79 g, 85% yield) as a white solid. The spectroscopic data matched with those 
previously described.  
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Preparation of tetramethyl (1α,4α,5α,8α)-3,7-hydroxy-bicyclo[3.3.0]octa-2,6-diene-
2,4,6,8-tetracarboxylate, 135504 
 
a) Formation of the disodium enolate salt of tetramethyl (1α,4α,5α,8α)-3,7-hydroxy-
bicyclo[3.3.0]octa-2,6-diene-2,4,6,8-tetracarboxylate, 134: 
 In 2 L round-bottom flask equipped with a pressure-equalizing dropping funnel, 
condenser apparatus, high temperature thermometer and stir bar a solution of sodium 
hydroxide (64 g, 1.64 mol) in methanol (1.15 L) was cooled to 10 ºC with an ice bath. Then 
dimethyl 1,3-acetondicarboxylate (273 g, 1.57 mol) was added dropwise over 1 hour. The 
mixture was heated at reflux, whereupon 40 wt. % glyoxal solution in water (128 g, 0.89 
mol) was added over 15-20 minutes, keeping the inner temperature at 65 ºC. Once added, 
the reaction mixture was stirred at room temperature overnight. The resulting solid was 
filtered under vacuo, washed with cold methanol and dried under reduced pressure to give 
134 as a disodium salt (339 g).  
b) Synthesis of tetramethyl (1α,4α,5α,8α)-3,7-hydroxy-bicyclo[3.3.0]octa-2,6-diene-
2,4,6,8-tetracarboxylate, 135: 
 In a 5 L Erlenmeyer flasks equipped with a large magnetic stirrer the disodium salt 134 
(339 g, 0.82 mol) was partitioned between water (1.9 L) and DCM (1.2 L). The two-phase 
mixture was vigorously stirred as 5 N HCl (400 mL) was added. The layers were separated 
and the aqueous phase was extracted with further DCM (2 x 500 mL). The combined 
organic layers were washed with brine (2 x 250 mL), dried over anh. Na2SO4, filtered and 
evaporated under vacuo, keeping the water bath temperature below 40 ºC. The resulting 
waxy oil was crystallized from 2:1 hexane/EtOAc affording 135 (179 g, 55% overall yield) 
as a white solid, which was used in next step without further characterization.  
 
Preparation of cis-bicyclo[3.3.0]octane-3,7-dione, 133504  
 
 A 2 L round-bottom flask equipped with three condenser apparatus and pumice stone 
as a stirrer was charged with the tetraester 135 (179 g, 0.48 mol), glacial acetic acid (90 mL) 
and 1 M HCl solution (800 mL). The reaction mixture was heated at reflux for 2.5 hours, 
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with vigorous foaming formation. Afterwards, the mixture was tempered to room 
temperature, the pumice stone decanted and the solution extracted with DCM (4 x 400 
mL). The combined organic phases were evaporated under vacuo, keeping the water bath 
temperature below 40 ºC, until most of the acetic acid was removed. The residue was 
dissolved in further DCM (400 mL) and the solution washed with saturated aqueous 
NaHCO3 solution (3 x 300 mL). The organic layer was dried over anh. Na2SO4, filtered and 
concentrated cautiously to give de diketone 133 (48 g, 71% yield) as a white solid, whose 
spectroscopic data were in accord to those described in the bibliography. 
 
Preparation of the stereoisomeric mixture of cis-3,7-dihydroxybicyclo[3.3.0]octa-3,7-
dicarbonitrile, 136505 
 
 In a 2 L round-bottom flask equipped with a pressure-equalizing dropping funnel, low 
temperature thermometer, magnetic stirrer and 10 N NaOH solution trap, a solution of 
diketone 133 (42 g, 0.3 mol) in water (315 mL) was prepared. To that, sodium cyanide (91 
g, 1.86 mol) was added and the solution was cooled to 10-15 ºC with an ice/NaCl bath. 
Then 40% H2SO4 (380 mL, 7.06 mol) was added dropwise while keeping the inner 
temperature < 15 ºC, with the formation of a thick slurry. After the addition, the ice/NaCl 
bath was removed and the reaction mixture was stirred at room temperature for 3 hours. 
Diethyl ether (300 mL) was added and the phases were separated. The aqueous layer was 
extracted with further Et2O (5 x 300 mL) and the combined organic layers were washed 
with water (2 x 150 mL), dried over Na2SO4 and filtered. Evaporation under vacuo gave the 
stereoisomeric mixture 136 (31 g, 53% yield) as a brown oil. The spectroscopic data 
matched with those previously described.   
 
Preparation of the mixture of cis-bicyclo[3.3.0]octa-2,7-diene-3,7-dicarbonitrile, 137, and 
cis-bicyclo[3.3.0]octa-2,6-diene-3,7-dicarbonitrile, 138505  
 
 In a round-bottom flask equipped with a pressure-equalizing dropping funnel, 
condenser apparatus and stir bar, thionyl chloride (40 mL) was added dropwise over 3 
hours to a solution of bis-cyanohydrines 136 (31 g, 0.16 mol) in pyridine (200 mL). The 
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black solution was heated at reflux for 5 hours. The mixture was tempered overnight and 
2 N HCl solution (200 mL) was carefully poured into reaching acid pH. The black 
precipitated was filtered under vacuo and washed diluted HCl solution and water (300 mL 
approx.). The solid was extracted with hot DCM (7 x 100 mL) and the combined organic 
extracts were washed with water (2 x 150 mL), dried over anh. Na2SO4, filtered and 
concentrated under vacuo to give a solid (7.9 g). In order to recover further product, the 
filtrate was concentrated until a third of its volume and DCM (300 mL) was added. The 
immiscible mixture was filtered through a Celite™ pad and the phases were separated. The 
aqueous phase was extracted with further DCM (200 mL) and the combined organic layers 
were dried over anh. Na2SO4, filtered and evaporated under vacuo to give an oil (12 g). 
Crystallization of the obtained product from EtOAc/hexane afforded the mixture of 
unsaturated dinitriles 137 and 138 (11.2 g, 44% yield) as a yellow solid. The spectroscopic 
data were identical to those described in the bibliography. 
 
Preparation of the stereoisomeric mixture of cis-bicyclo[3.3.0]octane-3,7-dicarbonitrile, 
139505 
 
 A suspension of the unsaturated dinitriles 137 and 139 (11.14 g, 70 mmol) and 10% 
wt. palladium on carbon (2.15 g) in methanol (200 mL) was stirred under hydrogen 
atmosphere (27 atm) at room temperature until no further hydrogen consumption was 
observed. The suspension was then filtered and the solid washed with methanol (50 mL). 
The solvent was evaporated under vacuo and crystallization of the residue from EtOAc gave 
the stereoisomeric mixture of saturated nitriles 139 (9.9 g, 87% yield) as a yellow solid in a 
ratio of 2:1.3:1; (1α,3α,5α,7α), (1α,3β,5α,7β) and (1α,3α,5α,7β) respectively. The 
spectroscopic data matched with those previously described.  
 
Preparation of the stereoisomeric mixture of dimethyl cis-bicyclo[3.3.0]octane-3,7-
dicarboxylate, 141506 
a) Synthesis of the stereoisomeric mixture of cis-bicyclo[3.3.0]octane-3,7-dicarboxylic 
acid, 140: 
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 A solution of the saturated dinitriles 139 (7.1 g, 44.2 mmol) in 40% (p/v) KOH in 
methanol (53 mL) was heated at reflux for 3 hours. Water (155 mL) was added and the 
reaction mixture was heated at reflux for further 3 hours. The solution was cooled with an 
ice bath and conc. HCl was added until acid pH. The resulting solution was concentrated 
under vacuo and the residue extracted with hot Et2O (5 x 100 mL). The combined organic 
extracts were dried over anh. Na2SO4, filtered and evaporated under vacuo to give the diacid 
mixture 140 (6.3 g, 72% yield) as a yellow solid which was used without any further 
purification or characterization. 
b) Synthesis of the stereoisomeric mixture of dimethyl cis-bicyclo[3.3.0]octane-3,7-
dicarboxylate, 141: 
 
 To a solution of diacid mixture 140 (6.45 g, 32.6 mmol) in anh. methanol (130 mL) 
was added conc. H2SO4 (13 mL) and the reaction mixture was heated at reflux overnight. 
Then the resulting solution was tempered to room temperature and anh. K2CO3 was added 
until reaching basic pH (~12). The solid was filtrated and the filtrate was concentrated 
under vacuo. The residue was dissolved in DCM (100 mL) and dried over anh. Na2SO4 and 
filtered. Evaporation under vacuo afforded the diester mixture 141 (6.3 g, 86% yield) as a 
brown oil, whose spectroscopic data belong to those previously described. Any further 
purification or characterization was carried out.  
 
 Preparation of dimethyl tricyclo[3.3.0.03,7]octane-1,5-dicarboxylate, 131505 
 
 In a three-necked round bottom flask equipped with a pressure-equalizing dropping 
funnel, low temperature thermometer and gas inlet, a solution of anh. diisopropylamine 
(10.8 mL, 77.0 mmol) in anh. THF (110 mL) was cooled to -78 ºC by means of a dry ice in 
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acetone bath. 2.5 M n-butyllithium in hexanes (25.6 mL, 64.2 mmol) was added dropwise 
and the resulting clear solution was stirred at ~0 ºC with an ice bath for 1 hour. Afterwards 
the reaction mixture was cooled down to -10 ºC and a solution of the diester mixture 141 
(6.3 g, 27.9 mmol) in anh. THF (82 mL) was added dropwise. The resulting beige 
suspension was stirred at -10 ºC for 1 hour and at -78 ºC for a further hour. Next, a solution 
of iodine (7.1 g, 27.9 mmol) in anh. THF (185 mL) was added dropwise over 2 hours. After 
the addition, the resulting deep-red solution was stirred at 0 ºC for 1 hour and then at 
room temperature overnight. The reaction mixture was acidified with 5 N HCl solution 
until acid pH (~25 mL) and the phases were separated. The aqueous layer was extracted 
with Et20 (5 x 50 mL) and the combined organic phases were washed with 10% NaS2O3 
solution (3 x 50 mL) and brine (2 x 50 mL), dried over anh. Na2SO4 and filtered. 
Concentration under vacuo gave a brown oil (6.6 g). The crude was purified by column 
chromatography (SiO2, Hexane/EtOAc mixture) and evaporation in vacuo of the 
appropriate fractions provided the desired tricyclic diester 131 (2.23 g, 36% yield) as yellow 
solid. The spectroscopic data were identical to those described in the bibliography.  
 
Preparation of tricyclo[3.3.0.03,7]octane-1,5-dicarboxylic acid, 141515 
 
 A suspension of diester 131 (2.23 g, 9.9 mmol) in 40% (p/v) KOH in methanol (15 
mL) was heated at reflux for 3 hours. Then water (15 mL) was added and the resulting 
brown solution was heated at reflux for further 3 hours. Cooling to ~0 ºC with an ice bath 
was followed by the addition of conc. HCl until acid pH, and the resulting suspension was 
concentrated under vacuo. The residue was extracted with hot Et2O (7 x 30 mL) and the 
combined organic extracts were dried over anh. Na2SO4, filtered and concentrated under 
vacuo to give 142 (1.90 g, 97% yield) as a brown solid, whose spectroscopic data matched 
with those described in the bibliography.  
 
Preparation of 3-oxatetracyclo[5.2.1.15,8.01,5]undeca-2,4-dione, 144172 
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 Diacid 142 (1.9 g, 9.7 mmol) was placed in a round bottom flask equipped with a 
condenser apparatus and a stir bar. Acetic anhydride (55 mL) was added and the solution 
was heated at reflux for 90 minutes. The reaction was tempered to room temperature prior 
the evaporation under vacuo to give a brown solid. Purification by sublimation at 105 ºC 
and 0.5 Torr provided the desired anhydride 144 (1.24 g, 72% yield) as a yellow solid. Its 
spectroscopic data were identical to those described.  
 
 Preparation of 5-(methoxycarbonyl)tricyclo[3.3.0.03,7]octane-1-carboxylic acid, 146172 
 
In a round bottom flask equipped with a condenser apparatus, CaCl2 tube and 
magnetic stirrer was prepared a solution of anhydride 144 (1.24 g, 7.0 mmol) in anh. 
methanol (100 mL). To that, sodium methoxide (1.88 g, 34.8 mmol) was added and the 
suspension was heated at reflux overnight. Thereupon the resulting solution was tempered 
to room temperature and the solvents were removed under vacuo. The residue was 
partitioned between water (25 mL) and EtOAc (25 mL) and the layers were separated. The 
aqueous phase was adjusted with conc. HCl to pH ~1 and extracted with EtOAc (3 x 30 
mL). The combined organic layers were dried over anh. Na2SO4, filtered and concentrated 
under reduced pressure to give an orange oil (1.36 g) as a mixture of the desired hemiester 
146 and the diacid 142. Purification by column chromatography (SiO2, hexane/EtOAc 
mixture) gave in order of elution the hemiester 146 (747 mg, 51% yield) and the diacid 
142 (601 mg, 44% yield). The spectroscopic data were identical to those previously 
published.  
 
Preparation of tricyclo[3.3.0.03,7]octane-1-carboxylic acid, 155172 
a) Synthesis of the methyl tricyclo[3.3.0.03,7]octane-1-carboxylate, 148: 
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In a three-necked round bottom flask equipped with a magnetic stirrer and gas inlet, 
2,2’-dithiobis(pyridine-N-oxide) (198 mg, 0.78 mmol) was added to a solution of hemiester 
148 (129 mg, 0.61 mmol) in anhydrous and deoxygenated CHCl3 (5 mL). The resulting 
solution was wrapped in aluminium foil and cooled to 0 ºC by means of an ice/NaCl bath. 
Then tributylphosphine (0.22 mL, 0.86 mmol) was added and the yellow solution stirred 
at room temperature for 2 hours. Next the aluminium foil removed and the reaction 
mixture stirred at room temperature under irradiation of a 100 W lamp for 3 hours. 
Afterwards the reaction mixture was washed with saturated aqueous NaHCO3 solution (3 
x 10 mL), 6 N HCl solution (3 x 10 mL), water (2 x 10 mL) and brine (2 x 10 mL). The 
organic layer was dried over anh. Na2SO4 and filtered. The solvents were distilled off to give 
the monoester 148 along with reaction by-products (aprox. 420 mg). The product was used 
in next step without any further purification or characterization due to its high volatility. 
b) Synthesis of the tricyclo[3.3.0.03,7]octane-1-carboxylic acid, 155: 
 
A suspension of monoester 148 (aprox. 420 mg, 2.56 mmol) in 10% (p/v) KOH in 
methanol (3.2 mL) was heated at reflux for 3 hours. Water (3.2 mL) was added and the 
reaction mixture was heated at reflux for further 3 hours. The solution was tempered to 
room temperature and then concentrated under vacuo. The residue was partitioned 
between water (10 mL) and EtOAc (10 mL). The phases were separated and the aqueous 
layer was washed with further EtOAc (10 mL) followed by acidification with 2 N HCl 
solution until acid pH and extraction with EtOAc (3 x 10 mL). The combined organic 
layers were dried over anh. Na2SO4, filtered and evaporated under vacuo to give a grey solid 
(93 mg). Purification by column chromatography (SiO2, Hexane/EtOAc mixture) afforded 
the desired monoacid 155 (68 mg, 73% yield) as a white solid, whose spectroscopic data 
were in accord to those previously described. 
 
Preparation of (tricyclo[3.3.0.03,7]octa-1-yl)amine hydrochloride, 122·HCl172 
 
 In a round bottom flask equipped with a condenser apparatus and magnetic stirrer a 
solution of acid 155 (71 mg, 0.47 mmol) in toluene (1.4 mL) was prepared, to which was 
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added diphenylphosphoryl azide (0.150 mL, 0.69 mmol) followed by triethylamine (0.09 
mL, 1.34 mmol). The solution was heated at reflux for 3 hours, whereupon the reaction 
mixture was tempered to room temperature and washed with cold 6 N HCl solution (8 x 5 
mL). Further 6 N HCl solution (2.3 mL) was added and the biphasic system heated at reflux 
for 24 hours. Then the reaction mixture was tempered to room temperature and the phases 
were separated. The aqueous layer was washed with Et2O (3 x 5 mL), the pH was adjusted 
to ~12 with 10 N NaOH solution and extracted with Et2O (4 x 5 mL). The combined 
organic phases were dried over anh. Na2SO4 and filtered. To the combined extracts an 
excess of Et2O·HCl was added and the solvent was removed under vacuo keeping the bath 
temperature below 40 ºC, to give the amine 122·HCl (23 mg, 31% yield). The spectroscopic 
data matched with those described in the literature.  
 
Preparation of 3,7-dimethyltricyclo[3.3.0.03,7]octane-1,5-dicarboxylic acid, 143600  
  
 A suspension of diester 132 (2 g, 7.9 mmol) in 40% (p/v) KOH in methanol (15 mL) 
was heated at reflux for 3 hours. Then water (15 mL) was added and the resulting brown 
solution was heated at reflux for further 3 hours. Cooling to ~0 ºC with an ice bath was 
followed by the addition of conc. HCl until acid pH, and the resulting suspension was 
concentrated under vacuo. The residue was extracted with hot Et2O (5 x 30 mL) and the 
combined organic extracts were dried over anh. Na2SO4, filtered and concentrated under 
vacuo to give 143 (1.77 g, quantitative yield) as a yellow solid, whose spectroscopic data 
matched with those described in the bibliography.  
 
Preparation of 7,8-dimethyl-3-oxatetracyclo[5.2.1.15,8.01,5]undeca-2,4-dione, 145524 
 
 Diacid 143 (2.6 g, 11.4 mmol) was placed in a round bottom flask equipped with a 
condenser apparatus and a stir bar. Acetic anhydride (70 mL) was added and the solution 
                                                          
600 Camps, P.; Font-Bardia, M.; Pérez, F.; Solans, X.; Vázquez, S. Angew. Chem. Int. Ed. Engl. 1995, 34, 
912-914. 
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was heated at reflux for 90 minutes. The reaction was tempered to room temperature prior 
the evaporation under vacuo to give the desired anhydride 145 (2.29 g, 97% yield) as a 
yellow solid, which was used in next step without any further purification or 
characterization. Its spectroscopic data were identical to those described.  
 
Preparation of 3,7-dimethyl-5-(methoxycarbonyl)tricyclo[3.3.0.03,7]octane-1-carboxylic 
acid, 147164  
 
In a round bottom flask equipped with a condenser apparatus, CaCl2 tube and 
magnetic stirrer was prepared a solution of anhydride 145 (2.29 g, 11.1 mmol) in anh. 
methanol (160 mL). To that, sodium methoxide (3.00 g, 55.6 mmol) was added and the 
solution was heated at reflux for 20 hours. Thereupon the resulting suspension was 
tempered to room temperature and the solvents were removed under vacuo. The residue 
was partitioned between water (100 mL) and EtOAc (50 mL) and the layers were separated. 
The aqueous phase was adjusted with conc. HCl to pH ~1 and extracted with EtOAc (3 x 
50 mL). The combined organic layers were dried over anh. Na2SO4, filtered and 
concentrated under reduced pressure to give an orange oil (2.52 g) as a mixture of the 
desired hemiester 147 and the diacid 143. Purification by column chromatography (SiO2, 
Hexane/EtOAc mixture) gave in order of elution a mixture of 147 and 143 in a 1:1 ratio 
(920 mg, 37% yield), the hemiester 147 (293 mg, 11% yield) and the diacid 143 (1.22 g, 
48% yield). The spectroscopic data were identical to those previously published.  
 
Preparation of methyl 3,7-dimethyltricyclo[3.3.0.03,7]octane-1-carboxylate, 149164 
 
In a three-necked round bottom flask equipped with a magnetic stirrer and gas inlet, 
2,2’-dithiobis(pyridine-N-oxide) (271 mg, 1.08 mmol) was added to a solution of hemiester 
147 (200 mg, 0.84 mmol) in anhydrous and deoxygenated CHCl3 (10 mL). The resulting 
solution was wrapped in aluminium foil and cooled to 0 ºC by means of an ice/NaCl bath. 
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Then tributylphosphine (0.29 mL, 1.18 mmol) was added and the yellow solution stirred 
at room temperature for 2 hours. Next the aluminium foil removed and the reaction 
mixture stirred at room temperature under irradiation of a 60 W lamp for 2 hours. 
Afterwards the reaction mixture was washed with saturated aqueous NaHCO3 solution (3 
x 10 mL), 6 N HCl solution (3 x 10 mL), water (2 x 10 mL) and brine (2 x 10 mL). The 
organic layer was dried over anh. Na2SO4, filtered and concentrated under vacuo to give a 
yellow oil. The crude was purified by column chromatography (SiO2, Hexane/EtOAc 
mixture), evaporation under vacuo of the appropriate fractions provided the monoester 149 
(138 mg, 86% yield). The spectroscopic data were in accord to those described in the 
bibliography. 
 
Preparation of 3,7-dimethyltricyclo[3.3.0.03,7]octane-1-carboxylic acid, 156164 
 
A solution of monoester 149 (454 mg, 2.34 mmol) in 10% (p/v) KOH in methanol (5 
mL) was heated at reflux for 3 hours. Water (5 mL) was added and the reaction mixture 
was heated at reflux for further 3 hours. The solution was tempered to room temperature 
and then concentrated under vacuo. The residue was partitioned between water (15 mL) 
and EtOAc (15 mL). The phases were separated and the aqueous layer was washed with 
further EtOAc (2 x 15 mL) followed by acidification with 5 N HCl solution until acid pH 
and extraction with EtOAc (4 x 15 mL). The combined organic layers were washed with 
brine (3 x 15 mL), dried over anh. Na2SO4, filtered and evaporated under vacuo to afforded 
the desired monoacid 156 (256 mg, 61% yield) as a yellow solid, whose spectroscopic data 
were in accord to those previously described. 
 
Preparation of 3,7-dimethyl(tricyclo[3.3.0.03,7]octa-1-yl)amine hydrochloride, 123·HCl95 
 
 In a round bottom flask equipped with a condenser apparatus and magnetic stirrer a 
solution of acid 36 (221 mg, 1.23 mmol) in toluene (3.7 mL) was prepared, to which was 
added diphenylphosphoryl azide (0.390 mL, 1.80 mmol) followed by triethylamine (0.230 
mL, 1.64 mmol). The solution was heated at reflux for 3 hours, whereupon the reaction 
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mixture was tempered to room temperature and washed with cold 6 N HCl solution (10 x 
5 mL). Further 6 N HCl solution (6 mL) was added and the biphasic system heated at reflux 
for 24 hours. Then the reaction mixture was tempered to room temperature and the phases 
were separated. The aqueous layer was washed with Et2O (3 x 5 mL), the pH was adjusted 
to ~12 with 10 N NaOH solution and extracted with Et2O (2 x 10 mL) and EtOAc (2 x 10 
mL). The combined organic phases were dried over anh. Na2SO4 and filtered. To the 
combined extracts an excess of Et2O·HCl was added and the solvent was removed under 
vacuo to give the amine 123·HCl (230 mg, quantitative yield). The spectroscopic data 
matched with those described in the literature.  
 
Preparation of 1-adamantanecarbonyl azide, 164601
a) Formation of 1-adamantanecarbonyl chloride, 163: 
 
 In a round-bottom flasks equipped with a stir bar, condenser apparatus and CaCl2 
tube, a solution of 1-adamantanecarboxylic acid (100 mg, 0.55 mmol) in thionyl chloride 
(2 mL) was heated at reflux for 1.5 hours. The reaction mixture was then tempered to room 
temperature and concentrated in vacuo. The residue was dissolved in toluene (5 mL) and 
the solvent removed under reduced pressure. The procedure was repeated twice to obtain 
163 (108 mg, 98% yield) as a yellow solid. The product was used in next step without any 
further purification or characterization. 
IR (ATR) ν: 1786 (CO band) cm-1. 
b) Preparation of 1-adamantanecarbonyl azide, 164: 
 
 A solution of acyl chloride 163 (108 mg, 0.55 mmol) in acetone (3.6 mL) was added 
dropwise to a solution of sodium azide (131 mg, 2.02 mmol) in water (1.9 mL) prior cooling 
at 0 ºC with an ice/NaCl bath. The resulting suspension was stirred at room temperature 
for 4 hours. Water (5 mL) and Et2O (5 mL) were added, the phases separated and the 
aqueous layer was extracted with further Et2O (2 x 5 mL). The combined organic layers 
were washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL), 
                                                          
601 Oliver, J. E.; Stokes, J. B. J. Med Chem. 1970, 13, 779-780. 
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dried over anh. Na2SO4, filtered and evaporated under vacuo to give the desired acyl azide 
164 (102 mg, 91% yield) as a yellow solid. The product was used in next step without 
further purification. 
IR (ATR) ν: 1702 (CO band), 2136 and 2905 (azide band) cm-1. 
 
Preparation of 1-(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea, 166525 
a) Formation of 1-isocyanatoadamantane, 165: 
 
 In a round-bottom flasks equipped with a stir bar and condenser apparatus anh. 
toluene (17 mL) was heated at reflux under nitrogen. Then a solution of 1-
adamantanecarbonyl azide 164 (102 mg, 0.50 mmol) in anh. toluene (3.5 mL) was added 
dropwise and the reaction heated at reflux overnight. The reaction completion was 
monitored by IR. 
IR (NaCl) ν: 2248 (isocyanate band) cm-1. 
b) Preparation of 1-(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea, 166: 
 
 2,3,4-trifluoroaniline (74 mg, 0.51 mmol) was added to anh. THF (10 mL) and cooled 
to -78 ºC by means of a dry ice in acetone bath. To that 2.5 M n-butyllithium in hexanes 
(0.21 mL, 0.51 mmol) was added dropwise. The reaction mixture was removed from the 
dry ice in acetone bath and tempered to 0 ºC with an ice bath. Afterwards the solution of 
the isocyanate in anh. toluene from the previous step already tempered to room 
temperature was added gradually and  the mixture stirred at room temperature overnight. 
Methanol (2 mL) was then added to quench any unreacted butyllithium. The solvents were 
evaporated under vacuo to give an impure mixture of the urea 166 plus reaction by-products 
(334 mg). Any further purification or characterization was fulfilled. 
IR (ATR) ν: 1509 (CO band) cm-1. 
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Preparation of pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8,9-dicarboxylic anhydride, 
160602 
 
Pentacyclic diacid 88 (14.5 g, 59.4 mmol) was placed in a round-bottom flask equipped 
with a magnetic stirrer and condenser apparatus and acetic anhydride (370 mL, 5.47 mol) 
was added. The suspension was heated at reflux for 1 hour. After that, the resulting solution 
was tempered to room temperature and then concentrated under vacuo. The crude was 
purified by sublimation at 100 ºC and 0.7 Torr giving pure anhydride 160 (11.82 g, 88% 
yield) as a white solid. The spectroscopic data matched with those described in the 
bibliography. 
 
Preparation of 9-methoxycarbonilpentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8-
carboxylic acid, 161164 
 
In a round-bottom flask equipped with a magnetic stirrer, condenser apparatus and 
CaCl2 tube was prepared a solution of pentacyclic anhydride 160 (1.98 g, 8.76 mmol) in 
anh. MeOH (130 mL). Sodium methoxide (2.36 g, 43.8 mmol) was added and the reaction 
mixture was heated at reflux for 14 hours. Thereupon the resulting solution was tempered 
to room temperature and the solvents were removed under vacuo. The residue was 
partitioned between water (100 mL) and EtOAc (50 mL) and the layers were separated. The 
aqueous phase was adjusted with conc. HCl to pH ~1 and extracted with EtOAc (3 x 100 
mL). The combined organic layers were dried over anh. Na2SO4, filtered and concentrated 
under reduced pressure to give a white solid (2.17 g) as a mixture of the desired hemiester 
161 and the diacid 88. Purification by column chromatography (SiO2, Hexane/EtOAc 
mixture) gave in order of elution the hemiester 161 (1.37 g, 60% yield), a mixture of 161 
and 88 in a 1:1 ratio (450 mg, 21% yield), and the diacid 88 (310 mg, 14% yield). The 
spectroscopic data were identical to those previously published.  
 
                                                          
602 Camps, P.; Pujol, X.; Rossi, R. A.; Vázquez, S. Synthesis 1999, 5, 854-858. 
 
322   Materials & Methods 
 
Preparation of methyl pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8-carboxylate, 
162164 
 
In a three-necked round bottom flask equipped with a magnetic stirrer and gas inlet, 
2,2’-dithiobis(pyridine-N-oxide) (1.49 g, 5.93 mmol) was added to a solution of hemiester 
161 (1.19 g, 4.63 mmol) in anhydrous and deoxygenated CHCl3 (43 mL). The resulting 
solution was wrapped in aluminium foil and cooled to 0 ºC by means of an ice/NaCl bath. 
Then tributylphosphine (1.61 mL, 6.48 mmol) was added and the yellow solution stirred 
at room temperature for 2 hours. Next the aluminium foil removed and the reaction 
mixture stirred at room temperature under irradiation of a 60 W lamp for 2 hours. 
Afterwards the reaction mixture was washed with saturated aqueous NaHCO3 solution (3 
x 20 mL), 6 N HCl solution (3 x 20 mL), water (2 x 20 mL) and brine (2 x 20 mL). The 
organic layer was dried over anh. Na2SO4, filtered and concentrated under vacuo to give a 
yellow oil (1.50 g). The crude was purified by column chromatography (SiO2, 
Hexane/EtOAc mixture), evaporation under vacuo of the appropriate fractions provided 
the monoester 162 (858 mg, 59% yield). The spectroscopic data matched with those 
described in the bibliography. 
 
Preparation of pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8-carboxylic acid, 159164 
 
 A solution of sodium hydroxide (1.05 g) in water (4 mL) was added to a solution of 
pentacyclic monoester 162 (858 mg, 4.00 mmol) in methanol (75 mL). The reaction 
mixture was heated at reflux for 1 hour. The solution was tempered to room temperature 
and the methanol evaporated under vacuo. Water (15 mL) was added and the solution was 
heated for further 5 hours. Thereafter, the reaction mixture was tempered to room 
temperature, activated charcoal (200 mg) was added and the black suspension was stirred 
at room temperature overnight. The suspension was filtered through Celite™ pad and the 
filtrate washed with EtOAc (3 x 30 mL). The aqueus layer was cooled to ~0 ºC with an ice 
bath and conc. HCl was added until pH ~1. The resulting white precipitated was filtered 
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under vacuo and washed with water (10 mL). The solid was left in the vacuum dryer until 
constant weight (103 mg). In order to recover further product, the aqueous phase was 
extracted with EtOAc (3 x 30 mL) and the combined organics were dried over anh. Na2SO4, 
filtered and concentrated under vacuo to give a total amount of 254 mg (31% yield) of 
monoacid 159. The spectroscopic data were identical to those previously published.  
 
Preparation of pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8-carbonyl azide, 169 
a) Formation of pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8-carbonyl chloride, 
168: 
 
 In a round-bottom flasks equipped with a stir bar, condenser apparatus and CaCl2 
tube, a solution of pentacyclic carboxylic acid 159 (100 mg, 0.50 mmol) in thionyl chloride 
(2 mL) was heated at reflux for 1 hour. The reaction mixture was then tempered to room 
temperature and concentrated in vacuo. The residue was dissolved in toluene (5 mL) and 
the solvent removed under reduced pressure. The procedure was repeated twice to obtain 
168 (108 mg, quantitative yield) as a beige solid. The product was used in next step without 
any further purification or characterization. 
IR (ATR) ν: 1778 (CO band) cm-1. 
b) Preparation of pentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene-8-carbonyl azide, 169: 
 
 A solution of acyl chloride 168 (108 mg, 0.50 mmol) in acetone (3.4 mL) was added 
dropwise to a solution of sodium azide (127 mg, 1.95 mmol) in water (1.8 mL) prior cooling 
at 0 ºC with an ice/NaCl bath. The resulting suspension was stirred at room temperature 
for 4 hours. Water (5 mL) and Et2O (10 mL) were added, the phases separated and the 
aqueous layer was extracted with further Et2O (2 x 5 mL). The combined organic layers 
were washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL), 
dried over anh. Na2SO4, filtered and evaporated under vacuo to give the desired acyl azide 
169 (98 mg, 88% yield) as a beige solid. Any further purification or characterization was 
carried out. 
IR (ATR) ν: 1697 (CO band), 2129 and 2964 (azide band) cm-1. 
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Preparation of 1-(pentacyclo[6.4.0.02,10.03,7.04,9]dodeca-5,11-diene-8-yl)-3-(2,3,4-
trifluorophenyl)urea, 157 
a) Formation of 8-isocyanatopentacyclo[6.4.02,10.03,7.04,9]dodeca-5,11-diene, 158: 
 
 In a round-bottom flasks equipped with a stir bar and condenser apparatus anh. 
toluene (15 mL) was heated at reflux under nitrogen. Then a solution of pentacyclic azide 
169 (98 mg, 0.43 mmol) in anh. toluene (3 mL) was added dropwise and the reaction 
heated at reflux overnight. The reaction completion was monitored by IR. 
IR (NaCl) ν: 2258 (NCO band) cm-1. 
b) Preparation of 1-(pentacyclo[6.4.0.02,10.03,7.04,9]dodeca-5,11-diene-8-yl)-3-(2,3,4-
trifluorophenyl)urea, 157: 
 
 2,3,4-trifluoroaniline (64 mg, 0.43 mmol) was added to anh. THF (8 mL) and cooled 
to -78 ºC by means of a dry ice in acetone bath. To that 2.23 M n-butyllithium in hexanes 
(0.19 mL, 0.43 mmol) was added dropwise. The reaction mixture was removed from the 
dry ice in acetone bath and tempered to 0 ºC with an ice bath. Afterwards the solution of 
the isocyanate in anh. toluene from the previous step already tempered to room 
temperature was added gradually and  the mixture stirred at room temperature for 20 hour. 
The reaction completion was controlled by 1H-NMR, and once there was any further 
progression, methanol (2 mL) was then added to quench any unreacted butyllithium. The 
solvents were evaporated under vacuo to give a brown solid (173 mg, IR (ATR) ν: 1509 (CO 
band) cm-1). Purification by column chromatography (SiO2, Hexane/EtOAc mixture) gave 
the desired urea 157 (37 mg, 25% yield). The analytical sample was obtained by 
crystallization from methanol/diethyl ether. 
Analytical and spectroscopic data of compound 157: 
Melting point: 217 - 219 ºC. 
 
 
CHAPTER 3   325 
IR (ATR) ν: 3350, 2964, 2522, 2158, 1977, 1656, 1639, 1562, 1511, 1471, 1339, 1290, 1246, 
1186, 1167, 1101, 1074, 1032, 1012, 999, 975, 882, 805, 767, 741, 725, 689, 661, 620 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.57 (s, 1 H, 9-H), 2.60 [d, J = 2.4 Hz, 2 H, 2(3)], 2.94 [broad 
s, 2 H, 4(10)-H], 3.60 [broad s, 2 H, 1(7)-H], 4.85 (broad s, 1 H, 1-NH), 5.93 [ddd, J = 6 Hz, 
J’ = 3 Hz, J’’ = 0.8 Hz, 2 H, 6(12)-H], 6.08 [ddd, J = 6 Hz, J’ = 3 Hz, J’’ = 0.8 Hz, 2 H, 5(11)-
H], 6.38 (broad s, 1 H, 3-NH), 6.90 (m, 1 H, 5’-H), 7.78 (m, 1 H, 6’-H). 
13C-NMR (100.6 MHz, CDCl3) δ: 58.5 (CH, C9), 60.2 [CH, C2(3) and C4(10)], 61.3 [CH, 
C1(7)], 73.7 (C, C8), 111.5 (CH, dd, 2JC-F = 17.5 Hz, 3JC-F = 3.8 Hz, C5’), 115.0 (CH, broad t, 
3JC-F = 5.4 Hz, C6’), 124.7 (C, dd, 2JC-F = 8 Hz, 3JC-F = 3.3 Hz Ar-C1’), 131.6 [CH, C6(12)], 
133.9 [CH, C5(11)], 139.8 (C, dd, 1JC-F = 250 Hz, 2JC-F = 15 Hz, Ar-C3’), 142.0 (C, dd, 1JC-F = 
245 Hz, 2JC-F = 15.5 Hz, Ar-C4’), 146.4 (C, dd, 1JC-F = 245 Hz, 2JC-F = 10 Hz, Ar-C2’), 153.9 (C, 
CO).  
MS (DIP), m/z (%); significant ions: 344 (M·+, 68), 279 (66), 171 (31), 170 [(C12H12N)+, 70], 
169 (15), 168 (26), 156 (26), 155 (31), 154 (73), 153 (60), 152 (24), 143 (15), 132 (25), 130 
(25), 129 (16), 128 (36), 127 (16), 119 (23), 115 (26), 106 (100), 93 (25), 91 (19), 80 (15), 78 
(22), 77 (28), 65 (16).  
HRMS-ESI+ m/z [M+H]+ calcd for [C19H15F3N2O+H]+: 345.1209, found: 345.12105. 
 
General method for the synthesis of urea compounds 108-109 and 170-183 
 
 In a round-bottom flask equipped with a stir bar under nitrogen atmosphere 1.2 eq. 
of the appropriate amine hydrochloride was added to anh. DCM (~110 mM). To this 
suspension 1.0 eq. of 2,3,4-trifluorophenyl isocyanate followed by 7 eq. of triethylamine 
was added. The reaction mixture was stirred at room temperature overnight. Then the 
solvent was removed under vacuo and the resulting crude was purified as specified in each 
compound (vide infra). 
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Preparation of 1-(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea, 108497  
 
 The crude was purified by column chromatography (SiO2, hexane/EtOAc mixture). 
Evaporation in vacuo of the appropriate fractions gave the urea 108 (280 mg, quantitative 
yield). The analytical sample was obtained by crystallization from methanol. The 
spectroscopic data coincide with those described in the bibliography. 
 
Preparation of 1-(2-adamantyl)-3-(2,3,4-trifluorophenyl)urea, 109497 
 
 The crude was purified by column chromatography (SiO2, hexane/EtOAc mixture). 
Evaporation in vacuo of the appropriate fractions gave the urea 109 (270 mg, 94% yield). 
The analytical sample was obtained by crystallization from EtOAc/pentane. The 
spectroscopic data were identical to those previously published. 
Preparation of 1-(2-oxaadamant-1-yl)-3-(2,3,4-trifluorophenyl)urea, 170  
 
 Purification by column chromatography (SiO2, hexane/EtOAc mixture) of the crude 
and evaporation in vacuo of the appropriate fractions gave the urea 170 (163 mg, 94% yield) 
as a white solid. 
Analytical and spectroscopic data of compound 170: 
Melting point: 196 - 198 ºC. 
IR (ATR) ν: 3300-2800 (3293, 3232, 3127, 2933, 2857), 1702, 1640, 1621, 1563, 1509, 
1489, 1471, 1446, 1373, 1349, 1340, 1317, 1294, 1257, 1239, 1227, 1200, 1165, 1117, 1099, 
1080, 1020, 996, 976, 963, 932, 912, 884, 840, 805, 788, 757, 683, 653 cm-1. 
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1H-NMR (500 MHz, CD3OD) δ: 1.68 [dm, J = 12.5 Hz, 2 H, 4(10)-Ha], 1.89 [complex signal, 
4 H, 6-H2, 8(9)-Ha], 2.00 [dm, J = 12.5 Hz, 2 H, 4(10)-Hb], 2.26 [broad signal, 2 H, 5(7)-H], 
2.32 [d, J = 12.5 Hz, 8(9)-Hb], 4.23 (broad s, 1 H, 3-H), 7.03 (m, 1 H, 5’-H), 7.75 (m, 1 H, 
6’-H). 
 13C-NMR (125.7 MHz, CD3OD) δ: 29.6 [CH, C5(7)], 35.6 [CH2, C4(10)], 35.8 (CH2, C6), 
40.9 [CH2, C8(9)], 72.5 (CH, C3), 82.2 (C, C1), 112.3 (CH, dd, 2JC-F = 18 Hz, 3JC-F = 4 Hz, 
C5’), 116.8 (CH, C6’), 126.5 (C, d, 2JC-F = 8.8 Hz, Ar-C1’), 141.0 (C, dt, 1JC-F = 246 Hz, 2JC-F = 
15 Hz, Ar-C3’), 143.8 (C, dd, 1JC-F = 244 Hz, 2JC-F = 11 Hz, Ar-C4’), 147.6 (C, dd, 1JC-F = 244 
Hz, 2JC-F = 9 Hz, Ar-C2’), 156.0 (C, CO). 
MS (DIP), m/z (%); significant ions: 328 (6), 327 (5), 179 (11), 172 (18), 149 (97), 148 (100), 
146 (36), 121 (12), 120 (10), 118 (13), 111 (11), 95 (17), 94 (26), 93 (11), 79 (20), 68 (18).  
Elemental analysis: 
Calculated for C16H17F3N2O2:               C  58.89%   H  5.25%   F   17.47%    N  8.58% 
Found:                             C  59.00%   H  5.60%    F   17.22%   N  8.57% 
 
Preparation of 1-(3-methyl-2-oxaadamant-1-yl)-3-(2,3,4-trifluorophenyl)urea, 171  
 
 Column chromatography (SiO2, hexane/EtOAc mixture) of the crude and 
concentration in vacuo of the appropriate fractions gave the urea 171 (156 mg, 93% yield) 
as a white solid. The analytical sample was obtained by crystallization from 
methanol/diethyl ether. 
Analytical and spectroscopic data of compound 171: 
Melting point: 195 - 197 ºC. 
IR (ATR) ν: 3300-2800 (3270, 3227, 3128, 2976, 2927, 2856), 1701, 1641, 1622, 1564, 1509, 
1492, 1471, 1373, 1341, 1322, 1301, 1286, 1256, 1228, 1213, 1200, 1171, 1136, 1106, 1090, 
1072, 1034, 1006, 991, 972, 959, 921, 899, 885, 804, 788, 755, 682, 670, 652 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.19 (s, 3 H, 3C-CH3), 1.63 [dm, J = 12.5 Hz, 2 H, 4(10)-
Ha], 1.73 [dm, J = 12.5 Hz, 2 H, 4(10)-Hb], 1.75-1.82 (complex signal, 2 H, 6-H2), 1.83 [dm, 
J = 12.5 Hz, 2 H, 8(9)-Ha], 2.15 [dm, J = 12.5 Hz, 2 H, 8(9)-Hb], 2.29 [m, 2 H, 5(7)-H], 7.03 
(m, 1 H, 5’-H), 7.80 (m, 1 H, 6’-H).  
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13C-NMR (125.7 MHz, CD3OD) δ: 29.2 (CH3, C3-CH3), 30.1 [CH, C5(7)], 34.9 (CH2, C6), 
40.3 [CH2, C8(9)], 41.5 [CH2, C4(10)], 75.1 (C, C3), 83.3 (C, C1), 112.4 (CH, dd, 2JC-F = 
17.8 Hz, 3JC-F = 4 Hz, C5’), 116.3 (CH, C6’), 126.6 (C, C1’), 141.0 (C, dt, 1JC-F = 248 Hz, 2JC-F 
= 15 Hz, Ar-C3’), 143.5 (C, dd, 1JC-F = 245.2 Hz, 2JC-F = 9.5 Hz, Ar-C4’), 147.5 (C, dd, 1JC-F = 
242.6 Hz, 2JC-F = 8.9 Hz, Ar-C2’), 156.3 (C, CO). 
MS (DIP), m/z (%); significant ions: 342 (7), 172 (13), 150 (14), 149 (100), 148 (80), 147 
(25), 109 (10), 108 (14), 107 (11), 95 (10), 93 (25). 
Elemental analysis: 
Calculated for C17H19F3N2O2:                C  59.99%   H  5.63%    F  16.75%   N  8.23% 
Found:                              C  59.91%   H  5.90%    F  16.52%   N  8.22% 
 
Preparation of 1-(3-ethyl-2-oxaadamant-1-yl)-3-(2,3,4-trifluorophenyl)urea, 172  
 
 The crude was purified by column chromatography (SiO2, hexane/EtOAc mixture). 
Evaporation in vacuo of the appropriate fractions gave the urea 172 (116 mg, 96% yield) as 
a white solid.  
Analytical and spectroscopic data of compound 172: 
Melting point: 165 - 166 ºC. 
IR (ATR) ν: 3300-2800 (3288, 3238, 3128, 2970, 2927, 2850), 1702, 1641, 1622, 1563, 
1509, 1471, 1371, 1341, 1322, 1301, 1254, 1227, 1209, 1172, 1091, 1010, 996, 965, 939, 921, 
896, 803, 788, 755, 669, 653 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 0.92 (t, J = 7.5 Hz, 3 H, 3C-CH2CH3), 1.50 (broad q, J = 
7.5 Hz, 2 H, 3C-CH2CH3), 1.60 [broad d, J = 12 Hz, 2 H, 4(10)-Ha], 1.69 [broad d, J = 12 
Hz, 2 H, 4(10)-Hb], 1.80 (complex signal, 2 H, 6-H2), 1.86 [broad d, J = 13 Hz, 2 H, 8(9)-Ha], 
2.13 [broad d, J = 13 Hz, 2 H, 8(9)-Hb], 2.31 [broad s, 2 H, 5(7)-H], 7.02 (m, 1 H, 5’-H), 7.80 
(m, 1 H, 6’-H). 
13C-NMR (125.7 MHz, CD3OD) δ: 7.4 (CH3, 3C-CH2CH3), 30.0 [CH, C5(7)], 35.3 (CH2, 
C6), 35.7 (CH2, 3C-CH2CH3), 39.0 [CH2, C4(10)], 40.6 [CH2, C8(9)], 77.3 (C, C3), 83.2 
(C, C1), 112.4 (CH, dd, 2JC-F = 18 Hz, 3JC-F = 4 Hz, C5’), 116.6 (CH, C6’), 126.5 (C, 2JC-F = 8 
Hz, C1’), 141.0 (C, dt, 1JC-F = 248.5 Hz, 2JC-F = 15 Hz, Ar-C3’), 143.7 (C, dd, 1JC-F = 245.5 Hz, 
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2JC-F = 10.7 Hz, Ar-C4’), 147.6 (C, dd, 1JC-F = 243.5 Hz, 2JC-F = 8.9 Hz, Ar-C2’), 156.3 (C, CO). 
MS (DIP), m/z (%); significant ions: 354 (M·+, 5), 148 (14), 147 [(C6H4F3N)·+, 100], 94 (10), 
93 (10). 
Elemental analysis:  
Calculated for C18H21F3N2O2:                 C  61.01%   H  5.97%    F  16.08%   N  7.91% 
Found:                               C  60.97%   H  6.06%    F  16.23%   N  7.84% 
 
Preparation of 1-(3-cyclohexyl-2-oxaadamant-1-yl)-3-(2,3,4-trifluorophenyl)urea, 173 
 
 Purification by column chromatography (SiO2, hexane/EtOAc mixture) of the crude 
and evaporation in vacuo of the appropriate fractions gave the urea 173 (70 mg, 94% yield) 
as a white solid. The analytical sample was obtained by crystallization from 
methanol/diethyl ether. 
Analytical and spectroscopic data of compound 173: 
Melting point: 193 - 195 ºC. 
IR (ATR) ν: 3300-2800 (3309, 3227, 3107, 2925, 2855), 1681, 1622, 1537, 1513, 1470, 1326, 
1300, 1256, 1234, 1211, 1084, 1061, 1014, 994, 975, 892, 853, 825, 809, 763, 702, 678, 655 
cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 0.98-1.06 [dq, J = 12.5 Hz, J’ = 3.0 Hz, 2 H, 12(16)-Hax], 1.10-
1.16 (tq, J = 13.0 Hz, J’ = 3.5 Hz, 1 H, 14-Hax), 1.21-1.29 [tq, J = 13 Hz, J’ = 3.5 Hz, 2 H, 
13(15)-Hax], 1.40 (tt, J = 12 Hz, J’ = 3 Hz, 1 H, 11-H), 1.62-1.72 [complex signal, 8 H, 4(10)-
H2, 8(9)-Ha, 6-H2], 1.75-1.84 [complex signal, 5 H, 12(16)-Heq, 13(15)-Heq and 14-Heq], 2.09 
[d, J = 14 Hz, 2 H, 8(9)-Hb], 2.35 [broad s, 2 H, 5(7)-H], 5.03 (broad s, 1 H, 1-NH), 6.91 (m, 
1 H, 5’-H), 7.88 (m, 1 H, 6’-H), 8.58 (broad s, 1 H, 3-NH).   
13C-NMR (125.7 MHz, CDCl3) δ: 26.4 [CH2, C12(16)], 26.6 [CH2, C14 and C13(15)], 28.4 
[CH, C5(7)], 34.5 (CH2, C6), 35.8 [CH2, C4(10)], 40.0 [CH2, C8(9)], 48.3 (CH, C11), 78.9 
(C, C3), 82.1 (C, C1), 111.4 (CH, d, 2JC-F = 18 Hz, C5’), 115.3 (CH, C6’), 124.3 (C, C1’), 
139.7 (C, dt, 1JC-F = 248.8 Hz, 2JC-F = 15 Hz, Ar-C3’), 142.3 (C, d, 1JC-F = 247.7 Hz, Ar-C4’), 
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146.6 (C, d, 1JC-F = 244 Hz, Ar-C2’), 155.4 (C, CO). 
MS (DIP), m/z (%); significant ions: 408 (M·+, 5), 178 (38), 176 (21), 173 (19), 152 (23), 148 
(11), 147 [(C6H4F3N)·+, 100], 135 (16), 94 (19), 83 [(C6H11)+, 15], 55 (16).  
Elemental analysis: 
Calculated for C22H27F3N2O2:                         C  64.69%   H  6.66%    N  6.86% 
Calculated for C22H27F3N2O2·0.50MeOH:     C  63.26%   H  6.91%     N  6.56% 
Found:                                       C  63.44%   H  7.17%    N  6.63% 
 
Preparation of 1-(3-phenyl-2-oxaadamant-1-yl)-3-(2,3,4-trifluorophenyl)urea, 174 
 
 Column chromatography (SiO2, hexane/EtOAc mixture) of the crude and 
concentration in vacuo of the appropriate fractions gave the urea 174 (31 mg, 70% yield) 
as a white solid.   
Analytical and spectroscopic data of compound 174: 
Melting point: 150 - 152 ºC. 
IR (ATR) ν: 3300-2800 (3312, 3238, 3118, 2922, 2856), 1697, 1621, 1555, 1514, 1470, 1324, 
1262, 1235, 1208, 1179, 1094, 1079, 1017, 993, 976, 945, 897, 803, 751, 696, 669, 653 cm-
1. 
1H-NMR (500 MHz, CDCl3) δ: 1.84 [d, J = 12.5 Hz, 2 H, 8(9)-Ha], 1.88-1.96 (complex signal, 
2 H, 6-H2), 1.98 [d, J = 11 Hz, 2 H, 4(10)-Ha], 2.05 [d, J = 12.5 Hz, 2 H, 4(10)-Hb], 2.24 [d, J 
= 13 Hz, 2 H, 8(9)-Hb], 2.48 [m, 2 H, 5(7)-H], 5.29 (broad s, 1 H, 1-NH),  6.89 (m, 1 H, 5’-
H), 7.28 (t, J = 7.5 Hz, 1 H, Ar’-Hpara), 7.37 (t, J = 7.5  Hz, 2 H, Ar’-Hmeta), 7.45 (d, J = 7 Hz, 2 
H, Ar’-Hortho), 7.88 (m, 1 H, 6’-H), 8.51 (broad s, 1 H, 3-NH). 
13C-NMR (125.7 MHz, CDCl3) δ: 28.7 [CH, C5(7)], 33.8 (CH2, C6), 39.6 [CH2, C8(9)], 
40.6 [CH2, C4(10)], 77.4 (C, C3), 82.5 (C, C1), 111.3 (CH, dd, 2JC-F = 17.6 Hz, 3JC-F = 3.9 Hz, 
C5’), 114.9 (CH, t, 3JC-F = 5.5 Hz, C6’), 123.7 (CH, Ar’-Cortho), 124.7 (C, dd, 2JC-F = 8 Hz, 3JC-F 
= 3.3 Hz, Ar-C1’), 127.2 (CH, Ar’-Cpara), 128.3 (CH, Ar’-Cmeta), 139.6 (C, dt, 1JC-F = 249.5 Hz, 
2JC-F = 15 Hz, Ar-C3’), 142.0 (C, ddd, 1JC-F = 245.5 Hz, 2JC-F = 10.7 Hz, 3JC-F = 2.4 Hz, Ar-C4’), 
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146.4 (C, dd, 1JC-F = 244 Hz, 2JC-F = 10 Hz, Ar-C2’), 145.7 (C, Ar’-Cipso), 154.5 (C, CO). 
MS (DIP), m/z (%); significant ions: 402 (M·+, 13), 255 (19), 184 (15), 172 (25), 171 (15), 
155 (22), 147 (100), 145 (15), 142 (27), 129 (16), 120 (16), 118 (26), 110 (17), 105 (26), 91 
(17), 77 (23).  
Elemental analysis: 
Calculated for C22H21F3N2O3:                        C  65.66%   H  5.26%    N  6.96% 
Calculated for C22H21F3N2O3·1.0H2O:           C  62.85%   H  5.51%     N  6.66% 
Found:                                      C  62.79%   H  5.45%    N  6.69% 
 
Preparation of 1-(2-oxaadamant-5-yl)-3-(2,3,4-trifluorophenyl)urea, 175  
 
 The crude was purified by column chromatography (SiO2, hexane/EtOAc mixture). 
Evaporation in vacuo of the appropriate fractions gave the urea 175 (24 mg, 83% yield) as 
a white solid.  
Analytical and spectroscopic data of compound 175: 
Melting point: 211 - 213 ºC. 
IR (ATR) ν: 3344, 2937, 2856, 2478, 2362, 1681, 1621, 1556, 1504, 1473, 1434, 1402, 1361, 
1320, 1288, 1236, 1183, 1146, 1107, 1076, 1035, 1020, 1005, 992, 948, 921, 890, 810, 793, 
775, 761, 724, 686, 656, 636 cm-1. 
1H-NMR (400 MHz, CD3OD) δ: 1.66 [dm, J = 12.8 Hz, 2 H, 8(10)-Ha], 1.98 [dm, J = 12.4 
Hz, 2 H, 8(10)-Hb], 2.06 [d, J = 12 Hz, 2 H, 4(9)-Ha], 2.14-2.21 [complex signal, 4 H, 4(9)-Ha, 
6-H2], 2.25 (m, 1 H, 7-H), 4.17 [broad s, 2 H, 1(3)-H], 7.01 (m, 1 H, 5’-H), 7.68 (m, 1 H, 6’-
H).  
13C-NMR (100.6 MHz, CD3OD) δ: 28.8 (CH, C7), 36.0 [CH2, C8(10)], 41.2 [CH2, C6], 
41.8 [CH2, C4(9)], 50.6 (C, C5), 70.9 [CH, C1(3)], 112.2 (CH, dd, 2JC-F = 17.8 Hz, 3JC-F = 3.7 
Hz, C5’), 116.8 (CH, C6’), 126.8 (C, d, 2JC-F = 6.5 Hz, Ar-C1’), 141.0 (C, d, 1JC-F = 247 Hz, Ar-
C3’), 143.5 (C, d, 1JC-F ~ 245 Hz, Ar-C4’), 147.5 (C, d, 1JC-F = 242 Hz, Ar-C2’), 156.2 (C, CO). 
MS (DIP), m/z (%); significant ions: 173 [(C7H2F3NO)·+, 4], 149 (100), 148 (62), 147 (16), 
137 [(C9H13O)+, 8], 93 (49). 
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Elemental analysis: 
Calculated for C16H17F3N2O2:                         C  58.89%   H  5.25%    N  8.58% 
Calculated for C16H17F3N2O2·0.50H2O:         C  57.31%   H  5.41%     N  8.35% 
Found:                                       C  57.46%   H  5.70%    N  8.22% 
 
Preparation of 1-(4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-yl)-3-(2,3,4-
trifluorophenyl)urea, 176 
 
 Purification by column chromatography (SiO2, hexane/EtOAc mixture) of the crude 
and evaporation in vacuo of the appropriate fractions gave the urea 176 (374 mg, 94% yield) 
as a white solid.  
Analytical and spectroscopic data of compound 176: 
Melting point: 152 - 154 ºC. 
IR (ATR) ν: 3329, 3192, 3118, 2975, 1701, 1641, 1621, 1559, 1509, 1470, 1342, 1321, 1287, 
1253, 1205, 1183, 1166, 1127, 1071, 1020, 996, 951, 933, 911, 867, 839, 798, 757, 708, 688, 
655, 635, 593 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.60 (dt, J = 10.8 Hz, J’ = 1.6 Hz, 1 H, 12-Ha), 1.95 (dt, J = 
10.8 Hz, J’ = 1.6 Hz, 1 H, 12-Hb), 2.50 (broad t, J = 5.2 Hz, 1 H, 7-H), 2.57 (t, J = 4.8 Hz, 1 
H, 1-H), 2.66 (m, 8 H, 2-H), 2.75-2.84 (complex signal, 3 H, 2-H, 10-H, 11-H), 2.88-3.01 
(complex signal, 2 H, 6-H, 9-H), 4.83 (t, J = 5.2 Hz, 1 H, 5-H), 5.94 (broad s, 1 H, 1-NH), 
6.90 (m, 1 H, 5’-H), 7.82 (m, 1 H, 6’-H), 8.06 (broad s, 1 H, 3-NH).   
13C-NMR (100.6 MHz, CDCl3) δ: 41.4 (CH, C8), 41.6 (CH, C11), 43.2 (CH, C1), 43.5 
(CH2, C12), 44.6 (CH, C9), 44.9 (CH, C7), 46.3 (CH, C10), 54.8 (CH, C6), 57.0 (CH, C2), 
84.1 (CH, C5), 103.1 (C, C3), 111.3 (CH, dd, 2JC-F = 17.7 Hz, 3JC-F = 3.9 Hz, C5’), 115.2 (CH, 
m, C6’), 124.5 (C, dd, 2JC-F = 8 Hz, 3JC-F = 3.5 Hz, C1’), 139.8 (C, ddd, 1JC-F = 252 Hz, 2JC-F = 
16.4 Hz, 2JC-F = 13.7 Hz, C3’), 142.3 (C, ddd, 1JC-F = 251 Hz, 2JC-F = 11.7 Hz, 3JC-F = 3.2 Hz, C4’), 
146.6 (C, ddd, 1JC-F = 245.8 Hz, 2JC-F  = 10 Hz, 3JC-F = 2.7 Hz, C2’), 154.7 (C, CO).  
MS (DIP), m/z (%); significant ions: 348 (M·+, 18), 173 [(C7H2F3NO)·+, 17], 159 [(C11H11O)+, 
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35], 147 (100), 146 (13), 131 (24), 91 (15). 
Elemental analysis: 
Calculated for C18H15F3N2O2:                      C  62.07%   H  4.34%    N  8.04% 
Found:                                    C  62.04%   H  4.43%    N  7.98% 
 
Preparation of 1-(tricyclo[3.3.0.03,7]oct-1-yl)-3-(2,3,4-trifluorophenyl)urea, 177 
 
 The crude was purified by column chromatography (SiO2, hexane/EtOAc mixture). 
Evaporation in vacuo of the appropriate fractions gave the urea 177 (24 mg, 66% yield) as 
a white solid.  
Analytical and spectroscopic data of compound 177: 
Melting point: 185 - 186 ºC. 
IR (ATR) ν: 3331, 3105, 2970, 2943, 2894, 2159, 1656, 1640, 1620, 1563, 1510, 1467, 1318, 
1288, 1244, 1204, 1171, 1107, 1076, 1065, 1017, 979, 823, 800, 764, 723, 710, 690, 668, 
645, 620 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.51 [d, J = 8.8 Hz, 2 H, 4(6)-Ha], 1.74 [complex signal, 6 H, 
4(6)-Ha, 2(8)-H2], 2.34 [broad s, 2 H, 3(7)-H], 2.42 (m, 1 H, 5-H), 5.42 (broad s, 1 H, 1-NH), 
6.67 (broad s, 1 H, 3-NH), 6.90 (m, 1 H, 5’-H), 7.82 (m, 1 H, 6’-H). 
13C-NMR (100.6 MHz, CDCl3) δ: 32.8 [CH, C3(7)], 43.0 (CH, C5), 46.6 [CH2, C4(6)], 51.1 
[CH2, C2(8)], 61.6 (C, C1), 111.4 (CH, dd, 2JC-F = 17.7 Hz, 3JC-F = 3.7 Hz, C5’), 115.1 (CH, t, 
3JC-F = 5.6 Hz, C6’), 124.8 (C, dd, 2JC-F = 8 Hz, 3JC-F = 3.5 Hz, C1’), 139.7 (C, dt, 1JC-F = 245 Hz, 
2JC-F = 15 Hz, C3’), 142.2 (C, dd, 1JC-F = 225 Hz, 2JC-F = 12 Hz, C4’), 141.5 (C, dd, 1JC-F = 246 
Hz, 2JC-F  = 10 Hz, Ar-C2’), 154.6 (C, CO). 
MS (DIP), m/z (%); significant ions: 296 (M·+, 34), 268 (14), 267 (24), 254 (22), 147 
[(C6H4F3N)·+, 77], 146 (23), 119 (14), 95 (29), 94 (100), 82 (29), 81 (62), 80 (20), 79 (18).  
Elemental analysis: 
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Calculated for C15H15F3N2O:                         C  60.81%   H  5.10%    N  9.45% 
Found:                                      C  60.87%   H  5.34%    N  9.19% 
 
Preparation of 1-(3,7-dimethyl(tricyclo[3.3.0.03,7]oct-1-yl))-3-(2,3,4-trifluorophenyl)urea, 
178 
 
 Purification by column chromatography (SiO2, hexane/EtOAc mixture) of the crude 
and evaporation in vacuo of the appropriate fractions gave the urea 178 (50 mg, 47% yield) 
as a white solid.  
Analytical and spectroscopic data of compound 178: 
Melting point: 174 - 175 ºC. 
IR (ATR) ν: 3335, 2957, 2930, 2882, 2158, 2005, 1686, 1656, 1637, 1621, 1565, 1509, 1471, 
1308, 1289, 1242, 1204, 1165, 1154, 1118, 1081, 1064, 1020, 1009, 964, 946, 816, 796, 719, 
694, 678, 657 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.15 [s, 6 H, 3(7)-CH3], 1.39 [dd, J = 8.4 Hz, J’ = 3.6 Hz, 2 
H, 4(6)-Ha], 1.64 [dd, J = 7.6 Hz, J’ = 3.6 Hz, 2 H, 2(8)-Ha], 1.76 [dd, J = 8.4 Hz, J’ = 3.0 Hz, 
2 H, 4(6)-Hb], 1.82 [d, J = 7.6 Hz, 2 H, 2(8)-Hb], 2.38 (t, J = 3.0 Hz, 1 H, 5-H), 5.47 (broad s, 
1 H, 1-NH), 6.75 (broad s, 1 H, 3-NH), 6.89 (m, 1 H, 5’-H), 7.80 (m, 1 H, 6’-H).   
13C-NMR (100.6 MHz, CDCl3) δ: 16.5 [CH3, C3(7)-CH3], 44.8 (CH, C5), 46.2 [C, C3(7)], 
53.1 [CH2, C4(6)], 57.5 [CH2, C2(8)], 61.8 (C, C1), 111.4 (CH, dd, 2JC-F = 17.7 Hz, 3JC-F = 3.8 
Hz, C5’), 115.0 (CH, t, 3JC-F = 5 Hz, C6’), 124.8 (C, dd, 2JC-F = 8 Hz, 3JC-F = 3.4 Hz, C1’), 139.7 
(C, ddd, 1JC-F = 249 Hz, 2JC-F = 16.3 Hz, 2JC-F = 13.7 Hz, C3’), 142.1 (C, ddd, 1JC-F = 244 Hz, 2JC-
F = 11.9 Hz, 3JC-F = 3.2 Hz, C4’), 141.4 (C, ddd, 1JC-F = 245 Hz, 2JC-F  = 10 Hz, 3JC-F = 2.8 Hz, C2’), 
154.6 (C, CO). 
MS (EI), m/z (%); significant ions: 324 (M·+, 8), 268 (15), 148 (44), 147 [(C6H4F3N)·+, 100], 
146 (23), 136 (17), 134 (84), 122 (89), 121 (54), 120 (40), 119 (81), 110 (20), 109 (51), 108 
(50), 107 (28), 106 (16), 105 (21), 96 (17), 95 (70), 94 (54), 93 (52), 92 (18), 91 (44), 81 (17), 
80 (18), 79 (37), 77 (33), 67 (24), 55 (16), 41 (23). 
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Elemental analysis: 
Calculated for C17H19F3N2O:                         C  62.95%   H  5.90%    N  8.64% 
Found:                                      C  63.12%   H  6.17%    N  8.48% 
 
Preparation of 1-[(3,7-dimethyl(tricyclo[3.3.0.03,7]oct-1-yl)methyl]-3-(2,3,4-
trifluorophenyl)urea, 179 
 
 Column chromatography (SiO2, hexane/EtOAc mixture) of the crude and 
concentration in vacuo of the appropriate fractions gave the urea 179 (82 mg, 97% yield) 
as a white solid.   
Analytical and spectroscopic data of compound 179: 
Melting point: 133 - 134 ºC. 
IR (ATR) ν: 3323, 2952, 2881, 1637, 1621, 1570, 1510, 1474, 1292, 1244, 1177, 1045, 1001, 
985, 809, 794, 755, 682, 653 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 1.17 [s, 6 H, C3(7)-CH3], 1.32-1.38 [complex signal, 4 H, 
4(6)-Ha and 2(8)-Ha], 1.42 [d, J = 7.5 Hz, 2 H, 2(8)-Hb], 1.59 [dd, J = 8 Hz, J’ = 3 Hz, 2 H, 
4(6)-Hb], 2.10 (t, J = 3 Hz, 1 H, 5-H), 3.42 (s, 2 H, CH2-N), 7.01 (m, 1 H, 5’-H), 7.75 (m, 1 
H, 6’-H).  
13C-NMR (125.7 MHz, CD3OD) δ: 17.1 [CH3, C3(7)-CH3], 42.7 (CH, C5), 43.8 [CH2, CH2-
N], 48.5 [C, C3(7)], 52.3 (C, C1), 54.9 [CH2, C4(6)], 57.2 [CH2, C2(8)], 112.3 (CH, dd, 2JC-
F = 17.7 Hz, 3JC-F = 3.9 Hz, C5’), 116.7 (CH, C6’), 127.0 (C, d, 2JC-F = 6 Hz, C1’), 141.5 (C, dt, 
1JC-F = 247 Hz, 2JC-F = 15 Hz, C3’), 143.6 (C, dd, 1JC-F = 246 Hz, 2JC-F = 12 Hz, C4’), 147.5 (C, 
dd, 1JC-F = 243 Hz, 2JC-F  = 9 Hz, C2’), 157.8 (C, CO). 
MS (DIP), m/z (%); significant ions: 338 (M·+, 1), 149 [(C11H17)+, 43], 148 (86), 147 
[(C6H4F3N)·+, 42], 136 (19), 135 [(C10H15)+, 100], 119 (18), 107 (56),  106 (15), 105 (15), 93 
(42), 91 (28), 79 (16), 77 (16).  
Elemental analysis: 
Calculated for C18H21F3N2O:                         C  63.89%   H  6.26%    N  8.28% 
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Found:                                     C  63.83%   H  6.52%    N  8.26% 
 
Preparation of 1(±)-[(tricyclo[3.3.1.03,7]non-3-yl)ethyl]-3-(2,3,4-trifluorophenyl)urea, 180 
 
 The crude was purified by column chromatography (SiO2, hexane/EtOAc mixture). 
Evaporation in vacuo of the appropriate fractions gave the urea 180 (53 mg, 63% yield) as 
a white solid. The analytical sample was obtained by crystallization from EtOAc/pentane. 
Analytical and spectroscopic data of the 180: 
Melting point: 148 - 150 ºC. 
IR (ATR) ν: 3302, 2929, 2861, 1717, 1637, 1620, 1561, 1509, 1474, 1291, 1242, 1190, 1173, 
1138, 1077, 1030, 1015, 964, 797, 754, 682, 653 cm-1.  
1H-NMR (500 MHz, CDCl3) δ (mixture of rotamers): 1.11 (d, J = 6.5 Hz) and 1.13 (d, J = 
6.5 Hz) (3 H, 2 CHCH3), 1.20-1.70 [complex signal, 10 H, 2(4)-H2, 6(8)-H2, 9-H2], 2.04 (t, J 
= 6.5 Hz) and 2.16 (t, J = 6.5 Hz) (1 H, 7-H), 2.18 (broad s) and 2.22 (broad s) [2 H, 1(5)-H], 
3.97 (m, 1 H, CHCH3), 5.00 (s) and 6.65 (s) (1 H, 1-NH), 6.90 (m, 1 H, 6’-H), 7.15 (m, 1 
H, 3-NH), 7.74 (m) and 7.81 (m) (1 H, 5’-H).   
13C-NMR (125.7 MHz, CDCl3) δ (mixture of rotamers):  17.4 and 17.9 (CH3, CHCH3), 35.1 
and 35.4 (CH2, C9), 36.9 and 37.1 (CH, C1 or C5), 37.4 and 37.5 (CH, C5 or C1), 41.1 
(CH, C7), 43.6 and 43.7 (CH2, C6 or C8), 44.0 and 44.1 (CH2, C8 or C6), 44.5 and 44.8 
(CH2, C2 or C4), 46.1 and 46.2 (CH2, C4 or C2), 51.4 and 52.4 (CH, CHCH3), 52.9 and 
53.3 (C, C3), 111.5 and 112.9 (CH, dt, 2JC-F = 17.7 Hz, 3JC-F = 4.3 Hz, C5’), 115.5 and 125.2 
(CH, broad s, C6’), 121.5-125.2 (C, several peaks, C1’), 138.7-153.0 (C, several peaks, C2’, 
C3’ and C4’), 151.6 and 154.6 (C, CO). 
MS (DIP), m/z (%); significant ions: 338 (M·+, 1), 146 (100). 
Elemental analysis: 
Calculated for C18H21F3N2O:                          C  63.89%   H  6.26%    N  8.28% 
Calculated for C18H21F3N2O ·0.15EtOAc:      C  63.55%   H  6.36%    N  7.97% 
Found:                                       C  63.26%   H  6.59%    N  8.26% 
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Preparation of 1-(pentacyclo[6.4.0.02,10.03,7.04,9]dodec-8-yl)-3-(2,3,4-trifluorophenyl)urea, 
181 
 
 Purification by column chromatography (SiO2, hexane/EtOAc mixture) of the crude 
and evaporation in vacuo of the appropriate fractions gave the urea 181 (14 mg, 60% yield) 
as a white solid.  
Analytical and spectroscopic data of compound 181: 
Melting point: > 220 ºC (dec.). 
IR (ATR) ν: 3388, 3260, 2958, 2932, 2866, 1645, 1546, 1504, 1481, 1324, 1267, 1248, 
1231, 1188, 1168, 1059, 1044, 991, 786, 719, 691, 670, 631 cm-1. 
1H-NMR (500 MHz, CDCl3) δ: 1.12 (t, J = 2.5 Hz, 1 H, 9-H),  1.49-1.67 [complex signal, 8 
H, 5(11)-H2 and 6(12)-H2], 2.19 [broad s, 2 H, 4(10)-H], 2.28 [broad s, 2 H, 2(3)-H], 2.71 
[broad s, 2 H, 1(7)-H], 4.92 (broad s, 1 H, NH-Al), 6.47 (broad s, 1 H, NH-Ar), 6.90 (m, 1 
H, 5’-H), 7.83 (m, 1 H, 6’-H).   
13C-NMR (125.7 MHz, CDCl3) δ: 21.5 [CH2, C6(12)], 24.4 [CH2, C5(11)], 46.9 [CH, C2(3)], 
52.8 [CH, C4(10)], 53.7 [CH, C1(7)], 55.6 (CH, C9), 65.6 (C, C8), 111.5 (CH, dd, 2JC-F = 
17.7 Hz, 3JC-F = 3.9 Hz, C5’), 114.9 (CH, C6’), 124.9 (C, dd, 2JC-F = 8.0 Hz, 3JC-F = 3.3 Hz Ar-
C1’), 139.7 (C, d, 1JC-F = 247.7 Hz, Ar-C3’), 146.4 (C, d, 1JC-F = 245.2 Hz, Ar-C4’), 151.8 (C, 
d, 1JC-F = 249.0 Hz, Ar-C2’), 154.2 (C, CO). 
MS (DIP), m/z (%); significant ions: 348 (M·+, 31), 320 (30), 202 [(C13H16NO)+, 12], 147 
[(C6H4F3N)·+, 100], 146 (19), 119 (16), 91 (11). 
HRMS-ESI+ m/z [M+H]+ calcd for [C19H19F3N2O+H]+: 349.1522, found: 349.152 
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Preparation of 1-(9-methyl-6,7,8,9,10,11-hexahydro-5H-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)-3-(2,3,4-trifluorophenyl)urea, 182 
 
 For the preparation of compound 182, the starting amine was used as a free base, 
hence less equivalents of triethylamine (4 eq.) were needed following the above general 
procedure.   
 Column chromatography (SiO2, hexane/EtOAc mixture) of the crude and 
concentration in vacuo of the appropriate fractions gave the urea 182 (38 mg, 13% yield) 
as a white solid.   
Analytical and spectroscopic data of compound 182: 
Melting point: 206 - 207 ºC. 
IR (ATR) ν: 3331, 2903, 2839, 1654, 1556, 1510, 1473, 1361, 1344, 1290, 1237, 1174, 1101, 
1038, 1019, 1004, 800, 756, 690, 669, 625 cm-1. 
1H-NMR (500 MHz, CD3OD) δ: 0.94 (s, 3 H, CH3), 1.50 [d, J = 13.5 Hz, 2 H, 10(13)-Hb], 
1.69 [m, 2 H, 10(13)-Ha], 1.77 (s, 2 H, 8-H), 2.10 [m, 2 H, 6(12)-Ha], 2.15 [d, J = 13 Hz, 2 H, 
6(12)-Hb], 3.08 [tt, J = 6 Hz, J’ = 1.5 Hz, 2 H, 5(11)-H], 6.98 (m, 1 H, 5’-H), 7.04 [s, 4 H, 
1(2,3,4)-H], 7.66 (m, 1 H, 6’-H).  
13C-NMR (125.7 MHz, CD3OD) δ: 32.9 (CH3, CH3), 34.6 (C, C9), 40.6 [CH2, C6(12)], 
42.5 [CH, C5(11)], 42.5 [CH2, C10(13)], 44.9 [CH2, C16(20)], 49.0 (CH2, C8), 54.5 (C, 
C7), 112.2 (CH, dd, 2JC-F = 17.8 Hz, 3JC-F = 3.9 Hz, C5’), 116.6 (CH, C6’), 127.0 (C, dd, 2JC-F = 
8.0 Hz, 3JC-F = 2.4 Hz Ar-C1’), 127.4 [CH, C2(3)], 129.0 [CH, C1(4)], 141.0 (C, dt, 1JC-F = 
247.8 Hz, 2JC-F = 14.9 Hz, Ar-C3’), 143.6 (C, dd, 1JC-F = 245.7 Hz, 2JC-F = 12.8 Hz, Ar-C4’), 147.3 
(C, dd, 1JC-F = 242.6 Hz, 2JC-F = 10.3 Hz, Ar-C2’), 147.6 [C, C4a(C11a)], 156.1 (C, CO). 
MS (DIP), m/z (%); significant ions: 400 (M·+, <1), 253 (19), 228 (14), 211 [(C16H19)+, 16], 
172 (23), 155 (54), 149 (56), 148 (100), 147 (52), 143 (22), 141 (20), 129 (21), 128 (18), 115 
(16). 
Elemental analysis: 
Calculated for C23H23F3N2O:                          C  68.99%   H  5.79%    N  7.00% 
Found:                                       C  68.94%   H  5.92%    N  6.71% 
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Preparation of 1-(5-methyl-1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4-benzoxonin-3-yl)-
3-(2,3,4-trifluorophenyl)urea, 183 
 
 For the preparation of compound 183, the starting amine was used as a free base, 
hence less equivalents of triethylamine (4 eq.) were needed following the above general 
procedure.   
 Any purification the urea was needed. The desired urea 183 was obtained as a white 
solid (205 mg, 54% yield) as a white solid.   
Analytical and spectroscopic data of compound 183: 
Melting point: 257 - 259 ºC. 
IR (ATR) ν: 3295, 3241, 3118, 2916, 2173, 1693, 1620, 1564, 1510, 1493, 1468, 1462, 1356, 
1345, 1320, 1302, 1286, 1273, 1254, 1229, 1210, 1181, 1167, 1111, 1091, 1074, 1049, 1035, 
1008, 999, 958, 906, 820, 812, 763, 646 cm-1. 
1H-NMR (400 MHz, DMSO-d6) δ: 1.18 (s, 3 H, CH3), 1.56 [d, J = 13.6 Hz, 2 H, 6(13)-Hb], 
1.84 [m, 2 H, 6(13)-Ha], 1.97 [d, J = 13.2 Hz, 2 H, 2(12)-Hb], 2.20 [m, 2 H, 2(12)-Ha], 3.16 [t, 
J = 5.5 Hz, 2 H, 1(7)-H], 4.06 (s, 1 H, NH-Al), 7.14 (complex signal, 5 H, 15-H, 5’-H), 7.84 
(m, 1 H, 6’-H), 8.52 (broad s, 1 H, NH-Ar).  
13C-NMR (100.6 MHz, DMSO-d6) δ: 31.1 (CH3, CH3), 37.4 [CH2, C2(12)], 38.1 [CH2, 
C6(13)], 38.2 [CH, C1(7)], 73.4 (C, C5), 82.7 (C, C3), 111.6 (CH, dd, 2JC-F = 17.2 Hz, 3JC-F = 
3.5 Hz, C5’), 114.3 (CH, broad s, C6’), 126.0 (C, dd, 2JC-F = 7.8 Hz, 3JC-F = 3.0 Hz Ar-C1’), 
126.5 [CH, C9(10)], 128.2 [CH, C8(11)], 139.0 (C, dd, 1JC-F = 246 Hz, 2JC-F = 15 Hz, Ar-C3’), 
141.0 (C, dd, 1JC-F = 248 Hz, 2JC-F = 12 Hz, Ar-C4’), 144.7 (C, dd, 1JC-F = 241 Hz, 2JC-F = 11 Hz, 
Ar-C2’), 145.5 [C, C7a(C11a)], 152.3 (C, CO). 
MS (DEPEI), m/z (%); significant ions:  402 (M·+, 48), 171 (13), 170 (34), 169 (21), 157 (20), 
156 (18), 155 (53), 154 (14), 153 (11), 148 (18), 147 [(C6H4F3N)·+, 100], 146 (53), 145 (15), 
143 (25), 142 (21), 141 (23), 131 (12), 130 (15), 129 (65), 128 (46), 127 (22), 116 (12), 115 
(55), 91 (17), 84 (19), 83 (28), 71 (15), 70 (16), 69 (21).  
Elemental analysis: 
Calculated for C22H21F3N2O2:                         C  65.66%   H  5.26%    N  6.96% 
Calculated for C22H21F3N2O2·0.1H2O:            C  65.37%   H  5.29%    N  6.93% 
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Found:                                       C  65.18%   H  5.31%    N  6.73% 
HRMS-ESI+ m/z [M+H]+ calcd for [C22H21F3N2O2+H]+: 403.1633, found: 403.1631. 
Preparation of (2-oxaadamant-1-yl)isocyanate, 185 
 
 In a three-necked round-bottom flask equipped with a stir bar, low temperature 
thermometer and gas inlet, triphosgene (392 mg, 1.32 mmol) was added in a single portion 
to a solution of amine hydrochloride 120·HCl (500 mg, 2.63 mmol) in DCM (35 mL) and 
saturated NaHCO3 solution (15 mL). The biphasic mixture was stirred vigorously at 4 ºC 
for 30 minutes. Afterwards, the phases were separated and the organic layer was washed 
with brine (20 mL), dried over anh. Na2SO4 and filtered. Evaporation under vacuo provided 
185 (408 mg, 86% yield), that was used in next step without further purification. 
IR (ATR) ν: 2235 (isocyanate band) cm-1. 
 
Preparation of 1-(1-acetylpiperidin-4-yl)-3-(oxaadamant-1-yl)urea, 184 
 
  Under anhydrous conditions, a solution of isocyanate 185 (323 mg, 1.80 mmol) in 
anh. DCM (20 mL) was added to a solution of 1-acetyl-4-aminopiperidine (308 mg, 2.16 
mmol) in anh. DCM (10 mL), followed by TEA (0.50 mL, 3.61 mmol). The reaction 
mixture was stirred at room temperature overnight. The solution was then concentrated 
under vacuo to give an orange gum (720 mg). Purification by column chromatography 
(SiO2, DCM/methanol mixture) gave the titled compound 184 (300 mg, 52% yield) as a 
white solid. The analytical sample was obtained by washing with pentane. 
Analytical and spectroscopic data of compound 184: 
Melting point: 172 - 173 ºC. 
IR (ATR) ν: 3322, 2920, 2850, 2188, 2153, 2000, 1637, 1549, 1428, 1369, 1313, 1264, 1234, 
1192, 1139, 1090, 1046, 995, 959, 879, 816, 773, 731 cm-1. 
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1H-NMR (400 MHz, CDCl3) δ: 1.28-1.41 (complex signal, 2 H, 3-Hax and 5-Hax), 1.58-1.96 
[complex signal, 9 H, 8’-Ha, 9’-Ha, 4’-H2, 10’-H2, 6’-H2, and 3-Heq or 5-Heq], 1.98-2.22 
(complex signal, 6 H, COCH3, 8’-Hb, 9’-Hb and 5-Heq or 3-Heq), 2.27 [broad s, 2 H, 5’(7’)-
H], 2.86 (dt, J = 11.2 Hz, J’ = 2.8 Hz, 1 H, 6-Hax or 2-Hax), 3.18 (dt, J = 10.8 Hz, J’ = 2.8 Hz, 
1 H, 2-Hax or 6-Hax), 3.70 (dm, J = 14 Hz, 1 H, 2-Heq or 6-Heq), 3.87 (m, 1 H, 4-H), 4.27 
(broad s, 1 H, 3’-H), 4.35 (broad d, J = 14.0 Hz, 1 H, 6-Heq or 2-Heq), 4.75 (s, 1 H, 3-NH), 
6.06 (d, J = 8 Hz, 1-NH).  
13C-NMR (100.6 MHz, CDCl3) δ: 21.4 (CH3, CH3CO), 27.9 [CH, C5’(7’)], 32.1 (CH2, C3 
or C5), 33.2 (CH2, C5 or C3), 34.6 (broad CH2, C4’, C6’ and C10’), 40.0 (CH2, C8’ or 
C9’), 40.2 (CH2, C9’ or C8’), 40.4 (CH2, C2 or C6), 45.1 (CH2, C6 or C2), 46.5 (CH, C4), 
71.0 (CH, C3’), 80.6 (C, C1’), 156.7 (C, NHCONH), 168.9 (C, CH3CO). 
MS (DIP), m/z (%); significant ions: 321 (M·+, 34), 197 (32), 179 [(C10H13NO2)·+, 34], 154 
(100), 153 (18), 137 [(C9H13O)+, 33], 136  (32), 126 (15), 125 (51), 122 (21), 111 (17), 96 (41), 
95 (18), 94 (45), 84 (19), 83 (37), 82 (54), 79 (22), 67 (20), 57 (23), 56 (32), 55 (15). 
Elemental analysis: 
Calculated for C17H27N3O3:                                         C  63.53%   H  8.47%    N  13.07% 
Calculated for C17H27N3O3·0.25H2O:                           C  62.65%   H  8.50%     N  12.89% 
Found:                                                    C  62.64%   H  8.61%    N  12.74% 
 
Preparation of N-(1-acetylpiperidin-4-yl)-1H-imidazole-1-carboxamide, 187 
 
 N,N’-carbonyldiimidazole (400 mg, 2.46 mmol) was suspended in anh. 1,2-
dichloroethane (15 mL) under nitrogen. Then 1-acetyl-4-aminopiperidine (250 mg, 1.76 
mmol) was added and the reaction mixture was heated to 50 ºC for 21 hours. With an 
external ice bath, the mixture was cooled down for 30 minutes. The resulting solid was 
collected by filtration under vacuo and washed with 1,2-DCE (20 mL) yielding the titled 
product 187 (312 mg, 75% yield) as a white solid.  
Analytical and spectroscopic data of compound 187: 
Melting point: 191 - 193 ºC. 
IR (ATR) ν: 3216, 3118, 3038, 2918, 2342, 2074, 1709, 1613, 1542, 1479, 1463, 1441, 1369, 
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1358, 1320, 1281, 1272, 1233, 1195, 1137, 1111, 1090, 1068, 1053, 1001, 984, 974, 916, 
902, 859, 799, 748, 652 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.37 (complex signal, 2 H, 3-Hax, 5-Hax), 1.99 (dm, J = 12.8 
Hz, J’ = 4 Hz, 1 H) and 2.21 (dm, J = 12.8 Hz, J’ = 4 Hz, 1 H)  (3’-Heq and 5’-Heq), 2.09 (s, 3 
H, COCH3), 2.69 (ddd,  J = 13 Hz, J’ = 2.6 Hz, 1 H) and 3.21 (ddd,  J = 13 Hz, J’ = 2.6 Hz, 
1 H) (2’-Hax and 6’-Hax), 3.86 (dm, J = 13.6 Hz, 1 H) and 4.67 (dm, J = 13.6 Hz, 1 H) (2’-Heq 
and 6’-Heq),  4.10 (m,  1 H, 4’-H), 7.06 (dd, J = 1.6 Hz, J’ = 0.8 Hz, 1 H, 4-H), 7.29 (broad d, 
J = 7.6 Hz, 1 H, NH),  7.60 (dd, J = 1.6 Hz, J’ =1.2 Hz, 1 H, 5-H),  8.29 (dd, J = 1.2 Hz, J’ = 
0.8 Hz, 1 H, 2-H).  
13C-NMR (100.6 MHz, CDCl3) δ: 21.5 (CH3, COCH3), 31.4 and 33.1 (CH2, C3’ and C5’), 
40.9 and 45.6 (CH2, C2’ and C6’), 48.2 (CH, C4’), 116.2 (CH, C5), 130.3 (CH, C4), 136.2 
(CH, C2), 148.5 (C, NHCNH), 169.2 (C, COCH3). 
MS (DIP), m/z (%); significant ions: 169 (10), 168 (100), 153 (19), 126 (53), 125 (31), 85 
(19), 84 (42), 83 (20), 82 (23), 81 (21), 68 (98), 57 (40), 56 (56), 55 (16). 
HRMS-ESI+ m/z [M+H]+ calcd for [C11H16N4O2+H]+: 237.1346, found: 237.1345. 
 
Preparation of 1-(1-acetylpiperidin-4-yl)-3-(oxaadamantan-1-yl)urea, 184 
 
 In a round bottom flask equipped with a condenser apparatus and magnetic stirrer a 
solution of amine hydrochloride 120·HCl (18 mg, 0.09 mmol) in chloroform (2 mL) was 
prepared, to which was added 187 (45 mg, 0.19 mmol) followed by triethylamine (10 mg, 
0.10 mmol). The solution was heated to 50 ºC for 16 hours, whereupon the reaction 
mixture was tempered to room temperature and evaporated under vacuo to dryness (78 mg). 
Purification by column chromatography (SiO2, DCM/methanol mixture) afforded the 
desired product 184 (16 mg, 53% yield) as a white solid.  
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Preparation of 4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodec-3-yl)isocyanate, 189 
 
 In a three-necked round-bottom flask equipped with a stir bar, low temperature 
thermometer and gas inlet, triphosgene (98 mg, 0.33 mmol) was added in a single portion 
to a solution of amine hydrochloride 121·HCl (50 mg, 0.24 mmol) in DCM (3.6 mL) and 
saturated NaHCO3 solution (2.3 mL). The biphasic mixture was stirred vigorously at 4 ºC 
for 30 minutes. Afterwards, the phases were separated and the organic layer was washed 
with brine (10 mL), dried over anh. Na2SO4 and filtered. Evaporation under vacuo provided 
the isocyanate 189 (47 mg, quantitative yield). Any purification or characterization was 
fulfilled and the product was used in next step. 
IR (ATR) ν: 2256 (NCO band) cm-1. 
 
Preparation of 1-(1-acetylpiperidin-4-yl)-3-(4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodec-3-
yl)urea, 188 
 
 Under anhydrous conditions, a solution of isocyanate 189 (365 mg, 1.81 mmol) in 
anh. DCM (20 mL) was added to a solution of 1-acetyl-4-aminopiperidine (309 mg, 2.18 
mmol) in anh. DCM (10 mL), followed by TEA (0.51 mL, 3.63 mmol). The reaction 
mixture was stirred at room temperature overnight. The solution was then concentrated 
under vacuo to give a beige solid (736 mg). Purification by column chromatography (SiO2, 
DCM/methanol mixture) gave the titled compound 188 (159 mg, 26% yield) as a white. 
The analytical sample was obtained by crystallization with ethyl acetate. 
Analytical and spectroscopic data of compound 188: 
Melting point: 164 - 166 ºC. 
IR (ATR) ν: 3501, 3455, 3272, 2948, 2857, 2180, 1985, 1650, 1543, 1425, 1357, 1310, 1300, 
1266, 1223, 1147, 1136, 1095, 1061, 1006, 973, 912, 870, 779, 731, 659 cm-1. 
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1H-NMR (400 MHz, CDCl3) δ: 1.32 [complex signal, 2 H, 3(5)-Hax], 1.57 (broad d, J = 10.4 
Hz, 1 H, 12’-Ha), 1.90 (complex signal, 2 H, 12’-Hb, 3-Heq or 5-Heq), 2.01 (complex signal, 1 
H, 3-Heq or 5-Heq), 2.07 (s, 3 H, COCH3), 2.46 (tt, J = 5.2 Hz, J’ = 4.4 Hz, 1 H, 7’-H), 2.51 
(t, J = 4.4 Hz, 1 H, 1’-H), 2.62 (m, 1 H, 8’-H), 2.72 (complex signal, 3 H, 2’-H, 10’-H, 11’-
H), 2.83 (complex signal, 3 H, 9’-H, 5’-H, 2-Hax or 6-Hax), 3.17 (m, 1 H, 6-Hax or 2-Hax), 3.70 
(dm, J = 13.6 Hz, 1 H,  2-Heq or 6-Heq), 3.86 (m, 1 H, 4-H), 4.36 (dm, J = 13.6 Hz, 1 H,  6-
Heq or 2-Heq), 4.71 (t, J = 5.2 Hz, 1 H, 5’-H), 5.32 (s, 1 H, 3-NH), 5.69 (dd, J = 10 Hz, J’ = 8 
Hz, 1 H, 1-NH). 
 13C-NMR (100.6 MHz, CDCl3) δ: 21.4 (CH3, COCH3), 32.0 (CH2, C3 or C5), 33.0 (CH2, 
C5 or C3), 40.3 (CH2, C2 or C6), 41.4 (CH, C8’), 41.6 (CH, C2’), 43.1 (CH, C1’), 43.4 
(CH2, C12’), 44.5 (CH, C9’), 44.8 (CH, C7’), 45.1 (CH2, C6 or C2), 45.7 (CH, C10’), 46.8 
(CH, C4), 54.6 (CH, C6’), 56.9 (CH, C11’), 83.7 (CH, C5’), 103.1 (C, C3’), 156.7 (C, 
NHCONH), 168.8 (C, COCH3).  
MS (DIP), m/z (%); significant ions: 343 (M·+, 16), 325 (62), 260 (42), 201 (15), 177 (12), 
176 (82), 168 (15), 160 (18), 159 [(C11H11O)+, 100], 158 (29), 146 (10), 132 (13), 131 (53), 
139 (20), 129 (26), 128 (15), 126 (15), 125 (33), 124 (89), 116 (16), 115 (19), 94 (17), 91 (37), 
84 (25), 83 (83), 82 (59), 81 (19), 80 (18), 56 (29), 55 (16). 
HRMS-ESI+ m/z [M+H]+ calcd for [C19H25N3O3+H]+: 344.1969, found: 344.1972. 
 
Preparation of trans-4-(4-amino-cyclohexyloxy)-benzonitrile, 191555 
 
 In a three-necked round bottom flask equipped with a condenser apparatus, magnetic 
stirrer and gas inlet a solution of trans-4-aminocyclohexanol (3 g, 26.0 mmol) in anh. DMF 
(130 mL) was cooled to 0 ºC with an ice/NaCl bath. Sodium hydride, 60% dispersion in 
mineral oil (1.15 g, 28.7 mmol) was added and the suspension was stirred for 1 hour while 
cooling. 4-fluorobenzonitrile (3.9 g, 32.6 mmol) was added and the reaction mixture was 
heated to 60 ºC for 2 hours and stirred at room temperature overnight. The resulting 
suspension was diluted with EtOAc (150 mL) and washed with water (2 x 100 mL) and 
brine (100 mL). The organic layer was extracted with 1N HCl solution (2 x 50 mL) and the 
combined aqueous phases were basified with 10N NaOH solution until pH ~12 and 
extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anh. 
Na2SO4, filtered and concentrated under vacuo to give a total amount of 2.59 g (46% yield) 
of nitrile 191. The spectroscopic data were identical to those previously published.  
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Preparation of trans-4-(4-amino-cyclohexyloxy)-benzoic acid, 190·HCl 
 
 6 N NaOH solution (30 mL) was added to a solution of nitrile 191 (2.58 g, 11.9 mmol) 
in ethanol (100 mL) and the reaction mixture was heated to 80 ºC for 18 hours. The 
solution was then tempered to room temperature and evaporated under vacuo. Water (100 
mL) was added and the solution was acidified with conc. HCl at 0 ºC until acidic pH. The 
resulting precipitate was filtered under vacuo to give the desired product 190·HCl (3.07 g, 
95% yield) as a white solid, whose spectroscopic were in good agreement with those 
previously published.  
 
Preparation of trans-4-[4-(3-oxaadamant-1-yl-ureido)-cyclohexyloxy]-benzoic acid, 192 
 
 
 A solution of isocyanate 185 (400 mg, 2.23 mmol) in anh. DCM (25 mL) was added 
to a solution of amine hydrochloride 190·HCl (728 mg, 2.68 mmol) in anh. DCM (12 mL), 
followed by TEA (1.24 mL, 8.94 mmol) under nitrogen. The reaction mixture was stirred 
at room temperature overnight. Water (50 mL) was then added and the phases were 
separated. The organic layer was extracted with further water (2 x 50 mL) and the pH of 
the combined aqueous phases was adjusted to pH ~2 with 5N HCl solution, prior 
extraction with DCM (3 x 50 mL). The combined organic layers were dried over anh. 
Na2SO4, filtered and concentrated under vacuo yielding 192 (220 mg, 24% yield) as a white 
solid. The analytical sample was obtained by crystallization with methanol/diethyl ether. 
 Analytical and spectroscopic data of compound 192: 
Melting point: 255 - 275 ºC. 
IR (ATR) ν: 3364, 3267, 3198, 3061, 2922, 2559, 2348, 2187, 2068, 2011, 1977, 1672, 1601, 
1552, 1443, 1369, 1347, 1320, 1231, 1196, 1172, 1110, 1091, 1049, 1027, 989, 959, 863, 
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828, 774, 698, 640 cm-1. 
1H-NMR (400 MHz, CD3OD) δ: 1.37 [m, 2 H, 3’(5’)-Hax], 1.55 [m, 2 H, 2’(6’)-Hax], 1.65 [dm, 
J = 12.4 Hz, 2 H, 4’’(10’’)-Ha], 1.78 [dm, J = 11.6 Hz, 2 H, 8’’(9’’)-Ha], 1.86 (complex signal, 
2 H, 6’’-H2), 1.94 [m, 2 H, 4’’(10’’)-Hb], 2.01 [m, 2 H, 3’(5’)-Heq], 2.10 [m, 2 H, 2’(6’)-Heq], 
2.22 [broad s, 2 H, 5’’(7’’)-H], 2.28 [dm, J = 15.5 Hz, 2 H, 8’’(9’’)-Hb], 3.57 (m, 1 H, 4’-H), 
4.18 (broad s, 1 H, 3’’-H), 4.40 (m, 1 H, 1’-H), 6.92 [d, J = 8.8 Hz, 2 H, 3(5)-H], 7.93 [d, J = 
8.8 Hz, 2 H, 2(6)-H].   
13C-NMR (100.6 MHz, CD3OD) δ: 29.6 [CH, C5’’(7’’)], 31.0 [CH2, C2’(6’)], 31.4 [CH2, 
C3’(5’)], 35.7 [CH2, C4’’(10’’)], 35.9 (CH2, C6’’), 41.0 [CH2, C8’’(9’’)], 48.6 (CH, C4’), 72.3 
(CH, C3’’), 75.8 (CH, C1’), 81.9 (C, C1’’), 115.9 [CH, C3(5)], 126.8 (C, C1), 132.6 [CH, 
C2(4)], 159.0 (C, NHCONH), 162.4 (C, C4 and CO2H). 
MS (DIP), m/z (%); significant ions: 414 (M·+, 0.2), 179 [(C10H13NO2)·+, 27], 138 [(C9H14O)+, 
(C7H5O3)+, 100], 122 (29), 121 (39), 111 (21), 108 (10), 98 (99), 96 (30), 94 (45), 82 (18), 81 
(97), 79 (41), 67 (19), 65 (15), 56 (42), 55 (16).  
Elemental analysis: 
Calculated for C23H30N2O5:                                          C  66.65%   H  7.30%    N  6.76% 
Calculated for C23H30N2O5·0.1H2O:                            C  66.36%   H  7.31%    N  6.73% 
Found:                                                    C  66.13%   H  7.32%    N  6.64% 
 
Preparation of trans-4-[4-[3-(4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodec-3-
yl)ureido]cyclohexyloxy]-benzoic acid, 193 
 
 A solution of isocyanate 189 (387 mg, 1.93 mmol) in anh. DCM (20 mL) was added 
to a solution of amine hydrochloride 190·HCl (627 mg, 1.93 mmol) in anh. DCM (10 mL), 
followed by TEA (1.07 mL, 7.70 mmol) under nitrogen. The reaction mixture was stirred 
at room temperature overnight. Water (80 mL) was then added and the phases were 
separated. The organic layer was extracted with further water (2 x 80 mL) and the pH of 
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the combined aqueous phases was adjusted to pH ~2 with 5N HCl solution, prior 
extraction with DCM (3 x 80 mL). The combined organic layers were dried over anh. 
Na2SO4, filtered and concentrated under vacuo to give a white solid (556 mg). Purification 
by column chromatography (SiO2, DCM/methanol mixture) yielded 193 (418 mg, 50% 
yield) as a white solid.  
 Analytical and spectroscopic data of compound 193: 
Melting point: 254 - 256 ºC. 
IR (ATR) ν: 3358, 3267, 2939, 2856, 2473, 2369, 2216, 2159, 1669, 1600, 1558, 1487, 1446, 
1305, 1242, 1168, 1108, 1033, 992, 910, 847, 776, 694 cm-1. 
1H-NMR (500 MHz, DMSO-d6) δ: 1.27 [complex signal, 2 H, 3’(5’)-Hax], 1.46 [complex 
signal, 4 H, 12-Ha, 2’(6’)-Hax], 1.86 [complex signal, 4 H, 12-Hb, 3’(5’)-Heq], 2.01 [complex 
signal, 2 H, 2’(6’)-Heq], 2.37 (complex signal, 2 H, 1’’-H and 7’’-H), 2.53 (m, 1 H, 2’’-H), 
2.62 (m, 1 H, 8’’-H), 2.70 (complex signal, 2 H, 6’’-H and 9’’-H), 2.84 (m, 1 H, 11’’-H), 2.90 
(t, J = 7.5 Hz, 1 H, 10’’-H), 3.42 (m, 1 H, 4’-H), 4.43 (m, 1 H, 1’-H), 4.54 (t, J = 5.5 Hz, 1 H, 
5’’-H), 5.84 (d, J = 7.5 Hz, 1 H, 1-NH), 6.69 (s, 1 H, 3-NH), 7.00 [m, 2 H, 3(5)-H], 7.85 [m, 
2 H, 2(6)-H].  
13C-NMR (125.7 MHz, DMSO-d6) δ: 29.6 [CH2, C2’(6’)], 30.1 [CH2, C3’(5’)], 40.8 (CH, 
C2’’), 41.0 (CH, C8’’), 42.5 (CH, C1’’), 43.0 (CH2, C12’’), 43.7 (CH, C9’’), 44.2 (CH, C7’’), 
44.6 (CH, C10’’), 46.9 (CH, C4’), 53.9 (CH, C6’’), 55.7 (CH, C11’’), 74.3 (CH, C1’), 81.7 
(CH, C5’’), 102.3 (C, C2’’), 115.0 [CH, C3(5)], 122.9 (C, C1), 131.3 [CH, C2(6)], 155.9 (C, 
C4), 161.0 (C, NHCONH), 167.0 (C, CO2H).  
MS (EI), m/z (%); significant ions: 200 (28), 158 (13), 135 (43), 132 (18), 131 (95), 130 (53), 
129 (41), 128 (21), 122 (18), 119 (19), 117 (17), 116 (28), 115 (36), 104 (19), 94 (16), 92 (30), 
91 (100), 81 (22), 79 (24), 78 (64), 77 (42), 70 (16), 66 (26), 65 (38), 64 (15), 63 (17).  
HRMS-ESI+ m/z [M+H]+ calcd for [C25H28N2O5+H]+: 437.2076, found: 437.2071.  
HRMS-ESI  m/z [M-H]+ calcd for [C25H28N2O5 H]+: 435.1920, found: 435.1905. 
Elemental analysis: 
Calculated for C25H28N2O5:                                           C  68.79%   H  6.47%    N  6.42% 
Calculated for C25H28N2O5·0.1CH3OH·0.2DCM:         C  66.54%   H  6.36%     N  6.13% 
Found:                                                      C  66.70%   H  6.55%    N  5.73% 
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Preparation of 1-(1-acetylpiperidin-4-yl)-3-(3,7-dimethyl(tricyclo[3.3.0.03,7]octa-1-yl)urea, 
195 
 
 In a round bottom flask equipped with a condenser apparatus and magnetic stirrer a 
solution of amine hydrochloride 123·HCl (68 mg, 0.36 mmol) in chloroform (5 mL) was 
prepared, to which was added 187 (172 mg, 0.73 mmol) followed by triethylamine (0.06 
mL, 0.40 mmol). The solution was heated to 50 ºC for 25 hours, whereupon the reaction 
mixture was tempered to room temperature and evaporated under vacuo to dryness (384 
mg). Purification by column chromatography (SiO2, DCM/methanol mixture) afforded the 
desired product 195 (90 mg, 77% yield) as a white solid.  
Analytical and spectroscopic data of compound 195: 
Melting point: 165 - 167 ºC. 
IR (ATR) ν: 3359, 3244, 2947, 2878, 2170, 2034, 1960, 1613, 1556, 1477, 1443, 1371, 1318, 
1264, 1227, 1151, 1096, 1033, 978, 717, 639 cm-1. 
1H-NMR (400 MHz, CDCl3) δ: 1.11 [s, 6 H, 3’(7’)-CH3], 1.22 [complex signal, 2 H, 2(6)-Ha], 
1.34 [dd, J = 8.2 Hz, J’ = 3.4 Hz, 2 H, 4’(6’)-Ha], 1.54 [dd, J = 7.4 Hz, J’ = 3.4 Hz, 2 H, 2’(8’)-
Ha], 1.70 [dd, J = 8.2 Hz, J’ = 2.6 Hz, 2 H, 4’(6’)-Hb], 1.75 [d, J = 7.6 Hz, 2 H, 2’(8’)-Hb], 1.90 
and 2.03 (complex signal, 2 H, 3-Hax and 5-Hax), 2.07 (s, 3 H, COCH3), 2.27 (t, J = 2.6 Hz, 
1 H, 5’-H), 2.75 (dt, J = 14.0 Hz, J’ = 2.8 Hz, 1 H, 2-Hax or 6-Hax), 3.14 (dt, J = 11.2 Hz, J’ = 
2.8 Hz, 2 H, 6-Hax or 2-Hax), 3.73 (broad d, J = 13 Hz, 2 H, 6-Heq or 2-Heq), 3.83 (m. 1 H, 4-
H), 4.42 (broad d, J = 13 Hz, 2 H, 2-Heq or 6-Heq), 4.79 (d, J = 7.6 Hz, 1 H, 1-NH), 5.18 
(broad s, 1 H, 3-NH).   
13C-NMR (100.6 MHz, CDCl3) δ: 319 (M·+, 1), 277 [(C16H27N3O)·+, 58], 263 (20), 177 
[(C11H15NO)·+, 61], 169 [(C8H13N2O2)+, 25], 151 (18), 150 [(C10H16N)+, 22], 148 (25), 143 
[(C6H13N3O)·+, 100], 136 (26), 135 [(C10H15)+, 43], 134 (31), 127 (16), 126 (23), 125 (17), 122 
(86), 121 (29), 119 (25), 110 (22), 109 (86), 108 (48), 96 (18), 95 (62), 94 (29), 93 (16), 91 
(15), 84 (31), 83 (16), 82 (33), 56 (25), 55 (17).  
MS (DIP), m/z (%); significant ions: 278 (10), 277 (58), 263 (20), 178 (10), 169 (25), 151 
(18), 150 (22), 148 (25), 143 (100), 136 (26), 135 (43), 134 (31), 127 (16), 126 (23), 125 (17), 
123 (11), 122 (86), 121 (29), 119 (25), 110 (22), 109 (86), 108 (48), 96 (18), 95 (62), 94 (29), 
 
CHAPTER 3   349 
93 (16), 91 (15), 84 (31), 83 (16), 82 (33), 80 (11), 79 (12), 77 (11), 67 (11), 57 (13), 56 (25), 
55 (17). 
Elemental analysis: 
Calculated for C18H29N3O2:                         C  67.68%   H  9.15%    N  13.15% 
Calculated for C18H29N3O2·1.0H2O:            C  64.07%   H  9.26%     N  12.45% 
Found:                                    C  64.00%   H  9.31%    N  12.40% 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
IC50 determination 
 
 
CHAPTER 3   353 
IC50 assay determination 
a) Buffer preparation: 
The buffer utilized was bis-tris with an ionic strength of 25 mM, supplemented with 
0.1 mg BSA fraction V per mL of buffer and prepared with water filtered through a MilliQ 
reagent water system (Millipore Corp., Bedford, MA, USA). The pH was adjusted to 7.0 
with 1 N HCl solution. 
b) Substrate preparation: 
(3-Phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester 
(PHOME, Cayman Chemical, item number 10009134) was employed as a fluorescent 
substrate at a final concentration of 5 μM. As the total volume of the assay is 200 μL in all 
the wells, a 200 μM-solution of PHOME in DMSO was prepared prior to the assay 
performance. 
c) Enzyme dilution: 
Beforehand to assaying, human recombinant sEH, purchased by Cayman Chemical, 
was diluted with cold assay buffer (588 μL) and kept on ice during the assay, no longer than 
4 hours.  
d) Preparation of inhibitors: 
Each compound was dissolved in DMSO so as to prepare an 800 μM-stock solution. 
Serial dilutions in DMSO were followed in order to have a range of concentrations for the 
compound testing (from 0.05 to 20 nM). In that the final concentration of the assay is 40x 
diluted, the compounds were prepared 40 times more concentrated (from 2 to 800 nM). 
Five different concentrations were used for each compound.  
e) Assay performance: 
For every determination, the 96-well black microplate (Greiner Bio-one, item nº 
655900) was designed so to have at least a duplicate of the background and a triplicate of 
each concentration of inhibitor, as well as a triplicate of 100% activity. 
Table 25 discloses the pipetting summary for performing the assay. 
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Table 25. Reagents of the inhibitory assay and addition order. 
Well Assay Buffer 
Solvent  
(DMSO) 
Inhibitor sEH 
Assay Buffer +  
Substrate 
Background 90 μL 5 μL - - 100 μL + 5 μL 
Positive control 85 μL 5 μL - 5 μL 100 μL + 5 μL 
Inhibitor 85 μL - 5 μL 5 μL 100 μL + 5 μL 
Addition order 1 2 3 4 5 
 
 
As shown in Table 25, a pre-mixture of the assay buffer and the substrate was prepared 
for its final addition with a multichannel pipette.   
After the addition of the substrate, the microplate was carefully shaken for 10 seconds 
and incubated for 5 minutes at room temperature. Enzyme activity was measured by means 
of the fluorescence appearance of the hydrolysed product 6-methoxy-2-naphthaldehyde 
over 10 min with a FLUOstar OPTIMA microplate reader (BMG) (excitation wavelength: 
337 nm; emission wavelength: 460 nm). 
f) Pharmacological results: 
Results were obtained by regression analysis from at least three data points in a linear 
region of the curve. IC50 values are average of minimum three independent replicates. 
Results are given as means ± standard error. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Water solubility 
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Apparent or semi-equilibrium solubility measurements  
a) Calibration curve of a standard, 109: 
Compound 109 was used as a standard for calculating the linear regression of 
concentration vs area. In this manner, the calibration curve was obtained from six standard 
stock solutions with UV detection at 225 and 254 nm (r = 0.99) (Table 26).  
Table 26. Area values for six standard stock solutions at 225 and 254 nm. 
Concentration Area 
μg/mL μmol/mL 225 nm 254 nm 
100 0.3042 6056764 965689 
50 0.1521 2966801 560875 
10 0.0304 503418 125001 
5 0.0152 200315 70518 
1 0.0030 34244 10530 
0,1 0.0003 30309 3147 
 
 
The measurement was performed by HPLC (Waters), with an Akady ODS-C18 
column (250 mm x 4.6 mm, 5 μm) at room temperature. Ten microliters of the samples 
were injected into the column. The conditions were the following: flow rate of 0.55 
mL/min with an isocratic elution for 25 min (0.1% formic acid in acetonitrile/0.1% formic 
acid in water, 75:25 (v/v)). 
b) Sample preparation for solubility measurements: 
Solubility samples were prepared according to the method described by Tsai et al.539 
Each compound (~1 mg) was added into sodium phosphate buffer (0.1 M sodium 
phosphate, pH 7.4, 1 mL) to create a suspension, which was equilibrated for 24 h at room 
temperature. The suspension was then centrifuged (8,000 rpm, 5 min, RT) using 
centrifuge. The supernatant was transferred to new Falcon™ tube and was diluted 10 times 
with methanol to precipitate the salts. The solution was centrifuged (8,000 rpm, 5 min, 
RT) by centrifuge and the supernatant was filtered through PTFE membrane filters (0.22 
μm) to a vial. The samples were kept at -20 ºC before being analysed by HPLC, if necessary. 
c) Solubility determination: 
Two different conditions were applied depending on the compound for testing:  
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· Conditions A: flow rate of 0.55 mL/min with an isocratic elution for 25 min (0.1% 
formic acid in acetonitrile/0.1% formic acid in water, 75:25 (v/v)). 
· Conditions B: flow rate of 0.60 mL/min with an isocratic elution for 15 min (0.1% 
formic acid in acetonitrile/0.1% formic acid in water, 92:8 (v/v)).  
Compounds 170-183 and 192-193 were measured applying conditions A, whereas 
compounds 184, 188 and 195 were tested using conditions B, either at 225 nm or at 254 
nm. 
d) Correction factor calculation: 
The absorbance of a 1 mM solution of 184, 188 and 195 in methanol was measured 
by HPLC, as well as of a 1 mM solution of the standard 109 in methanol. The correction 
factors were determined for each compound (Table 27).  
Table 27. Correction factor applied for the determination of the solubility of compounds 184, 
188 and 195. 
Comp. 
Correction 
factor 
184 2.28 
188 2.81 
195 3.27 
 
 
e) Results:  
Apparent solubility results are average of minimum two independent replicates in 
μg/mL ± standard deviation.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
In vitro studies 
 
 
CHAPTER 3   361 
In vitro cell cultures  
a) Cell culture: 
 Human Huh-7 were maintained in a humid atmosphere of 5% CO2 at 37 ºC in 
high glucose (25 mmol/L) Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 1% of penicillin/streptomycin (10.000 
units/mL of penicillin and 10.000 µg/mL of streptomycin) and 1% of amphotericin B (250 
µg/mL).  
b) Cell treatment: 
 Huh-7 cells were serum-starved overnight prior to treatment. Lipid-containing media 
were prepared by conjugation of palmitic acid with fatty acid-free BSA, as previously 
described.575 Cells were pre-treated with the inhibitors (final concentration 1 µmol/L) for 1 
hour before treatment with palmitate (final concentration 0.5 mmol/L) and inhibitors 
(final concentration 1 µmol/L). For each condition, at least 3 replicates were performed. 
Following 48 hours of incubation, RNA or protein were extracted as described below.  
c) Immunoblotting: 
 To obtain total protein, hepatocytes were homogenized in RIPA lysis buffer (Sigma) 
with 5 mmol/L NaF, 1 mmol/L phenylmethylsulfonyl fluoride, 10 mmol/L sodium 
orthovanadate and 5.4 µg/mL aprotinin at 4 ºC for 30 min. The homogenate was 
centrifuged at 10.000 g for 20 min at 4 ºC. Protein concentration was measured by the 
Bradford method. Total proteins (30 µg) were separated by SDS-PAGE on 10% separation 
gels and transferred to Immun-Blot® polyvinylidene difluoride membranes (BioRad). 
Western blot analysis was performed using antibodies against BiP, CHOP and ATF3 (Cell 
Signalling Technology or Santa Cruz Biotechnology). Detection was achieved exposing to 
Hyperfilm-ECL films, and analysed using an imaging system (Alpha Innotech, CA) to 
obtain densitometric values. The equal loading of proteins was assessed by detection of 
GAPDH. The size of proteins detected was estimated using protein molecular-mass 
standards (BioRad).  
d) Real-Time PCR: 
 Total RNA in hepatocytes was harvested by TRIsure (Bioline) according to the 
manufacturer’s instructions. The extracted RNA was dissolved in RNase-free water and 
concentrations of total RNA were quantified using a NanoDrop 2000c spectrophotometer 
(Thermo Scientific). First-stranded cDNA was synthesized from 0.5 µg total RNA 
(Fermentas Life Science). Primer Express Software (Applied Biosystems, Foster City, CA, 
USA) was used to design the primers examined with SYBR Green I (Table 28). The PCR 
reaction contained 10 ng of reverse-transcribed RNA, 2X IQ™ SYBRGreen Supermix 
(BioRad, Barcelona, Spain) and 900 nmol/L concentration of each primer. Optical primer 
amplification efficiency for each primer set was assessed and a dissociation protocol was 
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carried out to assure a single PCR product. PCR assays were performed on a 
MiniOpticon™ Real-Time PCR system (BioRad). Thermal cycling conditions were as 
follows: activation of Taq DNA polymerase at 95 ºC for 10 min, followed by 40 cycles of 
amplification at 95 ºC for 15 sec and 60 ºC for 1 min. The relative levels of specific mRNA 
were estimated from the value of the threshold cycle (Ct) of the real-time PCR adjusted by 
that of GAPDH through the formula 2∆Ct (∆Ct = Gene of interest Ct - GAPDH Ct).  
Table 28. Primer sequences of selected genes for quantitative real-time PCR. 
 
Gene Primer sequence 
hATF3 
Forward 5’-AAGAACGAGAAGCAGCATTTGAT-3’ 
Reverse 5’-TTCTGAGCCCGGACAATACAC-3’ 
hBIP 
Forward 5’- ACTATTGCTGGCCTAAATGTTATGAG-
3’ 
Reverse 5’-TTATCCAGGCCATAAGCAATAGC-3’ 
hCHOP 
Forward 5’- GGAAATGAAGAGGAAGAATCAAAAAT-
3’ 
Reverse 5’-GTTCTGGCTCCTCCTCAGTCA-3’ 
hGAPDH 
Forward 5’-GGCCTCCAAGGAGTAAGACC-3’ 
Reverse 5’-AGGGGTCTACATGGCAACTG-3’ 
 
 
e) Statistical analysis: 
Results are expressed as means ± SD of 3-6 separate experiments. Significant 
differences were stablished by one-way ANOVA using the GraphPad Instat programme 
(GraphPad Software V5.01; GraphPad Software Inc., San Diego, CA). When significant 
variations were found, the Tukey-Kramer multiple comparisons test was applied. 
Differences were considered at P < 0.05. 
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